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Transmissible spongiform encephalopathies (TSEs) are rare, uniformly fatal 
neurodegenerative disorders that can affect many mammalian species, including 
humans. A hallmark of these diseases is the conversion of cellular prion protein 
(PrPC) into an abnormally folded form. This misfolded PrPC is infectious, since it can 
provide a template for pathogenic conversion of PrPC in a new host. In addition to 
any toxicity of the misfolded protein, loss of normal PrPC function could be involved 
in the neurodegenerative processes. However, the physiological role of PrPC is still 
poorly understood and this project has aimed to address that lack of knowledge. Out 
of the many putative functions ascribed to PrPC, the most commonly proposed is that 
it protects cells from stress. In contrast, I have found that stable transfection of the 
prion protein gene into SH-SY5Y neuroblastoma cells increases cell death in 
response to serum removal from the culture medium. Following treatment with 
several chemical toxins, two out of four stably transfected clones did, generally, 
display greater viability than untransfected cells that do not express detectable levels 
of PrPC. However, knockdown of PrPC expression by RNA interference had no effect 
on this stress resistance, indicating that it may not have been mediated directly by 
PrPC. Given the lack of robust stress protection afforded by PrPC transfection, 
proteomic analyses of the cells were carried out to identify alternative processes that 
were perturbed as a result of PrPC expression. The results obtained suggested roles 
for PrPC in cytoskeletal organisation and cell cycle regulation. Various proteins 
involved in cytoskeletal organisation were confirmed by western blotting to be 
differentially expressed in some or all of the stably transfected clones. Additionally, 
the expression changes to proteins involved in cell cycle regulation resulted in slower 
proliferation of the clones compared with untransfected cells, a difference that was 
reduced following RNA interference-mediated knockdown of PrPC. Taken together, 
these data suggested that specific growth factor-activated pathways were 
differentially regulated in the stably transfected clones. One candidate pathway was 
nerve growth factor (NGF) signalling, which promotes neuronal survival and 
differentiation as well as regulating various processes outside of the nervous system. 
PrPC-transfection resulted in altered expression of receptors for NGF, suggesting that 
iv 
the stably transfected clones were, indeed, responding differently to NGF 
stimulation. However, the molecular mechanism responsible for these expression 
changes remains to be determined, since co-immunoprecipitation experiments did 
not identify any physical interactions between PrPC and the NGF receptors. 
Nonetheless, a role for PrPC in modulating NGF signalling has the potential to 
explain many of the diverse phenotypic observations in PrPC-null mice and might 













Lay summary  
Prion diseases are rare but fatal diseases of the nervous system that can affect 
humans and other mammals. An important feature of these diseases is the change in 
shape of a protein – the cellular prion protein (PrPC) – into an abnormally folded 
form known as a “prion”. When these prions come into contact with the normal form 
of the protein, it causes this PrPC to also change shape, resulting in an accumulation 
of abnormally folded protein. This process appears to be what allows prion diseases 
to spread from cell to cell and between individuals. Whilst the prions themselves are 
probably damaging to cells, the change in shape also prevents PrPC from carrying out 
its normal function, which may contribute towards the cell death observed in these 
diseases. Currently though, the normal function of PrPC is poorly understood, a lack 
of knowledge that this project has aimed to address. Much of the work was carried 
out using cultured cells genetically engineered to produce PrPC, allowing comparison 
with the original cells that lack the protein. Since previously published research 
suggests that PrPC can protect cells from stress, my first experiments were to expose 
the genetically engineered cells to various forms of stress. In contrast to most 
previous findings, the PrPC-positive cells displayed no robust improvement in stress 
resistance. However, subsequent experiments did find that the presence of PrPC 
affected the levels of proteins that maintain the structural integrity of cells and are 
involved in changing cell shape. Additionally, the PrPC-positive cells were shown to 
divide less frequently than cells lacking the protein. One possible explanation for 
these observations is that PrPC affects how cells respond to a protein called nerve 
growth factor (NGF). NGF interacts with receptor proteins on the cell surface, 
leading to activation of processes within the cell that mainly promote growth and 
survival. Intriguingly, the levels of the NGF receptors were found to be altered in the 
PrPC-positive cells, which suggests that the cells were, indeed, responding differently 
to NGF. A role for PrPC in regulating the cellular response to NGF might indicate that 
a loss of the normal function of PrPC plays an important role in the nervous system 
damage that occurs in prion diseases. 
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1.1 Transmissible spongiform encephalopathies  
Transmissible spongiform encephalopathies (TSEs), also referred to as prion 
diseases, are disorders characterized by long, pre-clinical incubation periods 
followed by rapidly progressing neurodegeneration. Although rare, TSEs are 
uniformly fatal and many mammalian species are susceptible (Fernandez-Borges et 
al., 2012). Animal TSEs include scrapie in sheep and goats, bovine spongiform 
encephalopathy (BSE) in cattle and also goats, and chronic wasting disease in deer, 
whilst sporadic Creutzfeldt-Jakob disease is the most common human TSE (Head, 
2013).  
As the name indicates, TSEs can be transmitted between individuals, although the 
degree of transmissibility varies considerably, for instance, chronic wasting disease 
has spread rapidly through deer populations in North America due largely to the high 
infectivity of bodily fluids from infected animals (Saunders et al., 2012). 
Transmission between humans was first recognised in the mid-20th century following 
studies of the Fore people of Papua New Guinea. This tribe suffered endemically 
from a TSE called Kuru and the accepted theory is that the disease spread as a 
consequence of now-outlawed cannibalistic rituals that were practiced when 
mourning dead relatives. (Collins et al., 2001). In rare circumstances, TSEs can also 
jump across species, as demonstrated by the emergence of variant Creutzfeldt-Jakob 
disease (vCJD) in humans. In the mid-1980s, a novel TSE of cattle was identified 
and this disease, known as BSE, dramatically increased in prevalence over the 
following years, mainly as a result of the feeding practices used at the time 
(Nathanson et al., 1997). The first case of vCJD was identified in the UK in 1996 
(Will et al., 1996) and later studies indicated that the disease may have been 
transmitted to humans via the consumption of BSE-infected beef (Ritchie et al., 
2009).  
Although the threat of a widespread vCJD epidemic has receded, sporadic TSEs, 
which lack a well-defined cause, and inherited TSEs, such as fatal familial insomnia 
and Gerstmann-Sträussler-Scheinker syndrome, continue to affect a small number of 
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people every year. Furthermore, chronic wasting disease represents an emerging 
threat, since it is growing rapidly in prevalence and has the potential to spread 
beyond deer to other livestock species and, conceivably, to humans (Saunders et al., 
2012). Consequently, there is an unmet need for effective treatments of TSEs. 
Various therapeutic approaches have been and are being investigated. However, like 
other neurodegenerative diseases, early diagnosis is a major issue – the preclinical 
stage of disease can last for years or even decades (Collins et al., 2004) and by the 
time clinical symptoms do appear the damage may be irreversible, at least using 
current technologies.     
1.1.1 The prion hypothesis  
TSEs are unusual infectious diseases, since no bacterium, virus or other living 
organism seems to be involved in their transmission. The initial evidence for this 
came from studies of mice experimentally infected with scrapie by intracerebral 
inoculation of infected brain homogenate. Prior to inoculation, the homogenates were 
exposed to UV radiation at wavelengths that would irreparably damage the nucleic 
acid genome of a virus or bacterium and yet the mice still developed disease, 
indicating that the infectious agent of scrapie does not contain nucleic acid (Alper et 
al., 1978). The estimated molecular weight of the scrapie agent also seemed to be too 
small for a virus (Alper et al., 1966; Alper, 1985). Subsequently, a novel protein was 
isolated from scrapie-infected hamster brain and its concentration appeared to be 
proportional to infectivity (Prusiner et al., 1982; McKinley et al., 1983). This 
discovery led to the prion hypothesis, which proposed that this protein was the major 
component of the infectious agent of all TSEs – the term “prion” derives from 
proteinaceous infectious particle (Prusiner, 1982). The protein in the scrapie agent 
was later shown to be a host-encoded protein that can undergo conversion to a 
partially protease-resistant, misfolded form (McKinley et al., 1983; Prusiner et al., 
1985; Horwich and Weissman, 1997). Known as PrPSc (scrapie isoform of the prion 
protein), the misfolded protein is thought to act as a template for converting the 
normally folded form, known as the cellular prion protein (PrPC), into more PrPSc 
(Horwich and Weissman, 1997). PrPSc is prone to aggregation, which results in the 
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formation of oligomers, proto-fibrils, and the large amyloid plaques commonly 
(although not always) found in TSE-infected brains (Kitamoto et al., 1986). 
However, the latest evidence suggests that it is the soluble, oligomeric species rather 
than the plaques that are the most neurotoxic (Ugalde et al., 2016).  
Recently, the prion concept has been extended to encompass other neurodegenerative 
diseases, including multiple systems atrophy (Prusiner et al., 2015), Alzheimer’s 
disease and Parkinson’s disease (Goedert, 2015). These diseases also involve 
accumulation of misfolded protein within the nervous system and the spread from 
cell to cell seems to occur in a “prion-like” manner.  
Whilst PrPSc appears to be toxic in its own right, loss of normal PrPC function may 
also play some role in the progression of TSEs (Mays et al., 2014). Therefore, a great 
deal of research has focused on investigating the physiological function of PrPC.  
This research will be summarised later in the chapter; firstly, we must consider the 
biochemistry/molecular biology of the protein itself.   
1.2 The cellular prion protein and its gene 
1.2.1 Evolutionary history of prion genes 
Homologs of the prion protein gene (PRNP) are present in all vertebrate lineages 
and, certainly among mammalian species, both the amino acid sequence and 
structure of PrPC are well-conserved; for example, human and sheep PrPC share 95 % 
sequence identity (Pastore and Zagari, 2007). The variability in sequence and 
structure that does exist is thought to give rise to the so-called “species barrier” that 
limits transmissibility of TSEs between species (Hagiwara et al., 2013).  
In addition to PRNP, the mammalian prion gene family includes SPRN, which 
encodes shadow of prion protein (shadoo), and PRND, which codes for a protein 
known as doppel. In the human genome, PRNP and PRND are situated directly 
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adjacent to one another on chromosome 20, whilst SPRN is found on chromosome 
10. It was proposed relatively recently that PRNP, PRND and possibly also SPRN are 
evolutionarily descended, at least in part, from the LIV-1 branch of the ZIP (Zrt-, 
Irt-like) metal ion transporter family (Schmitt-Ulms et al., 2009; Ehsani et al., 2011; 
Ehsani et al., 2012).    
1.2.2 Structure of the PRNP gene and its regulation 
In humans, the PRNP gene consists of a region of 35 kilobase pairs (kbp) on 
chromosome 20, whilst in mice the gene covers 38 kbp of sequence on chromosome 
2 (Sakudo et al., 2010). Figure 1.1 shows the structure of the gene in both species as 
well as the mature mRNA transcripts that are produced – the numbering comes from 
NCBI references sequences NM_011170.3 (murine Prnp, transcript variant 1) and 
NM_ 000311.4 (human PRNP, transcript variant 1), although other transcript 
variants with differing 5’ or 3’ untranslated regions seem to exist in humans and in 
mice. Murine Prnp consists of three exons, the first two of which are short sequences 
separated by an intron of ~2.2 kbp that both contribute to the 5’ untranslated region 
of the mature mRNA (Kim et al., 2008). A ~24 kbp intron separates exon 2 from 
exon 3, which contains the protein-coding sequence (CDS) of the gene. Human 
PRNP only has two exons that are separated by an intron of ~13 kbp but again the 
CDS is contained entirely within the final exon (Kim et al., 2008).  
Although PRNP has a short GC-rich region immediately upstream of the 
transcription start site, as well as other features common to housekeeping genes 
(Puckett et al., 1991; Sakudo et al., 2010), intron 1 and the sequences upstream of the 
transcription start site also contain evolutionarily conserved, putative binding sites 
for numerous transcription factors, including Sp1 (Basler et al., 1986), activator 
proteins 1 and 2 (Mahal et al., 2001), forkhead box protein 03 (Liu et al., 2013), 
regulatory factor X1, heat shock factor 2, GATA-binding factor 3, thyrotrophic 
embryonic factor, myocyte enhancer factor 2, ecotropic viral integration site 1, E4 
promoter-binding protein 4 and nuclear matrix protein 4/cas-interacting zinc finger 
protein (Kim et al., 2008). These regulatory sequences enable dynamic control of 
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Figure 1.1 – Structure of PRNP and its mRNA transcripts 
A & B) Schematic representations of the PRNP gene in the murine and human genomes 
in addition to the mature mRNA transcripts produced following removal of introns. The 
entire coding sequence (CDS) derives from a single exon in both species. The cut lines in 
image A indicate that the intron between exons 2 and 3 is much longer than the intron 
between exons 1 and 2 in image B. UTR = untranslated region.  
PrPC expression in response to various factors and conditions (Linden et al., 2008). 
For example, treatment of cultured cells with nerve growth factor (NGF), insulin or 
insulin-like growth factor induces PrPC expression (Kuwahara et al., 2000; Zawlik et 
al., 2006; Liu et al., 2013). Additionally, endoplasmic reticulum (ER) stress, 
oxidative stress and genotoxic stress are all reported to cause upregulation of 
expression (Dery et al., 2013; Cichon and Brown, 2014; Bravard et al., 2015). 
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1.2.3 PrPC structure  
This section focuses on the structure of PrPC in humans but, as previously mentioned, 
the main structural features are conserved among mammalian species. Figure 1.2 
shows these features in more detail. Briefly, PrPC is first synthesised as a precursor 
protein of 253 amino acids. The N-terminal signal sequence (residues 1-22) codes for 
entry into the endoplasmic reticulum (ER) and the C-terminal signal sequence 
(residues 231-253) for the later addition of a glycophosphatidylinositol (GPI) anchor. 
Following cleavage of these signal sequences, the mature protein of 208 amino acids 
(residues 23-230) is trafficked to the cell surface and attaches to the extracytoplasmic 
face of the cell membrane via its GPI anchor (Linden et al., 2008). The N-terminal 
domain of PrPC lacks stable secondary/tertiary structure; this is known as a “random 
coil” conformation and it may enable PrPC to interact with multiple partners 
(Bakkebo et al., 2015). The N-terminal domain also contains four tandem repeats of a 
sequence of eight amino acids. One study showed that this octapeptide repeat region 
was the most well-conserved part of the PrPC sequence among the 53 species 
analysed, which suggests it could be a functionally important domain (Kim et al., 
2008). A hydrophobic region (residues 112-133) spans the divide between the N- and 
C-terminal domains and may be involved in PrPC dimerisation (Rambold et al., 2008; 
Beland and Roucou, 2013). The C-terminal domain itself has a globular structure, 
consisting of three alpha-helices, two beta-strands and interconnecting loops (Riek et 
al., 1996; Haire et al., 2004). Pathogenic conversion of PrPC to PrPSc involves a 
reduction in the amount of alpha-helical structure and an increase in beta-sheet 
conformation (Pan et al., 1993). Two N-linked glycosylation sites (residues 181 and 
197) are also found within the C-terminal domain and the vast majority of PrPC is 
generally thought to be di-glycosylated, although this may not be the case for all 
tissue or cell types (Williams et al., 2004; Lee and Baskakov, 2014).  
Whilst doppel and shadoo are considerably smaller than PrPC, both share some of the 
structural features of the larger protein. Doppel is similar in structure to the 
PrPC C-terminal – it has three alpha helices and two beta sheets as well as two 
N-glycosylation sites. On the other hand, shadoo is comparable to the PrPC 
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Figure 1.2 – Representations of PrPC structure 
A) Ribbon diagram of the structure of PrPC. The globular C-terminal domain contains three 
alpha-helices shown in red and yellow and two beta-sheets shown in turquoise. The 
N-terminal domain is presented in a random coil configuration. B) Schematic representation 
of PrPC highlighting its key structural features. SIG = Signal peptide; HR = hydrophobic 
domain. Sites of proteolytic cleavage events are also marked on the diagram.    
N-terminal, since it contains a hydrophobic domain, a positively-charged region of 
tandem repeats and also appears to exist in a random coil configuration (Watts et al., 
2007). Both doppel and shadoo are GPI-anchored, like PrPC (Silverman et al., 2000; 
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1.2.4 Distribution of PrPC expression  
PrPC expression in the brain seems to increase throughout development, reaching a 
peak in early life before reducing somewhat in adulthood (Sales et al., 2002; Adle-
Biassette et al., 2006). The regions where PrPC remains particularly abundant in the 
adult brain, at least in the case of hamsters, appear to be areas with high levels of 
ongoing neurogenesis, specifically the hippocampus and olfactory bulb (Sales et al., 
2002). Interestingly, there is some evidence that neuronal PrPC expression is high in 
the vicinity of synapses and low or even undetectable in the cell soma (Sales et al., 
1998; Bailly et al., 2004; Adle-Biassette et al., 2006). It is unclear how PrPC 
expression in the brain is affected by the ageing process – one study reported 
increased PrPC levels in the brains of aged mice (Williams et al., 2004), whilst 
analysis of post-mortem human brain tissues showed that PrPC expression in the 
hippocampus was significantly reduced in older individuals (Whitehouse et al., 
2010). The glycan profile of PrPC also seems to undergo age-related changes, 
reportedly resulting in the increased abundance of complex oligosaccharides linked 
to PrPC (Goh et al., 2007)  
Most reports indicate that PrPC is present in glia, including astrocytes (Lima et al., 
2007; Hartmann et al., 2013), oligodendrocytes (Moser et al., 1995; Bribian et al., 
2012) and microglia (Adle-Biassette et al., 2006), although one study found PrPC 
expression to be inhibited following differentiation of neural precursors into glial cell 
types (Steele et al., 2006). Non-neural cells of the forebrain also stain for PrPC, 
including the endothelial cells in blood vessel walls (Adle-Biassette et al., 2006). 
Furthermore, at least during development, PrPC is expressed in the dorsal and ventral 
root ganglia of the spinal cord (Tremblay et al., 2007; Peralta et al., 2012; Ganley et 
al., 2015) as well as sensory and motor axons (Manson et al., 1992) and associated 
Schwann cells (Follet et al., 2002). Outside of the nervous system, PrPC is found in 
immune cells, including T lymphocytes, natural killer cells and mast cells (Durig et 
al., 2000; Haddon et al., 2009). PrPC expression has also been detected in teeth 
(Schneider et al., 2007) and in various organs, such as the heart, pancreas, intestine, 
spleen and kidneys (Peralta and Eyestone, 2009). 
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Within an individual cell, the majority of PrPC is GPI-anchored to the 
extracytoplasmic face of the cell membrane, specifically in microdomains called 
lipid rafts (Vey et al., 1996). However, presumably to control the cell surface pool of 
PrPC, the protein seems to be subject to cycles of internalisation followed by 
trafficking back to the cell membrane via recycling endosomes (Shyng et al., 1995; 
Sunyach et al., 2003). Indeed, studies using a GFP reporter system have suggested 
that PrPC is expressed in recycling endosomes and also in the Golgi apparatus (Lee et 
al., 2001a; Magalhaes et al., 2002; Nikles et al., 2008). There are also reports of 
nuclear and mitochondrial localisation of PrPC expression, which may be part of the 
response to stress (Morel et al., 2008; Sorice et al., 2012; Besnier et al., 2015; 
Bravard et al., 2015).  
1.2.5 Proteolytic processing of PrPC   
Mature PrPC can be proteolytically processed in several ways to produce a number of 
fragments, many of which appear to be bioactive. The sites within the PrPC molecule 
where these cleavage events can take place are indicated in Figure 1.2b. The major 
(alpha) cleavage is thought to occur within the Golgi apparatus (Walmsley et al., 
2009) or in an acidic endosomal compartment (Shyng et al., 1993), and results in the 
production of N- and C-terminal fragments respectively referred to as N1 and C1. 
Most N1 is subsequently shed from the cell, whilst C1 reportedly remains anchored 
to the cell membrane like the full length form (Harris et al., 1993; Vincent et al., 
2000; Laffont-Proust et al., 2006). Often, C1 makes up a large proportion of the total, 
cellular PrPC pool – around 50 % on average in sheep cerebral cortex, for example 
(Campbell et al., 2013). Alpha-cleavage occurs just outside of the hydrophobic 
domain of PrPC, seemingly at the codon 110/111 peptidyl bond (human numbering) 
(Chen et al., 1995; Watt et al., 2005), although a recent report suggested that the 
presence of copper ions can shift the cleavage site by a few amino acid residues 
(McDonald et al., 2014). The disintegrin and metalloproteinase domain-containing 
protein (ADAM) family may be responsible for alpha-cleavage, particularly 
ADAM17. The activity of ADAM17 and, therefore, the rate of alpha-cleavage can be 
modulated by protein kinase C through its effects on the extracellular signal-related 
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kinases 1 and 2 (ERK1/2) signalling pathway (Vincent et al., 2000; Cisse et al., 2008; 
Cisse et al., 2011). ADAMs 8 and 10 may also play a role in alpha-cleavage (Vincent 
et al., 2001; McDonald et al., 2014), although some more recent studies have found 
no evidence for any involvement of ADAMs in the process (Beland et al., 2012; Wik 
et al., 2012).  
Beta-cleavage of PrPC occurs within the octapeptide repeat region, which results in a 
longer C-terminal fragment called C2 and the shorter N-terminal fragment N2. A 
recent study suggested that PrPC can be cleaved between the adjacent His and Gly 
residues of each repeat (residues 61/62, 69/70, 77/78, 85/86 for human PrPC), 
although one of these sites may be favoured over the others in vivo (McDonald et al., 
2014). The beta form of proteolytic processing seems to take place at the cell surface, 
leading to release of N2 and retainment of C2 on the cell membrane (Mange et al., 
2004; Watt et al., 2005). The discovery that beta-cleavage is mainly driven by 
reactive oxygen species (ROS) in the presence of copper ions suggested that it could 
be a response to oxidative stress (McMahon et al., 2001; Mange et al., 2004; Watt et 
al., 2005; McDonald et al., 2014) but the process may also occur physiologically, 
since C2 is found in healthy brain tissues of various species, albeit in small amounts 
(Mange et al., 2004; Campbell et al., 2013). C2 contains the alpha-cleavage site, 
which raises the possibility that C2 levels are usually low not because beta-cleavage 
is rare but because C2 is rapidly processed to C1 (Watt et al., 2005), although 
whether this sequential cleavage actually takes place in vivo is debatable (Sunyach et 
al., 2007; McDonald et al., 2014).  
In the third form of processing, PrPC is cleaved by ADAM10 at the 227/228 peptidyl 
bond (mouse numbering), which removes the GPI anchor and the three adjacent 
amino acid residues, resulting in shedding of the remaining, virtually full-length 
protein, sometimes known as N3, into the extracellular medium (Taylor et al., 2009; 
McDonald et al., 2014). Although the overall effect seems to be beneficial, shedding 
has a complex effect on TSE disease progression. On the one hand, it reduces the 
pool of PrPC available for pathogenic conversion to PrPSc within cells; on the other, 
shedding may contribute to increased extracellular conversion and spreading of 
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misfolded protein by releasing PrPC and possibly also PrPSc from the cell surface 
(Altmeppen et al., 2013; Altmeppen et al., 2015). 
In addition to the various fragments produced by the aforementioned cleavage 
events, there are a few other forms of PrPC that can be found at low levels within 
cells. Their formation seems to arise from an inefficiency in the ER-targeting signal 
peptide of PrPC, which results in a small percentage of precursor molecules failing to 
translocate fully into the ER lumen. Some of this PrPC does not enter the ER at all 
and is simply retained in the cytoplasm with its signal sequences uncleaved and 
without a GPI anchor. Interestingly, the levels of this immature, non-translocated PrP 
seem to be upregulated by ER stress (Orsi et al., 2006). More attention has been 
focused on the so-called CtmPrP, which partially enters the ER – the hydrophobic 
domain of PrPC acts as a transmembrane domain, leaving the C-terminal domain 
within the ER lumen and the N-terminal domain in the cytoplasm. Reports suggest 
that CtmPrP is retained either in the ER or the Golgi before eventual degradation by 
the proteasome (Stewart et al., 2001; Stewart et al., 2005). Although usually 
produced at very low levels in vivo, mutations within the hydrophobic domain that 
make it more hydrophobic can increase CtmPrP levels and, if the increase is 
sufficiently extreme, this can lead to a neurodegenerative phenotype in mouse 
models (Hegde et al., 1998; Stewart et al., 2005; Chakrabarti et al., 2009; Beland and 
Roucou, 2013). Strikingly, several mutations that have this effect are risk factors for 
Gerstmann-Sträussler-Scheinker syndrome, which implicates CtmPrP in its 
pathogenesis (Mastrianni, 2010; Beland and Roucou, 2013). Another transmembrane 
form of PrPC called NtmPrP can be produced if the molecule inserts into the ER 
membrane in the opposite orientation to CtmPrP i.e. the C-terminal domain rather than 
the N-terminal domain protrudes into the cytoplasm. However, very little research 
has focused on NtmPrP (Chakrabarti et al., 2009). 
1.2.6 Why investigate PrPC function?  
It is important to understand the physiological function of PrPC in order to determine 
whether a loss of its function plays a role in the pathogenesis of TSEs. This is a 
Chapter 1: Introduction  13 
possibility given that data from various animal models indicate that PrPC levels fall 
as disease progresses (Mays et al., 2014). Interestingly, conversion to PrPSc seems to 
have a negligible impact on PrPC levels and, instead, PrPC may be downregulated as 
a protective response to inhibit prion replication, as has been proposed by Mays et al. 
(2014). In a similar manner, therapeutic interventions to further reduce PrPC 
expression or block its ability to interact with PrPSc (and, potentially, any other 
proteins) are being investigated; better knowledge of PrPC function would aid in 
assessing the safety of these approaches. Additionally, knowing which proteins 
interact with PrPC physiologically may be of use for developing other strategies for 
the treatment of TSEs. Finally, as described in later sections, there are some 
beneficial functions of PrPC that could be exploited independently for therapeutic 
purposes. For these reasons, a significant amount of research effort has gone towards 
uncovering the physiological role of PrPC and the knowledge gained from such work 
will be covered in the following sections.  
1.3 PrPC-knockout animal models  
1.3.1 PrPC knockout mice  
Various animal models have been used to investigate PrPC function. Firstly, in the 
early 1990s, two lines of PrPC-knockout mice, referred to as Zurich I (Bueler et al., 
1992) and Npu (Manson et al., 1994), were independently generated by gene 
targeting methods. PrPC knockout completely prevented scrapie transmission to these 
mice, which provided strong evidence for the prion hypothesis (Bueler et al., 1993; 
Prusiner et al., 1993). Additionally, the Zurich I and Npu PrPC-null mice were useful 
for generating antibodies against PrPC and PrPSc (Prusiner et al., 1993; McCutcheon 
et al., 2014), since wild type mice would not be expected to mount an effective 
immune response to a self-antigen. More relevant to this thesis, however, is that the 
function of PrPC could also be investigated in the PrPC-null mice. Initial analyses 
identified no striking phenotypes of either knockout line, although there were 
(non-significant) indications of worse performance by the Zurich I mice in certain 
learning tasks (Bueler et al., 1992; Manson et al., 1994). The lack of clear phenotype 
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was surprising given the high degree of conservation of PrPC structure among 
mammalian species (Pastore and Zagari, 2007), which suggests an important 
function for the protein. However, more recent studies have identified several 
phenotypes of these PrPC-null mice, which will be covered in the following sections.  
In the years after the generation of the Zurich I and Npu PrPC-null mice, several 
groups independently produced additional lines for various reasons; these are known 
as Rcm0 (Moore et al., 1995), Ngsk (Sakaguchi et al., 1996), Rikn (Yokoyama et al., 
2001) and Zurich II (Rossi et al., 2001). Unlike the Zurich I and Npu knockout mice, 
all the newer lines were shown to develop a late-onset ataxia due to death of 
cerebellar Purkinje neurons (Sakaguchi et al., 1996; Moore et al., 1999; Rossi et al., 
2001; Yokoyama et al., 2001). The reintroduction of PrPC into the Ngsk line rescued 
the ataxic phenotype, which seemed to confirm that it was caused by ablation of PrPC 
expression (Nishida et al., 1999). However, the particular gene targeting methods 
used for production of the Rcm0, Ngsk, Rikn and Zurich II knockouts resulted in the 
generation of intergenic mRNA transcripts consisting of the undisrupted, 
non-protein-coding exons of Prnp and the exons of the neighbouring Prnd. 
Therefore, doppel was expressed under the control of the Prnp regulatory sequences, 
leading to ectopic doppel expression in the brains of the PrPC-null mice but not the 
wild type controls (Moore et al., 1999) – according to the GeneAtlas U133A mouse 
transcriptome dataset (Su et al., 2004) accessible through the BioGPS gene 
annotation portal (Wu et al., 2016), doppel is normally expressed at high levels in the 
testes but at negligible levels in most other tissues, including the brain. The presence 
of the ataxic phenotype only in knockout mice with ectopic doppel expression in the 
brain suggested that the cerebellar Purkinje neurons were dying from 
doppel-mediated neurotoxicity rather than a lack of PrPC. Further evidence obtained 
in vitro confirmed that doppel was toxic to neuronal cells, but only in the absence of 
PrPC expression (Sakudo et al., 2005; Qin et al., 2006). Although the ability of PrPC 
to block the neurotoxic effects of doppel may derive from a physical interaction 
between the proteins (Qin et al., 2006), this is unlikely to be a physiological function 
of PrPC in the brain given that doppel is not usually expressed there.   
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The ectopic doppel expression makes it difficult to interpret the phenotypes of 
RcmO, Ngsk, Rikn and Zurich II PrPC knockout mice. Additionally, the mixed 
genetic background of the Zurich I line (and also the Ngsk, Rikn and Zurich II lines) 
means that PrPC-null individuals may differ from their wild type counterparts at 
genomic sites other than the Prnp locus (Steele et al., 2007). Even extensive 
backcrossing to one of the parental strains or to a different inbred strain may not 
eliminate this issue completely (Gerlai, 1996; Nuvolone et al., 2013), so some of the 
phenotypes observed in the Zurich I mice may be due to polymorphisms in Prnp-
linked genes compared with the wild type control mice rather than a lack of PrPC 
expression. Indeed, a specific phenotype associated with Zurich I (and Ngsk) 
PrPC-null mice – increased phagocytosis of apoptotic cells by macrophages – was 
traced to a polymorphism in the nearby gene encoding tyrosine-protein phosphatase 
non-receptor type substrate 1 (also known as signal-regulatory protein alpha-1) 
(Nuvolone et al., 2013). The Npu line and a new knockout line called Zurich III, 
created using transcription activator-like effector nuclease genome editing 
technology (Nuvolone et al., 2016), are free from the problem of interfering linked 
genes, since they were generated on pure genetic backgrounds.  
1.3.2 Other PrPC-null animal models 
In addition to the mouse models, PrPC expression has also been knocked out in cattle, 
a natural host of TSEs. Detailed clinical and histopathological examinations as well 
as analyses of blood samples and isolated peripheral blood lymphocytes identified no 
overt abnormalities in these PrPC-null cattle (Richt et al., 2007). However, these 
observations were made in relatively young cattle (up to 20 months of age) and the 
samples sizes were small, so subtle phenotypes would have been difficult to detect.  
Recently, the first non-laboratory animals lacking PrPC expression were identified. 
Naturally occurring PrPC-null animals represent a useful resource for studying 
PrPC function, since they are free from the confounding factors that can be 
introduced by genetic manipulation. The animals in question were goats of the 
Norwegian Dairy Goat breed that were homozygous for a Prnp allele with a 
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premature stop codon at residue 32 i.e. only a few amino acids after the end of the 
N-terminal signal sequence (Benestad et al., 2012). These PrPC-null goats appeared 
to reproduce and behave normally (Benestad et al., 2012), although they may have 
increased red blood cell and neutrophil counts (Reiten et al., 2015).  
1.4 PrPC function    
1.4.1 Stress-protection  
The most extensive body of work relating to PrPC function addresses the putative 
stress-protective properties of the protein. Initial evidence came from PrPC protecting 
neuronal cells from serum withdrawal (Kuwahara et al., 1999) – the loss of growth 
and survival factors present in serum results in activation of mitochondria-dependent 
apoptotic signalling driven by a protein called Bax (Deckwerth et al., 1996). Over 
subsequent years, further studies using primary neurons and neuronal cell lines 
appeared to confirm that PrPC expression confers protection against serum 
deprivation-induced apoptosis (Bounhar et al., 2001; Kim et al., 2004; Roucou et al., 
2005; Krebs et al., 2007; Wu et al., 2008). However, the interpretation of the data 
produced by Kuwahara et al. (1999), Kim et al. (2004) and Wu et al. (2008) is 
complicated by their use of “HpL” cell lines. Kuwahara et al. (1999) describe the 
generation of these cells via immortalisation of primary hippocampal neurons 
derived from Rikn PrPC-null mouse embryos. As described in section 1.3.1, the Rikn 
line of knockout mice display ectopic doppel expression in the brain and, 
consequently, the HpL cell lines also express doppel (Sakudo et al., 2005). Therefore, 
survival differences in response to serum deprivation between these cells and the 
control cell lines derived from wild type mice could have been due to the toxic 
effects of doppel expression. Additionally, the increased resistance to serum 
withdrawal following reintroduction of PrPC into the HpL cells (Kim et al., 2004; Wu 
et al., 2008) may simply have been caused by PrPC interacting with doppel and 
inhibiting its neurotoxicity (Moore et al., 1999; Sakudo et al., 2005; Qin et al., 2006), 
which, as explained in section 1.3, is unlikely to be a physiologically relevant 
function of PrPC. After the issue affecting the HpL cell lines was recognised, the 
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Zurich I PrPC-null mice that are not afflicted by the ectopic doppel expression were 
used for the production of additional immortalised hippocampal cell lines. However, 
there are conflicting reports over whether or not PrPC expression confers significant 
protection against serum deprivation in these cells (Nishimura et al., 2007; Oh et al., 
2008).  
A number of studies have assessed the impact of PrPC expression on the response to 
staurosporine (STS) treatment. STS is a potent but relatively non-selective adenosine 
triphosphate (ATP)-competitive kinase inhibitor (Ruegg and Burgess, 1989; Meggio 
et al., 1995), which seems to induce mitochondria-independent apoptotic signalling 
as well as affecting the same apoptotic pathways activated by serum deprivation 
(Zhang et al., 2004). PrPC has been reported to protect against STS-mediated cell 
death in primary hippocampal neurons isolated from Zurich I mice, possibly via 
interactions with stress-induced-phosphoprotein 1 (STI1) (Lopes et al., 2005; 
Beraldo et al., 2010; Ostapchenko et al., 2013). STI1 is a secreted protein thought to 
bind to PrPC and induce activation of the pro-survival protein kinase A signalling 
pathway. Interestingly, studies of primary cortical neurons derived from the Zurich I 
line of knockout mice found that expression of full length PrPC actually increased 
susceptibility to STS (Paitel et al., 2004; Guillot-Sestier et al., 2009), although the 
N1 fragment produced by alpha-cleavage was apparently neuroprotective (Guillot-
Sestier et al., 2009). Expression of full length PrPC in several other cell lines has also 
been associated with poorer viability following STS treatment (Paitel et al., 2002; 
Paitel et al., 2003; Sunyach et al., 2007; Guillot-Sestier et al., 2009).  
In addition to any direct effects on apoptosis, PrPC reportedly protects cells from 
oxidative stress. For example, basal levels of ROS and lipid peroxidation were lower 
in PrPC-transfected neuroblastoma and epithelial cell lines compared with 
untransfected controls (Rachidi et al., 2003; Zeng et al., 2003). Moreover, PrPC 
expression by primary neurons, astrocytes and cell lines has been associated with 
lower levels of damage following exposure to various compounds that induce 
oxidative stress (Brown et al., 1997b; Brown et al., 2002; Senator et al., 2004; 
Anantharam et al., 2008; Dupiereux et al., 2008; Bertuchi et al., 2012; Alfaidy et al., 
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2013). One potential mechanism is that PrPC modulates the activities of the 
antioxidant enzymes that convert ROS into less toxic products – several studies have 
shown lower superoxide dismutase (SOD) and glutathione peroxidase activities in 
the absence of PrPC expression (Brown et al., 1997b; Miele et al., 2002; Rachidi et 
al., 2003; Sakudo et al., 2003; Paterson et al., 2008). Since ROS appear to induce 
beta-cleavage of PrPC in the presence of copper ions (McMahon et al., 2001; Mange 
et al., 2004; Watt et al., 2005; McDonald et al., 2014), the C2 or N2 fragments could 
actually be responsible for these putative antioxidant properties of PrPC. Indeed, it 
has been reported that N2 lowers ROS production in response to serum deprivation 
in neuronal cell lines and neural stem cells (NSCs) (Haigh et al., 2015a; Haigh et al., 
2015b). As well as potentially increasing the activities of antioxidant enzymes, a 
recent study proposed that PrPC translocates to the nucleus in response to oxidative 
stress-induced DNA damage and directly activates the DNA base excision repair 
pathway by interacting with AP endonuclease and enhancing its activity (Bravard et 
al., 2015). Additionally, PrPC-mediated activation of the tyrosine-protein kinase Fyn 
may lead to a stress-protective release of calcium ions from stores in the ER (Krebs 
et al., 2007). Not all the evidence agrees with an antioxidant role for PrPC though – 
other studies have found no differences in SOD activity between PrPC-null and wild 
type mice in the spinal cord, spleen or brain (Hutter et al., 2003; Steinacker et al., 
2010). Additionally, although PrPC protected neuroblastoma cells from the oxidative 
toxin 3-morpholinosynonimine hydrochloride via activation of the 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-RAC-alpha serine/threonine-
protein kinase (Akt) signalling pathway, PrPC transfection actually increased 
susceptibility to hydrogen peroxide treatment (Vassallo et al., 2005). Incidentally, 
PI3K-Akt signalling can activate the mammalian target of rapamycin pathway, 
leading to reduced levels of autophagy and perhaps explaining the reported 
connections between PrPC and autophagy (Oh et al., 2008; Barbieri et al., 2011; Nah 
et al., 2013; Shin et al., 2014).  
Finally, PrPC has been implicated in the response to ER stress, which is caused by 
accumulation of unfolded/misfolded proteins within the ER. A cell responds to ER 
stress by triggering the unfolded protein response, which consists of the following: 
Chapter 1: Introduction  19 
1) upregulated expression of chaperones to improve protein folding; 2) global 
inhibition of protein synthesis; 3) an increase in ER volume; and 4) activation of the 
ER-associated protein degradation pathway (Halliday and Mallucci, 2014). 
Interestingly, ER stress-response elements have been found within the human PRNP 
promoter, explaining why PrPC expression was induced following treatment of breast 
carcinoma cells with toxins that induce ER stress. In the same study, knockdown of 
PrPC expression in several cancer cell lines resulted in increased cell death in 
response to these toxins (Dery et al., 2013). Higher PrPC expression in spite of the 
global ER-stress-induced reduction of protein synthesis suggests a potential role for 
PrPC in the unfolded protein response, although results from other studies argue 
against a protective role for PrPC during ER stress (Roucou et al., 2005; Anantharam 
et al., 2008).  
1.4.2 Cellular differentiation  
In addition to its reported role in neuroprotection, several studies have shown that 
PrPC promotes neurite outgrowth processes, and interactions of PrPC with STI1 
(Lopes et al., 2005), neural cell adhesion molecule 1 (Santuccione et al., 2005), 
epidermal growth factor receptor (Llorens et al., 2013), integrins (Loubet et al., 
2012), laminin (Graner et al., 2000) or metabotropic glutamate receptors (Beraldo et 
al., 2011) have been put forward as potential explanations. Downstream of these 
putative interactions appears to be activation of ERK1/2 signalling (Lopes et al., 
2005; Caetano et al., 2008), which may promote neurite extension by inhibiting the 
ras homolog gene family, member A (RhoA)-Rho-associated protein kinase (ROCK) 
pathway (Loubet et al., 2012; Llorens et al., 2013). RhoA-ROCK signalling stabilises 
the actin cytoskeleton, thereby inhibiting the development of filopodia – these 
dynamic protrusions from the neurite growth cone respond to the extracellular 
environment to guide migration of the developing neurite (O'Connor et al., 1990).  
Neurite outgrowth is a feature of neuronal differentiation, which raises the possibility 
that PrPC is not just involved in neurite outgrowth but instead plays a wider role in 
regulating differentiation, and perhaps not only within the nervous system. Indeed, it 
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has been proposed that PrPC influences some of the earliest differentiation processes 
that occur during embryogenesis; for example, indirect modulation of the 
polysialylation of neuronal cell adhesion molecule 1 by PrPC may be involved in the 
regulation of epithelial-to-mesenchymal transition, a process that enables cell 
migration and is, therefore, vital during development (Mehrabian et al., 2015; 
Mehrabian et al., 2016). Additionally, knockdown of PrPC expression in cultured 
human embryonic stem cells delayed spontaneous differentiation into the three germ 
layers (Lee and Baskakov, 2013). In a similar manner, PrPC expression has been 
shown to promote guided differentiation of human embryonic stem cells and neural 
precursors into neurons, astrocytes and oligodendrocytes (Steele et al., 2006; Lee and 
Baskakov, 2014). PrPC is also implicated in the regulation of T lymphocyte 
differentiation in the thymus (Aude-Garcia et al., 2011).  
Differentiation often involves a change in cell morphology, such as neurite extension, 
and this will likely require altered expression of cytoskeletal proteins. Several 
proteomic studies have identified such changes in cell lines in which PrPC has been 
knocked down or over-expressed and also in PrPC-null liver tissues compared with 
wild type controls (Provansal et al., 2010; Weiss et al., 2010; Arora et al., 2013; 
Mehrabian et al., 2014). Analyses of brain tissues have been less successful at 
detecting differential expression of cytoskeletal proteins or, indeed, of any proteins at 
all (Crecelius et al., 2008; Mehrabian et al., 2016), although this could be the result 
of the averaging out of cell type-specific effects of PrPC over an entire tissue. 
Another common feature of differentiation is a change to cell cycle progression; for 
instance, neural precursors withdraw from the cell cycle as they differentiate into 
post-mitotic neurons. PrPC has been shown to inhibit proliferation of oligodendrocyte 
precursors (Bribian et al., 2012), neuronal cells (Kim et al., 2005) and cells derived 
from the intestinal epithelium (Morel et al., 2008). In the case of NSCs, one study 
found that expression of full length PrPC promoted proliferation, whilst the cleavage 
fragments N1 and N2 appeared to be inhibitory (Haigh and Collins, 2014). Signalling 
mediated by ROS (Le Belle et al., 2011) may be important for regulating 
proliferation and self-renewal of NSCs as well as their differentiation into neurons, 
and, interestingly, the effects of the different N-terminal PrP fragments on NSC 
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proliferation apparently arose from modulation of intracellular ROS levels (Haigh 
and Collins, 2014). Therefore, the effect of PrPC on NSC proliferation could be a 
consequence of its supposed antioxidant properties or, conversely, protection from 
oxidative stress by PrPC may result from a role in regulating physiological levels of 
ROS. Positive regulation of proliferation by PrPC has also been observed in 
neuroblastoma cells – the proposed mechanism was PrPC interacting with EGFR to 
promote activation of the PI3K-Akt pathway (Llorens et al., 2013). PI3K-Akt-
dependent mammalian target of rapamycin activation might also drive the increased 
protein synthesis required for differentiation processes, such as changes in 
morphology (Roffe et al., 2010).  
1.4.3 Neuronal excitability  
As described in the previous section, an interaction between PrPC and metabotropic 
glutamate receptors has been linked to the regulation of neurite outgrowth (Beraldo 
et al., 2011). There are also reports of PrPC interacting with other neurotransmitter 
receptors, including α7 nicotinic acetylcholine receptors (Beraldo et al., 2010), 
kainate receptors (Carulla et al., 2011), α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (Kleene et al., 2007) and N-methyl-D-aspartate 
receptors (NMDARs) (Khosravani et al., 2008). NMDARs are a subclass of 
ionotropic glutamate receptors and are particularly implicated in excitotoxic death of 
neurons; this can occur when overactivation of NMDARs causes dysregulation of 
intracellular calcium homeostasis, leading to disruption of various physiological 
processes (Bondy and Lee, 1993). NMDAR-mediated excitotoxicity contributes to 
neuronal death in TSEs and other neurodegenerative disorders (Muller et al., 1993; 
Gorman, 2008). Intriguingly, PrPC has been reported to inhibit NMDAR activity, 
which suggests that PrPC may protect neurons from excitotoxic death (Khosravani et 
al., 2008). There is some evidence for this in vivo; for instance, PrPC knockout mice 
have been shown to display increased excitotoxicity in the hippocampus following 
N-methyl-D-aspartate1 injection or ischaemic insult and in the retina in response to 
                                                 
1 N-methyl-D-aspartate mimicks the effect of glutamate on NMDARs but does not activate any other 
type of glutamate receptor.  
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damaging light intensities (Sakurai-Yamashita et al., 2005; Frigg et al., 2006; 
Khosravani et al., 2008). Furthermore, knockout in zebrafish of one of its two Prnp 
paralogs affected NMDAR currents in a way that hinted at a greater susceptibility to 
excitotoxicity, suggesting that this putative function of PrPC may be conserved over 
wide evolutionary distance (Fleisch et al., 2013). Aside from affecting 
neurotransmitter receptor activity by direct interaction it has also been proposed that 
PrPC expression by astrocytes promotes glutamate clearance from the synapse 
(Brown and Mohn, 1999).  
If PrPC can modulate the activities of neurotransmitter receptors then a role in 
learning and memory also seems plausible. Indeed, Zurich I PrPC-null mice display 
abnormal behaviour in nest building and novel environment exploration tasks and 
their age-related decline in short-term memory is reported to be more pronounced 
than that of wild type controls (Schmitz et al., 2014). Moreover, the effect of ageing 
on memory can apparently be blocked by infusing wild type mice with a peptide 
containing the putative PrPC binding site of STI1 (Rial et al., 2009). Mice 
overexpressing PrPC were similarly protected from age-related memory decline (Rial 
et al., 2009).  
1.4.4 Myelin maintenance   
One of the clearest phenotypes of PrPC knockout mice is a widespread demyelination 
of the peripheral nervous system (PNS) that begins in early adulthood. This 
phenotype has been observed in the Zurich I and Npu knockout mice as well as the 
newly generated Zurich III line (Bremer et al., 2010; Nuvolone et al., 2016). Lack of 
PrPC seems to result in defective myelin maintenance, since signs of cycles of 
demyelination and remyelination can be observed in the mice (Bremer et al., 2010). 
Interestingly, Bremer et al. (2010) showed that neuron-specific PrPC expression was 
sufficient to rescue this phenotype, whilst PrPC expression purely in Schwann cells 
was not. Recently, it was reported that an interaction between the PrPC N-terminal 
and the G-protein coupled receptor 126 on the surface of Schwann cells could be 
responsible for the myelin maintenance signalling (Kuffer et al., 2016). In the 
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original paper by Bremer et al. (2010) there was also some evidence that alpha-
cleavage of neuronal PrPC was required to prevent demyelination, perhaps suggesting 
that N1 released by the cleavage interacts in some way with Schwann cells to 
promote myelin maintenance. No myelin-related abnormalities were seen in the 
central nervous system (CNS) of the knockout mice, although a reduction in spinal 
cord expression of PrPC has been found in human patients with multiple sclerosis, a 
demyelinating disease of the CNS (Scalabrino et al., 2015).  
1.4.5 Circadian rhythm    
The distinctive clinical feature of the TSE known as fatal familial insomnia is severe 
disruption of the sleep-wake cycle (Collins et al., 2001). Strikingly, PrPC-null mice 
also exhibit disruptions to their sleep structure, including faster cycling through the 
different stages of sleep and more brief awakenings than wild type mice (Tobler et 
al., 1996; Tobler et al., 1997; Sanchez-Alavez et al., 2007). The cause of these issues 
may be impaired production of melatonin, the hormone produced by the pineal gland 
that regulates sleep timing as well as other processes. Melatonin release is under 
control of the suprachiasmatic nucleus of the hippocampus, which is the master 
regulator of the circadian rhythms that drive the sleep-wake cycle. The result is that 
melatonin levels vary according to a 24 hour cycle – levels are highest in the hours of 
darkness and, for a nocturnal animal like a mouse, lower levels are required for sleep 
initiation. One study found that serum melatonin levels of PrPC-knockout mice were 
much lower than in wild type mice during the dark phase of the cycle but were 
higher during the light phase, which probably contributed to the sleep disruption 
(Brown et al., 2002). A network of proteins called the circadian clock work together 
to generate circadian rhythms and, strikingly, Prnp mRNA levels seem to be subject 
to circadian oscillations in the suprachiasmatic nucleus in addition to other areas of 
the rat forebrain (Cagampang et al., 1999). Therefore, PrPC may be involved in the 
regulation of the sleep-wake cycle, suggesting that a loss of this function could play a 
role in the pathogenesis of fatal familial insomnia.  
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Given that metabolic processes can also be regulated in a circadian manner (Dibner 
et al., 2010), one might expect PrPC-null mice to exhibit changes to such processes. It 
is therefore interesting to note that abnormalities in glucose homeostasis have been 
detected in these mice (Strom et al., 2011; Brito et al., 2013). Specifically, Strom et 
al. (2011) demonstrated that blood glucose levels in these mice were slower to return 
to normal after intraperitoneal injection of glucose, although insulin secretion by the 
pancreas and tissue sensitivity to insulin were not affected in this particular study. In 
contrast, Brito et al. (2013) reported that insulin resistance developed more quickly 
in response to a high fat diet in PrPC-knockout mice than in their wild type 
counterparts.  
1.4.6 Metal ion homeostasis     
A number of early studies of PrPC function focused on an apparent ability to bind 
copper ions at the cell membrane via the octapeptide repeat region of the protein 
(Hornshaw et al., 1995a; Hornshaw et al., 1995b; Brown et al., 1997a). 
Subsequently, PrPC interactions with Cu2+ have been implicated in the regulation of 
NMDAR activity (Gasperini et al., 2015), astrocytic glutamate uptake (Brown and 
Mohn, 1999), protection against oxidative stress (Watt et al., 2007) and maintenance 
of Cu2+ homeostasis in the placenta (Alfaidy et al., 2013). However, whilst it seems 
certain that PrPC can bind Cu2+, the relevance of this interaction in vivo has been 
questioned. Firstly, it has been reported that PrPC-dependent internalisation of Cu2+ 
by cells in culture did not occur when the concentration of Cu2+ in the extracellular 
medium was at a physiological relevant level (Rachidi et al., 2003). Secondly, whilst 
some studies have demonstrated that PrPC expression is protective against oxidative 
stress caused by excessive Cu2+ levels (Rachidi et al., 2003; Watt et al., 2007), 
Cingaram et al. (2015) showed that transfecting PrPC into the Zpl PrPC-null 
hippocampal cell line did not reduce Cu2+-mediated toxicity. Thirdly, binding of 
Cu2+ by PrPC in the presence of ROS is supposed to promote internalisation of PrPC 
followed by its beta-cleavage, possibly as part of the response to oxidative stress 
(McMahon et al., 2001; Watt et al., 2005; McDonald et al., 2014), and yet other 
researchers have found no evidence to connect Cu2+-mediated endocytosis of PrPC 
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with its antioxidant role (Zeng et al., 2003). Furthermore, one report suggests that 
Cu2+ binding is not involved in PrPC endocytosis at all (Sunyach et al., 2003), 
Studies of neuronal cell lines showed that PrPC transfection offered no protection 
against the oxidative DNA damage induced by treatment with high levels of Mn2+, 
Co2+ or Zn2+ (Cingaram et al., 2015). However, neuroblastoma cells were protected 
from the toxic effects of exposure to large amounts of Fe2+ (Watt et al., 2007). 
Interestingly, Zurich I PrPC-null mice show signs of iron deficiency in the brain, 
liver, spleen and kidneys (Singh et al., 2009; Haldar et al., 2015), and recent work 
has proposed that PrPC could have ferrireductase activity (i.e. it can convert Fe3+ to 
Fe2+) (Singh et al., 2013; Haldar et al., 2015), thereby enhancing iron uptake via 
divalent-metal transporter 1 and/or ZIP14 (Tripathi et al., 2015). Alternatively, PrPC 
may interact with a separate ferrireductase enzyme to modulate its activity (Tripathi 
et al., 2015). Together, these findings implicate PrPC in the cellular uptake of iron 
and any protective effect of PrPC against Fe2+-induced oxidative stress could be 
linked to this putative role.  
1.4.7 Roles in immune cells  
Because TSEs are neurodegenerative disorders, much of the research into PrPC 
function has focused on its role in the nervous system. However, PrPC is also 
expressed in immune cells, including T-lymphocytes, natural killer cells and mast 
cells (Durig et al., 2000; Haddon et al., 2009). Mast cells reportedly express high 
levels of PrPC, some of which is shed from the cell membrane as the N3 fragment 
(Haddon et al., 2009). When activated, mast cells release various inflammatory 
mediators, including histamine, prostaglandins and cytokines (Stempelj and Ferjan, 
2005). Interestingly, treatment of cultured mast cells with compounds that induce 
activation resulted in rapid shedding of a large proportion of the cellular pool of 
PrPC, suggesting that the protein could be involved in the inflammatory response 
(Haddon et al., 2009). Mast cells are also involved in angiogenesis (Cantarella et al., 
2011), a process that PrPC seems to modulate within the placenta, although this 
function may be more linked to the putative antioxidant properties of PrPC (Alfaidy 
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et al., 2013). Moreover, in addition to other pain mediators, mast cells secrete NGF, 
which sensitises nociceptive neurons to painful stimuli and has long-term effects on 
neuronal connectivity within the spinal cord, potentially leading to the development 
of chronic pain (Hefti et al., 2006; Pezet and McMahon, 2006; Gold and Gebhart, 
2010; Kuner, 2010; Cantarella et al., 2011). In a similar manner, PrPC knockout in 
mice is associated with altered sensitivity to pain, although the reports are 
inconsistent: one study found that the PrPC-null mice showed a hypersensitivity to 
pain (Gadotti and Zamponi, 2011), whilst another showed that PrPC-null mice were 
more resistant to pain than their wild type counterparts (Meotti et al., 2007). It is 
possible that PrPC expression could modulate pain sensitivity via a role in regulating 
mast cell function, although Gadotti and Zamponi (2011) reported that loss of PrPC-
dependent NMDAR inhibition was most likely responsible for the hypersensitivity to 
pain displayed by the PrPC-null mice in their study.   
PrPC expression by T-lymphocytes may be involved in their differentiation, since 
knockdown of PrPC resulted in an increased tendency for T-cells to develop a 
pro-inflammatory phenotype (Hu et al., 2010). Additionally, in a model of 
autoimmune encephalomyelitis, PrPC knockout mice experienced a more severe 
disease phenotype that was linked to increased T-cell-dependent neuroinflammation 
(Tsutsui et al., 2008), possibly because PrPC is involved in the signalling complexes 
that regulate T-cell activation (Mabbott et al., 1997; Mattei et al., 2004). 
Contrastingly, another study using the encephalomyelitis model found no evidence 
that PrPC knockout drove T-cells towards a more inflammatory phenotype; instead, 
the increased disease severity appeared to stem from the loss of PrPC expression 
within the CNS, not the immune system (Gourdain et al., 2012).  
As explained in section 1.3.2, the first non-laboratory animals lacking PrPC 
expression were identified recently (Benestad et al., 2012). No overt abnormalities 
were identified in these PrPC-null goats (Benestad et al., 2012), although they were 
reported recently to have increased neutrophil numbers compared with wild type 
goats (Reiten et al., 2015). Work is still ongoing to characterise fully the phenotypes 
of these animals. 
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1.4.8 Mitochondrial homeostasis  
Mouse studies have shown that PrPC knockout has no effect on the membrane 
potential or baseline respiration rate of mitochondria nor does it alter the activities of 
the individual complexes of the electron transport chain (Brown et al., 2002; Miele et 
al., 2002; Lobao-Soares et al., 2005). However, transcriptomic and proteomic 
analyses of brain tissue and cultured cells have identified specific subunits within 
each of the five electron transport chain complexes that vary in their expression 
according to the presence or absence of PrPC (Miele et al., 2002; Ramljak et al., 
2008; Stella et al., 2012). Furthermore, fewer mitochondria were found in the brains 
and myocardium of Npu PrPC-null mice than in wild type controls, although the 
mitochondria that were present were larger and had increased maximal respiratory 
capacities, presumably to compensate for the reduced numbers (Miele et al., 2002; 
Paterson et al., 2008). The enhanced maximal respiratory capacity of individual 
PrPC-null mitochondria was linked to a higher level of activity of electron transport 
chain complex I, which was, in turn, associated with an increase in superoxide 
production (Paterson et al., 2008). Dealing with this extra superoxide could explain 
why superoxide dismutase 2, which is found within mitochondria and converts 
superoxide into either hydrogen peroxide or molecular oxygen, is more active in 
PrPC-null mice (Brown et al., 1997b; Miele et al., 2002; Paterson et al., 2008). 
Additionally, it is possible the apparent antioxidant properties of PrPC could derive 
from a role in maintaining mitochondrial homeostasis and, consequently, preventing 
excessive production of ROS. 
1.4.9 Roles in regulating levels of amyloid beta and tau 
Beta-cleavage of the amyloid precursor protein (APP) by beta-secretase 1 produces a 
fragment called sAPPβ that is subsequently cleaved by gamma-secretase to produce 
amyloid beta peptides (Aβ). PrPC has been reported to inhibit beta-secretase 1 
(Parkin et al., 2007; Whitehouse et al., 2013), which suggests that PrPC expression 
should protect against the development of Alzheimer’s disease – accumulation of 
misfolded Aβ is a key feature of the disease. A feedback loop has also been proposed 
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that consists of the APP intracellular domain (the other fragment produced by 
cleavage of sAPPβ) activating cellular tumour antigen p53, which subsequently 
upregulates PrPC, leading to further inhibition of beta-secretase 1 activity (Vincent et 
al., 2009). However, recent work has questioned whether the APP intracellular 
domain is able to induce PrPC expression (Lewis et al., 2012) and one study found 
that PrPC expression was actually associated with higher rates of APP beta-cleavage 
(McHugh et al., 2012). 
It has been suggested that PrPC downregulates transcription of microtubule-
associated protein tau, which could also be protective against Alzheimer’s disease, 
since accumulation of neurofibrillary tangles consisting of hyperphosphorylated tau 
is the other major molecular feature of the disease (Chen et al., 2010). Conversely, 
oligomeric forms of Aβ are reported to bind to PrPC at either its extreme N-terminal 
region (Chen et al., 2010; Dohler et al., 2014) or between residues 92 and 110 
(Lauren et al., 2009), which may elicit toxic effects via hyperactivation of the 
tyrosine-protein kinase Fyn signalling pathway (Vergara et al., 2015). The C1 
fragment that is left at the cell membrane following alpha-cleavage of PrPC lacks 
both the putative Aβ binding sites. Therefore, the reduced levels of hippocampal 
PrPC and the increased rates of alpha-cleavage in the cortex that have been reported 
in the brains of patients with sporadic Alzheimer’s disease could be a protective 
response (Whitehouse et al., 2010; Beland et al., 2014). On the other hand, one study 
found that higher levels of PrPC in serum were correlated with poorer cognitive 
function in an elderly human population (Breitling et al., 2012), although the increase 
in serum PrPC could indicate a loss of PrPC from neuronal membranes.  
1.5 Overall conclusions on the current understanding of 
PrPC function  
As summarised in the previous sections, PrPC has been associated with a diverse 
array of functions. However, the issues described in section 1.3.1 that affect several 
of the PrPC knockout mouse lines – ectopic doppel expression in the brain and the 
impact of polymorphisms in genes flanking the Prnp locus – cast doubt upon the 
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results obtained from studies of these mice or of cells derived from them. This 
problem particularly affects the data showing that PrPC protects cells from apoptosis, 
so the idea that PrPC is a stress-protective protein is certainly open for debate. 
Arguably, the evidence that PrPC protects against oxidative stress is more consistent 
and convincing, although this putative function, as far as I am aware, has largely 
been observed in vitro or in the Zurich I knockout mice and has not been confirmed 
in Npu PrPC-null mice. Furthermore, it has been proposed that the recently identified 
role for PrPC in directly protecting cells from genotoxic stress (Bravard et al., 2015) 
may, instead, be due to polymorphisms between the Zurich I mice and their wild type 
counterparts in a neighbouring gene that encodes WD repeat-containing protein 76 
(Nuvolone et al., 2016).  
The deficits in myelin maintenance and control of the sleep-wake cycle are, perhaps, 
the most reliable phenotypes observed in PrPC knockout mice – adult-onset 
demyelination of the PNS has been observed in the Npu, Zurich I and Zurich III lines 
(Bremer et al., 2010; Nuvolone et al., 2016) and sleep abnormalities have been 
identified in Zurich I and Npu PrPC-null mice (Tobler et al., 1996; Sanchez-Alavez et 
al., 2007). Moreover, the observations that melatonin production is disrupted in PrPC-
knockout mice (Brown et al., 2002) and that Prnp mRNA expression oscillates in a 
circadian manner in the suprachiasmatic nucleus (and other regions) of the rat 
forebrain (Cagampang et al., 1999) warrant further attention, since they suggest a 
wider role for PrPC in the regulation of the sleep-wake cycle.  
There have been numerous studies linking PrPC expression to the induction of neurite 
outgrowth and PrPC also appears to modulate the expression of certain cytoskeletal 
proteins and affect cell proliferation. Together, these data hint at a role for PrPC in 
modulating differentiation processes, which will often include changes to cell 
morphology and to cell cycle regulation. This hypothesis is supported by recent 
studies that implicate PrPC in epithelial-to-mesenchymal transition (Mehrabian et al., 
2015; Mehrabian et al., 2016), stem cell differentiation (Steele et al., 2006; Lee and 
Baskakov, 2013; Lee and Baskakov, 2014) and T-lymphocyte differentiation (Aude-
Garcia et al., 2011). 
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Interactions between PrPC and several different neurotransmitter receptors have been 
identified, which may be a consequence of the random coil configuration of the PrPC 
N-terminal that reportedly enables the protein to bind to multiple partners (Bakkebo 
et al., 2015). However, there are some conflicts in the literature surrounding the 
putative role of PrPC in regulating neuronal excitability via these interactions. For 
example, the apparent ability of PrPC to inhibit NMDAR activity (Khosravani et al., 
2008) could potentially explain the observed protective effect of PrPC expression 
against excitotoxic neuronal death (Sakurai-Yamashita et al., 2005; Frigg et al., 2006; 
Khosravani et al., 2008) and yet, another study of Zurich I PrPC-null mice found that 
the contribution of NMDAR-mediated currents to excitatory postsynaptic potentials 
in the hippocampus was not affected by the absence of PrPC expression (Collinge et 
al., 1994). Collinge et al. (1994) reported instead that PrPC knockout weakened fast 
inhibitory postsynaptic potentials generated via gamma-aminobutyric acid receptors 
but, again, this finding was questioned by other researchers who identified no effects 
of PrPC ablation on these inhibitory currents (Lledo et al., 1996).    
Most of the effects of PrPC knockout on mitochondrial homeostasis are restricted to 
altered expression of a few proteins in the electron transport chain – any overall 
impairments to mitochondrial function appear to be quite subtle and, as far as I am 
aware, have only been observed in the Npu line of PrPC-knockout mice (Miele et al., 
2002; Paterson et al., 2008). Similarly, whilst the evidence for PrPC binding Cu2+ is 
strong (Hornshaw et al., 1995a; Hornshaw et al., 1995b; Brown et al., 1997a), this 
function may not have much impact in a physiological context (Rachidi et al., 2003; 
Sunyach et al., 2003; Zeng et al., 2003; Cingaram et al., 2015). The high levels of 
PrPC expression by mast cells and the reported shedding of the protein upon 
activation (Haddon et al., 2009) are certainly intriguing findings but, overall, there 
has been very little study of the functional consequences of PrPC expression in 
immune cells. Finally, the reported connection between PrPC and APP processing 
could be very important, given the ever-increasing heath and economic burden of 
Alzheimer’s disease. However, the conflicting nature of the evidence means that it is 
unclear whether PrPC expression is protective against the disease or not.    
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1.6 Project aims 
Whilst PrPC appears to contribute to a wide variety of cellular processes, knowledge 
of the underlying molecular mechanisms remains rather limited. The main aim of my 
project was to investigate these mechanisms to improve understanding of the 
physiological function of PrPC. A clearer description of PrPC function would be 
useful in two ways: firstly, it should aid the development of treatments for TSEs, 
diseases that currently lack any effective therapies; and secondly, medically useful 
properties of PrPC that are independent of its role in TSEs, such as its putative stress-
protective function, could also be exploited for therapeutic purposes.  
The specific objectives of the project were as follows:  
 Stably transfect the Prnp protein-coding sequence into the SH-SY5Y 
neuroblastoma cell line to create a cellular model for investigating PrPC 
function, and then characterise the model (Chapter 3)  
 Expose the stably transfected cells to various forms of stress in order to 
clarify the role that PrPC plays in the response to stress (Chapters 3 and 4)    
 Perform proteomic analyses comparing PrPC-transfected SH-SY5Y cells 
with untransfected controls to identify the proteins that vary in their 
expression levels as a result of PrPC transfection, and then use this 
information to identify potential pathways and processes regulated by PrPC 
(Chapters 4 and 5) 
 Follow up the putative functions of PrPC suggested by the proteomic 
analyses and, if possible, identify the molecular mechanisms responsible 
(Chapters 5 and 6)  
 Investigate whether putative functions of PrPC identified from the cellular 
model can be confirmed in vivo by performing molecular analyses using 
tissues from PrPC-null and wild type control mice (Chapters 5 and 6)  
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2.1 Generation of vector containing Prnp coding sequence 
The full coding sequence (CDS) of the murine Prnp gene was cloned into the 
pCI-neo mammalian expression vector as described in the following sections. All 
reagents were from Promega unless otherwise specified.  
2.1.1 Amplification of murine Prnp CDS by the polymerase chain 
reaction 
Genomic DNA was obtained from a wild type C3H mouse brain using the Wizard 
SV Genomic DNA Purification System. The Prnp2 CDS was amplified from 
genomic DNA by the polymerase chain reaction (PCR). Reactions consisted of 
template genomic DNA mixed with Platinum PCR SuperMix High Fidelity (Thermo 
Fisher Scientific) and 400 nM forward and reverse primers (Sigma-Aldrich). The 
forward primer contained an EcoRI restriction site (sequence: GGAATTCCACC-
ATGGCGAACCTTGGCTACTG) and the reverse primer a SalI site (sequence: 
GCGTCGACTCATCCCACGATCAGGAAGATG). For the forward primer, the 
“CACC” between the EcoRI site and the start codon provided a “Kozak” consensus 
sequence to ensure efficient ribosome binding of the mRNA. The PCR program used 
was as follows: initial denaturation at 95 °C for 3 min; 35 cycles of 30 s denaturation 
at 95 °C, 30 s primer annealing at 55 °C and 90 s extension time at 68 °C; and a final 
5 min extension at 68 °C. 
Blue/Orange loading dye was added to PCR products before they were loaded into a 
1 % (w/v) agarose gel containing SYBR Safe DNA stain (Thermo Fisher Scientific). 
The 50-base pairs (bp) DNA step ladder was also loaded for band sizing. The PCR 
products were separated by electrophoresis at 100 V in tris-acetate-
ethylenediaminetetraacetic acid running buffer. DNA was visualised using a UV 
transilluminator and bands were present around the 800 bp size expected for the Prnp 
                                                 
2 Mouse PrPC can vary at amino acids 108 and 189, depending on which Prnp allele (Prnpa or Prnpb) 
is encoded in the genome. The C3H inbred mouse strain carries the Prnpa allele.  
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CDS. These bands were excised and purified using the PureLink Quick Gel 
Extraction Kit (Thermo Fisher Scientific).  
2.1.2 Restriction enzyme digestions 
1 µg purified PCR product was digested overnight at 37 °C using 20 units of EcoRI 
(NEB). Buffer salts were removed by ethanol precipitation and the DNA resuspended 
in nuclease-free H2O. The DNA was further digested at 37 °C for 1 h using 10 units 
of SalI, which was then heat inactivated at 65 °C for 15 min. The digested DNA was 
electrophoresed as described in the previous section and the bands at ~800 bp were 
again excised and purified using the PureLink Quick Gel Extraction Kit. 
1 µg pCI-neo mammalian expression vector was simultaneously digested for 4 h at 
37 °C with 12 units of EcoRI and 10 units of SalI in restriction enzyme buffer D. 
One unit of thermosensitive alkaline phosphatase was also included in the reaction to 
dephosphorylate the vector ends. Enzymes were heat activated at 74 °C for 20 min 
before the digested plasmid DNA was electrophoresed and gel purified as described 
above. 
2.1.3 Insertion of PCR product into pCI-neo vector 
The PCR product and vector were ligated using the LigaFast Rapid DNA Ligation 
System. XL-1 Blue cells (Agilent) were transformed directly with the ligation 
product according to the manufacturer’s protocol. The cells were grown on lysogeny 
broth (LB) agar plates overnight at 37 °C. Antibiotic selection during this and 
subsequent steps was with 100 µg/ml ampicillin and 30 µg/ml tetracycline.  
Colonies were checked for the presence of the desired insert by colony PCR. 
Reactions consisted of 1 unit FastStart Taq DNA polymerase and the associated 
buffer (Roche), 200 µM deoxynucleotides (Thermo Fisher Scientific), nuclease-free 
H2O and 200 nM forward and reverse primers (AAGGCTAGAGTACTTAATACGA 
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and CATTAACCCTCACTAAAGGGA, respectively; Sigma-Aldrich). The primers 
were designed against vector sequences flanking the inserted DNA to ensure the 
insert was in the correct orientation. Individual colonies were sampled using pipette 
tips, which were placed into the reaction tubes. The PCR program used was as 
follows: initial denaturation at 95 °C for 4 min; 40 cycles of 30 s denaturation at 
95 °C, 30 s primer annealing at 50 °C and 90 s extension time at 72 °C; and a final 
5 min extension at 72 °C. PCR products were analysed by agarose gel 
electrophoresis as described previously; the only change was the use of tris-borate-
ethylenediaminetetraacetic acid running buffer instead of tris-acetate-
ethylenediaminetetraacetic acid to improve resolution of small DNA fragments. 
TrackIt 1 kb Plus DNA ladder (Thermo Fisher Scientific) was also loaded into the gel 
for band sizing. Presence of bands at ~850 bp indicated that the vector contained the 
Prnp CDS.  
Successfully transformed colonies were expanded overnight in 3 ml liquid LB 
medium at 37 °C. Glycerol stocks were prepared by mixing equal volumes of each 
culture with LB medium containing 30 % (v/v) glycerol and snap freezing on dry ice 
before storage at -80 °C. Plasmid DNA was isolated from the remainder of each 
culture using the Qiaprep Miniprep Kit (Qiagen).  
2.1.4 Sequencing of vectors containing the Prnp CDS insert 
Sequencing PCRs were set up using the BigDye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems). Reactions consisted of 1.5-2.5 µg purified plasmid DNA, 
10 % (v/v) BigDye Ready Reaction Mix, 15 % (v/v) sequencing buffer, 250 nM 
primer and nuclease-free H2O. For each plasmid clone, separate reactions were 
prepared to enable sequencing in forward and reverse directions. Each of these 
reactions contained either the forward or reverse primer described in the previous 
section. The PCR program used was 25 cycles of 10 s denaturation at 96 °C, 15 s 
primer annealing at 53 °C and 4 min extension time at 60 °C.  
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PCR products were purified by ethanol/ethylenediaminetetraacetic acid (EDTA) 
precipitation. Firstly, EDTA was added to a final concentration of 25 mM. Secondly, 
PCR products were mixed with pure ethanol in a ratio of 1:3 and incubated at room 
temperature (RT) for 15 min. Precipitated DNA was pelleted by centrifugation at 
1300 x g for 30 min at 4 °C. The supernatants were removed and the DNA 
resuspended in 70 % (v/v) ethanol. Precipitated DNA was again pelleted by 
centrifugation at 1300 x g, this time for 15 min at 4 °C. After removing the 
supernatants, the pelleted DNA samples were air dried for 15 min before storage at 
4 °C.    
Sequencing was carried out in-house by Ms. Paula Stewart, a research assistant who 
is an experienced user of the sequencing equipment. Paula resuspended the pelleted 
DNA in Hi-Di Formamide (Applied Biosystems) and analysed the samples using an 
Applied Biosystems 3130 Genetic Analyser. I manually checked the obtained 
sequence chromatograms using the DNASTAR Lasergene software suite to ensure 
that the automated base calling was accurate.   
2.1.5 Production of pCI-neo-MoPrnp 
Five out of six plasmid clones contained the Prnp CDS with no errors. The clone that 
gave the best quality sequencing data was chosen for further use. The corresponding 
glycerol stock was streaked onto LB agar and colonies were grown overnight at 
37 °C. Antibiotic selection was as described in section 2.1.3. One colony was 
selected and expanded in liquid LB medium, again at 37 °C. Once the culture had 
reached an optical density (at 600 nm) of approximately 2.0, plasmid DNA was 
purified using the PureLink HiPure Plasmid Maxiprep Kit (Thermo Fisher 
Scientific). Finally, 500 ng of the plasmid clone and 500 ng of empty pCI-neo vector 
were analysed by agarose gel electrophoresis as described in section 2.1.3. This was 
to confirm that the purified plasmid clone still contained the Prnp CDS, as indicated 
by slower migration on the gel due to its increased size. In later sections, the plasmid 
clone is referred to as pCI-neo-MoPrnp.   
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2.2 Routine culture of SH-SY5Y cells 
Human neuroblastoma SH-SY5Y cells were purchased from the European Collection 
of Cell Cultures. SH-SY5Y cells were routinely maintained as adherent cultures in 
Dulbecco’s modified Eagle’s medium (DMEM; formulation containing high glucose, 
GlutaMAX and pyruvate), supplemented with minimal essential medium non-
essential amino acids, 10 % (v/v) foetal bovine serum (FBS) and 1 % (v/v) penicillin-
streptomycin solution (final concentrations of 50 units/ml penicillin, 50 μg/ml 
streptomycin). All reagents were from Thermo Fisher Scientific. The medium 
described is referred to as “growth medium” and was used for all experiments unless 
stated otherwise. 
Unless stated otherwise, cells were cultured in Nunc tissue culture flasks or plates 
with the Nunclon Delta surface treatment. Cultures were incubated at 37 °C in 5 % 
CO2 and were normally subcultured 1-2 times per week. The growth medium was 
replaced every 3-5 days.  
2.2.1 Subculturing 
Cells were rinsed with Hank’s Balanced Salt Solution (HBSS) and detached by 
treatment with 0.05 % (w/v) trypsin/0.02 % (w/v) EDTA in HBSS for 5 min at 37 °C. 
Trypsin was neutralised by addition of at least an equal volume of growth medium. 
Cell clumps were dissociated by gently pipetting up and down ~15 times. The cell 
suspension was further diluted as required for seeding flasks or plates. If the cell 
suspension needed to be concentrated instead, cells were pelleted by centrifugation at 
200-300 x g for 10 min at RT and resuspended in an appropriate volume of growth 
medium.  
If a cell count was required before plating, a sample of cell suspension was mixed in 
equal parts with 0.4 % (w/v) trypan blue stain (Sigma-Aldrich).  A coverslip was 
affixed to a haemocytometer and one of the chambers filled with the stained cell 
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suspension sample. The total number of viable cells in the four large corner squares 
of the chamber was determined. Cells overlapping the top and left hand sides of the 
squares were included, while those overlapping the bottom and right hand sides were 
excluded. All blue-stained (dead) cells were excluded. The total count was multiplied 
by 5000 to give the number of cells per ml in the original suspension. 
2.2.2 Cryopreserving cells 
Cells were detached from tissue culture flasks as described in the previous section. 
Cells were centrifuged at 200-300 x g for 10 min at RT. Pelleted cells were 
resuspended in freeze medium (45 % (v/v) DMEM, 45 % (v/v) FBS, 10 % (v/v) 
dimethyl sulphoxide (DMSO) and 1 % (v/v) penicillin-streptomycin solution) that 
had been chilled to 4 °C. Cell clumps were dissociated by gently pipetting up and 
down ~15 times. Cells were aliquoted into cryovials at a concentration of 1 x 106/ml 
or greater and were slowly cooled overnight to -80 °C inside a Nalgene “Mr. Frosty” 
freezing container. Frozen cells were transferred to a -150 °C electric freezer for 
long-term storage.      
2.2.3 Reviving frozen cells 
Cryovials of frozen cells were transferred on dry ice from -150 °C storage to the 
laboratory. Cells were thawed rapidly in a 37 °C water bath and clumps were 
dissociated by gently pipetting up and down ~15 times. Cell suspensions were 
transferred to 15 ml Falcon tubes and diluted as required with pre-warmed growth 
medium prior to seeding flasks. If cells were to be cultured initially in small flasks 
(25 cm2 surface area) then the cell suspensions were first pelleted by centrifugation at 
200-300 x g for 10 min at RT. Pelleted cells were resuspended in growth medium 
before seeding flasks. These steps were necessary for culturing in smaller flasks as 
the DMSO concentration in the medium would have been toxic otherwise. 
Irrespective of the flask size, the growth medium was replaced after 24 h to remove 
cell debris and residual DMSO. Cells were then cultured as described in the previous 
sections.         
Chapter 2: Materials and Methods  40 
2.3 Generation of PrPC-expressing SH-SY5Y cells 
The following sections describe the stable transfection of SH-SY5Y cells with the 
pCI-neo-MoPrnp mammalian expression vector (see section 2.1 for details of 
production) and the subsequent derivation of monoclonal, PrPC-expressing lines.    
2.3.1 Determining appropriate concentration of selection antibiotic 
The pCI-neo plasmid carries a neomycin phosphotransferase gene that provides 
resistance to the antibiotic G-418. Prior to transfection, an appropriate G-418 
concentration for selection was determined by seeding a 96-well tissue culture plate 
with SH-SY5Y cells. The cell suspension was serially diluted so that the densities 
ranged from 2000 per well down to a single cell. Cells were exposed to G-418 
(Geneticin; Thermo Fisher Scientific) concentrations between 100 and 1200 µg/ml 
over a 12 day period. Growth medium changes (including G-418 at the appropriate 
concentrations) were carried out at 4, 8 and 10 days post treatment to remove dead 
cells and to maintain the antibiotic selection. The health of the cells was monitored 
regularly by observation under a light microscope. The lowest G-418 dose that 
resulted in zero viable cells after 12 days exposure was identified. A slightly higher 
dose was chosen for selection of stable transfectants to allow for batch-to-batch 
variation in G-418 activity. Proliferation from wells containing a single cell was also 
monitored by microscopic observation. This was to ensure that SH-SY5Y cultures 
could be grown successfully from just one original cell.     
2.3.2 Transfection procedure 
SH-SY5Y cells in growth medium were seeded into a 24-well tissue culture plate at 
two different densities: “high” i.e. ~70 % confluent at transfection; and “low” i.e. 
~35 % confluent. After 24 h cells were transfected using Lipofectamine LTx and the 
associated PLUS Reagent (Thermo Fisher Scientific). The manufacturer’s protocol 
was followed. A range of Lipofectamine LTx concentrations (1, 1.5, 2 and 2.5 µl per 
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well) were tested and 1 µg per well pCI-neo-MoPrnp DNA was used. Untreated cells 
and cells treated with just the transfection reagents (mock-transfected) were included 
on the same plate. After 6 h, the cells were subcultured into a 12-well tissue culture 
plate as described in section 2.2.1. pCI-neo-MoPrnp-transfected cells that had been 
subject to the different transfection conditions described above were pooled into a 
single cell suspension before plating. Cells were recovered for 72 h to allow 
transfected cells to start expressing neomycin phosphotransferase. Next, the growth 
medium was replaced with fresh growth medium containing 500 µg/ml G-418. 
Stable transfectants were selected for ~3 weeks and the growth medium (still 
containing 500 µg/ml G-418) was refreshed 3 times per week. Mock-transfected and 
untransfected cells were monitored over the same period to confirm that cells not 
transfected with pCI-neo-MoPrnp could not survive the antibiotic selection.   
2.3.3 Limiting dilution to generate monoclonal lines 
Polyclonal transfected SH-SY5Y cells in growth medium were seeded into a 96-well 
tissue culture plate. The cell suspension was serially diluted so that some wells 
should have contained just a single cell. The plate was viewed under a light 
microscope 4 days after plating. Based on the typical proliferation rate of the cells, 
those wells containing a single colony of fewer than 8 cells were assumed to have 
contained just 1 cell at plating. Wells not meeting this criteria were ignored from this 
point onwards. Clonal cultures were expanded over several weeks with regular 
growth medium changes (every 2-4 days). Clones were subcultured into plates with 
larger wells when necessary. Extremely slow growing clones were discarded. The 
remaining clones were expanded until sufficient numbers were present to 
cryopreserve stocks for later use (see section 2.2.2).     
2.3.4 Culturing transfected SH-SY5Y cells for experiments 
Genetic drift can cause phenotypic changes in long-term cell cultures. Therefore, 
pCI-neo-MoPrnp-transfected cells and untransfected control cells (SH-SY5YUntr) 
were cultured for 6 weeks only before restarting from frozen stocks. SH-SY5YUntr 
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cells were approximately matched to the stably transfected clones in terms of total 
weeks in culture.  
Transfected clones were routinely maintained in growth medium containing 
200 µg/ml G-418 to guard against epigenetic silencing of the Prnp transgene. G-418 
was removed from these cultures at least 48 h before use in experiments.  
2.4 Preparation of protein samples for western blotting 
2.4.1 Cell lysis 
Lysates were prepared from tissue culture plates or flasks of subconfluent SH-SY5Y 
cells. After removal of growth medium, the cell monolayers were gently washed 
twice with ice-cold phosphate-buffered saline (PBS; 10 mM Na2HPO4, 150 mM 
NaCl, pH 7.3-7.5). The subsequent steps were used when preparing cell lysates for 
the western blotting experiments described in Chapters 3-5. Cells were lysed in ice-
cold radioimmunoprecipitation assay lysis buffer (150 mM NaCl, 50 mM tris, 
1 % (v/v) Triton X-100, 0.5 % (w/v) sodium deoxycholate (SDA), 0.1 % (w/v) 
sodium dodecyl sulphate (SDS), pH 7.4) containing protease inhibitors (Roche 
Complete Mini Protease Inhibitor Cocktail tablets). Phosphatase inhibitors (Roche 
PhosSTOP Phosphatase Inhibitor Cocktail tablets) were also included when blotting 
for phosphorylated proteins. Following ~15 min incubation on ice, lysed cells were 
scraped into one corner of the wells and collected into tubes. Cell lysates were 
sonicated (on ice) for 5 min to shear DNA, before centrifugation at 16100 x g for 
10 min at 4 °C. Supernatants were either processed immediately for protein 
quantification and/or western blotting, or were snap frozen on dry ice and stored 
at -80 °C for later use.  
When performing western blots to detect a high-molecular weight, cell membrane-
associated receptor, I discovered that the aforementioned radioimmunoprecipitation 
assay lysis buffer was not effective at extracting and solubilising the protein. 
Chapter 2: Materials and Methods  43 
Subsequently, the lysis buffer was changed to the following formulation: 150 mM 
NaCl, 50 mM tris, 1 % (v/v) Triton X-100, 0.25 % (w/v) SDA and 1.5 % (w/v) 
N-octyl glucopyranoside, pH 7.4. Because this lysis buffer appeared to improve the 
yield of most proteins, it was used when preparing cell lysates for all the western blot 
experiments described in Chapter 6. Aside from the altered buffer, the lysis method 
was the same as detailed above except that the sonication step was omitted.   
2.4.2 Brain homogenisation 
Frozen mouse brain tissues were available from previous work to investigate 
proteomic and transcriptomic changes induced by PrPC knockout. In that study, the 
entire forebrain was removed, split in two and snap frozen in liquid nitrogen before 
storage at -80 °C. Age- and sex-matched PrPC-null (Npu knockout line) and wild 
type control (129/Ola strain) tissues were isolated from mice of various ages, the 
oldest being ~700 days of age. Here, tissues from mice ~550 days of age were used.    
Forebrain tissues were removed from -80 °C storage and placed in dounce 
homogenisers. An appropriate volume of ice-cold radioimmunoprecipitation assay 
lysis buffer (formulation given in the previous section) containing protease 
inhibitors, and phosphatase inhibitors if necessary, was added to give a 10 % (w/v) 
homogenate. Tissues were manually homogenized and the lysates transferred to 
Falcon tubes for 2 h incubation at 4 °C with agitation to allow lysis to complete. 
Lysates were centrifuged at 16100 x g for 20 min at 4 °C to remove debris. 
Supernatants were either processed immediately for protein quantification and/or 
western blotting, or were snap frozen on dry ice and stored at -80 °C for later use.    
2.4.3 Liver homogenisation 
Four wild type (129/Ola) and four PrPC-null (Npu) mice aged 14-15 weeks were 
culled prior to removal of their livers, which were subsequently snap frozen in liquid 
nitrogen. These steps were carried out by Ms. Rebecca Hogan, who is a senior 
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animal technician within the Roslin Institute Biological Resource Facility. 
Subsequently, I homogenised the tissues using the method detailed in the previous 
section.  
2.4.4 Protein quantification by dot blot 
Immobilon-P PVDF membranes (Millipore) were rehydrated in methanol for 2 min 
and equilibrated in PBS for 10 min. Reactivated membranes were secured into a 96-
well BioDot microfiltration apparatus (BioRad) according to the manufacturer’s 
instructions. 100 μl per well PBS were added to each well and a vacuum was applied. 
100 µl per well of cell or tissue lysate samples, as well as protein standards at a range 
of suitable concentrations (either bovine serum albumin or recombinant truncated 
ovine PrP), all diluted in PBS, were added in triplicate. Drainage was by gravity flow 
to facilitate sample binding to the membrane. The membrane was washed with 
100 μl per well PBS, followed by two washes with 200 μl per well PBS containing 
0.3 % (v/v) Tween-20. Again drainage was by gravity flow. Once all the wash 
solution had passed through, the membrane was removed from the apparatus and 
several washes were performed as follows: two 5 min washes with PBS with 
agitation; a 30 min wash at 37 °C with PBS/0.3 % Tween-20; three 5 min washes 
with PBS/0.3 % Tween-20 with agitation; and finally three rinses with Milli-Q H2O 
to remove buffer salts. Membranes were incubated for at least 2 h (up to overnight) 
with ~20 ml Protogold colloidal gold solution (BBI). Stained membranes were rinsed 
with Milli-Q H2O, air dried and scanned. ImageQuant TL or ImageJ software 
packages were used for densitometric analysis. A standard curve was produced in 
Excel based on the absorbance values from the protein standards and sample 
concentrations were determined accordingly.   
2.4.5 Protein quantification by bicinchoninic assay 
Bicinchoninic (BCA) assays were used as an alternative to dot blotting. The Pierce 
Microplate BCA Protein Assay Kit – Reducing Agent Compatible (Thermo Fisher 
Scientific) was used. The bovine serum albumin standard provided was serially 
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diluted in PBS to give concentrations of 125-2000 µg/ml. Cell or tissue lysate 
samples were also diluted as appropriate in PBS. 13 µl of standards and samples 
were pipetted in triplicate into wells of a kit-supplied 96-well plate. For samples in 
8 M urea buffer, 5 µl samples were loaded instead and 8 µl PBS added on top to 
reduce the urea concentration to ~ 3 M, the maximum compatible with this assay. 
The BCA working reagent was prepared by mixing 50 parts BCA reagent A with 
1 part BCA reagent B. 260 µl working reagent were added to each well. The plate 
was sealed, placed on a plate shaker for 1 min and then incubated at 37 °C for 
30 min. After 5 min to cool to RT, absorbance at 570 nm was quantified using a 
Synergy HT plate reader. A standard curve was produced in Excel based on the 
absorbance values from the protein standards and sample concentrations were 
determined accordingly.      
2.4.6 Peptide-N-glycosidase F-mediated digestion of protein samples 
An NEB Peptide-N-glycosidase F (PNGase F) kit was used. Protein samples were 
diluted in glycoprotein denaturing buffer (final concentrations of 0.5 % (w/v) SDS 
and 40 mM DTT) and then heated to 95 °C for 5 min. G7 reaction buffer, NP-40 and 
PNGase F were added to samples to final concentrations of 1X, 1 % (v/v) and 
50 units/µl, respectively. The remaining volume was made up with Milli-Q H2O. 
Reactions were incubated at 37 °C for 1 h to remove N-linked glycans from proteins. 
NuPAGE lithium dodecyl sulphate (LDS) sample buffer (Thermo Fisher Scientific) 
containing 5 % (v/v) β-mercaptoethanol was added to de-glycosylated protein 
samples at a ratio of 1:3. PNGase F was inactivated by heating the samples to 72 °C 
for 5 min. Samples were analysed by western blotting as described in the following 
sections. 
Chapter 2: Materials and Methods  46 
2.5  Western Blotting 
2.5.1 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis  
When necessary, the total protein contents of cell or tissues lysates were quantified as 
described in sections 2.4.4 and 2.4.5. The data were used to ensure equal sample 
loading for sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). However, a prior protein assay was normally omitted if the samples 
for comparison were known to be of approximately equal concentrations and if the 
gel loading control method described in the following section was to be used. 
SDS-PAGE was performed under reducing and denaturing conditions using the 
Novex NuPAGE gel system (Thermo Fisher Scientific). Protein samples were diluted 
as necessary in their original buffer. NuPAGE LDS sample buffer containing 
5 % (v/v) β-mercaptoethanol was added to diluted protein samples at a ratio of 1:3. 
Samples were denatured by heating to 70 °C for 10 min. Pre-cast NuPAGE gels were 
secured into an XCell SureLock Mini Cell and running buffer was added to both 
chambers. Gels of varying polyacrylamide concentrations and buffer systems (bis-tris 
or tris-acetate) were used depending on the molecular weight of the protein of 
interest. The running buffer also varied for the same reason (either 2-(N-
morpholino)ethanesulfonic acid (MES) SDS, 3-(N-morpholino)propanesulfonic acid 
SDS or tris-acetate SDS).  
Protein samples were loaded into the gels alongside appropriate protein standards. 
SeeBlue Plus2 Pre-Stained Standard was used for monitoring transfer, whilst 
MagicMark XP Western Protein Standard was used for molecular weight-sizing of 
bands when imaging blots. HiMark Pre-Stained Protein Standard was used in place 
of MagicMark for high-molecular weight proteins. Protein samples were separated 
by electrophoresis at constant voltage until the loading dye reached the bottom of the 
gel.   
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2.5.2 Loading control 
For each set of samples prepared for quantitative western blotting, a loading control 
gel was prepared to control for errors either in sample preparation or associated with 
the initial protein quantification assay (if performed). This is a published method 
(Eaton et al., 2013) and was preferred over normalisation to standard reference 
proteins because many such proteins appear to vary in their expression depending 
upon the presence or absence of PrPC. 
Briefly, the loading control gel was secured into the same tank as a gel used for 
blotting. Following electrophoresis as described in the previous section, loading 
control gels were incubated in ~20 ml InstantBlue stain (Expedeon) for 1 h. After 
several washes with Milli-Q H2O to reduce background, imaging and quantification 
were performed using the LI-COR Biosciences Odyssey Infrared Imaging System 
and associated ImageStudio software. A blank lane of the gel was used for setting the 
background correction. Rectangles were drawn over each sample-containing lane 
(normally covering bands from 20-180 kDa). The integrated intensity values 
obtained were used to correct the associated western blot data for loading error.  
2.5.3 Semi-dry transfer 
Following SDS-PAGE, gels were equilibrated for 10 min in ice-cold transfer buffer 
(100 mM tris, 190 mM glycine, pH not adjusted). The transfer buffer also contained 
methanol at concentrations from 5-20 % (v/v) depending upon the molecular weight 
of the protein of interest (higher concentrations for low-molecular weight proteins). 
Meanwhile, Immobilon FL PVDF membranes (Millipore) were briefly rehydrated in 
methanol, rinsed twice with Milli-Q H2O and equilibrated in transfer buffer for 
5 min. Transfer stacks were assembled in a Novex Semi-Dry Blotter (Thermo Fisher 
Scientific) according to the manufacturer’s protocol. Transfer was for 1 h at 140 mA 
for a single gel or at 280 mA for two gels. Membranes were air dried to optimize 
retainment of bound protein. 
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For high-molecular weight proteins that transferred poorly under the above 
conditions (generally > 100 kDa), the methanol-containing transfer buffer was used 
for the anode side of the transfer stack only (membrane; bottom filter papers). A 
transfer buffer of 100 mM Tris, 190 mM glycine and 0.1-0.2 % (w/v) SDS was used 
for the cathode side (gel; top filter papers) to improve movement of proteins out of 
the gel.  
2.5.4 Blocking and immunostaining 
Membranes were rehydrated in methanol, rinsed twice with Milli-Q H2O and placed 
in PBS for 2 min. All subsequent steps were carried out at RT and with agitation 
unless stated. Membranes were incubated in Odyssey Blocking Buffer (LI-COR 
Biosciences) for 1 h. After a PBS rinse, membranes were incubated overnight at 4 °C 
with primary antibodies diluted in Odyssey Blocking Buffer containing 0.1 % (v/v) 
Tween-20 (full details of primary antibodies used are provided in Appendix I). Next, 
membranes were washed four times for 5 min with PBS containing 0.1 % (v/v) 
Tween-20. Membranes were protected from light for all subsequent steps. 
Membranes were incubated for 1 h with either IRDye 680RD goat anti-mouse IgG or 
IRDye 800CW goat anti-rabbit IgG secondary antibodies (LI-COR Biosciences) 
diluted 1:10000 in a mixture of Odyssey Blocking Buffer and PBS (1 part to 3 parts, 
respectively), still with 0.1 % (v/v) Tween-20. Four washes with PBS/0.1 % (v/v) 
Tween-20 were again performed, followed by two washes with PBS to remove 
residual Tween-20. Membranes were air-dried again before imaging and 
quantification (if required) using the LI-COR Biosciences Odyssey Infrared Imaging 
System and associated ImageStudio software. Rectangles were drawn around each 
band and a local background correction applied (subtraction of the median intensity 
of pixels just outside the top and bottom edges of the rectangle). The integrated 
intensity values obtained were considered to be proportionate to the amount of 
protein present. To allow data from replicate blots to be combined, integrated 
intensity values were normalised to a common control sample or group of samples.  
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2.6 PrPC co-immunoprecipitation 
The buffer used for cell lysis consisted of either 150 mM NaCl, 50 mM tris, 
1 % (v/v) Triton X-100, 0.25 % (w/v) SDA and 1.5 % (w/v) N-octyl glucopyranoside 
(pH 7.4) or of the same components except for the omission of SDA. Cell lysis was 
performed as described in section 2.4.1. Lysates were kept on ice prior to 
measurement of total protein concentration by BCA assay as described in section 
2.4.5. Subsequently, lysates were diluted to 1 mg/ml using the appropriate lysis 
buffer i.e. the buffer that was used for cell lysis. Samples of each cell lysate were 
removed at this point and NuPAGE LDS sample buffer (Thermo Fisher Scientific) 
containing 5 % (v/v) β-mercaptoethanol was added at a ratio of 1:3. The samples 
were denatured by heating to 95 °C for 10 min and were then snap frozen until use.  
The stock solution of protein G-conjugated magnetic beads (Cell Signalling 
Technology) was vortexed gently to resuspend the beads. Appropriate volumes of 
bead slurry were added to microcentrifuge tubes (10 µl beads per 100 µl lysate). To 
wash the beads, lysis buffer was added at a ratio of 10 parts to 1 part bead slurry. 
Following gentle vortexing, the beads were pelleted by spinning the tubes in a 
microcentrifuge at 2000 rpm for 30 s. Next, the tubes were placed in a magnetic 
separation rack for 1 min to pull the beads to one side. Supernatants were removed 
and the cell lysates were added to the washed beads. After 1 h incubation at 4 °C 
with gentle agitation, the beads were separated from the lysates by centrifuging and 
placing the tubes in a magnetic rack, as described above. The pre-cleared lysates 
were transferred to fresh tubes and either BC6 anti-PrP antibody (McCutcheon et al., 
2014) or mouse IgG1 isotype control antibody (Cell Signalling Technology #5415) 
were added to final concentrations of 16 µg/ml. The lysates were incubated with the 
antibodies overnight at 4 °C with gentle agitation. Further tubes containing pre-
washed beads were prepared as described above. The lysate-antibody solutions were 
added to beads and incubated for 3 h at 4 °C with gentle agitation. The beads and any 
antibody-antigen complexes bound to them were separated from the solution as 
described above and these supernatants were then removed. Three washes of ~5 min 
with the appropriate lysis buffer (using a volume twice that of the original lysate) 
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were performed to remove non-specifically bound proteins. After the final wash, the 
antibody-antigen complexes were eluted from the beads by adding undiluted 
NuPAGE LDS sample buffer containing 5 % (v/v) β-mercaptoethanol, vortexing 
heavily and heating to 95 °C for 15 min to denature the proteins. Subsequently, the 
samples were vortexed again and centrifuged at 16100 x g for 2 min. The eluents 
were transferred to new tubes and either snap frozen or used immediately for further 
analysis.  
The samples obtained from PrPC co-immunoprecipitation experiments were analysed 
by western blotting as described in section 2.5 and also by SDS-PAGE followed by 
silver staining to detect protein bands. Silver staining was performed using the 
SilverQuest Silver Staining Kit (Thermo Fisher Scientific) and the basic staining 
protocol provided with the kit was followed. The stained gels were washed with 
Milli-Q H2O and imaged using a flatbed scanner.   
2.7 Immunofluorescence assays 
2.7.1 General protocol 
All following steps were carried out at RT unless stated. All wash steps were for 
5 min and were carried out with gentle agitation, while all other incubation steps 
involved no agitation.  
SH-SY5Y cells growing in culture were detached from flasks and pelleted as 
described in section 2.2.1. Pelleted cells were resuspended in growth medium and 
seeded either into cell culture surface-treated, 96-well, black-walled Nunc plates with 
a coverglass base (Thermo Scientific), if the cells were to be examined by confocal 
microscopy, or into optically clear tissue cultures plates, in the case of widefield 
fluorescence imaging. After 16 or 24 h incubation at 37 °C, cells were fixed by 
adding 10 % (w/v) paraformaldehyde (PFA) in PBS to the medium already present to 
give a final PFA concentration of 2 % (w/v). The PFA/medium solution was removed 
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and replaced with 2 % PFA in PBS for a further 10 min incubation. After three 
washes with PBS, cells were permeabilised if required (further details are given in 
the following section). Next, cells were treated with a blocking solution of 5 % (v/v) 
normal goat serum (Sigma-Aldrich) in PBS for 1 h. Cells were incubated overnight 
at 4 °C with the appropriate primary antibody diluted in 5 % normal goat serum in 
PBS. Full details of the primary antibodies used are provided in Appendix I. After 
three further PBS washes, cells were incubated in the dark for 1 h with goat anti-
mouse or goat anti-rabbit IgG Alexa Fluor 555-conjugated secondary antibodies 
(Thermo Fisher Scientific) diluted 1:500 in 5 % normal goat serum in PBS. Cells 
were again washed three times with PBS before 5 min incubation with the 
fluorescent nuclear stain 4’,6-diamidino-2-phenylindole (DAPI; Thermo Fisher 
Scientific) at a concentration of 300 nM in PBS. If actin cytoskeleton staining was 
required, DAPI solution was replaced with 5 units/ml Alexa Fluor 647 phalloidin 
(Thermo Fisher Scientific) for a 20 min incubation. After a final PBS wash, cells 
were left in PBS and the plates were sealed and stored in the dark at 4 °C until 
imaging.   
2.7.2 Permeabilisation treatments 
Depending on the staining requirements, one of the following permeabilisation 
methods was used: 1) incubation in PBS containing 0.1 % (v/v) Triton X-100 for 
10 min at RT; 2) incubation for 10 min at -20 °C in methanol that had been pre-
chilled to -20 °C; or 3) treatment with 0.1 % (w/v) saponin. For methods 1 and 2, 
cells were washed once with PBS before blocking. For method 1, 0.01 % (v/v) 
Triton X-100 was included in the blocking solution. For method 3, no separate 
permeabilisation step was included; instead, saponin was included in the blocking 
solution and at all subsequent incubation steps up until the final PBS wash.    
2.7.3 Fluorescence microscopy 
Confocal images were captured using a Zeiss LSM 710 microscope and the 
associated Zen Black software. The smart set-up function was used to minimise 
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crosstalk among the required imaging tracks. The range indicator was used to adjust 
laser power, master gain and digital offset settings to minimise the number of 
saturated and zero intensity pixels. The pinhole size was set to 1 airy unit for the 
imaging track with the longest wavelength (DAPI) and slice thickness in the z-plane 
was maintained across the other imaging tracks. All images were taken with a scan 
speed of 8 and bit depth of 12. The image resolution was either 1024 x 1024 or 2048 
x 2048 pixels. Image processing was performed using the Zen Black software and 
brightness settings were adjusted digitally if required.   
Widefield fluorescence images were taken using a Zeiss Axiovert inverted 
microscope using a triple pass filter (excitation at 407/494/576 nm; emission at 
457/530/628 nm). The Scion VisiCapture software was used for imaging. Exposure 
time was set manually according to the preview image and multiframe averaging (4 
frames) was used to minimise background noise. Images from the different 
fluorescence channels were assembled using ImageJ.  
2.8 Morphological analysis of cells by phase contrast 
microscopy 
SH-SY5Y cells growing in culture were detached from flasks and pelleted as 
described in section 2.2.1. Pelleted cells were resuspended in growth medium and 
seeded onto optically clear tissue culture plates. After 24 h incubation at 37 °C, cells 
were fixed with PFA as described in section 2.7.1. After three PBS washes, cells 
were left in PBS and the plates were sealed and stored at 4 °C until imaging. Phase 
contrast images were taken using a Zeiss Axiovert inverted microscope. Image 
capture was the same as described above for widefield fluorescence imaging.  
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2.9 RNA interference-mediated knockdown of PrPC 
expression 
Silencer Select small interfering RNAs (siRNAs) were purchased from Thermo 
Fisher Scientific. Sequences of sense strands for the PrP-specific siRNAs were 
CGUGAAAACAUGUACCGCUTT (referred to as s72188) and GCAGGCCCAUG-
AUCCAUUUTT (referred to as s72190). Negative control siRNA 1, which has “no 
significant sequence similarity to mouse, rat or human gene sequences” (Thermo 
Fisher Scientific, [n.d.]-b) and cyanine dye 3-labelled glyceraldehyde 3-phosphate 
dehydrogenase positive control siRNA were also purchased. The sequences for the 
control siRNAs are not publicly available.   
2.9.1 Initial assessment of siRNA transfection efficiency 
As an initial test of transfection efficiency, the cyanine dye 3-labelled glyceraldehyde 
3-phosphate dehydrogenase siRNA was reverse transfected into SH-SY5Y cells as 
follows. Firstly, the lyophilised siRNA was resuspended in nuclease-free H2O to 
make a 30 µM stock. This stock and Lipofectamine RNAi Max (Thermo Fisher 
Scientific) were both diluted in a modified form of Eagle’s minimal essential 
medium known as OptiMEM3 (Thermo Fisher Scientific) by factors of 1:17 and 
1:50, respectively. Equal parts of these solutions were mixed and incubated for 5 min 
at RT to form siRNA-lipid complexes at 10X the desired final concentrations. A 
mock transfection control, consisting of Lipofectamine RNAi Max incubated only 
with OptiMEM, was also prepared. 96-well, black-walled, clear-bottomed, tissue 
culture-treated Costar plates were pre-treated in duplicate with the complexes. 
SH-SY5Y cells growing in culture were detached from flasks and pelleted as 
described in section 2.2.1. Pelleted cells were resuspended in growth medium lacking 
antibiotics and were added to the plates, on top of the siRNA-lipid complexes, at a 
density of 30000 per well. After 16-18 h incubation the growth medium was removed 
                                                 
3 In addition to standard cell culture medium constituents, OptiMEM contains insulin, transferrin, 
thymidine and the purine derivative hypoxanthine (Thermo Fisher Scientific, [n.d.]-a). The exact 
concentrations of these components are not publicly available.   
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and, following a wash with HBSS, was replaced with serum-free medium (same 
constituents as growth medium, except for the addition of N-2 supplement (Thermo 
Fisher Scientific) and the lack of serum). Either immediately afterwards or 24 h later, 
Hoescht 33342 dye was added to the culture medium to give a final concentration of 
2.5 µg/ml. Following the method described in section 2.7.3, widefield fluorescence 
images were captured at both time points in order to visualise siRNA uptake. 
2.9.2 Optimisation of siRNA transfection 
PrP-specific and negative control siRNAs were resuspended in nuclease-free H2O to 
make 10 µM stocks. SH-SY5Y cells were reverse transfected with these siRNAs in 
duplicate as described in the previous section, except for the following changes: 
1) Lipofectamine RNAi Max was initially diluted 1:25 rather than 1:17; 2) the 
siRNAs were tested at final concentrations of 2.5, 5 and 10 nM; and 3) in addition to 
96-well plates, reverse transfections were also performed in 24-well tissue culture 
plates (120 000 cells per well). After 16-18 h incubation the growth medium was 
removed and, following a wash with HBSS, was replaced with serum-free medium 
(formulated as described in section 2.9.1). 24 h after serum deprivation, cell viability 
was assessed for the 96-well plates as described in section 2.10.5. The only change 
was that cells not treated with Lipofectamine RNAi Max and/or siRNAs were used 
as controls for 100 % viability. At the same time point, cells growing in 24-well 
plates were lysed as described in section 2.4.1. PrPC expression levels in the lysates 
were determined by quantitative western blotting as described in section 2.5. The 
lowest siRNA dose to give an acceptable level of PrPC knockdown was chosen for 
future use.  
2.9.3 Quantification of RNA interference-mediated PrPC knockdown  
To obtain reliable data on the typical PrPC knockdown achieved using 5 nM siRNA 
concentrations, five independent experiments were performed. The method was 
similar to that described in the previous section, except for the following changes: 
1) for the “untreated” controls, wells were pre-treated with OptiMEM only; 2) a 
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mock transfection condition was also included (see section 2.9.1); 3) cells were 
seeded at a density of 100 000 per well into 24-well tissue culture plates; and 4) cells 
were lysed at 44 and 68 h post transfection. PrPC levels in the treated samples were 
expressed as percentages of the “untreated” control level. To investigate the duration 
of PrPC knockdown when using 15 nM siRNA concentrations, a further experiment 
was performed. The method was the same as described above, except that cells were 
initially seeded at a density of 16000 per well into standard growth medium, 
prepared as described in section 2.2, and mock-transfected or siRNA s72190-
transfected cells were not included in the experiment. Cells were lysed at 4, 5, 6 or 7 
days post transfection. At each time point, PrPC expression in the siRNA 
s72188-transfected cells was expressed as a percentage of the expression level in 
negative control siRNA-transfected cells.   
2.9.4 Assessing the impact of PrPC knockdown on expression of 
other proteins  
Negative control siRNA 1 and PrP siRNA s72188 stocks were diluted to 300 nM 
with OptiMEM medium. Lipofectamine RNAi Max was diluted 1:25, also in 
OptiMEM. Equal parts of these solutions were mixed and incubated for 5 min at RT 
to form siRNA-lipid complexes at 10X the desired final concentrations. T25 tissue 
culture flasks were pre-treated with the complexes. Additional flasks were pre-treated 
with the same volume of pure OptiMEM in order to provide “untreated” controls. 
SH-SY5Y cells growing in culture were detached from flasks and pelleted as 
described in section 2.2.1. Pelleted cells were resuspended in growth medium lacking 
antibiotics and were added to the flasks, on top of the siRNA-lipid complexes, at a 
density of 400 000 cells per flask. The medium was removed after 16 h incubation 
and fresh growth medium was added. 72 h post transfection, cells were subcultured 
into 6-well tissue culture plates by following the method described in section 2.2.1 – 
this step was required to equalise the culture densities when cell lines with different 
proliferation rates were being compared. Cells were lysed 24 h later as described in 
section 2.4.1 and the lysates obtained were analysed by quantitative western blotting 
as described in section 2.5. 
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2.10 Stress treatment assays 
2.10.1 General protocol 
SH-SY5Y cells growing in culture were detached from flasks and pelleted as 
described in section 2.2.1. Pelleted cells were resuspended in growth medium and 
seeded onto 96-well, black-walled, clear-bottomed, tissue culture-treated Costar 
plates at a density of 30000 per well. After 16-18 h incubation, the growth medium 
was removed and, following a wash with HBSS, was replaced with serum-free 
medium (formulated as described in section 2.9.1) that contained toxins prepared as 
described in the following section. After 24 h incubation at 37 °C, cell viability and 
either cytotoxicity or morphological changes were assessed by the methods detailed 
in later sections.  
2.10.2 Information on stress treatments 
Toxins were serially diluted initially using the same diluents as the stock solutions. 
The diluted toxins were then added to serum-free medium before treating cells. This 
was to ensure potentially cytotoxic buffers were at the same concentrations in the 
culture medium irrespective of toxin dose. Toxin buffer-only treated cells were also 
included in each assay to control for any toxicity of the buffer. Paraquat dichloride 
hydrate (PQ; Sigma-Aldrich) dilutions were prepared in HBSS, yielding a final 
HBSS concentration in the culture medium of 3.3 % (v/v). Cells were exposed in 
duplicate to 500, 1000, 1500, 2000 or 10000 µM PQ. Staurosporine (STS) and 
tunicamycin (TM), both from Streptomyces spp. (Sigma-Aldrich), were diluted in 
DMSO, yielding a final concentration of DMSO in the culture medium of 
0.5 % (v/v). Cells were exposed in duplicate to 25, 50, 75, 100 or 600 nM STS, or 1, 
5, 10 or 15 µg/ml TM.   
For serum deprivation assays, cells were incubated for 7 days in serum-free medium 
containing no toxins and also no N-2 supplement since this promotes cell survival. 
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Cell viability and morphological changes were assessed in duplicate by the methods 
detailed in the following sections at 2 h or 1, 2, 4, 6 or 7 days after serum removal.  
2.10.3 Stress treatments incorporating siRNA transfection  
96-well, black-walled, clear-bottomed, tissue culture-treated Costar plates were 
pre-treated in duplicate with siRNA-lipid complexes that had been prepared as 
described in section 2.9.4, except that the final siRNA concentration was 5 nM not 
15 nM. Some wells were pre-treated with the same volume of pure OptiMEM to 
provide an “untreated” control. SH-SY5Y cells growing in culture were detached 
from flasks and pelleted as described in section 2.2.1. Pelleted cells were 
resuspended in growth medium lacking antibiotics and were added to the plates, on 
top of the siRNA-lipid complexes, at a density of 30000 per well. After 16-18 h 
incubation the growth medium was removed and, following a wash with HBSS, was 
replaced with 100 µl per well serum-free medium. 44 h after initially seeding the 
plates, 25 µl per well of serum-free medium containing PQ or STS were added on 
top of the medium already present. Final PQ and STS concentrations were 1000 µM 
and 50 nM, respectively. Concentrations of the original toxin buffers were as 
described in section 2.10.2. After 24 h incubation at 37 °C, cell viability and 
cytotoxicity were assessed by the methods detailed in the following sections.  
2.10.4 Lactate dehydrogenase cytotoxicity assays 
Lactate dehydrogenase (LDH) assays were carried out following PQ and STS 
treatments only. The LDH cytotoxicity kit II from Abcam was used. After 24 h toxin 
incubation the plate was shaken gently to ensure even distribution of LDH in the 
culture medium. The plate was centrifuged at 600 x g for 10 min to precipitate any 
floating cells on the well bottoms. Meanwhile, the kit-supplied substrate mix 
containing water-soluble tetrazolium salt 1 was reconstituted at 135 mg/ml in Milli-Q 
H2O. The LDH reaction mix was prepared by adding 50 parts LDH assay buffer to 
1 part water-soluble tetrazolium salt 1 substrate mix. 10 µl culture medium from each 
well was added to 100 µl LDH reaction mix. Reactions were prepared in an optically 
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clear 96-well plate. After mixing on a plate shaker, the plates were incubated at RT. 
Absorbance values were measured using a Wallac 1420 plate reader. The reference 
background absorbance at 620 nm was subtracted from the absorbance at 450 nm. 
The incubation time depended upon the reaction speed – absorbance values were 
measured periodically until either the 100 % cytotoxicity control samples had 
reached an absorbance at 450 nm of ~2.0 or the incubation time had exceeded 90 
min. The 100 % cytotoxicity controls were medium samples from cells treated with 
either 10000 µM PQ or 600 nM STS, depending on the assay. These toxin 
concentrations had been shown previously to result in 0 % viability as measured by 
the assay described in the following section. Cells treated only with the buffer were 
considered to be 0 % cytotoxicity controls. Percentage cytotoxicity values following 
toxin treatment were determined using these controls.  
2.10.5 Cell viability assays using PrestoBlue 
PrestoBlue viability assays were carried out after all four stress treatments. 1 part 
PrestoBlue (Thermo Fisher Scientific) was added to 10 parts culture medium for all 
cell-containing wells and serum-free medium-only control wells. Plates were placed 
on a shaker for 30 s to mix before incubation at 37 °C for 1 h. If fluorescence 
measurements could not be made immediately then reactions were stopped by adding 
SDS to 3 % (w/v) final concentration and the plates were stored in the dark at 4 °C 
until ready. Fluorescence readings were taken using a Fluostar Optima plate reader 
(BMG Labtech) with 550/10 nm excitation and 580/10 nm emission filters. The 
mean signal from serum-free medium was subtracted from the signals from the other 
wells. For toxin treatment assays, cells treated with only the toxin buffer were 
considered 100 % viable. Percentage viability values following toxin exposure were 
determined using these controls. For serum deprivation assays, background-corrected 
signals from the 1, 2, 4, 6 and 7 day time points were divided through by the 2 h time 
point signals. This was to correct for any small differences among the cell lines 
tested in terms of cell densities after serum deprivation and/or their efficiency at 
reducing PrestoBlue. At each time point from day 1 onwards, the mean corrected 
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signal from wells containing SH-SY5YUntr was set to 100 and the corrected data for 
the other cell lines were normalised accordingly.  
2.10.6 Capturing phase contrast images of cells after stress treatment 
For tunicamycin treatment and serum deprivation, phase contrast images of the cells 
were taken in place of the LDH assay. Cell plating and stress treatments were as 
described in section 2.10.1, except for the following changes: 1) cells were plated at 
a density of 100 000 cells per well into 24-well tissue culture plates; and 2) media 
were prepared using a DMEM formulation lacking phenol red (Thermo Fisher 
Scientific). Phase contrast images were taken using a Zeiss Axiovert inverted 
microscope at the same time points as for the viability assays. Cells were imaged live 
in their culture medium. Image capture was the same as described in section 2.7.3 for 
widefield fluorescence imaging.   
2.11 Proliferation assays 
2.11.1 Monitoring proliferation using PrestoBlue  
SH-SY5Y cells growing in culture were detached from flasks and pelleted as 
described in section 2.2.1. Pelleted cells were resuspended in growth medium and 
seeded into 96-well, black-walled, clear-bottomed, tissue culture-treated Costar 
plates at a density of 2500 per well. Over the following 7 days, cell numbers were 
assessed in duplicate at 24 h intervals using the PrestoBlue viability reagent. The 
method was as described in section 2.10.5. At each time point, the mean fluorescence 
signal from medium-only wells was subtracted from the signals from the cell-
containing wells. The mean signal from the wells containing the slowest growing cell 
line (PrPC-transfected clone 1G3) was set to 100 and signals from other wells were 
normalised accordingly.  
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2.11.2 Monitoring proliferation using nuclear staining and counting 
SH-SY5Y cells growing in culture were detached from flasks and pelleted as 
described in section 2.2.1. Pelleted cells were resuspended in growth medium lacking 
phenol red and seeded in duplicate onto 12-well tissue culture plates at a density of 
27000 per well. At 16 h or 4 days after plating, phenol red-negative growth medium 
containing 12.5 µg/ml Hoescht 33342 nuclear stain (Thermo Fisher Scientific) was 
added to cell-containing wells, giving a final concentration of 2.5 µg/ml. Cells were 
incubated in the dark at 37 °C for 20 min. Widefield fluorescence imaging was 
performed immediately afterwards according to the method described in section 
2.7.3. Three images per well were taken using the 5X objective. To control for the 
tendency of SH-SY5Y cells to congregate towards the well centre, images were 
always taken one field of view in from the well wall. Image files were converted to 
8-bit TIFFs within ImageJ and nuclei were distinguished from background using the 
“adjust threshold” function. A plug-in macro was used to count the number of nuclei 
present and measure their size. Since SH-SY5Y cells are prone to clumping, one 
image was examined manually and ~10 clumps of cells were matched to the 
corresponding “objects” identified by the macro. An average cell size was calculated 
from these clumps, allowing automated estimation of the number of cells in 
different-sized clumps. For both time points, the mean cell number per image for the 
slowest growing cell line (PrPC-transfected clone 1G3) was set to 100 and cell 
numbers for the other cell lines were normalised accordingly.  
2.11.3 Proliferation assays incorporating siRNA transfection 
The assay format described in the previous section was modified as follows to 
investigate how PrPC knockdown affected proliferation: 1) plates were pre-treated 
with siRNA-lipid complexes prepared as described in section 2.9.4; and 2) cells were 
cultured in growth medium lacking antibiotics. The mean fluorescence signal from 
the negative control siRNA-transfected cells was set to 100. The data from PrP 
siRNA s72188-transfected cells were normalised accordingly.  
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2.12 Nerve growth factor stimulation of SH-SY5Y cells 
SH-SY5Y cells growing in culture were detached from flasks and pelleted as 
described in section 2.2.1. Pelleted cells were resuspended in growth medium and 
seeded onto 6-well tissue culture plates at a density of 500 000 cells/ml. After 24 h 
incubation the growth medium was removed and, following a wash with HBSS, was 
replaced with serum-free medium (formulated as described in section 2.9.1). Cells 
were incubated in the serum-free medium for 3.5 h to allow growth factor-activated 
pathways to return to baseline activity levels. NGF was serially diluted in serum-free 
medium from a 100 µg/ml stock to give solutions containing 5X the desired final 
concentrations of 3, 10, 30 and 100 ng/ml. Subsequently, the NGF solutions were 
added to the appropriate wells in duplicate. Following 5 min stimulations, cells were 
lysed as described in section 2.4.1 and the lysates obtained were analysed by 
quantitative western blotting as described in section 2.5.  
2.13 Proteomic analyses of SH-SY5Y cell lysates 
2.13.1 Cell lysis for proteomic analysis 
Instead of lysing directly in the flasks, cells were detached and pelleted before lysis 
to allow samples with higher total protein concentrations to be prepared. Cells were 
detached and pelleted as described in section 2.2.1, except that soybean tryspin 
inhibitor (Sigma-Aldrich) was used for trypsin neutralisation if the cells had been 
cultured in serum-free medium i.e. during toxin exposure. The pelleted cells were 
gently resuspended in HBSS before further centrifugation at 200-300 x g for 10 min 
at RT. The supernatant was removed and cells were gently resuspended in 1 ml 
HBSS before transfer to low protein-binding microcentrifuge tubes (used for all 
subsequent steps). After a further spin at 200-300 x g for 10 min at RT, the 
supernatant was again removed. Cells were resuspended in freshly prepared urea 
lysis buffer (8 M urea, 0.1 % (w/v) SDS, 50 mM HEPES in HPLC quality H2O, 
pH 8.0) at a ratio of 7 volumes of buffer to 1 volume of cell pellet. Lysates were 
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vortexed and pipetted up and down vigorously to ensure total cell lysis prior to 
incubation at RT for 15 min. Lysates were subjected to multiple ~40 s pulses of 
sonication (on ice) until they were no longer viscous and were then centrifuged at 
16100 x g for 15 min at RT. The supernatants were removed and the total protein 
concentrations were determined by BCA assay as described in section 2.4.5. The cell 
lysates were then snap frozen and stored at -80 °C for later processing.  
2.13.2 Protein digestion, dimethyl-labelling and liquid 
chromatography-tandem mass spectrometry  
All steps in this section were carried out by staff at the Proteomics and Metabolomics 
Facility in Roslin, specifically Dr Dominic Kurian. Firstly, 100 µg of each sample 
were digested with Lys-C protease and subsequently by trypsin following standard 
methods of in-solution digestion. Stable isotopic reductive dimethylation of the 
resulting peptides was performed using Sep-Pak columns (Waters Corporation) by 
following standard methods (Boersema et al., 2009). The peptides were acidified by 
addition of trifluoroacetic acid to 0.1 % (v/v) concentration before loading onto 
conditioned Sep-Pak columns. Peptides from SH-SY5YUntr and stably transfected 
clones were labelled with ‘light’ and ‘heavy’ labelling reagents, respectively. The 
‘light’ buffer consisted of 0.8 % (w/v) formaldehyde and 0.12 M sodium 
cyanoborohydride carrying hydrogens in their natural isotopic distributions in MES 
buffer. The ‘heavy’ buffer consisted of 0.8 % (w/v) deuterated formaldehyde and 
0.12 M sodium cyanoborohydride in MES buffer. The loaded peptides were labelled 
by passing the respective labelling reagents through the columns five times. The 
peptides were washed and eluted with 0.1 % (v/v) trifluoroacetic acid in 70 % (v/v) 
acetonitrile. The eluted peptides were concentrated using a speed vacuum 
concentrator. The labelled ‘light’ and ‘heavy’ peptides were mixed together before 
fractionation by strong cation exchange chromatography on a Polysulphoethyl A 
column (PolyLC Inc USA). Fractions were desalted on Stage-Tip columns 
(Rappsilber et al., 2007). Each fraction of peptides was loaded onto an Acclaim 
PepMap100, C18, 3 μm, 100 Å, 75 μm (internal diameter) × 50 cm column (Thermo 
Fisher Scientific) using an UltiMate RSLCnano LC System (Dionex). Peptides eluted 
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by reverse phase chromatography were analysed by a micrOTOF-Q II mass 
spectrometer (Bruker) that was operated in data-dependent mode, automatically 
switching between MS and MS2 mode. The m/z values of tryptic peptides were 
measured using a MS scan (300-2000 m/z), followed by MS/MS scans of the six 
most intense peaks. Rolling collision energy for fragmentation was selected based on 
the precursor ion mass and a dynamic exclusion was applied for 60 s.  
2.13.3 Processing of raw mass spectral data 
Dr Dominic Kurian processed the raw spectral data using DataAnalysis software 
(Bruker) and the resulting peaklists were searched using the Mascot 2.4 server 
(Matrix Science) against the Uniprot human protein sequence database, which 
contained 89,796 entries at that time. Mass tolerance on peptide precursor ions was 
fixed at 25 ppm and on fragment ions at 0.1 Da. The peptide charge states were set as 
2+ and 3+. Carbamidomethylation of cystein was used as a fixed modification and 
oxidation of methionine and light and heavy dimethylation of N-terminus and lysine 
were chosen as variable modifications. The false discovery rate for peptide IDs was 
limited to < 1 % after searching decoy databases. Dimethyl quantification was 
performed using the WARP-LC 1.3 plug-in to the ProteinScape 3.1 software (Bruker) 
to integrate the extracted chromatograms of every precursor ion. Peptide ratios were 
normalised by setting the overall median of the peptide ratios to one, thereby 
correcting for unequal protein sampling. For each identified protein, ProteinScape 
calculated its overall expression ratio by converting the associated individual peptide 
ratios into the log scale and then determining the antilog of the median of those 
values. The software also calculated percentage coefficients of variation (%CV) 
based on these log-transformed peptide ratios.  
2.14 Analyses of publically available microarray data 
The GeneAtlas GNF1M and U133a microarray datasets, both originally reported by 
Su et al. (2004), were accessed using the BioGPS gene annotation portal (Wu et al., 
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2016) on 20-Nov-2015. The datasets contained baseline gene expression data from 
61 young adult mouse tissues (2-3 months of age) and 79 human tissues, 
respectively. The BioGPS correlation tool was used to select genes with similar 
expression patterns to PRNP (Pearson correlation coefficient > 0.75). The filtered 
datasets were analysed using Qiagen’s Ingenuity Pathway Analysis (IPA) software, 
as described below.    
2.15 Overall summary of data analysis and statistics 
For proteomic experiments, data output from the ProteinScape software was filtered 
to exclude proteins with expression ratios determined from < 3 unique peptides, since 
these ratios were considered unreliable. Next, fold change thresholds were applied to 
select proteins with high confidence of differential expression between the samples. 
The criteria used for these filtering processes are explained in detail in Chapter 4. 
Pathway analyses of the proteomic datasets were performed using the IPA core 
analysis suite. The software was set to use all available data sources and to consider 
only experimentally confirmed interactions between proteins, both direct and 
indirect. The network analysis settings were 35 molecules per network and 10 
networks per analysis (if possible), with endogenous chemicals not included within 
the networks. The same settings were applied when analysing the filtered microarray 
datasets using IPA.    
For all other quantitative experiments (western blotting, viability assays, cytotoxicity 
assays and proliferation assays), summary graphs showing the arithmetic mean 
values (+/- standard error of the mean) from multiple independent experiments or 
multiple biologically independent samples were prepared using Microsoft Excel. 
Statistical analyses of such data were also performed in Excel. Differences between 
groups were tested for significance (p < 0.05) using one- or two-sample t-tests as 
appropriate. In all cases the unpaired form of the two-sample t-test (not assuming 
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3.1 Introduction 
The aim of my project has been to investigate the molecular mechanisms regulated 
by PrPC to improve understanding of its physiological role. Initial studies of PrPC 
function focused on PrPC-knockout mice, which were produced independently by 
several laboratories. No clear developmental or behavioural alterations were 
identified at first (Bueler et al., 1992; Manson et al., 1994) but more recent work has 
identified various abnormalities in these mice (Tobler et al., 1996; Miele et al., 2002; 
Sakurai-Yamashita et al., 2005; Bremer et al., 2010; Strom et al., 2011; Rial et al., 
2014). Analysing PrPC function by studying knockout mice is useful for identifying 
the downstream consequences of a lack of PrPC expression but the underlying 
molecular mechanisms are more easily investigated in vitro. Given that PrPC is 
highly expressed in the nervous system (Sales et al., 2002; Adle-Biassette et al., 
2006), one option for investigating PrPC function in vitro is to isolate primary 
neurons from embryonic mice. Since primary neurons retain many of their in vivo 
characteristics, they can be considered more physiologically relevant than cell lines, 
which either have a cancerous origin or were artificially immortalised after isolation. 
However, there are a number of caveats associated with the use of primary cells. 
Firstly, each time primary cells are isolated, the resulting cultures will differ slightly, 
whereas cell lines can be cryopreserved, allowing repeated study of cells at similar 
passage numbers. Secondly, compensatory mechanisms active during the 
development of PrPC-null mice might complicate analysis of PrPC function in 
primary neurons. As an alternative, genetic manipulations such as PrPC 
overexpression, knockout or knockdown can be performed in culture instead but 
primary cells are relatively difficult to transfect using standard methods (Karra and 
Dahm, 2010). Finally, culturing of mammalian primary neurons can be problematic 
due to their sensitivity to “physical stress, alterations in temperature, pH shifts, or 
changes in osmolarity” (Karra and Dahm, 2010). For the above reasons, we decided 
to use a well-characterised cell line called SH-SY5Y for investigating PrPC function 
in vitro – background information on these cells is provided in the following section. 
My first steps using the SH-SY5Y cells were to generate monoclonal lines that stably 
expressed PrPC. Although polyclonal cultures can be obtained more quickly, their 
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behaviour can change over time as rapidly proliferating cells outgrow those that 
proliferate slower. Monoclonal lines, on the other hand, should remain stable, at least 
in the short term. Having isolated several stably transfected clones, initial 
characterisation work consisted of assessing the level and localisation of PrPC 
expression and determining whether PrPC transfection had any impact on cell 
morphology. 
3.1.1 Background on SH-SY5Y neuroblastoma cells 
The parental cell line of SH-SY5Y is SK-N-SH, which was itself derived in 1970 
from a bone marrow biopsy taken from a 4-year-old female patient with metastatic 
neuroblastoma (Biedler et al., 1973) – this rare form of cancer arises from an element 
of the sympathetic nervous system and mainly affects young children (Cheung and 
Dyer, 2013). SK-N-SH cultures reportedly consist of two distinct, co-existing types 
of cell with either neuroblast-like or epithelial-like morphologies (Biedler et al., 
1973). Subcloning of SK-N-SH led to the creation of the SH-SY5Y cell line, which 
was originally reported to consist entirely of neuroblast-like cells that extend short, 
neurite-like processes (Biedler et al., 1978; Encinas et al., 2000). More recently, 
however, it has been recognised that SH-SY5Y cultures also contain a low proportion 
of “S-type” cells in addition to the neuroblast-like cells that are known as “N-type” 
(Encinas et al., 2000). The S-type cells are so-named due to their increased substrate-
adherence; therefore, these cells are selected against when subculturing because they 
tend to remain attached to the previous culture vessel (Encinas et al., 2000).  
SH-SY5Y cells in standard culture are reported to show characteristics of immature 
catecholaminergic neurons (Kovalevich and Langford, 2013) – catecholamines 
include the neurotransmitters dopamine and noradrenalin. This feature of the 
SH-SY5Y cell line has led to its widespread adoption as a model for Parkinson’s 
disease (Xicoy et al., 2017), which is characterised by loss of dopaminergic neurons 
within the substantia nigra of the brain. SH-SY5Y cells can be further differentiated 
towards a mature dopaminergic phenotype by treating first with retinoic acid and 
then with the phorbol ester 12-O-tetradecanoyl phorbol-13 actetate (Xicoy et al., 
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2017). Researchers have also developed other differentiation protocols that drive the 
cells towards alternative mature neuronal phenotypes; for instance, exposure solely 
to 12-O-tetradecanoyl phorbol-13 actetate seems to promote differentiation into a 
noradrenergic/adrenergic neuronal population (Pahlman et al., 1981), whilst 
treatment purely with retinoic acid appears to induce a cholinergic phenotype 
(Presgraves et al., 2004). Furthermore, sequentially exposing SH-SY5Y cells to 
retinoic acid and then brain-derived neurotrophic factor may prevent the S-type cells 
overgrowing the neuronal cells, a problem that seems affect cultures differentiated 
with retinoic acid alone (Encinas et al., 2000). Other, more advanced cell culture 
approaches have also been taken, such as growing the cells in an extracellular matrix 
gel and inducing differentiation by treating with a cocktail of growth factors 
consisting of brain-derived neurotrophic factor, neuregulin, nerve growth factor and 
vitamin D3 (Agholme et al., 2010).         
As will always be the case for tumour-derived cell lines, SH-SY5Y cells display 
several chromosomal abnormalities, including chromosome 7 trisomy and 
duplication of the short arm of chromosome 1 (Yusuf et al., 2013). In addition to the 
main karyotype, there appears to be a sideline karyotype that becomes more 
prevalent with increasing passage number (Yusuf et al., 2013) – this could reflect 
accumulation of the rarer S-type cells and suggests that the phenotype of the cell line 
may not remain stable over prolonged periods in culture.      
Unlike most neuron-like cells, SH-SY5Y cells lack detectable PrPC expression 
(Perera and Hooper, 1999), which means that the effects of introducing PrPC into the 
cells can be studied without any meaningful interference from endogenously 
expressed PrPC. As a consequence, this cell line has been used extensively to 
investigate PrPC function (Watt et al., 2005; Parkin et al., 2007; Watt et al., 2007; 
Dupiereux et al., 2008; Rambold et al., 2008; Wang et al., 2009; Weiss et al., 2010; 
Bravard et al., 2015). All of these cited studies solely used the undifferentiated form 
of the cell line in their reported experiments.     
Chapter 3: Production and characterisation of stable, 
PrPC-expressing, monoclonal cell lines  69 
3.2 Production of stable, PrPC-expressing, monoclonal 
SH-SY5Y cell lines  
The entire murine Prnp coding sequence (CDS) (NCBI ref: NM_011170.3; Prnpa 
allele) was amplified by polymerase chain reaction (PCR) from genomic DNA before 
being inserted into the pCI-neo mammalian expression vector between the EcoRI and 
SalI sites of its multiple cloning region. This vector contains a cytomegalovirus 
immediate-early enhancer/promoter element that drives constitutive expression of 
inserted transgenes in most cell types (Promega, 2009). Figure 3.1a shows this and 
other features of the vector in diagrammatic form, whilst Figure 3.1b & c show the 
sequence of the multiple cloning region before and after insertion of the Prnp CDS. 
The “CACC” between the EcoRI site and the start codon in the final construct 
provided a “Kozak” consensus sequence to ensure efficient ribosome binding of the 
mRNA.  
Agarose gel electrophoresis of the expression construct confirmed that it contained 
extra DNA, since it migrated more slowly than the empty vector (Figure 3.2a). After 
transformation with the recombinant vector, XL-1 Blue E.coli were cultured 
overnight and eight of the resulting colonies were tested for presence of the transgene 
by colony PCR. Primers designed to bind to vector sequences flanking the inserted 
DNA were used to ensure the Prnp CDS was correctly orientated. Figure 3.2b 
confirms that DNA fragments matching the expected length of ~840 base pairs (bp) 
could be amplified by PCR from six of the eight colonies. Plasmid DNA containing 
the transgene was isolated from the six colonies for sequencing, which was 
performed in both directions to improve accuracy. Although the inserted DNA 
exactly matched the murine Prnp CDS for five of the six clones, the best quality 
sequencing data was obtained from clone 4. Therefore, this clone, hereafter referred 
to as pCI-neo-MoPrnp, was chosen for transfection into the SH-SY5Y cells.  
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B) Multiple cloning region of empty vector 
 
 





Figure 3.1 – Generating the pCI-neo-MoPrnp expression construct 
A) Diagram showing the various features of the pCI-neo vector (base pair-numbering shown 
in brackets). Expression of sequences inserted into the multiple coding region is driven by a 
cytomegalovirus (CMV) immediate-early (I.E) enhancer/promoter. B) The multiple cloning 
region sequence of pCI-neo highlighting the EcoRI and SalI sites used for insertion of the 
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Prnp CDS. C) The multiple cloning region sequence after insertion of the Prnp CDS. Vector 
sequence is coloured in grey; the insert is in black. The Prnp CDS covered bases 1106-1870 
of the sense strand of the pCI-neo-MoPrnp construct and the start and stop codons are 
underlined in the diagram.   
 














pCI-neo carries a resistance gene against the antibiotic G-418, which enabled 
selection for cells that had stably integrated the vector into their genome. Firstly 
though, I needed to determine the optimum G-418 dose for selection. Therefore, 
Figure 3.2 – Successful insertion of Prnp coding sequence into pCI-neo 
vector 
A) Agarose gel electrophoresis of the pCI-neo vector before and after insertion of the Prnp 
CDS. The recombinant vector (RV) band migrated slower than the empty vector (EV) band 
due to the inserted DNA fragment. Because the vectors are supercoiled, whereas the 
ladder consists of linear DNA fragments, the bp sizes given should not be taken as exact. 
B) Agarose gel electrophoresis of PCRs to confirm that the E.coli colonies obtained after 
transformation with the recombinant vector contained the Prnp CDS. DNA fragments of the 
expected size (around 840 bp) were amplified from six out of the eight colonies tested. The 
other colonies may have been transformed with empty vector that had re-ligated after 





Chapter 3: Production and characterisation of stable, 
PrPC-expressing, monoclonal cell lines  72 
cultured SH-SY5Y cells were exposed to G-418 concentrations between 100 and 
1200 µg/ml over a 12-day period. Cell viability was monitored by observation under 
a light microscope. 400 µg/ml G-418 was the lowest dose to cause total cell death 
within the assay time period but, in order to control for batch-to-batch variation in 
G-418 activity, a slightly higher dose of 500 µg/ml was chosen for selection of stable 
transfectants. 
pCI-neo-MoPrnp was transfected into SH-SY5Y cells using Lipofectamine LTx. 
Several transfection reactions were set up using dilutions of Lipofectamine LTx stock 
between 1:200 and 1:500. After 6 hours, the transfected cells were pooled and 
allowed to recover for a further 72 hours before addition of G-418. Significant cell 
death was observed over the next few days due to loss of the vector. However, after a 
week of G-418 selection, colonies of stably transfected cells were visible and this 
polyclonal culture was maintained until 3 weeks post transfection. At this point, PrPC 
expression was assessed by immunofluorescence microscopy using the 6H4 anti-PrP 
primary antibody from Thermo Fisher Scientific. PrPC staining of varying intensity 
was visible in most cells in the transfected culture (Figure 3.3a) and the staining was 
often punctate, which may have been caused by PrPC aggregation due to 
overexpression or, alternatively, may have been an artefact of permeabilising the 
cells with Triton X-100. As expected, no PrPC expression could be detected in 
untransfected SH-SY5Y cells that had been cultured alongside the transfected cells 
(Figure 3.3b). 
 
Polyclonal, PrPC-transfected SH-SY5Y cells were serially diluted in a 96-well tissue 
culture plate so that some wells contained just a single cell. 4 days later, wells 
containing a single colony of fewer than eight cells were assumed to have contained 
a single cell at plating. Monoclonal lines were derived from these wells and were 
cultured over the next few weeks until they had expanded sufficiently for frozen 
stocks to be prepared. This was achieved for nine clones; several others were 
discarded due to extremely slow rates of proliferation. Subsequently, six clones were 
assayed for PrPC expression by seeding the cells into tissue culture plates, lysing 24 
hours later and then analysing by western blotting using the BC6 anti-PrPC primary 
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antibody (McCutcheon et al., 2014). Based on a single replicate, quantification of 
PrPC immunostaining appeared to separate the clones into a group of four high-
expressors and a group of two low-expressors (Figure 3.4). I decided to select two 
clones with high expression (1G3 and 1F3) and two with lower expression (2E3 and 




Figure 3.3 – Polyclonal, transfected SH-SY5Y cells express PrPC 
Widefield fluorescence images of fixed, Triton-permeabilised, untransfected (A) or PrPC-
transfected (B) SH-SY5Y cells taken using a x10 objective. Nuclei were stained with DAPI and 
are shown in blue. PrPC was detected by use of the 6H4 anti-PrPC primary antibody (Thermo 
Fisher Scientific #7500996) and is shown in red. The scale bar shown applies to both panels. 
Camera exposure settings were the same for both images. PrPC staining was absent in 
untransfected cells but was detectable in most transfected cells. Staining intensity varied 
among the transfected cells, suggesting that different cells expressed different amounts of 
PrPC.   
 
Frozen stocks were also prepared from the untransfected cells that had been cultured 
alongside the transfected cells. These cells, subsequently referred to as SH-SY5YUntr, 
were used in all experiments involving the transfected cells to provide a control 
A)                                                              B)   
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Figure 3.4 - Initial assessment of PrPC expression in stably transfected clones 
A) Fluorescent western blot image showing PrPC immunostaining in a mouse brain 
homogenate and in cell lysates from stably transfected clones. PrPC was detected by use of 
the BC6 anti-PrPC primary antibody (McCutcheon et al., 2014). B) Table summarising 
quantification data from the western blot. For each lane, the entire band pattern shown 
was included when calculating staining intensity. After correcting for loading errors, signals 
were normalised to the signal from the brain homogenate.   
population approximately matched in terms of weeks in culture. Since SH-SY5YUntr 
could not be cultured in the presence of G-418, the selection antibiotic was removed 
from transfected cultures at least 48 h before an experiment. 
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3.3 Characterisation of stably transfected SH-SY5Y clones  
3.3.1 Similar level of PrPC expression among clones analysed  
Before using the stably transfected clones to investigate PrPC function, I needed to 
specifically determine the magnitude and localisation of their PrPC expression. The 
levels of PrPC in clones 2E3, 1B5, 1G3 and 1F3 had previously been estimated by 
western blotting of a single set of cell lysates (Figure 3.4); however, to improve the 
accuracies of these estimates, three more sets of cell lysates were prepared and 
analysed by western blotting. The experimental format was the same as before – the 
stably transfected clones were seeded into tissue culture plates and lysed 24 hours 
later. The results from these experiments4 showed that, on average, all four clones 
expressed similar amounts of PrPC (Figure 3.5), whilst the mean expression level 
among the clones was around four times that of mouse forebrain (C3H strain). Given 
that brain tissue contains multiple cell types and that neurons reportedly express 
more PrPC than glial cells (Witusik et al., 2007), PrPC expression by the stably 
transfected clones was probably at a physiologically relevant level for a neuronal 
cell. These results conflict with those shown in Figure 3.4, which suggested that 
clones 1G3 and 1F3 expressed more PrPC than 2E3 and 1B5. One explanation is that 
the Figure 3.4 data derived from a single biological replicate and is, therefore, less 
reliable. However, the data shown in Figure 3.4 was an early assessment of PrPC 
expression, whereas the Figure 3.5 data includes analyses of cells that had spent 
several more weeks in culture. Therefore, it may be that there was an initial period of 
instability in PrPC expression followed by normalisation to a level of expression that 
was similar in all clones.   
Figure 3.5a demonstrates in diagrammatic form the PrPC immunostaining pattern that 
would be expected from brain tissue: a strong band corresponding to di-glycosylated, 
full length PrPC at ~33 kDa; fainter bands at ~29 and ~26 kDa for mono- and 
                                                 
4 Note that Figure 3.5c summarises data from all four independently prepared sets of cell lysates i.e. 
including the single set that was used to obtain the data for Figure 3.4.  
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un-glycosylated, full length PrPC, respectively; and, potentially, further faint bands at 
~23, 19 and 16 kDa representing the different glycoforms of the C1 fragment.  
  












Figure 3.5 – Stably transfected clones expressed similar levels of PrPC 
A) Diagrammatic representation of the typical PrPC immunostaining pattern obtained from 
brain tissue, showing the approximate molecular weights of the di-, mono- and un-
glycosylated forms of full length (FL) PrPC and the C1 fragment. B) PrPC expression was 
assessed by western blotting of four independently prepared sets of cell lysates. A 
representative blot image is shown. PrPC was detected by use of the BC6 anti-PrPC primary 
antibody (McCutcheon et al., 2014). “Brain” = mouse forebrain homogenate; “Untr” = 
SH-SY5YUntr. For each lane, staining intensity was calculated from the entire band pattern 
shown except for the band at around 50 kDa in the mouse brain lane, which was thought to 
be non-specific. C) Bar chart summarising PrPC quantification data from the western blotting 
experiments. For each membrane, after correction for loading errors, signals from the 
clones were normalised to the brain homogenate signal. The mean normalised expression 
values (+/- standard error of the mean) are displayed in the bar chart.  
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Figure 3.5b shows that, whilst the mouse forebrain homogenate approximately 
displayed this expected band pattern, the bands obtained from the lysates of the 
stably transfected clones were shifted to higher apparent molecular weights. One 
hypothesis for this was altered glycosylation, which was investigated by digesting a 
clone 2E3 cell lysate with peptide-N-glycosidase F (PNGase F), an enzyme that 
removes N-linked glycans from glycoproteins (Gates et al., 2004). Both 
oligosaccharides linked to the PrPC C-terminal domain are susceptible to this 
enzyme, although the GPI anchor is not removed. Following PNGase F treatment, 
western blotting for PrPC revealed two strong bands at ~17 and 26 kDa in the brain 
homogenate and cell lysate lanes (Figure 3.6). These bands correspond to the un-
glycosylated forms of C1 and full length PrPC, respectively, whilst the very faint 
bands in between may be due to incomplete PNGase F digestion. In conclusion, these 
results confirmed that the abnormal SDS-PAGE migration of the transgenic PrPC 






Figure 3.6 – Differential PrPC glycosylation explains altered SDS-PAGE 
migration 
Fluorescent western blot image comparing PrPC immunostaining patterns obtained from 
PNGase F-treated and mock-treated cell and tissue lysates. PrPC was detected by use of the 
BC6 anti-PrPC primary antibody (McCutcheon et al., 2014). Labels are as follows: 1 = mouse 
brain homogenate, mock treatment; 2 = SH-SY5Y clone 2E3, mock treatment; 3 = mouse 
brain homogenate, PNGase treatment; 4 = clone 2E3, PNGase treatment. For mock 
treatments, buffer components were the same but PNGase F was not included. PrPC band 
patterns from brain and clone 2E3 samples were virtually identical after PNGase F digestion 
of N-glycans.   
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Glycan intermediates are generated in the ER before being attached to newly-
synthesised proteins. Subsequent modifications of these glycans occur partly in the 
ER but mainly in the Golgi (Gates et al., 2004). Therefore, altered expression 
compared to brain of the transferases that carry out these modifications could explain 
the increased size of the glycans on the transgenic PrPC. Such alterations to 
glycosylation are reported to occur frequently in cell lines but are thought to have 
few biological consequences (Varki and Lowe, 2009). Aside from the differences in 
glycan size, the majority of PrPC expressed by the stably transfected clones was 
di-glycosylated as was the case in mouse forebrain.  
 
The glycans attached to forebrain PrPC increased its apparent molecular weight by 
~7 kDa, whilst those on the transgenic PrPC expressed by clone 2E3 added 10-
11 kDa. Interestingly, a band that could have been mono-glycosylated C1 was 
observed at the expected apparent molecular weight of ~19 kDa in the clone 2E3 
lysate that had not been digested with PNGase F (Figure 3.6, lane 2). Assuming that 
the relatively strong band at 28/29 kDa, also in lane 2, corresponds to di-glycosylated 
C1 then it is possible that only one of the glycans was larger than normal.   
 
As mentioned above, PNGase F digestion confirmed that the C1 fragment was 
present in clone 2E3. Furthermore, the PrPC band patterns obtained by western 
blotting were virtually identical among the clones analysed (Figures 3.4 and 3.5), 
which indicates that alpha-cleavage of PrPC occurred in all of them. Quantification of 
the bands in Figure 3.6 revealed that C1 made up 40 % of total PrPC expressed by 
clone 2E3 compared with 28 % for the forebrain homogenate. Whilst these figures 
may not be exact since the primary antibody affinities for full length PrPC and C1 
may differ, the data certainly suggest that more PrPC was subject to alpha-cleavage in 
the transfected cells than in mouse forebrain. 
3.3.2 Similar PrPC localisation patterns among clones analysed  
After analysing PrPC expression by the stably transfected clones by western blotting, 
the subcellular distribution of PrPC staining was assessed by immunofluorescence…  
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Figure 3.7 – Stably transfected clones expressed PrPC on the cell surface 
A-E) Confocal images of fixed, non-permeabilised SH-SY5Y cells taken using a x40 objective. 
Images are maximum intensity projections from z-stacks. Nuclei were stained with DAPI and 
are shown in blue. PrPC was detected by use of the 6H4 anti-PrPC primary antibody (Thermo 
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Fisher Scientific #7500996) and is shown in green. The scale bar shown applies to all panels. 
Cell surface-associated PrPC staining is visible for all the transfected clones (A-D), whilst no 
PrPC expression was detected in SH-SY5YUntr cultures (E). Microscope settings were adjusted 
when capturing images A-D to best reveal the distribution of PrPC expression. Therefore, 
variation in staining intensity between images does not necessarily represent variation in 
PrPC expression levels. 
 
 …microscopy to check that the protein was expressed in a physiologically relevant 
location. The cells were seeded into tissue culture plates and fixed 24 hours later. No 
permeabilisation step was included prior to staining to ensure that only cell surface-
associated PrPC could be detected. Following PrP
C immunostaining and nuclear 
counterstaining, images were captured using a confocal microscope. These images 
again confirmed the lack of PrPC expression by SH-SY5YUntr (Figure 3.7e), whereas 
the clones were shown to express PrPC on the cell surface as expected (Figure 3.7a-d) 
– generally, PrPC is GPI-anchored to the extracytoplasmic face of the cell membrane 
and is concentrated in lipid rafts microdomains (Vey et al., 1996). A few individual 
cells, particularly from clone 1F3, displayed no detectable PrPC expression 
(Figure 3.7d). This is unlikely to have been due to cells clumping on top of each 
other since the images shown in Figure 3.7 are maximum intensity projections from 
z-stacks – some PrPC staining would be expected at some of the z-coordinates even if 
cells were in different planes. Therefore, it is possible that “clone” 1F3 was not 
entirely clonal i.e. some cells within the culture were expressing a very low level of 
PrPC, which was undetectable under the imaging settings used. 
After confirming that the stably transfected clones expressed PrPC at the cell surface, 
I assessed whether any intracellular PrPC was expressed. The experimental format 
was the same except that cells were methanol-permeablised after fixation to enable 
detection of intracellular epitopes by the antibody. Again, confocal z-stack images 
were acquired. High-magnification, single z-slice images hinted at the presence of 
cytoplasmic staining, although the cell-surface staining intensity was considerably 
more intense for all four clones (Figure 3.8a-d).  
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Figure 3.8 – Low levels of intracellular PrPC staining in stably transfected 
clones 
A-D) Confocal images of fixed, methanol-permeabilised SH-SY5Y cells taken using a x40 
objective. Nuclei were stained with DAPI and are shown in blue. PrPC was detected by use of 
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the 6H4 anti-PrPC primary antibody (Thermo Fisher Scientific #7500996) and is shown in 
green. The images show slices through the middle of the cells in the z-plane and single-
channel and merged versions are provided in each case. The scale bar shown applies to all 
panels. Microscope settings were adjusted when capturing each image to best reveal the 
distribution of PrPC expression. Therefore, staining intensity is not necessarily 
representative of PrPC expression level. For all clones, the highest-intensity PrPC 
immunostaining is at the cell surface but some intracellular staining is also visible.  
 
Some of the intracellular staining may have been newly synthesised PrPC in the 
process of being trafficked to the cell membrane. Another explanation is that PrPC is 
reported to undergo cycles of internalisation followed by trafficking back to the cell 
membrane via recycling endosomes (Shyng et al., 1995; Sunyach et al., 2003), which 
presumably is a mechanism to enable rapid control of the level of PrPC at the cell 
surface. 
3.3.3 Morphological differences between stably transfected clones 
and untransfected SH-SY5Y cells  
Having obtained confirmation that the majority of PrPC expressed by the stably 
transfected clones was trafficked to the cell surface as expected, I further 
characterised the PrPC-transfected cells by analysing their morphology. Once again, 
the cells were seeded into tissue culture plates and fixed 24 hours later before images 
were captured using a phase contrast microscope. These images showed that the 
morphologies of clones 2E3 and 1B5 were very similar to SH-SY5YUntr – the cells 
had the same stellate morphology with short, occasionally branching, neurite-like 
protrusions (Figure 3.9a-c). This morphology is very similar to images of SH-SY5Y 
cells that have been published in other studies (Prince and Oreland, 1997; Weiss et 
al., 2010). However, clone 1G3 was rather different in appearance to SH-SY5YUntr 
and clones 2E3 and 1B5 – adjacent cells appeared to be joined together by their 
somas and almost none of the fine, neurite-like protrusions were evident in the 
culture (Figure 3.9d).   
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Figure 3.9 – Clone-specific morphological alterations identified among the 
stably transfected clones  
A-E) Phase contrast images of fixed SH-SY5Y cells taken using a x40 objective. The scale bar 
shown applies to all panels. Clone 1G3 displayed an altered morphology compared with 
SH-SY5YUntr – the cell bodies were shaped differently and clone 1G3 cells produced almost 
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no neurite-like protrusions. Clone 1F3 exhibited some morphological changes that similar to 
clone 1G3, whereas clones 2E3 and 1B5 seemed almost identical to SH-SY5YUntr.   
 
Clone 1F3 also displayed similar morphological alterations (Figure 3.9e), although 
the changes were arguably less dramatic than those exhibited by clone 1G3. The 
variations in morphology were surprising given that the levels and localisation 
patterns of PrPC expression were similar among the clones. Consequently, it seemed 
that some factor other than PrP
C was responsible and Chapter 4 covers work that was 
carried out to address this possibility.     
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3.4 Alterations to stress responses in the stably 
transfected clones  
The previous sections reported on experiments to characterise four SH-SY5Y clones 
that stably expressed PrPC. The results showed that the clones expressed similar 
levels of PrPC and that the exogenous PrPC was mainly expressed at the cell surface, 
although some limited cytoplasmic staining was detected – this subcellular 
distribution of PrPC expression was consistent with results from other studies (Vey et 
al., 1996; Lee et al., 2001a; Nikles et al., 2008). Additionally, phase contrast imaging 
of the cells identified some as yet unexplained clone-specific morphological 
alterations compared with SH-SY5YUntr.  
The first experiments I performed using the stably transfected SH-SY5Y clones were 
to investigate the role played by PrPC in the response to stress. Arguably, stress-
protection is the function most commonly ascribed to PrPC; this is because a large 
number of studies have found that PrPC expression enhances the survival of cultured 
cells in response to toxins and other treatments that induce apoptosis (Kuwahara et 
al., 1999; Lopes et al., 2005; Roucou et al., 2005; Beraldo et al., 2010). PrPC 
expression also reportedly protects cells from damage caused by various agents that 
induce oxidative stress (Brown et al., 2002; Senator et al., 2004; Anantharam et al., 
2008; Bertuchi et al., 2012; Bravard et al., 2015). However, there are conflicting 
reports of a lack of stress protection by PrPC and some studies have even found that 
PrPC expression enhances cell death in response to stress (Paitel et al., 2004; Vassallo 
et al., 2005; Sunyach et al., 2007; Steinacker et al., 2010). Furthermore, the issues 
described in section 1.3 that affect several of the PrPC-knockout mouse lines – 
ectopic doppel expression in the brain and the problems caused by creating the lines 
on mixed genetic backgrounds – cast doubt upon the results obtained from studies of 
these mice or of cells derived from them. Consequently, the putative involvement of 
PrPC in cellular stress-protection required clarification. To achieve this, I exposed the 
stably transfected SH-SY5Y clones to a range of different stresses that broadly 
covered the spectrum of previously reported stress-protective functions of PrPC. 
Firstly, the cells were treated with the oxidative toxin paraquat dichloride (PQ). 
Chapter 3: Production and characterisation of stable, 
PrPC-expressing, monoclonal cell lines  86 
Within a cell, various enzymes convert PQ into a reduced intermediate that, in turn, 
causes the production of ROS (Senator et al., 2004). The toxin treatment protocol 
reported by Dupiereux et al. (2008) was followed – this study found that PrPC 
transfection into SH-SY5Y cells was protective against exposure to PQ. Briefly, cells 
were seeded into plates in serum-containing medium and allowed to recover for 16-
18 hours. Next, the medium was exchanged for serum-free medium containing the 
neuronal supplement N-2 and the toxin. Serum deprivation should inactivate 
receptors that are constitutively activated by growth factors present in serum, thereby 
removing potential confounding elements from an experiment. The N-2 supplement 
promotes survival of neuroblastoma cells and was included to mitigate against the 
stress caused by serum deprivation itself. Otherwise, it would have been difficult to 
separate out the impact of serum removal from that of the toxin treatment. Unlike 
serum, N-2 is chemically defined, consisting of transferrin, insulin, progesterone, 
putrescine and selenite (Thermo Fisher Scientific, [n.d.]-c). Typically, serum would 
be removed a few hours before carrying out a treatment to allow growth factor 
signalling pathways to return to baseline. However, Dupiereux et al. (2008) did not 
do this. Since we were initially attempting to replicate their results for PQ treatment 
of PrPC-expressing SH-SY5Y cells, we decided to follow their method exactly. In 
order to be consistent, the same method was also used for treatment with the other 
toxins. Following a 24-hour incubation with the toxin, cell survival in response to PQ 
was assessed by use of the PrestoBlue cell viability reagent. PrestoBlue contains the 
weakly fluorescent dye resazurin, which is converted in the reducing environment of 
the cytoplasm to the highly fluorescent resorufin (Invitrogen, 2012). This reaction 
does not take place in dead cells. Therefore, fluorescence intensity should be directly 
proportional to the number of viable cells.  
SH-SY5Y cells were exposed to PQ concentrations between 500 and 2000 µM as 
well as a higher dose of 10000 µM. The results from five independent experiments 
showed that clone 1F3 was significantly more resistant to 500 and 1000 µM PQ than 
SH-SY5YUntr (p < 0.001 in both cases; Figure 3.10a). This difference in viability was 
most marked at 500 µM (96 % viability for clone 1F3 vs 54 % for SH-SY5YUntr). 
Clone 1G3 displayed improved viability compared with SH-SY5YUntr following 
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treatment with 500 µM PQ (p < 0.001) but was slightly more sensitive than 
SH-SY5YUntr at 1500 µM (p = 0.016). Clones 2E3 and 1B5 responded similarly to 
SH-SY5YUntr, although clone 1B5 did show slightly reduced viability at 500 and 
1500 µM doses of PQ (p = 0.036 and p = 0.047, respectively). However, PQ has been 
shown previously to interfere with mitochondrial function in SH-SY5Y cells, 
probably before causing cell death (Dupiereux et al., 2008). Since nicotinamide 
adenine dinucleotide phosphate (NADH) produced by mitochondria is the main 
compound responsible for resazurin reduction, impaired mitochondrial function can 
result in lower fluorescence signals independent of any reduction in viable cell 
number. Therefore, to confirm the results obtained from the viability assays, PQ-
mediated cytotoxicity was assessed by measuring lactate dehydrogenase (LDH) 
release. Damage to the cell membrane causes LDH to leak out into the culture 
medium. Consequently, the amount of LDH activity in a sample of medium should 
be proportional the number of dead or damaged cells (Abcam, 2012). Treatment with 
10000 µM PQ resulted in approximately 0 % viability, as measured using the 
PrestoBlue reagent, for all clones and SH-SY5YUntr. This dose was used as the 100 % 
cytotoxicity control for the LDH assays. The results from four independent 
experiments showed that the differences between the stably transfected clones in 
terms of their responses to PQ exposure were generally more extreme according to 
the LDH assay than they were when assessing viability (Figure 3.10b). At all PQ 
doses tested, clones 1G3 and 1F3 displayed significantly lower levels of cytotoxicity 
than SH-SY5YUntr, whilst clones 2E3 and 1B5 did not. For example, at 2000 µM PQ, 
cytotoxicity was ~100 % for SH-SY5YUntr (and clones 2E3 and 1B5) but just 20 % 
for clone 1F3. Overall, the viability and cytotoxicity measurements obtained after PQ 
treatment were highly consistent – both assay formats ranked the transfected clones 
similarly in terms of their resistance to the toxin and percentage survival and 
percentage cytotoxicity at a particular dose of PQ generally added up to ~100 %. 
Interestingly though, cytotoxicity remained low for clones 1G3 and 1F3 even at PQ 
doses that reduced viability, as measured using the PrestoBlue reagent, to very low 
levels. 
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Figure 3.10 – Clone-specific resistance of stably transfected cells to paraquat 
treatment 
Bar charts showing viability (A) and cytotoxicity (B) of SH-SY5Y cells after 24 h exposure to a 
range of PQ concentrations. The mean values (+/- standard error of the mean) from five (A) 
or four (B) independent experiments are displayed in the bar charts. Differences between 
SH-SY5YUntr and each transfected clone were tested for significance (p < 0.05) using 
unpaired, two-sample t-tests. Key: * for p < 0.05; ** for p < 0.01; and *** for p < 0.001.  
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During routine culturing of the SH-SY5Y cells, I observed that cultures of the stably 
transfected clones seemed to have more non-adherent cells than SH-SY5YUntr 
cultures and it was difficult to determine whether these floating cells were alive or 
not. Interestingly, the American Type Culture Collection (ATCC) advise treating 
SH-SY5Y cells supplied by them as semi-adherent i.e. the monolayer and cells in 
suspension should be taken forward together when subculturing (ATCC, [n.d.]). The 
cells I used were purchased from the European Collection of Cell Cultures, which 
instead recommends subculture of purely the monolayer cells – I cultured the cells 
according to this method. However, when optimising conditions for PQ treatment, I 
performed an assay using cells that had been processed for plating as if they were 
semi-adherent. Although only SH-SY5YUntr and clone 2E3 cells were included in this 
experiment, the viability data were very similar to those obtained with cells harvested 
purely from the monolayer (data not shown). This suggests that excluding non-
adherent cells from the cultures prior to stress-exposure had little impact on the 
results obtained.   
Having assessed the responses of the SH-SY5Y cell lines to PQ treatment, the effect 
of exposing the cells to the ATP-competitive protein kinase inhibitor staurosporine 
(STS) was investigated. STS binds to many kinases with high affinity but low 
selectivity (Ruegg and Burgess, 1989; Meggio et al., 1995) and is thought to induce 
both mitochondria-dependent and mitochondria-independent apoptotic signalling 
processes (Zhang et al., 2004). Since STS is solubilised in dimethyl sulphoxide 
(DMSO), I first confirmed that presence of relatively low DMSO concentrations of 
up to 1 % (v/v) in the culture medium had no discernible impact on cell viability over 
a 24-hour period, as measured using the PrestoBlue reagent (data not shown). 
Subsequently, toxicity caused by STS concentrations between 50 and 200 nM as well 
as a higher dose of 600 nM was assessed in the same way as for PQ. Six independent 
experiments were performed and data from PrestoBlue viability assays reported in 
Figure 3.11a & b show that clones 1G3 and 1F3 were more viable than SH-SY5YUntr 
in response to 25 nM (p = 0.028 and p = 0.016, respectively) and 50 nM doses of 
STS (p = 0.020 and p = 0.044, respectively). Clone 1G3 also displayed significantly 
greater viability than SH-SY5YUntr when exposed to 100 nM STS (p = 0.049). 
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Figure 3.11 – Clone-specific resistance of stably transfected cells to 
staurosporine treatment  
See following page for legend… 
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Figure 3.11 – Clone-specific resistance of stably transfected cells to 
staurosporine treatment 
Bar charts showing viability (A & B) and cytotoxicity (C & D) of SH-SY5Y cells after 24 h 
exposure to a range of STS concentrations. The mean values (+/- standard error of the 
mean) from at least five independent experiments are displayed in the bar charts. 
Differences between SH-SY5YUntr and each transfected clone were tested for significance 
(p < 0.05) using unpaired, two-sample t-tests. Key: * for p < 0.05; ** for p < 0.01; and *** 
for p < 0.001. The first biological replicate for clones 2E3 and 1G3 was performed separately 
to the first replicate for clones 1B5 and 1F3. Therefore, the charts had to be split up to 
accommodate this data. 
 
The largest difference between PrPC-transfected and untransfected cells was 
observed following treatment of clone 1G3 with 50 nM STS (71 % viability vs 42 % 
for SH-SY5YUntr). In a similar manner to the PQ treatments, clones 2E3 and 1B5 as 
well as SH-SY5YUntr were all comparable in terms of their viability in response to 
STS. To confirm these results, measurements of cytotoxicity were again obtained by 
LDH assay. Since cell viability was ~0 % for all clones and SH-SY5YUntr following 
600 nM STS treatment, this dose was used as the 100 % cytotoxicity control for 
these experiments. Figure 3.11c & d show the data from six independent 
experiments, which indicate that percentage cytotoxicity was significantly lower for 
clone 1G3 than for SH-SY5YUntr at all STS doses tested. Any reduction in 
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cytotoxicity was less convincing for clone 1F3, although it was statistically 
significant at 50 nM (p = 0.017) and at 100 nM (p = 0.030). Small but statistically 
significant reductions compared with SH-SY5YUntr were also observed for clone 2E3 
and 1B5 at some doses but not all.  
The third toxin that the SH-SY5Y cells were exposed to was tunicamycin (TM), 
which inhibits protein N-glycosylation within the ER (Sigma-Aldrich, [n.d.]), 
thereby inducing ER stress. TM was included in these experiments due to a recent 
finding that PrPC expression is induced by ER stress (Dery et al., 2013), although the 
importance of PrPC in the response to this form of stress is unclear. I assessed cell 
viability of the SH-SY5Y cell lines following treatment with TM concentrations of 
1-15 µg/ml and, once again, the PrestoBlue reagent was used. The results from four 
independent experiments showed that clones 1G3 and 1F3 were more viable than 









Figure 3.12 – Clone-specific resistance of stably transfected cells to 
tunicamycin treatment  
See following page for legend… 
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Figure 3.12 – Clone-specific resistance of stably transfected cells to 
tunicamycin treatment 
A) Bar chart showing viability of SH-SY5Y cells after 24 h exposure to a range of TM 
concentrations. The mean values (+/- standard error of the mean) from four independent 
experiments are displayed in the bar chart. Differences between SH-SY5YUntr and each 
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transfected clone were tested for significance (p < 0.05) using unpaired, two-sample t-tests. 
Key: * for p < 0.05; ** for p < 0.01; and *** for p < 0.001. B) Phase contrast images of live 
SH-SY5Y cells taken using a x10 objective following 24 h exposure to 5 or 10 µg/ml TM. The 
scale bar shown applies to all panels.    
 
…statistically significant only at the 5 µg/ml concentration for clone 1G3 (p = 0.009) 
and at 1 and 15 µg/ml for clone 1F3 (p < 0.001 and p = 0.037, respectively). Clone 
1B5 was slightly but significantly less viable than SH-SY5YUntr at 1 and 5 µg/ml 
(p = 0.030 and p = 0.005, respectively). For all the cell lines, percentage viability 
changed little between 1 and 10 µg/ml TM but a 15 µg/ml dose was much more 
toxic. Interestingly, when considering all four clones together, the mean viability 
measurements for PrPC-transfected cells were almost the same as for SH-SY5YUntr 
over the 1-10 µg/ml dose range.  
 
I was unable to assess TM-mediated cytotoxicity by measuring LDH release, because 
TM could not be prepared at a high enough concentration to kill all cells for the 
100 % cytotoxicity control. Such a concentration would have exposed the cells to so 
much DMSO that it would have been hard to separate out its effect from that of the 
toxin. Another option for a 100 % cytotoxicity control was to treat cells with a lysis 
buffer but this gave unreliable results (data not shown). As a further alternative, I 
tried to optimise a viability assay based on nuclear staining using the Hoescht 33342 
dye. This method allows discrimination of viable and dead cells based on the shape 
and/or size of their nuclei. Unfortunately, SH-SY5Y cells are prone to clumping, 
especially when stressed, which meant that individual cells were hard to identify, 
thereby affecting the accuracy of the analysis. Instead, I decided to capture and 
analyse phase contrast images of the cells after they had been cultured in the 
presence of TM for 24 hours. It was difficult to discern visual signs of toxicity after 
treatment with 1 or 5 µg/ml TM (Figure 3.12b shows the images for 5 µg/ml TM). 
This is in spite of the reduction in viability at this dose for some of the cell lines 
(Figure 3.12a). However, when treated with 10 µg/ml TM, clone 2E3 and 1B5 
cultures consisted almost entirely of clumped, floating cells that were presumably 
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either dead or dying (Figure 3.12b). At the same concentration of TM, there were still 
some healthy-looking SH-SY5YUntr that remained attached to the plate, although 
many had detached, whilst clones 1G3 and 1F3 appeared entirely unaffected. The 
images for 15 µg/ml TM treatment were very similar to those from 10 µg/ml, except 
that clone 1F3 cells were also starting to clump and float (data not shown). 
 
Finally, I assessed how the stably transfected clones survived in response to serum 
deprivation – this activates mitochondria-dependent apoptosis driven by a protein 
called Bax (Deckwerth et al., 1996) and also mimics the neuronal death in response 
to trophic factor deprivation that plays a key role in the development of the nervous 
system. As per the toxin treatments, cells were plated in serum-containing medium 
and allowed to recover for 16-18 hours. This time though, when the medium was 
changed to serum-free, the N2 supplement was not included as this would have 
promoted survival. Again using the PrestoBlue reagent, cell viability was quantified 
at several time points over a week of serum deprivation. Comparing resorufin 
fluorescence signals across different time points is not particularly accurate since 
day-to-day environmental variations can affect fluorescence values when the plate is 
scanned. Therefore, for each time point, signals were normalised against those 
obtained from SH-SY5YUntr. For this reason, viability is not reported as a percentage 
of the viability at the point of serum depriving. Four independent experiments were 
performed and Figure 3.13a shows that, in contrast to the toxin treatments, the stably 
transfected clones were more susceptibility to serum deprivation than SH-SY5YUntr. 
Reduced viability compared with SH-SY5YUntr was statistically significant from 
day 1 onwards for clone 1G3, from day 2 for clone 1F3 and from day 6 for clones 
2E3 and 1B5. Clone 1G3 appeared to be most affected by serum withdrawal – by 
day 7, the mean resorufin fluorescence signal from wells containing clone 1G3 was 
only 12 % of that from wells containing SH-SY5YUntr. As was the case for TM 
treatment, phase contrast images of the cells were analysed to corroborate the results 
from the viability assays. Figure 3.13b shows that the toxic effects of serum 
deprivation were visually evident by day 4 for clone 1G3 – the monolayer was quite 
sparse and there were many rounded-up, floating cells – and, by day 6, clone 1G3 
cells were mainly dead. The other cultures, with the possible exception of clone 1F3, 
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appeared healthy after 4 days serum deprivation but, by day 6, quite a few floating 
cells were visible for all the clones, less so for SH-SY5YUntr. Images taken at day 7 
(not shown) were very similar to those from day 6. Overall, these results were highly 
consistent with the viability data shown in Figure 3.13a.   
In conclusion, the only difference between clone 2E3 and SH-SY5YUntr in terms of 
their responses to the three toxins was a slight but significant reduction in 
cytotoxicity following exposure to 100 nM STS for clone 2E3. Apart from significant 
reductions in cytotoxicity when treated with 75 or 100 nM doses of STS, clone 1B5 
was also no more resistant than SH-SY5YUntr; in fact, the viability of clone 1B5 was 
significantly lower than SH-SY5YUntr in response to 500 or 1500 µM PQ and 1 or 
5 µg/ml TM. In contrast, clones 1G3 and 1F3 generally displayed enhanced viability 
and reduced cytotoxicity compared with SH-SY5YUntr following exposure to the 
toxins. All four clones were significantly more susceptible to serum deprivation than 
SH-SY5YUntr cells and, interestingly, the reductions in viability seemed to be more 










Figure 3.13 – PrPC transfection increased susceptibility to serum deprivation  
See following page for legend… 
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Figure 3.13 – PrPC transfection increased susceptibility to serum deprivation 
A) Bar chart showing viability of SH-SY5Y cells in response to serum deprivation. The mean 
values (+/- standard error of the mean) from five independent experiments are displayed in 
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the bar chart. Differences between SH-SY5YUntr and each transfected clone were tested for 
significance (p < 0.05) using unpaired, two-sample t-tests. Key: * for p < 0.05; ** for 
p < 0.01; and *** for p < 0.001. B) Phase contrast images of live SH-SY5Y cells taken using a 
x10 objective after 4 or 6 days serum deprivation. The scale bar shown applies to all panels.  
  
3.4.1 Discussion 
Although a large number of studies have found that PrPC expression protects cells 
from stress, there is some controversy in the literature relating to this putative 
function. Consequently, I attempted to clarify whether or not PrPC was 
stress-protective by exposing the stably transfected clones to several different forms 
of stress. Two clones, 1G3 and 1F3, displayed improved survival compared with 
SH-SY5YUntr in response to treatment with the oxidative toxin PQ, whereas two 
other clones showed no such improvement; in fact, the viability of clone 1B5 was 
significantly reduced compared with the control line when treated with 500 or 
1500 µM PQ. Interestingly, the magnitude of the enhanced resistance of clones 1G3 
and 1F3 to PQ exposure appeared to be greater when measuring cytotoxicity based 
on LDH release compared to using reduction of resazurin, the active component of 
the PrestoBlue reagent, as a measure of cell viability. Since resazurin is mainly 
reduced by NADH produced by mitochondria, this finding might indicate that clones 
1G3 and 1F3 could tolerate more mitochondrial dysfunction caused by PQ-induced 
oxidative stress than SH-SY5YUntr (and the other clones) before cell death started to 
occur, at which point LDH would be released.  
Stable transfection of PrPC into SH-SY5Y cells had a similar clone-specific effect on 
resistance to the protein kinase inhibitor STS, which is thought to induce apoptosis 
through both mitochondria-dependent and mitochondria-independent pathways 
(Zhang et al., 2004). Again, survival of clones 1G3 and 1F3 was enhanced compared 
with SH-SY5YUntr, whilst clones 2E3 and 1B5 were generally as susceptible to STS 
as the control line, although cytotoxicity measurements were slightly but 
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significantly lower for these clones at specific doses of STS. Largely the same 
pattern was observed when exposing the SH-SY5Y cells to the N-glycosylation 
inhibitor TM – clones 1G3 and 1F3 showed significantly improved viability 
compared with SH-SY5YUntr, at least at some doses of TM, whereas no such effect 
was observed for clones 2E3 and 1B5. Intriguingly, in spite of apparent reductions in 
viability for some of the cell lines following treatment with 1 µg/ml TM, percentage 
viability measurements were similar at 5 and 10 µg/ml concentrations. However, 
increasing the dose to 15 µg/ml TM resulted in greatly reduced viability for all the 
lines. One interpretation of these results is that there are two phases of TM-mediated 
toxicity: induction of ER stress at relatively low concentrations of the toxin and cell 
death at higher doses. This suggests that the reductions in “viability” of SH-SY5YUntr 
and clones 2E3 and 1B5 that were observed at 1 and 5 µg/ml doses of TM may not 
have been due to cell death. Further evidence for this is that dead, floating cells were 
absent from images of the cell lines that were captured following exposure to 
5 µg/ml TM. Therefore, the observed reductions in fluorescence signals in the 
viability assay at the lower doses of TM may have been caused by an impairment of 
mitochondrial function resulting from inhibition of protein synthesis, which is part of 
the unfolded protein response that is triggered by ER stress. Reduced mitochondrial 
activity and, consequently, a lower level of NADH production would result in less 
resazurin reduction even if no cell death had occurred. Therefore, the fact that 
reductions in fluorescence signals in the viability assays following treatment with 1 
or 5 µg/ml TM were not observed for clones 1G3 and 1F3 might indicate that these 
clones were more resistant than SH-SY5YUntr (and the other clones) to mitochondrial 
impairment caused by ER stress. 
Various studies have identified a protective role for PrPC in the response to oxidative 
stress (Brown et al., 2002; Anantharam et al., 2008; Bertuchi et al., 2012; Bravard et 
al., 2015), including when this form of stress was induced by treating cells with PQ 
(Senator et al., 2004; Dupiereux et al., 2008). However, other reports suggest that 
PrPC does not protect cells from oxidative damage (Hutter et al., 2003; Steinacker et 
al., 2010). Again, there is mixed evidence of a beneficial effect of PrPC expression 
when cells are exposed to STS – some studies find that PrPC expression confers 
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protection (Lopes et al., 2005; Beraldo et al., 2010; Ostapchenko et al., 2013), others 
report that it enhances toxicity (Sunyach et al., 2007; Guillot-Sestier et al., 2009). 
Finally, a recent study found that PrPC expression appears to be induced under ER 
stress, whilst knockdown of PrPC levels resulted in increased death in response to 
toxins that induce ER stress, such as TM (Dery et al., 2013). Once again though, 
other published data suggests that PrPC expression is not associated with protection 
from ER stress (Roucou et al., 2005; Anantharam et al., 2008). Taken together, the 
results presented in this chapter partially support a protective role for PrPC in the 
cellular responses to these forms of stress, although the clone-specific nature of this 
putative stress-protection requires further investigation, especially since PrPC 
expression levels and subcellular localisation patterns were similar among the clones. 
One possible explanation for the variability in stress responses among the clones is 
that small differences in the levels and/or localisation patterns of PrPC expression 
were present but were not detected in the characterisation experiments that were 
reported on in section 3.3. However, it seems unlikely that small differences in PrPC 
expression would cause any great variability in stress responses given that PrPC 
levels in all four clones were higher than the overall expression level in mouse 
forebrain. A second possibility is that PrPC expression was initially higher in clones 
1G3 and 1F3 than in the other clones, as was suggested by the results of a single 
western blot experiment that was carried out prior to preparing frozen stocks of each 
clone (Figure 3.4). Later, PrPC expression may have normalised to a stable level that 
was relatively consistent among the clones. If this were the case then it is 
conceivable that PrPC expression in clones 1G3 and 1F3 initially exceeded some kind 
of threshold that resulted in a permanent change to the cells i.e. a change that 
persisted even after a subsequent reduction in PrPC expression. The lack of 
stress-resistance observed for clones 2E3 and 1B5 could be because the PrPC 
expression levels of these clones never reached this hypothetical threshold. Thirdly, 
stable transfection requires integration of the expression vector into the host cell 
genome, and insertion within a gene or regulatory region can result in phenotypic 
changes that are independent of expression of the transgene. However, to explain the 
variability in stress responses, disruptive insertion events would have needed to have 
occurred in two of the four clones, which seems highly unlikely. A related possibility 
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is that the process of isolating clones was responsible for the differences between 
them. This is because in addition to the neuroblast-like cells with their short, neurite-
like processes, SH-SY5Y cultures reportedly contain some cells that are known as 
“S-type” due to their greater substrate adherence (Encinas et al., 2000). Since the 
clones were theoretically derived from single cells, it may be that clones 2E3 and 
1B5 originated from N-type cells, whilst clones 2E3 and 1B5 were from S-type cells 
– this would be consistent with morphologies of the clones. However, I did not 
observe these two distinct phenotypes in the SH-SY5Y cultures before transfection; 
all the cells appeared to fit the “N-type” description. 
In addition to the three toxins, the SH-SY5Y cells were also subjected to serum 
deprivation, which reportedly induces mitochondria-dependent apoptosis (Deckwerth 
et al., 1996). In contrast to the results obtained with the toxins, all four stably 
transfected clones displayed significantly poorer viability in response to serum 
withdrawal than SH-SY5YUntr. Although these data seemingly contradict an 
extensive body of research suggesting that PrPC expression is protective against 
serum deprivation (Bounhar et al., 2001; Kim et al., 2004; Roucou et al., 2005; Krebs 
et al., 2007; Wu et al., 2008), the results from several of these studies (Kuwahara et 
al., 1999; Kim et al., 2004; Wu et al., 2008) are questionable due to the expression of 
doppel by the hippocampal neuronal cell line used in the experiments. PrPC appears 
to be able to interact with doppel to suppress its reported neurotoxic properties 
(Moore et al., 1999; Sakudo et al., 2005; Qin et al., 2006). Therefore, the 
stress-protective effect of PrPC expression in the hippocampal cell line may have 
been due to this interaction, which is of limited physiological relevance considering 
that doppel is not normally expressed in neuronal cells (GeneAtlas U133A dataset 
(Su et al., 2004) accessed through BioGPS (Wu et al., 2016)).  
The results in this chapter provide good evidence that PrPC expression was 
responsible, either directly or indirectly, for increasing SH-SY5Y cell death in 
response to serum deprivation. However, the clone-specific nature of the altered 
responses to toxin treatment meant that some artefact of the transfection and/or clone 
isolation process could have caused the enhanced resistance of clones 1G3 and 1F3. 
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This issue was addressed by transiently knocking down PrPC expression in the stably 
transfected clones – partial rescue of the increased resistance to toxin treatment of 
clones 1G3 and 1F3 would support the involvement of PrPC in the altered stress 
responses displayed by these clones. Results from these experiments are reported in 
the following chapter, as are data from proteomic analyses of the molecular changes 
caused by stable transfection of PrPC into SH-SY5Y cells. The dual aims of these 
proteomic experiments were to identify processes regulated by PrPC and to determine 
why the clones differed in their responses to stress. These differences among the 
clones were further probed by comparing the proteomic changes that were induced 
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4.1 Assessing whether PrPC expression was responsible 
for the enhanced resistance to toxin treatment of 
clones 1G3 and 1F3 
The previous chapter covered the production and characterisation of stably 
transfected, PrPC-expressing SH-SY5Y clones. When serum was withdrawn from the 
culture medium, all four clones were more susceptible to apoptosis than 
SH-SY5YUntr, providing good evidence that PrPC expression enhances the sensitivity 
of SH-SY5Y cells to serum deprivation. In contrast, following exposure to three 
chemical toxins that induce different forms of cellular stress, two of four clones (1G3 
and 1F3) displayed enhanced survival compared with SH-SY5YUntr, whilst the other 
two clones (2E3 and 1B5) generally did not. Clones 1G3 and 1F3 were also 
morphologically different from the others. The clone-specific nature of these changes 
in the absence of any detectable variations among the clones in the levels and 
localisation patterns of PrPC expression cast doubt upon whether the resistance to 
toxin treatment of clones 1G3 and 1F3 was a result of PrPC expression or simply an 
artefact of the transfection and/or clone isolation process. To test this, I examined the 
effect of PrPC knockdown on the resistance to stress of the stably transfected clones. 
For practical reasons, these experiments and most others covered in this chapter were 
restricted to just two stably transfected clones: one clone that exhibited the 
morphological changes and enhanced resistance to toxin treatment (1G3) and one 
that did not (2E3).  
After reviewing several options for knocking down protein expression, I decided to 
use a small interfering RNA (siRNA). This method is arguably the easiest and the 
quickest to optimise, although use of a suitable negative control siRNA is essential to 
control for confounding effects, including off-target activity of the siRNA and 
potential activation of the anti-viral interferon response5. Previous studies had shown 
that SH-SY5Y cells could be transfected successfully with siRNAs using cationic 
                                                 
5 Since the siRNA duplexes used in these experiments were less than 30 bp in length, the interferon 
response should not have been activated (Kleinschmidt et al., 1968 cited by Whitehead et al., 2011).   
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lipid reagents (Van Kolen et al., 2013; Zhang et al., 2013). Additionally, PrPC 
expression had previously been knocked down using this method in a similar mouse 
neuroblastoma cell line (Daude et al., 2003; Parkin et al., 2007).  
4.1.1 Optimisation of PrPC knockdown by RNA interference  
Before attempting to knock down PrPC expression in the stably transfected SH-SY5Y 
clones, the efficiency of siRNA transfection needed to be optimised. I chose a reverse 
transfection method i.e. wells were treated with the siRNA-transfection reagent 
complexes and the cell suspensions (in this case clone 1G3) were added on top. 
16-18 hours after reverse transfection with a positive control siRNA labelled with a 
fluorescent dye (cyanine dye 3), the medium was exchanged for serum-free medium 
containing the N-2 supplement in order to match the format of the toxin treatment 
assays. Widefield fluorescence images were captured immediately and 24 hours later 
to assess transfection efficiency. Figure 4.1 demonstrates that, ~40 hours post 
transfection, most cells contained the fluorescent siRNA molecules. The data from 
~16 hours post transfection was very similar (not shown). After this successful initial 
experiment, two PrP-specific siRNAs were tested for their ability to knock down 
PrPC expression. SiRNA s72188 targets PRNP mRNA codons 152-159 while s72190 
targets 137-143. Since purchasing these siRNAs, s72188 has been shown to knock 
down PrPC successfully in an epithelial cell line (Mehrabian et al., 2015). I tested 2.5, 
5 and 10 nM doses of the siRNAs using the same method described above, except 
that PrPC expression levels were analysed by western blotting at the two time points. 
Neither siRNA was effective at knocking down PrPC expression at the early time 
point (data not shown). However, by ~40 hours post transfection, PrPC levels were 
greatly reduced (Figure 4.2a & b). At all concentrations, s72188 appeared to be more 
effective than s72190 at knocking down PrPC expression and transfection with 5 or 
10 nM s72188 reduced PrPC levels by similar amounts (Figure 4.2a & b). PrestoBlue 
viability assays also showed that transfection with either siRNA at 2.5 or 5 nM 
concentrations had no detectable effect on cell viability (Figure 4.2c). Transfection 
with 10 nM s72190 may have reduced viability slightly, although this could have 
been an artefact since the data were from a single experiment only.  
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Figure 4.1 – Successful transfection of SH-SY5Y cells with a control siRNA 
Widefield fluorescence image of live clone 1G3 cells taken 40 h after transient transfection 
with cyanine dye 3-labelled positive control siRNA. The image was taken using a x20 
objective. Nuclei were stained with DAPI and are shown in blue. Fluorescent siRNA 
molecules appear red. Red staining was visible in most cells, indicating that they had taken 
up some siRNA molecules.   
 
For future experiments, I decided to use a 5 nM concentration of siRNA to ensure 
sufficient PrPC knockdown, whilst minimising the effects of off-target binding. 
Oddly, a negative control siRNA reported to have “no significant sequence similarity 
to mouse, rat, or human gene sequences” (Thermo Fisher Scientific, [n.d.]-b) also 
seemed to affect PrPC expression in this initial experiment (Figure 4.2a & b) but no 
such effect was observed subsequently. Given that PrPC appeared to be effectively 
knocked down by siRNA s72188 by ~40 hours post transfection, the plan was to 
expose the cells to toxins for 24 hours from this point onwards. In order to make the 
timings work from a practical point of view, the toxin treatments were actually 
performed ~44 hours after transfecting the cells. Five independent experiments 
confirmed that siRNA s72188 significantly reduced PrPC expression at… 
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Figure 4.2 – Optimisation of siRNA concentration for transfection 
A) Fluorescent western blot image showing PrPC immunostaining in clone 1F3 lysates 
prepared 40 h after transient transfection with a negative control siRNA (neg ctrl) or PrP 
siRNAs s72188 or s72190. PrPC was detected by use of the BC6 anti-PrPC primary antibody 
(McCutcheon et al., 2014). “Untreat” = no siRNA transfection. siRNA concentrations (nM) 
are given in brackets. B) Bar chart summarising PrPC quantification data from the western 
blot. After correcting for loading errors, data were normalised to the signal from the cells 
not transfected with any siRNA. C) Bar chart showing viability of clone 1F3 40 h after 
transient transfection with a range of concentrations of the siRNAs described above. The 
mean values (+/- standard deviation) from two technical replicates are displayed in the bar 
chart. 
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Figure 4.3 – SiRNA s72188 efficiently knocked down PrPC expression in clones 
2E3 and 1G3 
See following page for legend… 
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Figure 4.3 – SiRNA s72188 efficiently knocked down PrPC expression in clones 
2E3 and 1G3   
A-D) Representative western blot images and bar charts summarising quantification of PrPC 
immunostaining from at least four independent experiments. PrPC was detected by use of 
the BC6 anti-PrPC primary antibody (McCutcheon et al., 2014). Data are shown for clones 
2E3 and 1G3 at both 44 and 68 h after mock-transfection or transient transfection with a 
negative control siRNA (neg ctrl) or PrP siRNAs s72188 or s72190. For each membrane, after 
correction for loading errors, data were normalised to the signal from the cells not 
transfected with any siRNA (“untreat”). The mean normalised expression values (+/- 
standard error of the mean) are displayed in the bar charts. Differences between 
“untreated” and mock- or siRNA-transfected cells were tested for significance (p< 0.05) 
using one-sample t-tests. Key: * for p < 0.05; ** for p < 0.01.  
 
…around 44 and 68 hours post transfection in clones 2E3 and 1G3 compared with 
controls (Figure 4.3a-d). The degree of knockdown was 67-72 %, which is 
comparable to other studies that employed siRNA-mediated knockdown of PrPC 
(Parkin et al., 2007; Silber et al., 2014). Furthermore, PrPC expression was not 
significantly altered in my experiments by mock transfection or transfection with the 
negative control siRNA. SiRNA s72190 significantly reduced PrPC expression by 
clone 2E3 at the 44 hour time point but the expression level had returned to normal 
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by the later time point. Therefore, I chose siRNA s72188 for use in future 
experiments.  
4.1.2 Lack of effect of PrPC knockdown on the resistance to stress of 
the stably transfected clones 
Having optimised knockdown of PrPC expression using siRNA s72188, I assessed 
whether this would affect the resistance of clone 1G3 to PQ treatment. Clone 2E3 
and SH-SY5YUntr were also included in the experiments. Cells were reverse 
transfected as described previously and, 16 hours later, the medium was exchanged 
for serum-free medium containing the N-2 supplement. Around 44 hours post 
transfection, cells were treated with 1000 µM PQ – this dose was chosen because it 
had resulted in the largest differences between cell lines in the earlier experiments in 
terms of viability and cytotoxicity measurements (Figure 3.10). Following a 24-hour 
exposure to the toxin, PrestoBlue viability and LDH cytotoxicity assays were 
performed. The results of three independent experiments showed that, when not 
transfected with siRNAs, SH-SY5YUntr and clone 2E3 cultures had similar levels of 
viability (36 and 35 %, respectively), as expected, whereas viability of clone 1G3 
was maintained around 85 % (Figure 4.4a). Similarly, percentage cytotoxicity for 
clone 1G3 was much lower than for the other cell lines (Figure 4.4b). However, for 
all the cell lines, there were no significant differences in viability or cytotoxicity 
following transfection with the negative control siRNA compared with the PrP 
siRNA. Indeed, the non-significant trend towards increased viability of clone 1G3 
following transfection with the PrP siRNA was in the opposite direction to what 
would have been expected if PrPC expression had been responsible for the increased 
resistance to PQ treatment of that clone.  
The effect of PrPC knockdown on cell survival in response to STS exposure was 
investigated using the same assay format as per treatment with PQ. Cells were 
treated with 50 nM STS since this was the concentration that had produced the 
greatest differences in survival among the cell lines (Figure 3.10). Again, three 
independent experiments were performed. In contrast to the data shown in… 
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Figure 4.4 – Knockdown of PrPC expression did not rescue the enhanced 
survival of clone 1G3 in response to paraquat or staurosporine treatment  
Bar charts showing viability (A & C) and cytotoxicity (B & D) values for SH-SY5Y cultures 
after 24 h exposure to 1000 µM PQ (A & B) or 50 nM STS (C & D). 44 h before PQ or STS 
treatment, cells had been transiently transfected with negative control siRNA or PrP siRNA 
(s72188) or had not been transfected with any siRNA (“untreat”). The mean normalised 
values (+/- standard error of the mean) from three independent experiments are displayed 
in the bar charts. For each cell type, differences in viability or cytotoxicity between negative 
control- and PrP siRNA-transfected cells were tested for significance (p < 0.05) using 
unpaired, two-sample t-tests. No comparisons met the significance threshold.  
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...Chapter 3, when not transfected with either siRNA, viability and cytotoxicity 
measurements from clone 1G3 cultures were not greatly different from cultures the 
other cell lines (Figure 4.4c & d). The poorer survival of clone 1G3 in these 
experiments could have been due to the extended period spent in serum-free medium 
compared with the previous experiments, since clone 1G3 was particularly sensitive 
to serum deprivation (Figure 3.13). However, the survival-promoting N-2 
supplement present in the serum-free medium should have prevented any cell death 
resulting from serum deprivation. As was the case for PQ treatment, transfection with 
the PrP siRNA did not alter viability or cytotoxicity compared with negative control 
siRNA transfection for any of the cell lines, although the fact that clone 1G3 did not 
exhibit any enhanced resistance to STS treatment in these particular experiments 
means that any effect of the PrP siRNA might have been difficult to detect. 
Taken together, the above results suggest that PrPC expression was not directly 
responsible for the enhanced resistance to treatment with PQ or STS that was 
displayed by clones 1G3 and 1F3 in comparison with SH-SY5YUntr. This lack of 
PrPC-mediated protection from the oxidative damage induced by PQ is in contrast 
with a number of previous studies that report a protective role for PrPC against 
oxidative stress (Brown et al., 2002; Senator et al., 2004; Anantharam et al., 2008; 
Dupiereux et al., 2008; Bertuchi et al., 2012; Bravard et al., 2015). Having said this, 
potential mechanisms put forward to explain this putative protective effect include 
modulation of antioxidant enzyme activity (Brown et al., 1997b; Miele et al., 2002; 
Rachidi et al., 2003; Sakudo et al., 2003; Paterson et al., 2008) and direct 
enhancement of DNA repair processes by PrPC (Bravard et al., 2015), both of which 
have been questioned by other studies (Hutter et al., 2003; Zanetti et al., 2014; 
Nuvolone et al., 2016). The reports of how PrPC expression affects the cellular 
response to STS exposure are quite mixed: it has been suggested that PrPC expression 
is protective against STS-induced apoptosis (Lopes et al., 2005; Beraldo et al., 2010; 
Ostapchenko et al., 2013) and yet other studies have found that it enhances 
vulnerability to the toxin (Sunyach et al., 2007; Guillot-Sestier et al., 2009). My 
results seem to fit between these two opposing sides, since they suggest no positive 
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or negative effect of PrPC expression on susceptibility to the toxicity resulting from 
STS treatment. 
One caveat associated with these knockdown experiments is that reducing PrPC 
levels by ~70 % for a short period may not have been sufficient to reverse the effects 
of stable transfection, especially given that ~30 % of the normal PrPC expression 
level of the clones is roughly equivalent to the overall PrPC expression level in 
mouse forebrain (based on data shown in Figure 3.5). Therefore, whilst the enhanced 
resistance to toxin treatment of clones 1G3 and 1F3 may have been the result of an 
artefact of the transfection and/or clone isolation process, it cannot be ruled out that 
PrPC was involved in some way. For example, western blot analysis of PrPC 
expression by the clones suggested that clones 1G3 and 1F3 might initially have 
expressed higher levels of the protein than clones 2E3 and 1B5 (see Figure 3.4).    
This could have resulted in changes to the phenotypes of clones 1G3 and 1F3 that did 
not occur in the other clones and were not reversible by knocking down PrPC 
expression.   
Data presented in Chapter 3 shows that clones 1G3 and 1F3 were more resistant to 
TM than SH-SY5YUntr, as was the case for the other toxins. However, mainly due to 
time constraints, no experiments were performed to assess the effects of PrPC 
knockdown on susceptibility to TM treatment. The other reason was that evidence 
from the initial experiments of a protective role for PrPC against TM exposure was 
less convincing than for PQ and STS – when considering all four clones together, the 
mean viability measurements for the PrPC-transfected cells were almost the same as 
for SH-SY5YUntr at most of the TM doses. However, experiments were carried out to 
assess whether knocking down PrPC expression affected the responses of the 
SH-SY5Y cell lines to serum deprivation. The method consisted of reverse 
transfecting the cells with the siRNAs and serum depriving 72 hours later to ensure 
that PrPC levels had reduced sufficiently by the time of inducing stress. Viability 
measurements were subsequently made at 2 and 4 days post serum deprivation. 
Unexpectedly, extremely poor viability was observed for all the cell lines – large 
numbers of dead, floating cells were present by day 4 even in the wells containing 
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SH-SY5YUntr (data not shown), which contrasts with the healthy appearance of the 
untransfected cultures at this time point in the initial experiments (Figure 3.13b). The 
consequence of the enhanced toxicity of serum deprivation in the experiments 
incorporating PrPC knockdown was that viability of clone 1G3 was so low at the 
point of measurement that the results were not reliable. Unfortunately, I did not have 
time to solve these issues to enable the acquisition of meaningful data. Nevertheless, 
the original data reported in Chapter 3 provides good evidence that PrPC expression 
was responsible for increasing the sensitivity of SH-SY5Y cells to serum 
deprivation; this is because, in spite of some variability among the stably transfected 
clones, all four clones displayed significantly reduced viability compared with 
SH-SY5YUntr. This finding contradicts several studies that found that PrPC expression 
protected cells from serum withdrawal (Bounhar et al., 2001; Kim et al., 2004; 
Roucou et al., 2005; Krebs et al., 2007; Wu et al., 2008) but, as discussed in the 
previous chapter, there are issues surrounding the reliability of several of those 
studies (Kuwahara et al., 1999; Kim et al., 2004; Wu et al., 2008).  
The results reported in this section suggest that the clone-specific increase in 
resistance to toxin treatment that resulted from PrPC transfection may have been 
independent of PrPC expression. However, there was still no explanation of what 
might have been responsible for the variability in stress responses among the clones.  
Global proteomic analyses of the cells were carried out in an attempt to answer this 
question and others.    
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4.2 Proteomic changes in stably transfected clones 2E3 
and 1G3 compared with untransfected cells  
The results described in the previous section suggested that PrPC expression may not 
have been directly responsible for the enhanced resistance to toxin treatment of 
clones 1G3 and 1F3 compared with SH-SY5YUntr. Consequently, proteomic analyses 
of the SH-SY5Y cells were carried out with the dual aims of identifying processes 
regulated by PrPC (covered in Chapter 5) and to investigate in more detail the reasons 
for the variability in stress responses among the clones. Proteomic studies enable the 
expression levels of thousands of proteins to be quantified simultaneously and the 
focus on proteins gives this approach a distinct advantage over other methods of 
analysing global gene expression patterns, such as microarrays or RNAseq, which 
quantify mRNA levels instead; mRNA abundance can often be a poor predictor of 
protein expression level (Gygi et al., 1999; Schwanhausser et al., 2011) and it is 
proteins not mRNAs that are the “active agents of the cell” (Steen and Mann, 2004).  
At the time of starting our experiments, most published proteomic investigations of 
PrPC function had used traditional two-dimensional gel-based protein separation 
methods (Ramljak et al., 2008; Weiss et al., 2010). Membrane-associated and low-
abundance proteins are poorly detected by this approach and there are issues with 
reproducibility (Abdallah et al., 2012). In contrast, modern “shotgun” proteomic 
methods, as used here, are faster and offer much improved proteome coverage 
compared with 2-D gel electrophoresis, although specific proteins isoforms are 
harder to identify since peptide fragments are detected rather than intact proteins 
(Steen and Mann, 2004). In our experiments, separate comparisons between 
SH-SY5YUntr and clone 2E3 and between SH-SY5YUntr and clone 1G3 were 
performed. This format enabled comparison of the proteomic changes present in a 
clone (1G3) that exhibited the altered morphology and enhanced resistance to toxin 
treatment with the proteomic changes identified in a clone that did not display these 
phenotypes (2E3). A triplex experiment to simultaneously compare all three lines 
was theoretically possible but the required methods had not yet been optimised. For 
each comparison, two independently prepared sets of lysates were analysed 
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separately. Following enzymatic digestion of the proteins in the lysates, the resulting 
peptides from the SH-SY5YUntr sample were labelled with a “light” dimethyl label 
and the peptides from the clone 2E3 or clone 1G3 sample were labelled with the 
“heavy” version. Next, the samples were mixed together and fractionated by liquid 
chromatography methods. The eluted peptides were subsequently analysed by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). The raw spectral data 
obtained were analysed using computer software to identify peptides and the small 
mass difference imparted by the label enabled discrimination of which sample the 
peptides were from and, consequently, the calculation of expression ratios. The 
peptides were searched against the Uniprot human protein sequence database to 
determine the proteins present in the original samples. Protein expression ratios were 
calculated by the ProteinScape 3.1 software by averaging the abundance ratios for all 
the peptides associated with a particular protein. Percentage coefficients of variation 
(%CV) for the expression ratios were also calculated. The lists of proteins were then 
filtered according to several criteria to identify those differentially expressed between 
the samples. Firstly, only proteins identified from more than two quantified unique 
peptides in both replicate datasets were included to ensure that the expression ratios 
could be relied upon. Secondly, various fold change thresholds were assessed to 
judge at what point the “noise” in the data, caused by technical and biological 
variability, became unacceptable. For the datasets comparing SH-SY5YUntr with 
clone 2E3, applying fold change cut-offs of (+/-) 1.2, 1.3 or 1.4 resulted in 138, 59 or 
23 differentially-expressed proteins6, respectively. Of these proteins, ~80 % were 
differentially expressed in the same direction in both biological replicates for the 
(+/-) 1.2 or 1.3 cut-offs, whereas this proportion rose to 91 % for a (+/-) 1.4 cut-off 
(Figure 4.5). These results suggested that, for the less stringent cut-offs, a sizeable 
proportion of proteins could have been identified as upregulated or downregulated in 
both biological replicates simply due to technical or biological variability rather…  
                                                 
6 These figures are underestimates since the initial identification of proteins common to both 
experimental replicates was carried out using an Excel macro that missed a small number of proteins 
that should have been included – these were identified manually and later added into the final list.  
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Figure 4.5 – Selection of appropriate fold change cut-off for proteomic data 
Scatter plots of protein expression ratios obtained from the two replicate proteomic 
experiments comparing SH-SY5YUntr with clone 2E3. Only proteins with expression ratios 
calculated from more than two unique peptides were included. Fold change cut-offs of (+/-) 
1.2 (A), 1.3 (B) or 1.4 (C) were then applied. Expression ratios were converted to log ratios 
(LR; base 2) for the plots to enable better visualisation of negative fold changes. If a data 
point appears in either the top right or bottom left corner squares this indicates that the 
expression level of that protein was altered in the same direction for both biological 
replicates. Linear trendlines fitted by Excel are shown on the graphs as are the associated 
R-squared values.    
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…than a true, consistent difference in expression. Therefore, the stricter (+/-) 1.4 fold 
change cut-off was chosen to reduce the number of false positives. The same cut-off 
was also used for the SH-SY5YUntr vs clone 1G3 proteomic experiments to make it 
easier to compare between the analyses. The third filtering step was to check the 
individual peptide abundance ratios for the few proteins with %CVs greater than 100, 
since such a high %CV suggested that the expression ratio was not particularly 
reliable. In the absence of an objective statistical test, I was cautious not to arbitrarily 
exclude proteins; at the same time, it was important not to falsely identify proteins as 
differentially expressed if their expression ratios were plainly inaccurate. 
Consequently, three proteins were removed from the final, filtered list of proteomic 
differences between SH-SY5YUntr and clone 2E3 due to outlying peptide abundance 
ratios skewing the overall expression ratio for the protein7. The numbers of proteins 
remaining after each of the filtering steps are shown in Table 4.1.  
After carrying out the aforementioned filtering steps, there were 346 proteins 
differentially expressed between SH-SY5YUntr and clone 1G3, consisting of 131 
upregulated and 215 downregulated proteins. Only 22 proteins were differentially 
expressed between SH-SY5YUntr and clone 2E3, 12 upregulated and 10 
downregulated. This disparity may be because clone 2E3 was more similar to 
SH-SY5YUntr in terms of its morphology and stress responses than was the case for 
clone 1G3. All the differentially expressed proteins in clone 2E3 are reported in 
Table 4.2, whilst Table 4.3 contains a subset of the proteomic changes observed in 
clone 1G3 (the 12 most upregulated and 12 most downregulated proteins). The full 
list of 346 differentially expressed proteins is provided in Appendix II. Prior to any 
subsequent analysis, the proteomic data were validated as described in the following 
section. 
                                                 
7 All three proteins excluded were reported to be differentially expressed by < 2 fold and yet, in each 
case, an expression ratio of > 10 or < 0.1 was reported for one of the peptides. Removal of these 
clearly anomalous peptides from the quantification resulted in protein expression ratios of close to 
1.00, therefore suggesting that these proteins were not differentially expressed.  
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 Number of identified proteins 
 SH-SY5YUntr vs clone 2E3  SH-SY5YUntr vs clone 1G3 
Total (expt 1, expt 2) 2349, 2886 3224, 3018 
Total (in both expts) 1677* 2438* 
# quant. peptides > 2 840* 1203* 
Expr. ratio >= 1.4 or <= 0.83 25 346 
Final list after error checking 22 346 
Final list (upreg., downreg.) 12, 10 131, 215 
 
Table 4.1 – Filtering of proteomic datasets to generate lists of differentially 
expressed proteins 
The table shows the numbers of remaining proteins from the proteomic datasets after 
cumulatively applying the described filtering criteria – these had to be met for both 
experimental replicates. “# quant. peptides > 2” means that only proteins with expression 
ratios calculated from more than two associated unique peptides were included. “error 
checking” means checking protein expression ratios with %CVs > 100. *these figures are 
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4.2.1 Successful validation of proteomic data by western blotting of 
cell lysates  
The accuracy of the proteomic data described in the previous section was validated 
by quantitative western blotting for a subset of the targets. To make this process more 
efficient, I aimed to select targets that were differentially expressed in clones 2E3 
and 1G3 compared with SH-SY5YUntr based on the proteomic data – this enabled 
simultaneous validation of the accuracy of both datasets. Clone 1B5 and 1F3 lysates 
were also included in these western blotting experiments for completeness. As in 
previous experiments, cells were seeded into tissue culture plates and lysed 24 hours 
later. Expression levels of the selected proteins (11 in total) were assessed in at least 
four independently prepared sets of cell lysates by quantitative western blotting. 
Figure 4.6 shows a representative western blot for each protein as well as bar charts 
providing the mean relative expression levels in each clone compared with 
SH-SY5YUntr. These data indicate that three of the 11 targets – annexin A2 
(Figure 4.6a), neuromodulin (Figure 4.6b) and zyxin (Figure 4.6c) – were expressed 
at higher levels in all four stably transfected clones compared with SH-SY5YUntr. 
Neurosecretory protein VGF (Figure 4.6d) and vimentin (Figure 4.6e) were both 
significantly upregulated in clones 2E3, 1G3 and 1F3 compared with SH-SY5YUntr 
and displayed non-significant trends towards upregulation in clone 1B5 (one-sample 
t-tests: p = 0.096 and p = 0.058, respectively). Caldesmon (Figure 4.6f) was 
significantly more abundant in clones 2E3 and 1F3 than in the control cells and, 
again, non-significant trends towards upregulation were evident in the other clones 
(one-sample t-tests: p = 0.059 and p = 0.065 for clones 1B5 and 1G3, respectively). 
In general, the magnitudes of the expression changes were greater for clone 1G3 and 
1F3 than the other clones, although in the case of neurosecretory protein VGF this 
trend was reversed. The biological significance of the altered expression levels of 
these six proteins is explored in Chapter 5. Contrastingly, ribonucleoside-diphosphate 
reductase large subunit (Figure 4.6g) was significantly downregulated in clones 1B5, 
1G3 and 1F3 compared with SH-SY5YUntr and a non-significant trend towards 
downregulation was also observed in clone 2E3 (one-sample t-test: p = 0.077).  
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Table 4.3 – Subset of proteins differentially expressed in clone 1G3 compared 
with untransfected SH-SY5Y cells 
Table 4.2 – List of proteins differentially expressed in clone 2E3 compared 
with untransfected SH-SY5Y cells 



















Figure 4.6 – Successful validation of proteomic data by western blotting 
See p. 128 for legend… 
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Figure 4.6 – Successful validation of proteomic data by western blotting  
A-K) Representative images of western blots for various protein targets and bar charts 
summarising quantification of immunostaining from at least four independently prepared 
sets of cell lysates. For each membrane, after correction for loading errors, data were 
normalised to the signal from the SH-SY5YUntr lane. The mean normalised expression values 
(+/- standard error of the mean) are displayed in the bar charts. Expression differences 
between SH-SY5YUntr and each clone were tested for significance (p< 0.05) using one-sample 
t-tests. Key: * for p < 0.05; ** for p < 0.01; and *** for p < 0.001. Primary antibodies for all 
targets except VGF were from Cell Signalling Technology – catalogue numbers were: #8235 
(A), #5307 (B), #3553 (C), #5741 (E), #12503 (F), #8637 (G), #11974 (H), #12496 (I), #13110 
(J), #2056 (K). Anti-VGF antibody was from Abcam (#ab74140).   
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 Expression fold change vs SH-SY5YUntr 
 Clone 1G3 Clone 2E3 
Protein target Proteomic data Western data Proteomic data Western data 
Annexin A2 +3.50 +4.12 +1.51 +1.97 
Caldesmon +2.29 +2.02 (n.s.) (+1.34) +1.55 
Neuromodulin +3.48 +3.01 +1.79 +2.28 
VGF +2.46 +4.05 +6.79 +15.61 
Vimentin +4.30 +3.12 +2.20 +2.26 
Zyxin +3.88 +4.14 N/A +2.10 
RRM1 -2.20 -1.92 -1.89 -1.20 (n.s.) 
BRE1A -1.69 -1.21 N/A -1.06 (n.s.) 
eIF1 -1.83 -1.19 (-1.16) +1.08 (n.s.) 
PCNA -2.09 -1.45 (-1.18) +1.10 (n.s.) 
PRKCA +1.89 +2.77 (-1.62) -1.61 
 
Table 4.4 – Proteomic analyses and western blotting produced similar 
measures of fold change  
This table summarises proteomic and western blot data for 11 protein targets. Shown are 
the mean fold changes in expression between SH-SY5YUntr and clone 1G3 or clone 2E3 
determined from proteomic data (see Tables 4.2 & 4.3) and also from western blotting (see 
Figure 4.6). All of the proteins were identified as differentially expressed in the proteomic 
data unless: 1) the fold change value is shown in brackets, in which case the (+/-) 1.4 fold 
change cut-off was not met in at least one of the replicate datasets; or 2) the fold change is 
shown as “N/A”, in which case the protein was identified from fewer than three quantified 
unique peptides in at least one of the replicate datasets, thereby potential making the fold 
change estimate unreliable. For the western blotting data, all fold changes were statistically 
significant unless described as “n.s.”. Full protein names are given in Figure 4.6.     
 
E3 ubiquitin-protein ligase BRE1A (Figure 4.6h), eukaryotic translation initiation 
factor 1 (Figure 4.6i) and proliferating cell nuclear antigen (Figure 4.6j) were also 
significantly downregulated in clones 1G3 and 1F3 but displayed no trends towards 
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differential expression in the other clones compared with the control line, whereas 
protein kinase C alpha type (Figure 4.6k) was upregulated in clones 1G3 and 1F3 but 
downregulated in 2E3 and 1B5. In keeping with the results described in Chapter 3, 
clone 1F3 was similar to 1G3 and clone 1B5 similar to 2E3 in terms of their 
expression profiles for these 11 proteins.  
 
Importantly, 10 out of 11 targets differentially expressed between SH-SY5YUntr and 
clone 1G3 according to the proteomic data were similarly altered when analysed by 
western blotting. Although the remaining target, caldesmon, was not significantly 
affected in its expression (p = 0.065) as measured by western blotting, the fold 
change estimate of +2.02 was very close to that obtained by proteomic analysis 
(+2.29). Six of the 11 targets were also altered in their expression in clone 2E3 
compared with SH-SY5YUntr according on the proteomic data, and western blotting 
confirmed differential expression for five of the six. The only one not confirmed was 
ribonucleoside-diphosphate reductase large subunit, which was downregulated 
according to the proteomic data (-1.89) and was not significantly altered when 
analysing expression by western blotting (fold change of -1.20; p = 0.077). Overall 
though, the western blotting data suggested that the expression ratios obtained from 
the proteomic analyses were accurate. Indeed, as shown in Table 4.4, the expression 
ratios determined by the different methods were relatively consistent in terms of 
magnitude, including when proteins showed no clear expression change between the 
samples.  
4.2.2 Insights from the proteomic data into the differences among the 
clones in their responses to stress  
One of the reasons for performing the aforementioned proteomic experiments was to 
investigate the reasons for the variability in stress responses among the clones. When 
applying the same filtering criteria to both datasets, 346 proteins were differentially 
expressed in clone 1G3 compared with SH-SY5YUntr but only 22 were altered in their 
expression in clone 2E3 compared with the control line. This disparity is probably a 
result of the molecular changes specific to clone 1G3 that were responsible for the 
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altered morphology and enhanced resistance to toxin treatment of that clone. An 
initial assessment of the pathways and processes overrepresented among these 
differentially expressed proteins was performed using the Ingenuity Pathway 
Analysis (IPA) software. However, the dataset from the clone 2E3 vs SH-SY5YUntr 
experiments was too small (only 22 proteins) to generate meaningful results (data not 
shown). Nonetheless, some insights into the differences between clones 1G3 and 2E3 
can be obtained from the proteomic data. For example, one interesting finding was 
that neuroblast differentiation-associated protein AHNAK was upregulated by 
2.82 fold8 in clone 1G3 compared with SH-SY5YUntr and yet largely unchanged in 
clone 2E3 (fold change of -1.14). Additionally, the neurotransmitter neuropeptide Y 
was approximately 7 fold more abundant in clone 1G3 compared with SH-SY5YUntr. 
This fold change estimate may be unreliable since it is based upon quantification of a 
single peptide, although the detection of just one peptide in the proteomic analyses 
may have been because neuropeptide Y is only 36 amino acids in length. In any case, 
these data raised the possibility that clone 1G3 was more differentiated towards a 
mature neuronal phenotype than clone 2E3. Interestingly, a previous study found that 
various agents, including the phorbol ester 12-O-tetradecanoyl phorbol-13 acetate, 
induced differentiation of SH-SY5Y cells into a mature sympathetic noradrenergic 
phenotype, and this resulted in increased expression of neuropeptide Y and the 
axonal growth cone protein neuromodulin (Prince and Oreland, 1997). My western 
blotting data showed that neuromodulin was also upregulated in clone 1G3 compared 
with SH-SY5YUntr, although the same was admittedly true for clone 2E3 (Figure 
4.6b). Protein kinase C may also be involved in SH-SY5Y differentiation (Bjelfman 
et al., 1990) and protein kinase C alpha type expression was upregulated in clones 
1G3 and 1F3 compared with the control line but downregulated in clones 2E3 and 
1B5 (Figure 4.6k). Reduced expression of proliferating cell nuclear antigen, an 
immature neuronal marker, in clones 1G3 and 1F3 provides further evidence of 
neuronal differentiation (Figure 4.6j). However, it is important to state that not all the 
data fits this hypothesis. Firstly, dopamine beta-hydroxylase, which catalyses an 
intermediate step in noradrenalin synthesis from dopamine, was actually strongly 
                                                 
8 Mean expression ratios from the two replicate proteomic experiments were calculated and then 
converted to fold change. This was the case for all such fold change values given in Chapter 4.  
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downregulated (-6.67 fold) in clone 1G3 compared with SH-SY5YUntr. This could 
suggest differentiation into a non-noradrenergic phenotype but there were no clear 
signs of this in the proteomic data. Secondly, the immature neuronal marker nestin 
was upregulated in clone 1G3 (+1.75 fold) but seemingly unchanged (+1.14 fold) in 
clone 2E3. Thirdly, imaging data presented in Chapter 3 showed that clones 1G3 and 
1F3 produced fewer neurite-like protrusions than the others clones. Given that 
neuritogenesis is part of neuronal differentiation, this finding suggests that clones 
2E3 and 1B5 were the more differentiated.   
Overall, these proteomic analyses identified some molecular differences between the 
clones but did not result in a conclusive explanation for the variability in stress 
responses. Therefore, further proteomic experiments were performed to identify the 
proteins differentially expressed following STS treatment in SH-SY5YUntr, clone 2E3 
and clone 1G3. It was hoped that subsequent comparisons between the cell lines 
would identify the molecular changes underlying the differences in stress response.   
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4.3 Proteomic analyses of staurosporine-treated SH-SY5Y 
cells  
4.3.1 Optimisation of staurosporine treatment conditions   
As previously explained, the fact that the level and subcellular localisation of PrPC 
expression appeared to vary little among the stably transfected clones (Figures 3.5, 
3.7 and 3.8) suggested that the differences among the clones in terms of morphology 
and stress response may have been an artefact of the transfection and/or clone 
isolation process. Further evidence was provided by the lack of effect of PrPC 
knockdown on survival of the stably transfected clones in response to toxin treatment 
(Figure 4.4). However, the data shown in Figure 3.4 suggests that clones 1G3 and 
1F3 might, initially, have expressed higher levels of the PrPC than clones 2E3 and 
1B5. This could have resulted in changes to the phenotypes of clones 1G3 and 1F3 
that did not occur in the other clones and were not affected by subsequent 
normalisation of PrPC levels among the clones or by siRNA-mediated knockdown of 
expression. Whatever the reasons underlying the differences between the clones, the 
proteomic analyses described in the previous section did not shed much light on the 
downstream molecular changes that could have been mediating the variable 
responses to stress. To investigate this further, proteomic experiments comparing 
stressed and unstressed cells were carried out. Again, SH-SY5YUntr and clones 2E3 
and 1G3 were analysed in these experiments, which allowed additional comparisons 
with the datasets of baseline proteomic alterations. Cells were stressed by exposure 
to 50 nM STS, which was chosen because the enhanced survival of clone 1G3 
compared with SH-SY5YUntr was greatest in response to this toxin and at this dose 
(see Figures 3.10-3.12). However, in these experiments, the key was to detect the 
initial molecular changes induced by STS treatment, since these would define the 
cellular response to stress; proteomic alterations caused by cell death processes were 
of less interest. Because 24-hour exposure to 50 nM STS reduced viability of 
SH-SY5YUntr by almost 60 % (Figure 3.11), the time interval of STS treatment 
needed to be shortened so that cell death did not occur. In order to optimise this time 
interval, SH-SY5YUntr cells were seeded into a tissue culture plate and allowed to 
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recover for ~18 hours. Subsequently, the growth medium was exchanged for serum-
free medium containing the N-2 supplement and 50 nM STS. The PrestoBlue 
viability assay was used to quantify survival after cells had been exposed to STS for 
4, 6, 8 or 24 hours. Figure 4.7 shows that 24-hour STS treatment resulted in a ~60 % 
reduction in cell viability, as expected. Some cell death also seemed to have occurred 
after 8 hours and possibly after just 6 hours. Consequently, the 4-hour time interval 
was chosen. Next, phase contrast images of the cell lines were captured following 
4-hour exposure to STS in order to determine whether visual signs of a response to 
the toxin were evident. Figure 4.8 indicates that the cells were responding to STS, as 
demonstrated by morphological changes to their networks of neurite-like protrusions, 
changes that seemed less obvious for clone 1G3 than the other cell lines. Taken 
together, these results suggested that treating the cells with STS for 4 hours would 
enable detection of the proteomic changes that were part of the initial stress response. 
 
Figure 4.7 – Optimisation of staurosporine treatment duration  
Bar chart showing viability of SH-SY5YUntr after several different time periods of exposure to 
50 nM STS. The mean values (+/- standard deviation) from two technical replicates are 
displayed in the chart. A trend towards reduced viability was evident from 8 h onwards. 
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Figure 4.8 – Morphological changes to SH-SY5Y cells induced by 
staurosporine exposure  
Phase contrast images of cells fixed after 4 h treatment with 50 nM STS were taken using a 
x10 objective. The scale bar shown applies to all panels. For all the cell lines, morphological 
changes were evident following STS treatment, specifically in terms of alterations to their 
neurite-like protrusions. These changes seemed to be least pronounced for clone 1G3.  
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4.3.2 Stress-induced proteomic changes in untransfected and stably 
transfected SH-SY5Y cells  
The experimental format consisted of separate, two-way comparisons between 
stressed and unstressed cells from each cell line. For each experiment, cells were 
exposed for 4 hours either to 50 nM STS or to the toxin buffer alone (in this case 
DMSO). Subsequently, cells were lysed and the protein samples obtained were 
digested by proteases, labelled either with heavy or light dimethyl labels and 
analysed by LC-MS/MS, as described in section 4.2. To ensure that the proteomic 
changes induced by stress could be accurately compared among the cell lines, care 
was taken to ensure that the time intervals of toxin exposure and the time taken to 
perform the cell lysis steps were absolutely identical across the individual 
experiments. Due to time and resource constraints, only one set of cell lysates were 
analysed for each comparison. As before, the raw spectral data obtained from 
LC-MS/MS were analysed using computer software to identify peptides and, 
subsequently, proteins and to calculate expression ratios and the associated %CV 
values. Subsequently, the lists of proteins were filtered according to several criteria 
to identify those differentially expressed between the samples. Firstly, only proteins 
identified from more than two quantified unique peptides in both replicate datasets 
were included. Secondly, proteins with a %CV for their expression ratio of 50 or 
more were excluded to minimise the inclusion of false positives resulting from the 
lack of biological replication. Next, the datasets were uploaded to the Ingenuity 
Pathway Analysis (IPA) software and a fold change threshold was chosen. The plan 
was to carry out pathway analyses of the individual datasets and then perform a 
further comparison analysis using IPA (see the following section for more details) to 
identify the differences between the cell lines in terms of their responses to STS 
treatment. For the comparison analysis to work effectively, the datasets of 
differentially expressed proteins could not be too small. Therefore, the (+/-) 1.4 fold 
change cut-off used previously was not used again for these experiments, since the 
number of proteins meeting this threshold in clone 1G3 was only 29. Instead, the cut-
off was lowered to (+/-) 1.3, which was still considered sufficiently stringent because 
applying the %CV cut-off removed a large number of proteins with potentially 
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unreliable expression ratios that would otherwise have been classed as differentially 
expressed. The numbers of proteins remaining after each of the filtering steps are 
shown in Table 4.5. After the final fold change cut-off was applied, SH-SY5YUntr had 
the most differentially-expressed proteins (187) after STS treatment, followed by 
clone 2E3 (110) and clone 1G3 (65). Many more proteins were downregulated than 
upregulated for all the cell lines – the proportions of differentially-expressed proteins 
upregulated were 20 %, 31 % and 18 % for SH-SY5YUntr, clone 2E3 and clone 1G3, 
respectively (Table 4.5). Tables 4.6-4.8 show the proteins with the largest expression 
changes in each dataset, whilst the full lists are provided in Appendix II. Since this 
method of proteomic analysis had already been validated successfully by western 
blotting (see section 4.2.1), this process was not repeated for the datasets reported 
here. The results of the pathway analyses are explored in the following section.  
 
 Number of identified proteins 
 SH-SY5YUntr Clone 2E3 Clone 1G3 
Total  3093 3328 3164 
# quant. peptides > 2 1516 1608 1467 
%CV < 50 1363 1518 1370 
Data entered into Ingenuity Pathway Analysis 
Mapped 1353 1510 1364 
Expr. ratio >= 1.3 or <= 0.76 187 110 65 
Final list (upreg., downreg.) 38, 149 34, 76 12, 53 
 
Table 4.5 – Filtering of proteomic datasets for pathway analysis  
This table shows the numbers of remaining proteins in the proteomic datasets from the STS-
treatment experiments after cumulatively applying the described filtering criteria. “# quant. 
peptides > 2” means that only proteins with expression ratios calculated from > 2 quantified 
unique peptides were included. A few proteins were not “mapped” by the IPA software and 
were therefore not included in subsequent analyses; this was either because the accession 
numbers were not recognised or because of duplicate entries in the datasets (only one of 
which would be mapped).  
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4.3.3 Pathway analysis of stress-induced proteomic changes  
After uploading the proteomic data to IPA and filtering for fold change as described 
in the previous section, core analyses were run for each dataset. The IPA core 
analysis suite has a number of features, including those that identify the canonical 
pathways and disease/biofunction categories that are most overrepresented among 
the proteins/genes in the uploaded dataset. Canonical pathways are standard, 
well-characterised signalling pathways, whereas disease/biofunction categories are 
groupings of genes with similar functions according to the database used by the 
software (known as the Ingenuity Knowledge Base). Another feature of the software 
is that it can generate de novo protein-protein interaction networks. This is achieved 
by use of an algorithm, which is explained in detail in a whitepaper from Ingenuity 
Systems (2005). Briefly, proteins are sorted into networks based on information 
about experimentally confirmed direct and indirect interactions that is recorded in the 
Ingenuity Knowledge Base. A direct interaction could be transcription factor X 
inducing expression of protein Y by binding to its promoter, while protein X 
upregulating protein Y via one or more intermediate proteins would be an indirect 
interaction.  
Once each proteomic dataset had been analysed by IPA individually, a comparison 
analysis was performed within the software to identify differences among the cell 
lines in terms of the molecular response to STS treatment. This approach enabled 
side-by-side viewing of the STS-induced changes to individual biofunctions, 
canonical pathways and networks etc. that were observed in the different cell lines.  
Table 4.9 shows the disease/biofunction categories that showed the most overlap 
with the datasets of differentially expressed proteins, as determined by the 
right-tailed Fisher exact test. When possible, activation state z-scores are also 
provided for each category. These z-scores are calculated based upon information 
from the Ingenuity Knowledge Base about how the expression changes to individual 
proteins should affect the activity of the entire disease process or biofunction. IPA 
adds together these predictions to generate an overall z-score, which represents the 
degree of confidence that the disease process or biofunction is activated (positive 
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value) or inhibited (negative value). Z-scores > 2 or < -2 are generally considered 
statistically significant (Ingenuity Systems, [n.d.]), although lower values may still 




 Activation state z-score after STS treatment 
Diseases and biofunctions SHSY5YUntr Clone 2E3 Clone 1G3 
Proliferation of cells -2.55 -1.99 -2.42 
Migration of cells -3.53 -0.94 -0.79 
Cell movement of leukaemia cell lines -2.43 -2.22 0.00 
Invasion of cells -2.47 -1.00 -1.15 
Invasion of breast cancer cell lines -2.62 -1.73 0.00 
Cell movement -2.84 -0.65 -0.80 
Viral infection -2.47 0.00 -1.63 
Proliferation of tumour cell lines -2.03 0.00 -2.04 
Cell death +2.49 +0.68 -0.79 
Apoptosis +2.60 +0.85 -0.51 
Invasion of tumour cell lines -2.04 -1.38 0.00 
Cell viability of breast cancer cell lines -1.41 -1.94 0.00 
Migration of fibroblasts -1.22 -1.99 0.00 
Necrosis 1.78 0.00 -1.16 
Proliferation of muscle cells -2.93 0.00 0.00 
 
Table 4.9 – Key downstream processes altered by staurosporine treatment  
This table displays the disease/biofunction categories that had the greatest overlap, 
according to IPA, with the datasets of STS-induced proteomic changes. The categories are 
ranked according to the moduli of the means of the activation state z-scores (see main text 
for more details about z-scores) from the three cell lines. A z-score of 0 is reported either if 
the overlap p-value (calculated by IPA using the right-tailed Fisher exact test) was not 
statistically significant or if it was significant (p < 0.05) but the Ingenuity Knowledge Base did 
not contain information on whether the associated proteins were activators or inhibitors of 
the particular disease process or biofunction.  
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The “proliferation of cells” biofunction is top of the list in Table 4.9 and had a 
similarly negative z-score in all the datasets. Inhibition of proliferation by the protein 
kinase inhibitor STS is not surprising given that long-term treatment with the toxin is 
known to induce growth arrest of SH-SY5Y cells (Prince and Oreland, 1997), 
presumably by inactivating the protein kinases involved in driving proliferation. 
Probably for similar reasons, cell movement/migration of SH-SY5YUntr was also 
reduced by exposure to STS. In general, this effect of STS treatment was less 
dramatic in clones 2E3 and 1G3, although the lack of difference between the clones 
in this regard means that variable responses to STS in terms of changes to cell 
movement cannot obviously be linked to the differing responses to stress among the 
clones. Additionally, the data in Table 4.9 clearly show that apoptotic/necrotic 
pathways were induced in SH-SY5YUntr, although the relevant proteomic changes 
probably represent the initial stages of cell death, since cell viability was not reduced 
by the STS treatment regime used for these experiments (Figure 4.7). Activation of 
apoptosis/necrosis was less evident for clone 2E3, whilst these processes were 
actually predicted to be less active in clone 1G3 following STS exposure, albeit with 
low confidence. These results approximately matched the viability and cytotoxicity 
data for STS treatment (Figure 3.11a & c), which showed that clone 1G3 was 
considerably more resistant than SH-SY5YUntr and that clone 2E3 was, perhaps, 
marginally more resistant.  
The conclusion from the diseases and biofunctions analysis was that clone 1G3 
displayed no obvious protective molecular response to STS treatment but, 
nevertheless, did seem to be less negatively affected by the toxin than the other cell 
lines. Further emphasising this point is that protein-protein interaction networks, 
generated de novo by IPA from the proteomic datasets, tended to overlap with each 
other in a manner that appeared to be largely independent of cell line (Figure 4.9). 
However, the canonical pathway most convincingly affected by STS treatment 
provided more interesting insights; this was the extracellular signal-regulated kinase 
(ERK)/mitogen-activated protein kinase (MAPK) pathway, which is generally 
pro-survival, although not always (Mebratu and Tesfaigzi, 2009). Table 4.10 shows 
the proteins in this pathway that were differentially expressed upon STS treatment…  
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Figure 4.9 – Interrelatedness of networks generated by IPA from the datasets 
of staurosporine-induced proteomic changes  
This diagram highlights that networks, generated de novo by IPA from the proteomic 
changes caused by STS treatment, do not cluster into cell line-specific groups. This suggests 
that the proteomic changes induced by STS were similar among the cell lines. Connecting 
lines indicate that those networks share at least one common protein. Networks for 
SH-SY5YUntr are coloured dark blue, those for clone 2E3 are a lighter blue and those for clone 














…in at least one of the cell lines. The activation state z-scores suggested inhibition of 
ERK/MAPK signalling in SH-SY5YUntr and clone 2E3, which would be expected 
due to inhibition of protein kinases in the pathway by STS. However, the 
components of the ERK/MAPK pathway were not significantly overrepresented 
(right-tailed Fisher exact test; p = 0.119) among the differentially expressed proteins 
for clone 1G3. Interestingly, one of the terminal transcription factors directly…  
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 Fold expression change 
Protein SH-SY5YUntr Clone 2E3 Clone 1G3 
V-crk avian sarcoma virus CT10 oncogene 
homolog-like 
-1.41 -1.14 -1.22 
Phospholipase C, gamma 1 -1.37 -1.32 -1.16 
Protein phosphatase 1, catalytic subunit, beta 
isozyme 
-1.49 -1.01 -1.12 
Protein phosphatase 2, regulatory subunit B, 
alpha 
-1.37 -1.09 -1.12 
Protein kinase, cAMP-dependent, regulatory, 
type I, alpha 
-1.67 -1.75 -1.47 
Ras-related C3 botulinum toxin substrate 1 -1.39 -1.33 -1.19 
Signal transducer and activator of 
transcription 3  
-2.22 -1.92 -1.11 
Talin 2 -2.08 -1.27 -1.30 
     
Overlap p-value for the canonical pathway 0.00283 0.0172 0.119 (n.s.) 
Activation state z-score -1.414 -2.000 N/A 
 
Table 4.10 – Effects of staurosporine treatment on ERK/MAPK pathway  
The table shows proteins in the ERK/MAPK canonical pathway, as defined by IPA, that were 
differentially expressed upon STS treatment in at least one of the cell lines. Fold change 
values are reported for each protein and those shown in black met the (+/-) 1.3 fold change 
threshold, whilst those in grey did not. Overlap p-values for the pathway were calculated by 
IPA using the right-tailed Fisher exact test. The activation state z-scores (see main text for 
more details about z-scores) suggest that the pathway may have been inhibited in 
SH-SY5YUntr and clone 2E3. No z-score was calculated for the pathway in clone 1G3, since the 
overlap p-value was non-significant (n.s.).  
 
… activated by ERK1/2, signal transducer and activator of transcription 3 (STAT3), 
was downregulated by around two fold in SH-SY5Untr and clone 2E3 as a result of 
STS treatment but was virtually unchanged in its expression in clone 1G3. STAT3 is 
thought to act in a pro-survival manner (Megison et al., 2013), and the proteomic 
data described in section 4.2 suggested that the baseline level of STAT3 expression 
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might have been higher in clone 1G3 (mean fold change of +1.690) than 
SH-SY5YUntr, although clone 2E3 might also have expressed slightly higher levels of 
the protein than the control line (fold change of +1.265). As a consequence of higher 
STAT3 expression levels, STAT3 activity might have been greater in clone 1G3 than 
the other cell lines prior to STS treatment, resulting in a reduced inhibitory effect of 
the toxin and improved survival. It should be pointed out though that the baseline 
expression level estimates may not have been that reliable, because STAT3 did not 
meet the criteria of more than two quantified unique peptides in either of the 
proteomic datasets reported in section 4.2. 
As previously described, the apparently similar levels and subcellular localisation 
patterns of PrPC expression among the stably transfected clones suggested that the 
differences in their responses to toxin treatment may have been artefacts of the 
transfection and/or clone isolation process. Further evidence was provided by the 
lack of effect of PrPC knockdown on survival of the stably transfected clones in 
response to PQ or STS treatment. Nonetheless, there had to be some molecular 
changes that were responsible for the variability in stress responses among the clones 
and increased activity of the ERK/MAPK pathway in clones 1G3 (and, presumably, 
also clone 1F3) under normal growth conditions is one potential explanation. An 
obvious caveat is that these proteomic experiments involved exposure to STS, 
whereas PQ and TM are not protein kinase inhibitors and so may affect the 
ERK/MAPK pathway in quite different ways. However, increased ERK/MAPK 
signalling would be expected to be protective under most circumstances.    
Aside from investigating the differences between the clones, the proteomic analyses 
described in section 4.2 were also carried out with the aim of identifying functions of 
PrPC not directly related to stress-protection. The hypothesis was that the proteomic 
changes common to clones 2E3 and 1G3 were most likely to have resulted from PrPC 
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5.1 Identification of molecular changes compared with 
untransfected cells that were common to clones 2E3 
and 1G3     
A large number of studies have found that PrPC expression protects cells from stress, 
although there is considerable controversy in the literature relating to this putative 
function. Accordingly, the first experiments performed using the PrPC-transfected 
SH-SY5Y cells were to assess their responses to stress. Results showed that the 
stably transfected clones were less viable than SH-SY5YUntr following serum 
deprivation, although clone-specific protection against three chemical toxins was 
observed. However, knocking down PrPC did not affect the resistance to toxin 
treatment of the clones, suggesting that this property was independent of PrPC 
expression. Therefore, the results reported in this thesis are not consistent with a 
direct role for PrPC in stress protection. This is not the only function that has been 
linked to PrPC though; others include neurite outgrowth (Graner et al., 2000; Loubet 
et al., 2012), circadian rhythm generation (Tobler et al., 1996; Sanchez-Alavez et al., 
2007) and myelin maintenance (Bremer et al., 2010; Nuvolone et al., 2016).  
Consequently, stable transfection of the Prnp CDS into the SH-SY5Y cells could 
have affected other processes; to investigate what these were, the proteomic data 
reported in section 4.2 were re-analysed. We hypothesised that the expression 
changes common to both clones were most likely to have resulted from PrPC 
expression, so I combined the datasets to identify the proteins that were differentially 
expressed in clones 2E3 and 1G3 compared with SH-SY5YUntr. The criteria were: 1) 
identification from more than two quantified unique peptides in all replicate datasets; 
and 2) fold change of >= 1.2 or <= -1.2 in all replicate datasets. Since the combined 
proteomic dataset effectively consisted of four biological replicates (two comparing 
SH-SY5YUntr and clone 2E3, and two comparing SH-SY5YUntr and clone 1G3), the 
fold change cut-off of (+/-) 1.2 was considered sufficiently stringent. Table 5.1 shows 
the 60 proteins that met these criteria, 11 of which were upregulated and 49 
downregulated.  
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Table 5.1 – List of proteins differentially 
expressed in both clones 2E3 and 1G3 
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Importantly, this list contained more than half (12 out of 22) of the proteins showing 
altered expression in clone 2E3 compared with SH-SY5YUntr according to the (+/-) 
1.4 fold change cut-off used for the initial analysis (see Table 4.2). This suggested 
that many of the proteomic changes observed in clone 2E3 were shared by clone 
1G3. As described in section 4.2.1, the accuracy of the proteomic data had already 
been validated by western blotting for a subset of targets. Subsequently, pathway 
analysis of the dataset shown in Table 5.1 was carried out using the IPA core analysis 
suite, as described previously.  
5.1.1 Cell cycle regulation 
IPA biofunction categories are groupings of genes known to have similar functions 
based upon the data contained with the software database (Ingenuity Knowledge 
Base). Summary data from the pathway analysis, shown in Table 5.2, indicates that 
the cell cycle biofunction was the fourth most overrepresented among the proteins 
differentially expressed between the stably transfected clones and SH-SY5YUntr. 
“Cell cycle” was also one of the biofunction categories making up the 
highest-confidence protein-protein interaction network generated by IPA – this 
feature of the software groups together proteins from the dataset that are known to 
interact with each other either directly or indirectly. Each biofunction consists of 
multiple subfunctions and Table 5.3 details the 12 differentially expressed proteins 
that were part of the cell cycle progression subfunction (overlap p-value9 = 
0.000538). One of these proteins was cyclin-dependent kinase 1 (CDK1), which was 
downregulated in clones 2E3 (expression fold change10 of -1.39) and 1G3 (-1.85 
fold) compared with SH-SY5YUntr. CDK1 plays a key role in the cell cycle; in fact 
CDK1 appears capable of driving the mammalian cell cycle in the absence of any 
other CDKs (Santamaria et al., 2007). Therefore, CDK1 downregulation by the… 
                                                 
9 IPA uses the right-tailed Fisher exact test to calculate p-values for overrepresentation of biofunctions 
and pathways in the analysed dataset.  
10 Mean expression ratios for the two replicate proteomic experiments were calculated and converted 
to fold change. This was the case for all fold change values derived from the proteomic data that are 
reported in Chapter 5. 
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Table 5.2 – Summary 
of pathway analysis 
of proteomic changes 
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…stably transfected clones suggested that PrPC transfection had slowed down cell 
cycle progression in the SH-SY5Y cells. Indeed, IPA calculated the activation state 
z-score11 for cell cycle progression to be -0.958, which suggests inhibition of the 
biofunction. 
Protein 
Mean expression fold change 
compared with SH-SY5YUntr 
Predicted effect 
on function 
Caldesmon +1.81 Affected 
U4/U6 small nuclear 
ribonucleoprotein Prp4 
-1.30 Increased 




Replication protein A 70 kDa DNA-
binding subunit 
+1.43 Decreased 
Peroxiredoxin-1 -1.48 Affected 
DNA mismatch repair protein Msh2 -1.49 Affected 
Suppressor of G2 allele of SKP1 
homolog 
-1.54 Affected 
60S ribosomal protein L11 -1.56 Affected 
Cyclin-dependent kinase 1 -1.59 Decreased 




reductase large subunit 
-2.03 Affected 
Table 5.3 – Proteins involved in cell cycle progression showed altered 
expression upon PrPC transfection  
This table shows the 12 proteins in the cell cycle progression biofunction, as defined by IPA, 
that were differentially expressed in stably transfected clones 2E3 and 1G3 compared with 
SH-SY5YUntr. For each protein, the predicted effect on cell cycle progression of the 
expression change is reported. “Affected” indicates that IPA could not determine the 
direction of the effect from the data contained in the Ingenuity Knowledge Base.    
                                                 
11 These z-scores represent the degree of confidence that a biofunction is activated (positive value) or 
inhibited (negative value). Z-scores > 2 or < -2 are generally considered statistically significant 
(Ingenuity Systems, [n.d.]), although lower values may still be informative, especially when the 
analysed datasets are quite small.    
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In addition to biofunctions and networks, IPA identifies the canonical pathways 
displaying the greatest overlap with the dataset being analysed. The top canonical 
pathway identified from the proteins differentially expressed as a result of PrPC 
transfection was ras-related nuclear protein signalling (overlap p-value = 0.0000162), 
which the Ingenuity Knowledge Base reports as vital for nucleocytoplasmic transport 
of macromolecules through the nuclear pore complex. Interestingly, altered ras-
related nuclear protein signalling could be a consequence of CDK1 downregulation, 
since CDK1 is known to phosphorylate the nuclear pore complex to promote its 
disassembly during mitosis (Onischenko et al., 2005). Therefore, any change to the 
activity of the ras-related nuclear protein signalling pathway could have resulted 
from the altered cell cycle regulation of the stably transfected clones. The same could 
be true for the apparent alterations to DNA replication, recombination and repair – 
this was the top biofunction identified from the proteomic data (Table 5.2) and the 
canonical pathway with the second-highest overlap p-value (0.0000362) was 
pyrimidine deoxyribonucleotide de novo biosynthesis I, which converts 
ribonucleotides to deoxyribonucleotides, an important step in DNA synthesis. 
Interestingly, ribonucleoside-diphosphate reductase large subunit is a key protein in 
the pyrimidine deoxyribonucleotide de novo biosynthesis I pathway and was shown 
by western blotting to be significantly downregulated in three out of four stably 
transfected clones compared with SH-SY5YUntr (Figure 4.6g). The proteomic data 
also showed that clones 2E3 and 1G3 expressed lower levels of condensin complex 
subunit 1 and structural maintenance of chromosomes protein 2, which are 
components of the condensin complex that reorganises chromatin prior to cell 
division and is required for effective segregation of sister chromatids (Hagstrom and 
Meyer, 2003). Reduced expression of these proteins and of ribonucleoside-
diphosphate reductase large subunit could be explained by slower cell cycle 
progression, since the need for DNA synthesis would be reduced and a smaller 
proportion of cells would be in mitosis at any one time.   
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5.1.2 Cytoskeletal organisation 
Cellular assembly and organisation was the second most overrepresented biofunction 
and was also strongly represented in the two highest-confidence protein-protein 
interaction networks generated by IPA (Table 5.2). Table 5.4 specifically highlights 
the 11 proteins from the dataset of differentially expressed proteins that were in the 
organisation of cytoplasm subfunction (overlap p-value = 0.0357). This subfunction 
had a positive activation state z-score of +1.524 and includes many proteins involved 
in cytoskeletal organisation. Furthermore, three of the top five most upregulated 
proteins in the proteomic dataset were part of the organisation of cytoplasm 
subfunction: neuromodulin, vimentin and caldesmon. The accuracies of these 
expression changes were largely confirmed by western blotting (Figure 4.6b, e & f), 
although the increased caldesmon expression by clone 1G3 was not statistically 
significant according to this method of analysis (one-sample t-test: p = 0.065). 
Vimentin is a class-III intermediate filament protein and is, therefore, an integral part 
of the cytoskeleton. Changes to vimentin expression can also affect cell shape 
(Mendez et al., 2010), which is of note given the morphological alterations displayed 
by clones 1G3 and 1F3 (Figure 3.9d & e). Furthermore, Table 5.2 shows that the cell 
morphology biofunction was overrepresented among the proteins that were 
differentially expressed as a result of PrPC transfection. This might indicate that 
clone 2E3 and, by extension, clone 1B5 may also have differed morphologically 
from SH-SY5YUntr in ways that could not be picked up visually.  
Change in expression of the actin-binding protein caldesmon is known to cause 
dramatic reorganisations of the actin cytoskeleton (Grosheva et al., 2006) and 
caldesmon can also modulate how cells interact with each other and the extracellular 
environment. For example, caldesmon binds to myosin to inhibit the formation of 
focal adhesions, which are connections between cells and the extracellular matrix  
(Helfman et al., 1999). Additionally, caldesmon overexpression can induce broad 
lamellipodial protrusions (Grosheva et al., 2006), which bear some similarities to the 
broad connections between cells that were observed in cultures of clones 1G3 and 
1F3 (Figure 3.9d & e).   
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Protein 
Mean expression fold change 
compared with SH-SY5YUntr 
Predicted effect 
on function 
Caldesmon +1.81 Affected 
Cyclin-dependent kinase 1 -1.59 Affected 
Protein 4.1 -1.59 Increased 
Lysosomal alpha-glucosidase +2.75 Affected 
Neuromodulin +2.63 Increased 
Unconventional myosin-Ib -1.70 Affected 
Nucleoside diphosphate kinase A -1.38 Increased 
Neuronal cell adhesion molecule -1.46 Decreased 
Regulator of chromosome 
condensation 
-1.65 Affected 
Neurosecretory protein VGF +4.62 Increased 
Vimentin +3.25 Affected 
 
Table 5.4 – Proteins involved in organisation of the cytoplasm showed altered 
expression upon PrPC transfection  
This table shows the 11 proteins in the organisation of the cytoplasm biofunction, as 
defined by IPA, that were differentially expressed in stably transfected clones 2E3 and 1G3 
compared with SH-SY5YUntr. For each protein, the predicted effect on cytoplasmic 
organisation of the expression change is reported. “Affected” indicates that IPA could not 
determine the direction of the effect from the data contained in the Ingenuity Knowledge 
Base.    
 
Although not appearing in the list of differentially expressed proteins from the 
proteomic experiments due to not meeting the requirement for the number of 
quantified unique peptides in one of the replicates, a protein called zyxin was 
confirmed by western blotting as upregulated in all four clones compared with 
SH-SY5YUntr (Figure 4.6c). Like caldesmon, zyxin can be localised to actin bundles, 
seemingly for repair processes (Smith et al., 2010). Zyxin is also present in focal 
adhesions and adherens junctions that connect neighbouring cells (Hirata et al., 
2008). Altered expression of neuronal cell adhesion molecule in the stably 
transfected clones provides further evidence suggesting that PrPC can modulate 
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cell-cell interactions. Furthermore, zyxin appears to have a role in maintaining the 
integrity of neuritic branches that interact with other cells (Luo et al., 2014). In 
addition to neurite maintenance, the stably transfected clones exhibited altered 
expression of proteins involved in neurite outgrowth, a process requiring 
considerable cytoskeletal remodelling. For example, western blotting analyses 
showed that neuromodulin, a vital part of the axon growth cone, was upregulated in 
all four clones compared with SH-SY5YUntr (Figure 4.6b) and neurosecretory protein 
VGF, which is also thought to be involved in neuritogenesis (Sakamoto et al., 2015), 
was the most upregulated protein identified by the proteomic analysis. Indeed, 
western blotting showed that neurosecretory protein VGF was upregulated by an 
average of ~15 fold in the stably transfected clones. On the other hand, the pathway 
analysis suggested that the growth of neurites was largely unchanged by PrPC 
transfection (5 proteins from the proteomic dataset; overlap p-value = 0.0299; 
activation state z-score of +0.372) and, as reported previously, clones 1G3 and 1F3 
seemed to produce fewer neurite-like protrusions than SH-SY5YUntr (Figure 3.9d & 
e). It is unclear why PrPC transfection resulted in proteomic changes associated with 
increased neurite outgrowth, whilst the actual production of neurite-like protrusions 
was inhibited.   
5.1.3 Ubiquitination 
Whilst many of the proteomic changes induced by PrPC transfection can be explained 
by alterations to cell cycle regulation and cytoskeletal organisation, the third 
highest-confidence protein-protein interaction network generated by IPA should also 
be mentioned. Figure 5.1 shows this network, which is centred on polyubiquitin C 
(UBC) and contains 17 of the proteins that were differentially expressed between the 
stably transfected clones and SH-SY5YUntr. UBC is involved in ubiquitination, a 
post-translational modification that usually targets proteins for degradation. Aside 
from general degradation of unrequired or damaged proteins, ubiquitination is 
involved in DNA repair processes and also plays a key role in regulating the 
expression levels of the cyclins and cyclin-dependent kinases that control the cell 
cycle (Komander and Rape, 2012). A trivial explanation for generation of this…  
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Figure 5.1 – Network generated from the differentially expressed proteins with 
polyubiquitin C at the centre  
This figure shows one of the protein-protein interaction networks generated by IPA from the 
dataset of proteins that were differentially expressed in the clones 2E3 and 1G3 compared 
with SH-SY5YUntr. Experimentally confirmed direct interactions are given by solid lines, 
indirect interactions by dotted lines. Arrows indicate the direction of regulation i.e. GNPTG 
upregulates GAA through an indirect interaction. Red-highlighted proteins are those 
upregulated in the stably transfected clones, green-highlighted proteins were 
downregulated. An absence of highlighting indicates proteins that were not differentially 































Chapter 5: Elucidating the downstream processes 
regulated by PrPC in SH-SY5Y cells  165 
…network is that IPA simply connected together lots of proteins that can be 
ubiquitinated and PrPC is not involved in this process. Nevertheless, given the 
relatively high network p-score12 of 35, it seemed possible that PrPC could modulate 
overall levels of protein ubiquitination and this is further explored in section 5.4. 
Another possibility was that any changes to ubiquitination were linked specifically to 
the apparently altered cell cycle regulation of the stably transfected clones. For 
example, the nuclear pore complex protein Nup205 is part of the network shown in 
Figure 5.1, as are three proteins - transportin-1 (TNPO1), importin-5 (IPO5) and 
karyopherin beta – that are involved in the transport of cargo through the nuclear 
membrane. Since the nuclear pore complex is disassembled during mitosis, changes 
to cell cycle progression might affect expression levels of proteins within the 
complex. These expression changes might have been mediated, at least in part, by 
differential regulation of ubiquitination of the nuclear pore complex proteins 
(Hayakawa et al., 2012).   
Although not part of the network shown in Figure 5.1, several E3 ubiquitin protein 
ligases, which are required for transferring ubiquitin to protein substrates, were 
differentially expressed in the stably transfected clones. For example, pre-mRNA-
processing factor 19 (PRPF19) and suppressor of G2 allele of S-phase kinase-
associated protein 1 homolog (SUGT1) were both downregulated in clones 2E3 and 
1G3 according to the proteomic analyses. Additionally, the expression of E3 
ubiquitin-protein ligase BRE1A was assessed by western blotting (see Figure 4.6h) 
and was shown to be reduced by small but significant amounts in clones 1G3 and 
1F3 compared with SH-SY5YUntr. However, no such downregulation was observed 
in clones 2E3 and 1B5, suggesting that any expression changes to BRE1A may have 
been independent of PrPC expression.  
                                                 
12 P-scores are the negative logarithms of p-values determined by the right-tailed Fisher exact test. 
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5.1.4 Cell death and survival 
The third most overrepresented biofunction identified by the pathway analysis was 
cell death and survival. Within the overall category, 11 proteins from the dataset of 
differentially expressed proteins were part of the cell survival subfunction (overlap 
p-value = 0.0187), which had an activation z-score of -1.382. Moreover, 25 proteins 
from the dataset were included in the cell death subfunction (overlap p-value = 
0.000862), which had a positive activation z-score (+1.376). These results suggest 
that the stably transfected clones were less viable than SH-SY5YUntr under normal 
culture conditions, which is consistent with the increased sensitivity to serum 
deprivation that resulted from PrPC transfection (Figure 3.13) and provides further 
evidence that PrPC expression is not stress-protective in SH-SY5Y cells.  
The role of PrPC in the response to stress had already been investigated in detail, as 
described in Chapters 3 and 4. Therefore, follow-up experiments concentrated on 
exploring the putative roles of PrPC in cell cycle regulation (section 5.2), cytoskeletal 
organisation (section 5.3) and protein ubiquitination (section 5.4).   
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5.2 PrPC expression inhibits proliferation of SH-SY5Y cells  
The altered expression of proteins involved in cell cycle regulation, combined with 
my own observations from culturing the cells, strongly suggested that PrPC 
transfection reduced the proliferation rate of the SH-SY5Y cells. To obtain 
confirmation that this was the case, the different cell lines were seeded into tissue 
culture plates at equal densities and allowed to proliferate in standard medium 
containing foetal bovine serum. Cell counts were performed by staining nuclei with 
Hoescht 33342, capturing fluorescence images and then using a macro plug-in to the 
imaging software ImageJ to identify the nuclei and quantify the number of cells in 
each image. Initial counting was performed ~16 h after seeding to allow cells to 
adhere to the surface – the presence of floating, non-adherent cells would have 
disrupted the counting. At this 16 h time point, SH-SY5YUntr cells were present in 
slightly greater numbers than the stably transfected clones, although this difference 
was not significant (Figure 5.2a). However, four days after seeding, the differences in 
relative cell numbers between SH-SY5YUntr and the stably transfected clones were 
much greater and were statistically significant (Figure 5.2b). This confirmed that 
SH-SY5YUntr proliferated faster than clones 2E3 and 1G3 and, perhaps, suggests that 
any differences at 16 h could have been due to some proliferation having already 
occurred by this point. Additionally, there was no significant difference between the 
clones in terms of relative cell numbers at Day 4 (one-sample t-test: p = 0.0673).  
 
Whilst the results described above seemed clear, a potential confounding factor was 
the tendency for SH-SY5Y cells to move towards the middle of the well before 
adhering; this occurred even if the cells were evenly spread over the well surface 
upon seeding. This was partially controlled for by taking three images per well in 
exactly the same positions each time. However, to get further confirmation of slower 
proliferation by the stably transfected clones, an alternative method was employed. 
This consisted of using the PrestoBlue viability reagent (see Chapter 3 for further 
information) to quantify the total metabolic activity in each well, which should be 
proportional to the number of cells present. As before, the cell lines were seeded into 
plates at equal densities but, this time, cell numbers were measured daily for 6 days.  
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Figure 5.2 – Stably transfected clones proliferated slower than untransfected 
cells  
Bar charts A and B show relative cell numbers for the different cell lines at 16 h (A) and 
4 days (B) after seeding at equal densities. Nuclear staining followed by automated cell 
counting from microscope images using ImageJ gave absolute numbers for each cell line, 
which were then normalised to the slowest-growing line (clone 1G3). Bar chart C shows 
relative cell numbers determined at daily intervals using the PrestoBlue viability reagent 
instead. The mean normalised values (+/- standard error of the mean) from three (A & C) or 
four (B) independent experiments are displayed in the bar charts. Differences in relative cell 
numbers were tested for significance (p < 0.05; indicated with *) using unpaired, two-
sample t-tests or one-sample t-tests as appropriate.   
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Each time point was considered separately, since fluorescence signals obtained on 
different days could not be accurately compared. The data show that there were 
significantly more cells in the SH-SY5YUntr wells than in the clone 1G3 wells from 
day 3 onwards and this disparity consistently increased over subsequent days 
(Figure 5.2c). Clone 2E3 proliferated faster than clone 1G3, as shown by a 
significant difference in relative cell number at day 6. Nonetheless, SH-SY5YUntr 
cells were present in significantly greater numbers than both clones at day 6. 
 
Given the potentially PrPC-independent differences in stress responses and 
morphology between SH-SY5YUntr and at least some of the stably transfected clones, 
it was important to confirm that the effect on proliferation was dependent upon PrPC. 
This was assessed by reverse transfecting the cells either with a negative control 
siRNA or with the PrP siRNA s72188 – this was performed as described in section 
4.1, except that the siRNA dose was increased to 15 nM (from 5 nM) to ensure more 
effective reduction of PrPC expression. Subsequently, total well metabolic activity 
was quantified daily over the course of one week using the PrestoBlue viability 
reagent. Initial findings showed that the transfection procedure was rather toxic to the 
cells (data not shown), most likely because cells were transfected at low densities (to 
allow space for proliferation) and sparse cultures are more sensitive to this process. 
The toxicity manifested in lower total well metabolic activity at Day 1 compared 
with cells not exposed to the transfection reagent. However, this was not considered 
an issue, since data from later time points indicated no long-lasting effect on 
proliferation/viability and, in any case, PrP siRNA-transfected cells could be 
compared directly with negative control siRNA-transfected cells. Indeed, as would 
be predicted based on an anti-proliferative role for PrPC, these comparisons showed 
that PrPC knockdown increased proliferation of clone 1G3 - differences in relative 
cell numbers compared with negative control siRNA-transfected cultures were 
significant at 4, 6 and 7 days after seeding at equal densities and the magnitude of the 
differences increased with time (Figure 5.3c). For clone 2E3, PrP siRNA transfection 
led to significantly greater cell numbers at day 3, whilst a similar (non-significant) 
trend could be observed at most other time points (Figure 5.3b), a trend not evident 
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Figure 5.3 – SiRNA-mediated PrPC knockdown enhanced proliferation of 
clones 2E3 and 1G3  
Bar charts showing the cell numbers of PrP siRNA (s72188)-transfected cultures relative to 
those of negative control siRNA-transfected cultures (marked with dotted line) for the 
different cell lines at daily intervals after seeding plates at equal densities. Cells were 
transiently transfected with siRNAs at Day 0 and relative cell numbers were determined 
using the PrestoBlue viability reagent. The mean normalised values (+/- standard error of 
the mean) from five independent experiments are displayed in the bar charts. Differences in 
relative cell numbers were tested for significance (p < 0.05; indicated with *) using one-
sample t-tests.   
in the data for SH-SY5YUntr (Figure 5.3a). These results, therefore, provide 
reasonable proof that PrPC is a negative regulator of proliferation in SH-SY5Y cells.   
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One question raised by the proliferation data is why the PrP siRNA was less effective 
at increasing the proliferation rate of clone 2E3 than that of clone 1G3. Firstly, in the 
absence of any siRNA transfection, clone 2E3 proliferated faster than clone 1G3 and, 
therefore, at a rate closer to that of SH-SY5YUntr, which meant there was less of a 
difference that could be rescued by knocking down PrPC. Secondly, siRNA-mediated 
knockdown of expression loses effectiveness over time due to reduction in the 
siRNA concentration as the cells divide. The degree of PrPC knockdown had been 
shown previously to be similar for both clones up to 68 h after transfection (Figure 
4.3). However, it seemed likely that the faster proliferation rate of clone 2E3 would 
have caused PrPC expression to begin increasing again earlier than for clone 1G3. To 
test this, PrPC expression levels in PrP siRNA- and negative control siRNA-
transfected cells were compared by western blotting at days 4, 5, 6 and 7 post 
transfection. Albeit from a single experiment, the data showed that PrPC knockdown 
was at ~85 % in both clones at Day 4 and PrPC expression began to recover from 
then onwards (Figure 5.4). Furthermore, at all time points, the percentage 
knockdown of PrPC expression appeared to be greater for clone 2E3 than clone 1G3, 
a difference that was most marked at Day 7. This may have contributed towards the 
relatively limited effect of the PrP siRNA on proliferation of clone 2E3.  
   
The results reported in this section confirm that PrPC acts as a negative regulator of 
proliferation in SH-SY5Y cells. This is in line with published data from 
oligodendrocyte precursor cells (Bribian et al., 2012), neuronal cell lines derived 
from Zurich I PrPC-null mice (Kim et al., 2005) and cells derived from the intestinal 
epithelium (Morel et al., 2008). Contrastingly, Steele et al. (2006) describe a role for 
PrPC in promoting proliferation of neural precursors in mouse brain regions that 
exhibit adult neurogenesis and one study that used a mouse neuroblastoma cell line 
(N2a) found that PrPC transfection enhanced proliferation (Llorens et al., 2013). This 
cell type-specificity could be explained by PrPC modulating the cellular response to 
specific growth factors that different cell types have differing sensitivities to. 
Intriguingly, Llorens et al. (2013) did identify a potential interaction in N2a cells 
between PrPC and the epidermal growth factor receptor, and expression of PrPC itself 
can be induced by other growth factors, including nerve growth factor (NGF) 
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Figure 5.4 – SiRNA-mediated PrPC knockdown may have lasted for a longer 
period in clone 1G3 cells compared with clone 2E3  
Western blot images and bar chart summarising quantification of PrPC immunostaining from 
a single experiment. PrPC was detected by use of the BC6 anti-PrPC primary antibody 
(McCutcheon et al., 2014). Data is shown for clone 2E3 and clone 1G3 lysates that were 
prepared 4, 5, 6 or 7 days after transient transfection with a negative control siRNA or the 
PrP siRNA (s72188). After correction for loading errors, data were normalised to the signal 
from the negative control siRNA-transfected lysate for that time point.   
(Kuwahara et al., 2000; Zawlik et al., 2006) and insulin-like growth factor 1 (Liu et 
al., 2013). Potential links between PrPC and growth factor signalling are explored 
further in Chapter 6.  
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5.3 Further investigating the links between PrPC and 
cytoskeletal organisation  
5.3.1 Proteins involved in cytoskeletal organisation displayed no 
significant expression changes in the mouse forebrain as a 
result of PrPC knockout  
A number of proteins involved in cytoskeletal organisation were differentially 
expressed in some or all the stably transfected clones compared with SH-SY5YUntr 
and, in several cases, the fold changes were large. To investigate the physiological 
relevance of these data, expression levels of six of these targets – zyxin, vimentin, 
caldesmon, neuromodulin, annexin A2 and neurosecretory protein VGF - were 
assessed in PrPC-null mouse forebrain tissues. The tissues were available from an 
earlier study carried out by my research group that investigated proteomic and 
transcriptomic changes induced by PrPC knockout in mice. These mice are on the 
129/Ola background and were originally produced by gene targeting methods in 
Edinburgh in the early 1990s (Manson et al., 1994) – the knockout line is referred to 
as “Npu”. Age- and sex-matched wild type (129/Ola) and PrPC-null tissues were 
available from adult mice of various ages. However, for reasons explained in 
section 5.5, tissues from mice culled at ~550 days of age were used in this analysis. 
In the original study, the forebrains were removed and the two hemispheres split 
apart before freezing in separate tubes. I homogenised 10 half-forebrains of each 
genotype (five male, five female) and confirmed by western blotting that PrPC 
expression was absent in the PrPC-null tissues (Figure 5.5a). Zyxin was undetectable, 
which is consistent with previous data from adult mouse brain (Fujita et al., 2009), 
and, although vimentin could be detected, expression was at an insufficient level for 
accurate quantification. Caldesmon and neuromodulin were quantifiable but, as 
shown in Figure 5.5, there was no significant effect of genotype on their expression 
levels (unpaired, two-sample t-tests: p = 0.46 and p = 0.54, respectively).  
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A) PrPC 
 























E) Neurosecretory protein VGF   
 
Figure 5.5 – PrPC knockout did not affect overall mouse forebrain expression 
of several proteins linked to cytoskeletal organisation 
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10 PrPC-null mouse forebrain homogenates (5 of each sex for both genotypes). PrPC was 
detected by use of the BC6 anti-PrPC primary antibody (McCutcheon et al., 2014). 
B-E) Representative images of western blots for caldesmon, neuromodulin, annexin A2 and 
VGF using the same brain homogenates as in A (only 6 of each genotype were used when 
blotting for VGF). Anti-VGF primary antibody was from Abcam (#ab74140); the others were 
from Cell Signalling Technology and had the following catalogue numbers: #12503 (B), 
#5307 (C) and #8235 (D). F) Bar chart summarising quantification of immunostaining for the 
various protein targets. After correction for loading errors, signals on each blot for 
caldesmon, neuromodulin or annexin A2 were normalised to a fixed reference sample – a 
“pool” consisting of equal amounts of all 20 brain homogenates. For each tissue, the mean 
normalised expression values from at least three technical replicates were calculated. For 
VGF, the data were normalised to the mean signal from the WT tissues. The far left band in 
image E was not included in quantification due to obvious issues with transfer and/or 
immunostaining. For all protein targets, overall mean normalised expression values for each 
genotype were calculated and these are indicated in the bar charts (+/- standard error of 
the mean). Expression differences between genotypes were tested for significance 
(p < 0.05) using unpaired, two-sample t-tests but no comparisons met the threshold. 
 
Whilst the function of annexin A2 is still poorly understood, it has been implicated in 
cytoskeletal reorganisation (Singh et al., 2004; Falsey et al., 2006) and was shown by 
western blotting to be highly upregulated in all four stably transfected clones 
compared with SH-SY5YUntr (Figure 4.6a). However, as per the other targets, mouse 
forebrain expression of annexin A2 was not significantly affected by PrPC knockout 
(p = 0.16; Figure 5.5). Similarly, neurosecretory protein VGF expression level did 
not vary with genotype (p = 0.64), although these data were obtained from only six 
wild type and six PrPC-null tissues due to time constraints.    
 
Whilst these negative results might indicate that PrPC does not influence cytoskeletal 
organisation in vivo, there are other potential explanations. Firstly, PrPC expression 
may have distinct effects depending on the cell type, which could result in changes 
arising from PrPC knockout being averaged out over an entire tissue (Mehrabian et 
al., 2014; Mehrabian et al., 2016). Secondly, the tissues used in these experiments 
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were from relatively old, adult mice, whereas SH-SY5Y cells are thought to be 
similar to immature catecholaminergic neurons in terms of phenotype (Kovalevich 
and Langford, 2013). Therefore, the expression changes seen in SH-SY5Y cells 
might be replicated only in embryonic or neonatal mouse brains and not in the adult. 
Thirdly, other studies have identified connections between PrPC and cytoskeletal 
organisation before. For example, PrPC has been proposed to interact directly with 
annexin A2 (Morel et al., 2008) and vimentin (Zafar et al., 2014; Lappas Gimenez et 
al., 2015), whilst proteomic analyses of an epithelial cell line showed that PrPC 
knockout or knockdown affected expression of annexins as well as cytoskeletal 
keratins, which are another family of intermediate filament proteins (Mehrabian et 
al., 2014). Interestingly, induction of PrPC overexpression in a mouse neuroblastoma 
cell line downregulated expression of vimentin, as well as other cytoskeletal proteins 
(Provansal et al., 2010), whereas my experiments showed that vimentin was greatly 
upregulated in human neuroblastoma cells stably expressing PrPC. 
5.3.2 Alterations to cytoskeletal organisation in clone 1G3 but not in 
clone 2E3 compared with untransfected SH-SY5Y cells 
Whilst several previous studies have identified PrPC-induced expression changes to 
proteins involved in cytoskeletal organisation, there has been limited assessment of 
whether these molecular changes translate into an actual reorganisation of the 
cytoskeleton. Therefore, I decided to compare the cytoskeletal architectures of 
SH-SY5YUntr and stably transfected clones 2E3 and 1G3 by immunofluorescence 
staining. Briefly, cells were cultured in optically-clear 96-well plates and fixed 
24 hours later. Intermediate filaments and microfilaments were detected using a 
vimentin antibody and the filamentous actin-binding toxin phalloidin, respectively. 
After immunostaining, high-magnification z-stack images of the cells were taken 
using a confocal microscope and maximum intensity projections from these images 
are shown in Figure 5.6. Overall, the vimentin staining pattern was similar in all 
cases, although there were subtle differences between clone 1G3 and the other cell 
lines; specifically, intermediate filaments were visible in the cytoplasm above the…  
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…nucleus (in the z-plane) for SH-SY5YUntr and clone 2E3 but not clone 1G3. These 
data might indicate that the clone 1G3 cells were flatter but, equally, the observable 
differences may have been an artefact of the imaging process itself. However, whilst 
SH-SY5YUntr and clone 2E3 also had similarly organised actin cytoskeletons, clone 
1G3 appeared quite different – the broad strands of intense red colour in Figure 5.6c 
suggested organisation of actin microfilaments into large stress fibres, which are 
contractile structures required to power processes like cell migration, cell division 
and neurite outgrowth (Tojkander et al., 2012). These cytoskeletal changes can be 
explained at the molecular level by downregulation of unconventional myosin-1b 
(MYO1B; -2.15 fold in proteomic data) and upregulation of non-muscle myosins 
(+3.25 fold for myosin-9 and +1.68 fold for myosin-10) in clone 1G3 compared with 
SH-SY5YUntr. Myosins 9 and 10 are myosin class II proteins, which polymerise into 
filaments that form stress fibres in conjunction with actin (Tojkander et al., 2012), 
whilst knockdown of MYO1B reportedly increases the abundance of stress fibres 
(Makowska et al., 2015). Thick stress fibres, like those found in clone 1G3, are 
thought to inhibit both cell motility and the ability to undergo shape changes 
(Tojkander et al., 2012). Indeed, neurite outgrowth seems to require disassembly of 
stress fibres (Troller and Larsson, 2006), potentially explaining why clone 1G3 
produced fewer neurites than the other cell lines (Figure 3.8). Intriguingly, one study 
found that control, PrPC-expressing 1C11 neuroepithelial progenitor cells displayed 
reduced actin microfilament stability and enhanced neurite outgrowth compared with 
cells in which PrPC expression was stably knocked down (Loubet et al., 2012). The 
authors proposed that PrPC negatively regulates integrin beta-1 signalling, leading to 
inhibition of the ras homolog gene family, member A (RhoA)/Rho-associated protein 
kinase (ROCK) pathway that represses neurite outgrowth. Given that integrin beta-1 
expression was increased by 2.33 fold in clone 1G3 according to the proteomic data 
but largely unchanged (+1.21 fold upregulation) in clone 2E3 compared with 
SH-SY5YUntr, it may be that enhanced integrin signalling in clone 1G3 led to the 
formation of thicker, less dynamic stress fibres and reduced levels of neurite 
outgrowth. Whether this process could have been driven by PrPC expression is 
unclear given that PrPC inhibited integrin signalling in 1C11 cells (Loubet et al., 
2012) and several other studies have also found that PrPC can promote neurite 
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outgrowth (Lopes et al., 2005; Llorens et al., 2013). However, Loubet et al. (2012) 
discovered that 1C11 cells overexpressing PrPC did not extend neurites, which 
suggests that PrPC expression may need to be within a certain range for neurite 
outgrowth to occur. This could explain why clone 2E3 could produce neurite-like 
protrusions but clone 1G3 could not, since clone 1G3 might have initially expressed 
more PrPC than clone 2E3 (see Figure 3.4). Furthermore, in spite of the lack of visual 
differences between the actin cytoskeletons of clone 2E3 and SH-SY5YUntr 
(Figure 5.6a & b), expression levels of actin-binding proteins zyxin and caldesmon 
were upregulated in clone 2E3 as they were in clone 1G3 (Figure 4.6c & f), whilst 
MYO1B was also downregulated in both clones 2E3 and 1G3. The only difference 
between the clones was that the expression changes were generally of lower 
magnitude in clone 2E3. Therefore, it is possible that clone 2E3 would have 
contained thicker stress fibres and produced fewer neurite-like protrusions had the 
relevant molecular changes been more extreme.  
Figure 5.6 – Alterations to actin cytoskeleton in clone 1G3 compared 
with clone 2E3 and untransfected SH-SY5Y cells 
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5.4 Further investigating the potential links between PrPC 
and ubiquitination  
5.4.1 Overall levels of protein ubiquitination in SH-SY5Y cells were 
unaffected by PrPC transfection  
Pathway analysis of the proteomic changes induced by PrPC transfection suggested 
that protein ubiquitination might have been altered in some way in the stably 
transfected clones. Whilst no clear link between PrPC and ubiquitination can be made 
from the literature, deficits in ubiquitination have been shown to precede the 
neuronal loss and subsequent behavioural changes that occur in TSEs (McKinnon et 
al., 2016) as well as other neurodegenerative disorders (Figueiredo-Pereira et al., 
2015; Opattova et al., 2015). Therefore, protein ubiquitination by the SH-SY5Y cell 
lines was assessed. As in previous experiments, cells were seeded into tissue culture 
plates and lysed 24 hours later. Two independently prepared sets of lysates were 
analysed by western blotting, making use of an antibody that binds to ubiquitin 
conjugated to proteins as well as the unconjugated form. Figure 5.7a shows the 
staining pattern obtained – a band at ~8.5 kDa corresponding to monomeric, 
unconjugated ubiquitin (known as monoubiquitin) and a smear at higher molecular 
weights indicating detection of ubiquitinated proteins. Although the gaps between 
lanes for the monoubiquitin bands were difficult to define by eye, the ImageStudio 
software used for quantification can automatically detect the lane edges based on 
where the signal intensity drops; therefore, the quantification should have been 
accurate. Neither the total amount of conjugated ubiquitin nor the abundance of 
monoubiquitin varied noticeably among clones 2E3, 1B5 and SH-SY5YUntr 
(Figure 5.7b & c). By both these measures, ubiquitination appeared slightly reduced 
in clones 1G3 and 1F3 but there was a great deal of variability between the two 
replicate sets of cell lysates. In any case, the levels of conjugated ubiquitin and 
monoubiquitin did not vary significantly between SH-SY5YUntr and the group of 
stably transfected clones as a whole (one-sample t-tests; n = 4; p = 0.56 and p = 0.18, 
respectively).   
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Figure 5.7 – No significant differences in overall protein ubiquitination 
between untransfected SH-SY5Y cells and stably transfected clones  
A) Representative western blot images showing immunostaining of SH-SY5Y cell lysates 
produced by use of an anti-ubiquitin primary antibody (Millipore #MAB1510). B & C) Bar 
charts summarising quantification of the smear of ubiquitinated proteins (B; only quantified 
staining from 80-200 kDa since bands were extremely faint below 80 kDa) and also 
monoubiquitin (C) from two independently prepared sets of cell lysates. After correction for 
loading errors, the data were normalised to the signal from the SH-SY5YUntr lysate. The 
mean normalised expression values (+/- standard error of the mean) are indicated in the 
bar charts. There were no clear effects of PrPC transfection on overall protein ubiquitination 























Chapter 5: Elucidating the downstream processes 
regulated by PrPC in SH-SY5Y cells  182 
5.4.2 Evidence for regulation of specific ubiquitin ligases by PrPC 
Although it appeared that PrPC was not regulating protein ubiquitination at a gross 
level, a more targeted effect was conceivable. One possibility was that PrPC might 
regulate ubiquitination of proteins involved in cell cycle progression. Indeed, the 
aforementioned proteomic analyses showed that E3 ubiquitin-protein ligase SUGT1 
was downregulated by 1.39 fold in clone 2E3 and 1.69 fold in clone 1G3 compared 
with SH-SY5YUntr. SUGT1 is part of the SCF ubiquitin ligase complex, which 
targets specific cyclins and CDK-regulating proteins for degradation (Kitagawa et al., 
1999). Loss of SUGT1 in yeast prevents the G1/S and G2/M cell cycle phase 
transitions (Kitagawa et al., 1999), whilst SUGT1 overexpression is associated with 
cancer (Iwatsuki et al., 2010). Therefore, reduced SUGT1 expression may have been 
a consequence of the slower proliferation of the stably transfected clones.  
PRPF19 is another E3 ubiquitin-protein ligase that was downregulated in the stably 
transfected clones (-1.22 fold in clone 2E3 and -1.72 fold in clone 1G3). As a 
member of the Nineteen complex, PRPF19 is associated with the spliceosome, a 
large molecular machine that carries out alternative splicing of pre-mRNAs. Splicing 
factors, such as U4/U6 small nuclear ribonucleoprotein Prp3 are ubiquitinated by 
PRPF19 in order to modify spliceosome function (Chanarat and Strasser, 2013). Two 
other proteins involved in pre-mRNA splicing, the U4/U6 small nuclear 
ribonucleoprotein Prp4 and splicing factor 3A subunit 2, were also downregulated in 
clones 2E3 and 1G3. However, in addition to its role at the spliceosome, PRPF19 is 
thought to mediate repair of DNA damage via its interaction with replication protein 
A (RPA). RPA binds exposed, single-stranded DNA and can recruit ATR-interacting 
protein (ATRIP), leading to activation of the serine/threonine-protein kinase ATR, 
which, in turn, initiates various DNA damage response pathways; ubiquitination of 
the 32 kDa RPA subunit by PRPF19 in response to DNA damage appears to enhance 
the RPA-ATRIP interaction (Marechal et al., 2014). RPA consists of 70, 32 and 
14 kDa subunits, all of which were downregulated in clone 2E3 (-1.35, -1.40 
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and -1.87 fold, respectively) and clone 1G3 (-1.52, -1.90 and -1.50, respectively13) 
compared with SH-SY5YUntr. Furthermore, the DNA mismatch repair protein Msh2 
was also downregulated in the stably transfected clones (-1.35 fold in clone 2E3 and 
-1.64 fold in clone 1G3). Overall, it seems likely that the stably transfected clones 
had reduced spliceosome activity and less active DNA repair processes. Whether 
these changes were directly controlled by PrPC is unclear; it is conceivable that they 
were indirect consequences of slower cell cycle progression, for example. One 
unanswered question is whether less active DNA repair processes led to greater basal 
levels of DNA damage in the stably transfected clones or, conversely, whether the 
repair process were downregulated because of reduced damage. The latter argument 
is supported by previous reports of a role for PrPC in protecting against DNA damage 
(Senator et al., 2004; Watt et al., 2007; Bravard et al., 2015).  
The results presented in this chapter so far have shown that PrPC is a negative 
regulator of proliferation in SH-SY5Y cells and that PrPC transfection results in 
altered expression of various proteins involved in cytoskeletal organisation. In one of 
two clones tested, these molecular changes resulted in modifications to the actin 
cytoskeleton; specifically, the actin microfilaments of clone 1G3 cells seemed to be 
organised into fibres that were thicker and, presumably, less dynamic than those of 
the SH-SY5YUntr cytoskeleton. Specific E3 ubiquitin-protein ligases involved in 
pre-mRNA splicing, DNA repair and in modulating the expression of elements of the 
cell cycle regulatory machinery were also differentially expressed in the stably 
transfected clones. However, all of these data were obtained from in vitro 
experiments. In contrast, the following section reports on validation of an earlier 
study to investigate PrPC function that identified protein/gene expression changes 
resulting from PrPC knockout in mice.   
                                                 
13 Some of these expression ratios were determined from only two quantified unique peptides and, 
therefore, may not be particularly reliable.   
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5.5 Validating proteomic and transcriptomic changes 
induced by PrPC knockout in mice  
The previous sections of this chapter focused on investigations of PrPC function in 
the SH-SY5Y neuroblastoma cell line. To complement the data from the cell model, I 
returned to an earlier study carried out by my research group that identified 
proteomic and transcriptomic changes that occurred in the forebrain as a result of 
PrPC ablation in mice. The original hypothesis of this study was that the proposed 
stress-protective role of PrPC might become more important with age, since oxidative 
damage and other forms of cellular stress would be expected to build up over time. 
Therefore, the experiments were designed to examine the molecular changes found 
in older mice, specifically those culled at either 400 or 700 days old. The proteomic 
and transcriptomic datasets were combined to generate a list of proteins/genes that 
were differentially expressed at either or both time points and a subset of these 
targets was chosen for validation by western blotting. At the time, we were interested 
in proteins involved in mitochondrial function, neuronal excitability, oxidative stress 
responses or anti-apoptotic processes, since these were some of the functions most 
commonly associated with PrPC in the literature. Antibodies against 17 such proteins 
were purchased and 11 successfully detected their targets in homogenised forebrain 
tissues. These were the same homogenates used for quantifying expression of 
proteins involved in cytoskeletal organisation (see section 5.3.1). However, for the 
experiments described here, only four wild type and four PrPC-null forebrain 
homogenates were analysed (two of each sex for each genotype). Given that the 
proteomic/transcriptomic data were obtained from mice either 400 or 700 days old, 
we decided to use forebrain tissues from mice culled in between these time points 
(~550 days) for initial validation. Data for each of the 11 targets are shown in 
Figure 5.8 and a summary is provided in Table 5.5. Only two of the 11 targets were 
confirmed as differentially expressed between wild type and PrPC-null forebrains; 
these proteins were connexin-43 and glutamate dehydrogenase 1 (GLUD1), both of 
which were upregulated as a result of PrPC knockout (+1.26 and +1.14 fold, 
respectively). The expression change for connexin-43 was in the same direction as 
determined by transcriptomic analysis, although the magnitude was much smaller 
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B) Glutamate dehydrogenase 
1, mitochondrial (GLUD1) 
C) ATP synthase subunit alpha, 
mitochondrial (ATP5A1) 
 
D) Voltage-dependent anion-selective 
channel protein 2 (VDAC2) 
Figure 5.8 – Connexin-43 and glutamate dehydrogenase 1 confirmed as 
differentially expressed in PrPC-null mouse forebrains compared with wild 
type 
See following page for legend… 
(4.2 fold upregulation at the mRNA level). For GLUD1, the proteomic analyses gave 
two opposing fold change estimates (+1.5 and -2.4 in the PrPC-null tissues). Of the 
remaining nine targets, only peroxiredoxin-6 and solute carrier family 25 member 36 
showed any hints of differential expression by western blotting but these putative 
changes were not close to significance (unpaired, two-sample t-tests: p = 0.47 and 
p = 0.34, respectively). 
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G) Microsomal glutathione S-
transferase 3 (MGST3) 
 
J) Pantothenate kinase 2, 
mitochondrial (PANK2) 
 
K) Solute carrier family 25 
member 36 (SLC25A36) 
 


















Figure 5.8 – Connexin-43 and glutamate dehydrogenase 1 confirmed as 
differentially expressed in PrPC-null mouse forebrains compared with wild 
type controls  
A-K) Representative images of western blots for 11 protein targets identified from 
proteomic and transcriptomic analyses of wild type (WT) and PrPC-null mice. 4 WT and 4 
PrPC-null mouse forebrain homogenates were analysed in each case (2 of each sex for both 
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genotypes). Anti-connexin primary antibody was from Cell Signalling Technology (#3512) 
and anti-ATP5A1 was from Sigma (#SAB4502040). All the other primary antibodies were 
from AVIVA Systems Biology and had the following catalogue numbers: #ARP45709 (B), 
#ARP35124 (D), #ARP48267 (E), #ARP48454 (F), #ARP60342 (G), #ARP56078 (H), 
#ARP61851 (I), #ARP43984 (J), #ARP43984 (K). L) Bar chart summarising quantification of 
immunostaining for the various protein targets. Arrows in images D, E and J indicate the 
bands that were quantified. For each membrane, after correction for loading errors, signals 
were normalised to the mean signal from the WT homogenates. Next, the mean normalised 
expression values from at least three technical replicates were calculated for each tissue. 
Finally, overall mean expression values for each genotype were calculated and these are 
indicated in the bar charts (+/- standard error of the mean). Expression differences between 
genotypes were tested for significance (p < 0.05) using unpaired, two-sample t-tests. Key: 
* for p < 0.05; ** for p < 0.01.  
 
Before considering the implications of the western blotting data, the band patterns 
obtained by use of the antibodies to peroxiredoxin-6 (Figure 5.8e) and pantothenate 
kinase 2 (Figure 5.8j) should be explained further. Whilst a strong band was visible 
at ~33-34 kDa on blots for peroxiredoxin-6, the actual molecular weight of the 
protein matches the band at 25 kDa and this was also the apparent molecular weight 
reported by the antibody manufacturer. Therefore, the 25 kDa band was quantified 
and the identity of the higher molecular weight band remains unknown. The 
pantothenate kinase 2 antibody strongly detected a protein at ~90 kDa, which 
approximates to the molecular weight of the related protein pantothenate kinase 4 
(92 kDa). Murine pantothenate kinase 2 has a molecular weight of 49 kDa and a 
previous publication reported detection of the protein at ~47 kDa in whole mouse 
brain homogenate (Brunetti et al., 2012). Therefore, I considered the fainter 45 kDa 
band to be pantothenate kinase 2. The higher band was also quantified but, like the 
45 kDa band, there was no significant difference between genotypes (data not 
shown). 
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 Expression fold change (PrPC-null vs WT) 
Protein target ‘Omics data (age) P/T Western data 
Connexin-43 +4.2 (700) T +1.26 (p = 0.0014) 
GLUD1 +1.5/-2.4 (400) P +1.14 (p = 0.0306) 
ATP5A1 -1.8 (700) T -1.05 (n.s) 
VDAC2 -1.7 (700) P +1.03 (n.s) 
Peroxiredoxin-6 -1.4 (700) P +1.13 (n.s) 
Peroxiredoxin-1 -1.4 (700) P +1.03 (n.s) 
MGST3 +1.6 (700) T -1.06 (n.s) 
Myotubularin +2.0 (700) T +1.03 (n.s) 
SRSF protein kinase 2 +2.3 (700) T +1.02 (n.s) 
PANK2 +2.2 (700) T -1.02 (n.s) 
SLC25A36 +1.9 (700) T +1.20 (n.s) 
 
Table 5.5 – Comparison of western blotting and proteomic/transcriptomic data  
This table compares ‘omics data for the 11 protein targets with the western blot data shown 
in Figure 5.8. Shown are the mean fold changes in expression in PrPC-null mouse forebrains 
compared with wild type. The age shown in brackets for the ‘omics data is the age in days of 
the mice at the point of culling. Also indicated is whether the ‘omics fold change value came 
from proteomic (P) or transcriptomic (T) analyses. “n.s.” = not significant. Full protein 
names are given in Figure 5.8.        
 
Of the 11 targets analysed by western blotting, seven were chosen based on the 
transcriptomic data and only one (connexin-43) was validated as differentially 
expressed in PrPC-null mouse forebrains at the protein level. This is, perhaps, to be 
expected, given that changes in mRNA abundance do not always translate into 
changes at the protein level. Indeed, the mRNA coding for connexin-43 displayed the 
largest fold change of all those identified from the microarray experiments and yet 
connexin-43 protein was only 1.26 fold upregulated in the PrPC-null tissues. 
Furthermore, a systematic analysis of the transcriptome and proteome of a 
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mammalian cell line found that only 40 % of the variation in protein level can be 
explained by variation in mRNA abundance (Schwanhausser et al., 2011). Validation 
of the proteomic data obtained from mouse forebrain was not much more successful, 
however – one out of four proteins were confirmed as differentially expressed, whilst 
the other three were not. This may be a reflection of the relative unreliability of the 
2-D gel-based proteomic method that was used for the forebrain tissues. In this 
approach, following 2-D separation of proteins, the end result is a gel that can be 
stained to identify protein spots. Images obtained from electrophoresis of different 
samples can be matched up and densitometric analysis of common spots carried out 
to detect any differential expression. The proteins present within in a spot can be 
determined by mass spectrometry but if the same spot contains multiple proteins then 
the expression ratios obtained will be inaccurate (Steen and Mann, 2004; Abdallah et 
al., 2012). Additionally, errors can be made when matching up the gel images, 
resulting in incorrect fold change estimates (Abdallah et al., 2012). These reasons 
could explain the opposing fold change estimates that were obtained for GLUD1, 
although it is conceivable that two distinct GLUD1 isoforms were detected.   
In spite of the lack of validation of the proteomic/transcriptomic data from PrPC-null 
mouse forebrains, it is still of note that the expression levels of two proteins were 
affected by PrPC knockout, especially since some published proteomic studies did 
not identify a single differentially expressed protein in the brains of knockout mice 
compared with controls (Crecelius et al., 2008; Mehrabian et al., 2016). The 
upregulation of GLUD1 is intriguing given that it is involved in glutamate 
metabolism and PrPC expression has been suggested to protect neurons from 
glutamate-mediated excitotoxicity (Sakurai-Yamashita et al., 2005; Frigg et al., 2006; 
Khosravani et al., 2008). Furthermore, GLUD1 can modulate cellular ATP 
production since it converts L-glutamate into alpha-ketoglutarate, an intermediate in 
the tricarboxylic acid cycle. Connexin-43, on the other hand, is a member of the 
connexin family of channel proteins that form cell-cell connections called gap 
junctions. These junctions provide cytoplasmic connections between neighbouring 
cells, allowing regulated intercellular transport of molecules (Evans and Martin, 
2002). Gap junctions between neighbouring neurons, referred to as electrical 
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synapses, are widespread in the developing CNS. By allowing ions to flow between 
cells, electrical synapses enable primitive, synchronised firing of large neuronal 
networks. As the CNS matures, electrical synapses become rarer and chemical 
(neurotransmitter-driven) synapses seem to dominate (Arumugam et al., 2005). 
Therefore, higher connexin-43 expression in the adult forebrain, as was the case for 
the PrPC-null mice, could be indicative of impaired maturation of the CNS, which, in 
turn, could be linked to the subtle learning and memory deficits previously reported 
in PrPC-null mice (Bueler et al., 1992; Schmitz et al., 2014).  
5.5.1 Altered expression levels of connexin-43 and glutamate 
dehydrogenase 1 in SH-SY5Y cells following PrPC transfection 
Connexin-43 and GLUD1 expression levels were analysed in the SH-SY5 cell line to 
investigate if they were altered upon PrPC transfection in the same manner as they 
were in the forebrains of PrPC-null mice. The aim was to obtain further evidence of 
the physiological relevance of the cell model. Again, as in previous experiments, 
cells were seeded into tissue culture plates and lysed 24 hours later. Connexin-43 
levels were assessed by western blotting of five independently prepared sets of cell 
lysates and GLUD1 levels were similarly measured using four sets of lysates. 
Figure 5.9a shows that connexin-43 was dramatically upregulated (+23.2 fold) in 
clone 1G3 compared with SH-SY5YUntr. Connexin-43 expression by clone 2E3 was 
not significantly different from the level in the control cell line, although there was a 
trend towards upregulation (+4.37 fold; one-sample t-test: p = 0.053). Therefore, 
PrPC appeared to upregulate connexin-43 expression in the cells, whilst 
downregulating it in mouse forebrain. This could be explained by the presence of 
binding sites in the connexin-43 promoter for numerous cell type-specific 
transcription factors. However, there are also binding sites for ubiquitous 
transcription factors, such as those activated by MAPK signalling pathways 
(Oyamada et al., 2013). PrPC may modulate these pathways differently in 
SH-SY5Y cells compared with brain, perhaps, as has been suggested previously in 
this chapter, by affecting the cellular responses to specific growth factors.   
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Figure 5.9 – Differential expression of connexin-43 and glutamate 
dehydrogenase 1 in stably transfected clones compared with untransfected 
cells  
Representative western blot images and bar charts summarising quantification of 
immunostaining for connexin-43 (A) and GLUD1 (B) from at least four independently 
prepared sets of cell lysates. For each membrane, after correction for loading errors, data 
were normalised to the signal from the SH-SY5YUntr lane. The mean normalised expression 
values (+/- standard error of the mean) are displayed in the bar charts. Expression 
differences between the clones and SH-SY5YUntr were tested for significance (p < 0.05) using 
one-sample t-tests. Key: * for p < 0.05; *** for p < 0.001. Anti-connexin primary antibody 
was from Cell Signalling Technology (#3512) and anti-GLUD1 antibody was from AVIVA 



















Chapter 5: Elucidating the downstream processes 
regulated by PrPC in SH-SY5Y cells  192 
Whilst the increased connexin-43 expression and the slower proliferation rate of the 
stably transfected clones could both have been consequences of altered growth factor 
signalling, it is possible that connexin-43 expression itself was the driver of the 
reduced proliferation. Connexin-43 is thought to repress proliferation by inhibiting 
the expression of S-phase kinase-associated protein 2 (SKP2) via gap junction-
dependent and gap junction-independent mechanisms. Interestingly, SPK2 is a 
member of the same SCF ubiquitin ligase complex as SUGT1 (see section 5.4.2), 
which was downregulated in the stably transfected clones. SPK2 ubiquitinates 
cyclin-dependent kinase inhibitor 1B, thereby targeting it for degradation. Therefore, 
reduced levels of SPK2 lead to increased levels of the CDK inhibitor, in turn 
resulting in slower cell cycle progression (Zhang et al., 2003). The fact that 
connexin-43 expression was much less dramatically upregulated in clone 2E3 
compared with SH-SY5YUntr than it was in clone 1G3 could, therefore, explain why 
clone 2E3 proliferated faster than clone 1G3. 
GLUD1 expression was significantly higher in clone 1G3 (+1.91 fold) than in 
SH-SY5YUntr but was downregulated by 1.44 fold in clone 2E3 (Figure 5.9b). There 
is a paucity of information about how GLUD1 expression is regulated, although its 
activity is known to be enhanced by depletion of cellular ATP stores (Spanaki et al., 
2012). If overall GLUD1 expression levels are similarly regulated then the higher 
expression in clone 1G3 might suggest a faster metabolic rate, since this would lead 
to quicker depletion of ATP. However, the reduced GLUD1 levels in clone 2E3 
compared with SH-SY5YUntr argues against any regulation of overall metabolic rate 
by PrPC.  
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5.6 Discussion 
The proteomic datasets reported in section 4.2 of this thesis were combined to 
identify the proteins that were differentially expressed in stably transfected clones 
2E3 and 1G3 compared with SH-SY5YUntr – we hypothesised that these changes 
were most likely to have resulted from PrPC expression. Pathway analysis of these 
data suggested roles for PrPC in cell cycle regulation, cytoskeletal organisation and 
ubiquitination, among other processes. Sections 5.2-5.4 of this chapter covered the 
follow-up studies that were undertaken to investigate these putative functions of 
PrPC.  
The stably transfected clones were shown to proliferate slower than the control line 
and transient knockdown of PrPC expression using an siRNA partially rescued this 
phenotype. These results suggest that PrPC is a negative regulator of proliferation in 
SH-SY5Y cells. An anti-proliferative role for PrPC has been identified previously in 
several cell types (Kim et al., 2005; Morel et al., 2008; Bribian et al., 2012), although 
other studies have found that PrPC promotes proliferation of neural precursors and 
mouse neuroblastoma cells (Steele et al., 2006; Llorens et al., 2013; Haigh and 
Collins, 2014). Interestingly, although PrPC transfection did not seem to have 
affected overall levels of protein ubiquitination in the SH-SY5Y cells, specific 
ubiquitination processes may have been altered as a consequence of the changes to 
cell cycle regulation. For example, the E3 ubiquitin-protein ligase SUGT1, which is 
part of the SCF ubiquitin ligase complex that modulates the expression levels of 
elements of the cell cycle regulatory machinery, was downregulated in clones 2E3 
and 1G3 compared with the control line.  
Pathway analysis of the proteomic changes induced by PrPC transfection suggested 
that proteins involved in cytoskeletal organisation were overrepresented. The 
upregulation of caldesmon expression in the stably transfected clones was 
particularly striking, since the protein is reportedly involved in Schwann cell 
migration during peripheral nerve regeneration (Han et al., 2007) and an adult-onset 
demyelination of the PNS has been observed in several PrPC knockout mouse lines 
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(Bremer et al., 2010; Nuvolone et al., 2016). The intermediate filament protein 
vimentin was also upregulated in the clones but confocal analyses of the cells did not 
uncover obvious changes in the distribution of vimentin staining as a result of the 
differential expression. In contrast, changes to the actin cytoskeleton were evident in 
clone 1G3; specifically, the actin microfilaments seemed to be organised into fibres 
that were thicker than those of the SH-SY5YUntr cytoskeleton. Thicker actin stress 
fibres are associated with greater cytoskeletal stability and inhibition of neurite 
outgrowth (O'Connor et al., 1990; Troller and Larsson, 2006), which could explain 
why clone 1G3 (and clone 1F3) produced fewer neurite-like protrusions than the 
other lines, as was reported in Chapter 3. The alterations to the actin cytoskeleton 
that were observed in clone 1G3 may have been due to greater activation of the 
RhoA-ROCK pathway, which PrPC has previously been reported to modulate 
(Loubet et al., 2012). However, this is not a complete explanation since this pathway 
is reported to promote proliferation (Yu and Brown, 2015) and yet clone 1G3 
proliferated slower than SH-SY5YUntr. Interestingly, whilst the actin cytoskeleton of 
clone 2E3 appeared grossly similar to that of the control line, some of the molecular 
changes underlying the altered cytoskeletal architecture of clone 1G3 were shared by 
clone 2E3. The difference between the clones was that these expression changes 
were generally less dramatic in clone 2E3. Therefore, it is possible that clone 2E3 
cells would have contained thicker stress fibres and produced fewer neurite-like 
protrusions had the relevant molecular changes been of greater magnitudes.  
In spite of the apparent inhibition of neurite outgrowth in clone 1G3, several proteins 
that positively correlate with neurite outgrowth – annexin A2, neurosecretory protein 
VGF, zyxin and neuromodulin – were upregulated in all four stably transfected 
clones compared with SH-SY5YUntr. These molecular changes are in line with 
previous reports that PrPC expression can promote neurite outgrowth (Graner et al., 
2000; Loubet et al., 2012). Furthermore, a recent proteomic study found that the 
expression levels of neuromodulin and another component of the axonal growth 
cone, brain acid soluble protein 1, were perturbed by knockout or knockdown of 
PrPC expression in more than one cell model (Mehrabian et al., 2016). It is unclear 
why PrPC transfection resulted in proteomic alterations associated with increased 
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neurite outgrowth, whilst simultaneously causing molecular changes linked to its 
repression.  
To complement the data obtained from the SH-SY5Y cell model, I followed up 
previous work carried out by my research group that had identified proteomic and 
transcriptomic changes that occurred in the forebrain as a result of PrPC ablation in 
mice. A subset of targets from this study was chosen for validation by western 
blotting and, although the success of this was mixed at best, two proteins – GLUD1 
and connexin-43 – were confirmed as upregulated in PrPC-null tissues compared with 
wild type controls. Importantly, these forebrain tissues were from the Npu line of 
knockout mice, which is free from the issues of Prnp genotype-independent 
polymorphisms in neighbouring genes and ectopic doppel expression in the brain that 
affect some of the other knockout lines. Consequently, the differential expression of 
connexin-43 and GLUD1 is highly likely to have been caused by an absence of PrPC 
expression. The increase in GLUD1 expression is of note given its role in glutamate 
metabolism and the previously reported role of PrPC in protecting neurons from 
glutamate-mediated excitotoxicity (Sakurai-Yamashita et al., 2005; Frigg et al., 2006; 
Khosravani et al., 2008). Additionally, the upregulation of connexin-43 suggests that 
the PrPC-null forebrains may have had a greater density of electrical synapses, 
perhaps reflecting a subtle impairment to the maturation of the CNS as a result of 
PrPC knockout (Ben-Ari, 2001; Arumugam et al., 2005). This provides a potential 
alternative explanation for the reported deficits in learning and memory of PrPC-null 
mice (Bueler et al., 1992; Schmitz et al., 2014). Furthermore, connexin-43 is thought 
to indirectly regulate cell cycle progression by affecting the expression of a subunit 
of the SCF ubiquitin ligase complex. Therefore, increased expression of connexin-43 
in the PrPC-null forebrain might indicate that PrPC has a role in regulating 
proliferation in vivo as well as in vitro.    
The results presented in this chapter show that the proliferation rate of SH-SY5Y 
cells was inhibited by PrPC transfection and it appeared that the differential 
expression of specific ubiquitin ligases may have resulted from the changes to cell 
cycle regulation. One explanation for the ability of PrPC to regulate proliferation is 
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that it modulates the cellular responses to specific growth factors. Growth factors can 
promote differentiation processes, which may involve changes to cell shape, 
potentially requiring reorganisation of cytoskeletal architecture. Therefore, the 
differential expression of proteins involved in cytoskeletal organisation that was 
observed in the stably transfected clones may have resulted from some kind of 
differentiation process. Links between PrPC and growth factor signalling have been 
made before, although the evidence is rather limited. For example, PrPC has been 
proposed to interact with the receptor for epidermal growth factor, thereby altering 
its responsiveness to its ligand (Llorens et al., 2013). PrPC expression can also be 
induced by growth factors, such as NGF (Kuwahara et al., 2000; Zawlik et al., 2006) 
and insulin-like growth factor 1 (Liu et al., 2013). The putative connections between 
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6.1 Identifying upstream regulators of the proteomic 
changes induced by PrPC transfection  
Chapter 5 focused on the downstream consequences of transfecting the Prnp CDS 
into SH-SY5Y cells. The main findings were altered expression of various proteins 
linked to cytoskeletal organisation and slower proliferation of the stably transfected 
clones compared with SH-SY5YUntr. A potential explanation for these effects was 
that PrPC was modulating the cellular response to specific growth factors, either 
those present in the foetal bovine serum (FBS) used to supplement the culture 
medium or any synthesised by the cells themselves. This hypothesis is supported by 
a small number of previous studies that have made connections between PrPC and 
growth factor signalling. For example, PrPC was shown to interact with the receptor 
for epidermal growth factor, thereby altering its responsiveness to its ligand (Llorens 
et al., 2013). PrPC expression can also be induced by growth factors, such as NGF 
(Kuwahara et al., 2000; Zawlik et al., 2006) and insulin-like growth factor 1 (Liu et 
al., 2013).  
This chapter covers the work carried out to determine the links between PrPC and 
growth factor signalling. As a starting point, I returned to the dataset of proteins with 
altered expression levels in stably transfected clones 2E3 and 1G3 compared with 
SH-SY5YUntr (Table 5.1). As described in detail in section 5.1, IPA was used for 
pathway analysis of this proteomic dataset. The core analysis suite of the software 
includes a feature that identifies the most likely upstream regulators of the proteomic 
changes. These regulator molecules could be transcription factors, proteins kinases, 
growth factors, microRNAs, endogenous chemicals, drugs etc. In a similar manner to 
other IPA features, the right-tailed Fisher exact test is used to determine whether 
there is significant (p < 0.01) overlap between the proteins/genes in the uploaded 
dataset and the proteins/genes that are known targets of the upstream regulator. If 
sufficient directional information about the interaction between a regulator and its 
target is available within the database used by the software (the Ingenuity Knowledge 
Base) then IPA can also predict whether the regulator molecule is more activated or 
more inhibited based on the expression change of the target protein/gene. IPA 
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combines these predictions for all the targets present in the uploaded dataset to 
generate an activation state z-score for the upstream regulator; these scores represent 
the degree of confidence that a particular regulator molecule is activated (positive 
value) or inhibited (negative value). Z-scores > 2 or < -2 are generally considered 
statistically significant but upstream regulators not meeting these thresholds might 
still warrant further investigation.      
Table 6.1 reports the highest confidence upstream regulators of the PrPC transfection-
induced proteomic changes observed in SH-SY5Y cells. Following exclusion of 
chemical toxicants or drugs, which were considered irrelevant for this analysis, the 
top regulators, ranked by overlap p-value, are shown. Lower-ranked regulator 
molecules were not considered worthy of follow-up since most targeted only one or 
two of the 60 differentially expressed proteins in the dataset. A systematic search 
using the protein database Uniprot showed that many of the putative upstream 
regulators were involved in cell cycle regulation. For example, Table 6.1 contains 
members 1, 3, 4 and 5 of the E2F transcription factor family. E2Fs 1 and 3 are 
activators of cell cycle progression, whilst E2Fs 4 and 5 are repressors. E2F1 had the 
smallest overlap p-value of all the entries in Table 6.1 and was predicted to be less 
active in the stably transfected clones than SH-SY5YUntr (activation state z-score 
of -1.710), as would be expected given the inhibitory effect of PrPC expression on 
SH-SY5Y proliferation that was reported in section 5.2. The second-ranked upstream 
regulator, myc proto-oncogene protein, another positive regulator of proliferation, 
was also predicted to be inhibited in the stably transfected clones compared with 
SH-SY5YUntr. Additional putative upstream regulators involved in cell cycle 
regulation included the transcription factors retinoblastoma-like protein 1, T-box 
transcription factor TBX2 and N-myc proto-oncogene protein as well as protein 
kinases like ribosomal protein S6 kinase beta-1 and cyclin-dependent kinase 
inhibitor 1. However, since these proteins reside in the cytoplasm and/or nucleus, 
direct interactions with the mainly cell surface-associated PrPC seemed unlikely; 
much more plausible were interactions with receptors (such as those for growth 
factors) at the cell membrane. For this reason as well as the potential link between…  
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Table 6.1 – 
Potential 
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regulators of the 
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…PrPC and growth factor signalling that was suggested by the effect of PrPC 
transfection on proliferation, the two growth factors present in Table 6.1, 
transforming growth factor beta-1 (TGFB1) and NGF, were of more interest. TGFB1 
modulates proliferation, differentiation and other processes in various cell types 
(Massague, 2012) and 12 targets of TGFB1 signalling were among the proteins 
differentially expressed upon PrPC transfection. Additionally, PrPC reportedly 
modulates epithelial-mesenchymal transition processes driven by TGFB1 
(Mehrabian et al., 2015) and potentially interacts directly with TGFB1 itself (Lappas 
Gimenez et al., 2015). However, of the 12 TGFB1 targets in the dataset, IPA 
determined that the expression changes to three proteins suggested activation of 
TGFB1, expression changes to a further two suggested inhibition and no predictions 
could be made from the remaining seven due to insufficient directional information 
about the interactions. Because of these data, the activation state z-score calculated 
for TGFB1 was not greatly different from zero (+0.571). Therefore, the proteomic 
alterations in the stably transfected clones were not obviously consistent with PrPC 
enhancing or repressing TGFB1 signalling. NGF was, however, a better candidate. 
Although only four direct targets of NGF signalling were present in the dataset of 
differentially expressed proteins, these did include three of the five most upregulated 
proteins: neurosecretory protein VGF, neuromodulin and annexin A2 (see Table 5.1), 
which are all implicated in neurite outgrowth and/or cytoskeletal remodelling 
processes (Singh et al., 2004; Falsey et al., 2006; Sakamoto et al., 2015). CDK1, 
which was downregulated in the stably transfected clones and plays a key role in 
regulating the cell cycle (Santamaria et al., 2007), is also a target of NGF signalling. 
Furthermore, the directionality of the expression changes to the four NGF targets in 
the dataset all suggested activation of NGF signalling (overall activation state z-score 
for NGF of +1.944). These findings indicated that the slower proliferation of the 
stably transfected clones and at least some of the expression changes to proteins 
involved in cytoskeletal organisation or remodelling could be explained by PrPC 
modulating NGF signalling pathways. Although there has been no direct evidence of 
such a role for PrPC, as far as I am aware, a recent study found that PrPC and TrkA, 
the high affinity receptor for NGF, both appear to interact with the ganglioside GM1 
within lipid rafts (Mantuano et al., 2014). The authors proposed that PrPC, TrkA, 
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GM1 and lipoprotein receptor-related protein-1 form a multimolecular complex that 
modulates neurite outgrowth and other cell signalling processes in neurons.  
Before further exploring the putative connection between PrPC and NGF signalling in 
the SH-SY5Y cells, we attempted to obtain additional evidence of the involvement of 
PrPC in the pathway. The approach taken was to identify the genes with similar 
spatial expression patterns to PRNP in vivo, since genes are likely to be involved in 
the same processes as other genes that are similarly regulated. The following section 
summarises the results obtained from this analysis.   
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6.2 Investigating the genes displaying similar spatial 
expression patterns to PRNP in vivo 
Upstream analysis of the proteomic changes induced by PrPC transfection into 
SH-SY5Y cells suggested that the protein might modulate NGF signalling. To my 
knowledge, no direct effect of PrPC on NGF signalling has been reported previously, 
although NGF does appear to induce PrPC expression in neuronal cell lines 
(Kuwahara et al., 2000; Zawlik et al., 2006) and PrPC has been proposed to be part of 
a multimolecular complex also containing the NGF receptor TrkA (Mantuano et al., 
2014). To obtain further evidence of the processes potentially involving PrPC, I 
aimed to identify the genes with similar spatial expression patterns to PRNP in vivo, 
since genes are likely to be involved in the same processes as other genes that are 
similarly regulated. Two publically available microarray datasets, both originally 
reported by Su et al. (2004), were used for this purpose: the GeneAtlas GNF1M and 
U133A datasets, which were both accessed through the BioGPS gene annotation 
portal (Wu et al., 2016). The GNF1M and U133A datasets contained baseline gene 
expression data from 61 young adult (2-3 month old) mouse tissues and 79 human 
tissues, respectively. The correlation tool on the BioGPS website was used to select 
those genes that were highly correlated14 with PRNP in terms of their expression 
patterns (Pearson correlation coefficient > 0.75). Although neither NGF nor its 
receptors were among the highly coexpressed genes, the datasets were analysed 
using IPA to determine whether genes involved in NGF signalling or related 
pathways were overrepresented. IPA identified 267 analysis-ready genes for the 
mouse and 113 for the human coexpression datasets. These figures exclude any 
unannotated genes and duplicate entries (i.e. multiple microarray probes 
corresponding to the same gene) that were in the original data. Full tables of the 
analysis-ready genes are provided in Appendix III.  
The IPA core analysis suite has a number of features, including those that identify the 
canonical pathways and molecular and cellular functions that are most 
                                                 
14 Data from two microarray probes for detection of PRNP mRNA were available from the U133A 
dataset. For this thesis, data from the 201300_s_at probe was used.  
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overrepresented among the proteins/genes in the uploaded dataset. Canonical 
pathways are standard, well-characterised signalling pathways, whereas molecular 
and cellular functions are groupings of genes with similar functions, according to the 
Ingenuity Knowledge Base. Table 6.2 shows the top five canonical pathways and 
molecular and cellular functions identified from the genes that were highly 
coexpressed with Prnp in the mouse. The ranking is based upon overlap p-value 
(right-tailed Fisher exact test), which represents the statistical significance of the 
overrepresentation of the members of the pathway or function among the genes in the 
dataset. Most of the top canonical pathways identified were those important in the 
nervous system, as would be predicted from the high neuronal expression of PrPC 
(Linden et al., 2008). The canonical pathway with the smallest overlap p-value was 
cyclin-dependent kinase 5 signalling, which regulates processes like neuronal 
migration and differentiation as well as synaptic development and function (Cheung 
and Ip, 2012). Cyclin-dependent kinase 5 is also vital for repressing cell cycle 
progression in neurons, thereby maintaining their post-mitotic state. This connection 
is striking given the links between PrPC and proliferation of neuronal cells that have 
been reported in this thesis and elsewhere (Kim et al., 2005; Steele et al., 2006; 
Llorens et al., 2013). The fourth- and fifth-ranked canonical pathway identified from 
the mouse and human coexpression datasets, respectively, was melatonin signalling - 
melatonin is a hormone secreted by the pineal gland that plays a key role in 
regulating circadian rhythm. This result is in line with the disrupted circadian 
oscillation of melatonin production (Brown et al., 2002) and altered sleep patterns 
(Tobler et al., 1996; Sanchez-Alavez et al., 2007) that have been observed in PrPC-
null mice. Interestingly, the U133A transcriptomic data also indicates that the mRNA 
encoding the high affinity NGF receptor TrkA is expressed in the human pineal gland 
at much higher levels than in any other tissue.  
The top five molecular and cellular functions identified from the genes highly 
coexpressed with PRNP in human tissues (Table 6.3) included three of the five most 
overrepresented functions among the proteins differentially expressed in…  
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…stably transfected clones 2E3 and 1G3 compared with SH-SY5YUntr (Table 5.2) – 
the functional categories in question were cellular assembly and organisation, cell 
death and survival, and cell morphology. These data, perhaps, provide some evidence 
of the physiological relevance of the proteomic alterations to SH-SY5Y cells that 
were induced by PrPC transfection.  
As described in section 6.1, IPA can suggest likely upstream regulators of the 
proteins/genes in a dataset. Again ranked by overlap p-value, Tables 6.4 and 6.5 
show the 15 highest-confidence upstream regulators identified from the genes highly 
coexpressed with PRNP in mouse and human tissues, respectively. Given the links 
between PrPC and cytoskeletal organisation that were reported in the previous 
chapter, it was striking that several of the putative regulator proteins had roles in 
cytoskeleton dynamics. For example, Nck-associated protein 1-like can regulate actin 
remodelling (Park et al., 2010a), whilst reticulon-4 and neurofascin are involved in 
neurite outgrowth processes. Reelin signalling, the second- and first-ranked 
canonical pathway in Tables 6.2 and 6.3, respectively, is also linked to neuritogenesis 
(D'Archangelo, 2014). Furthermore, although NGF was not among the 
highest-confidence upstream regulators identified from either dataset, the 
third-ranked protein in Table 6.4 is brain-derived neurotrophic factor (BDNF), 
which, like NGF, is a member of the neurotrophin family. BDNF and its high affinity 
receptor TrkB were also among the top 15 upstream regulators identified from the 
human coexpression dataset. Given that BDNF and NGF are both able to interact 
with the p75 neurotrophin receptor (p75NTR), these results in combination with those 
reported in section 6.1 raise the possibility that PrPC could influence cellular 
responses to all neurotrophins, not just NGF. The work carried out to further 
investigate the potential connection between PrPC and NGF signalling is covered 
later in the chapter; the following section provides some background information on 
the downstream pathways and processes regulated by NGF. 
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6.3 Background on nerve growth factor signalling  
NGF is a member of the neurotrophin family of growth factors that also includes 
BDNF, neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4). Neurotrophins generally 
promote survival, growth and differentiation of specific neuronal populations. For 
example, a major role of NGF is to guide the development of sensory and 
sympathetic neurons in early life (Hefti et al., 2006). In the adult, NGF is still 
required for survival of the cholinergic neurons in the basal forebrain and is involved 
in nervous system repair processes after injury (Sofroniew et al., 2001; Chen et al., 
2015). NGF also plays a key role as a pain mediator by increasing the sensitivity of 
nociceptive neurons to painful stimuli (Pezet and McMahon, 2006).   
The canonical actions of the neurotrophins are mediated largely via high affinity 
interactions with receptor tyrosine kinases known as Trk receptors 
(tropomyosin-related kinases). As shown in Figure 6.1, each neurotrophic factor 
binds to one Trk receptor with high affinity: NGF binds to TrkA, BDNF and NT-4 to 
TrkB, and NT-3 to TrkC. NT-3 can also form weaker interactions with TrkA and 
TrkB, and NT-4 can similarly interact with TrkC (Gilbert, 2006). In addition to the 
Trk receptors, all neurotrophins can bind to the receptor encoded by the NGFR gene. 
This protein is member 16 of the tumour necrosis factor receptor superfamily but is 
more commonly known as the p75 neurotrophin receptor (p75NTR). Neurotrophins 
interact with p75NTR at considerably lower affinities than with the Trk receptors 
(Covaceuszach et al., 2009).  
Mature neurotrophins are formed by proteolytic cleavage of precursor proteins 
known as pro-neurotrophins (Fahnestock et al., 2004). Relatively recently, these 
pro-neurotrophins were shown to be biologically active themselves (Arnett et al., 
2007). For example, pro-NGF is known to bind to p75NTR, although there are 
differences in opinion over whether NGF or pro-NGF is the preferred ligand (Lee et 
al., 2001b; Clewes et al., 2008). Pro-NGF can also activate signalling through TrkA, 
although it has a lower affinity for the receptor than NGF (Clewes et al., 2008). 
Furthermore, pro-NGF can interact via its “pro” domain with a third receptor called 
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sortilin (Nykjaer et al., 2004; Skeldal et al., 2012), which is a member of the vacuolar 
protein sorting 10 protein-domain receptor family (Willnow et al., 2008). The 
“mature” domain of pro-NGF can simultaneously bind to p75NTR, reportedly leading 
to a crosslinking of the receptors that modulates downstream signalling (Nykjaer et 
al., 2004). Interestingly, pro-NGF seems to be more abundant than mature NGF in 
the adult brain (Arnett et al., 2007).          
 
 
Figure 6.1 – Interactions between neurotrophins and their receptors  
Adapted from a figure by Gilbert (2006), this diagram shows the receptor interactions of the 
four neurotrophins (NGF, BDNF, NT-3 and NT-4). Each neurotrophin binds one of the Trk 
receptors with high affinity (solid arrows), whilst all neurotrophins can form lower affinity 
interactions (dotted arrows) with p75NTR. NT-3 and NT-4 can also bind other Trk receptors 
with relatively low affinities.  
 
NGF binding to TrkA causes receptor dimerisation that activates the intracellular 
tyrosine kinase domains, leading to cross-phosphorylation of several tyrosine 
residues. This process is rapid – activation levels peak around five minutes after 
initiation of NGF stimulation (Chang et al., 2003). Phosphorylation of TrkA enables 
docking of adaptor proteins connected to various intracellular signalling pathways 
(Hefti et al., 2006). One key pathway is the MAPK cascade that culminates in 
phosphorylation of ERK1/2. Once activated, ERK1/2 can, in turn, activate 
transcription factors that promote neuronal differentiation, a process that includes 
induction of neurite outgrowth and cell cycle withdrawal (Huang and Reichardt, 
2003). Another pathway downstream of TrkA is phosphatidylinositol-4,5-
Chapter 6: Investigating the links between 
PrPC and growth factor signalling  213 
bisphosphate 3-kinase (PI3K)-RAC-alpha serine/threonine-protein kinase (Akt) 
signalling. Although multifunctional, the PI3K-Akt pathway seems most important 
for NGF-mediated neuronal survival (Chang et al., 2003).  
 
One role for p75NTR appears to be to interact with TrkA, thereby enhancing the 
affinity of TrkA for NGF (He and Garcia, 2004; Chen et al., 2009). However, if 
TrkA levels are low in comparison to p75NTR then NGF can initiate alternative 
signalling through p75NTR alone (Obata et al., 2006). Depending on the cellular 
context, this TrkA-independent signalling can either promote survival through PI3K-
Akt and nuclear factor-kappa B pathways or apoptosis via activation of c-Jun 
N-terminal kinase and increased production of ceramide (Brann et al., 2002; Chen et 
al., 2009). It is thought that pro-apoptotic signalling mediated by p75NTR requires the 
presence of sortilin. Therefore, activation of these pathways by NGF may rely on the 
proposed weak interaction between NGF and sortilin (Nykjaer et al., 2004). Pro-NGF 
is more efficient than NGF at initiating apoptosis due to its higher affinity for sortilin 
that is conferred by its “pro” domain.  
 
Although signalling pathways downstream of TrkA are usually considered 
responsible for NGF-mediated neurite outgrowth, some studies suggest that 
independent binding of NGF to p75NTR is more important. In the absence of 
neurotrophins, p75NTR is thought to be part of a receptor complex at the cell 
membrane that promotes activity of the RhoA-ROCK pathway, resulting in increased 
stability of the actin cytoskeleton (Mi et al., 2004; Chen et al., 2009). This disrupts 
the formation, extension and movement of filopodia, which are dynamic protrusions 
from the neurite growth cone that respond to extracellular signals to guide migration 
of the developing neurite (O'Connor et al., 1990). However, interactions between 
neurotrophins (and possibly pro-neurotrophins) and p75NTR seem to inhibit 
RhoA-ROCK signalling, which alleviates the block on neurite outgrowth (Gehler et 
al., 2004; Howard et al., 2013).  
 
One feature that adds to the complexity of p75NTR-mediated signalling is that the 
receptor can undergo sequential proteolytic cleavage events: firstly, alpha-cleavage 
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by disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) 
releases the extracellular domain and leaves a C-terminal fragment (p75-CTF) at the 
cell membrane (Weskamp et al., 2004; Zampieri et al., 2005); secondly, p75-CTF is 
processed further by the gamma-secretase complex to allow the intracellular domain 
(p75-ICD) to move into the cytoplasm (Jung et al., 2003). Previously, it was thought 
that neurotrophins did not modulate p75NTR cleavage rates (Jung et al., 2003; 
Zampieri et al., 2005) but more recent in vitro data suggests that NGF can enhance 
p75-CTF (Coulson et al., 2008) and p75-ICD (Matusica et al., 2013) production. The 
mechanism seems to be NGF activating TrkA signalling, which promotes ADAM17 
activity and, consequently, increases the rate of p75NTR cleavage (Kommaddi et al., 
2011). The function of p75-CTF is still unclear: evidence suggests it can either be 
pro-survival (Verbeke et al., 2013) or pro-apoptotic (Coulson et al., 2008), perhaps 
depending on the cellular context. It has been proposed that p75-ICD is the active 
agent responsible for pro-apoptotic signalling induced by pro-neurotrophins 
(Kenchappa et al., 2006) and, interestingly, sortilin appears to enhance p75-ICD 
production, possibly by mediating the endocytosis of p75-CTF (Skeldal et al., 2012). 
Cleavage of the full length receptor to produce p75-ICD also reportedly prevents 
interaction with TrkA, leading to reduced affinity of TrkA for NGF (Jung et al., 
2003). Contrastingly, another study suggests that only p75-ICD, not full length 
p75NTR, can interact with TrkA (Matusica et al., 2013).    
Overall, the NGF signalling pathways are highly complex and not fully understood. 
What is certain is that any protein modulating signalling through TrkA or p75NTR (or 
both) would have effects on a wide variety of different processes.  
  
Chapter 6: Investigating the links between 
PrPC and growth factor signalling  215 
6.4 Investigating whether PrPC expression alters the 
expression levels of neurotrophin receptors  
6.4.1 Initial analysis of expression of neurotrophin receptors by 
SH-SY5Y cells  
The proteomic changes observed in stably transfected clones 2E3 and 1G3 compared 
with SH-SY5YUntr suggested that PrPC might modulate NGF signalling pathways. 
Additionally, analysis of the genes with similar expression patterns to PrPC in vivo 
uncovered a potential link between PrPC and BDNF signalling. These findings could 
be explained by PrPC affecting neurotrophin signalling through the Trk receptors 
and/or p75NTR. To follow up these results, I decided to investigate whether stable 
transfection of Prnp into SH-SY5Y cells had affected the expression levels of the 
relevant neurotrophin receptors. Firstly though, I needed to determine which of these 
receptors were expressed by the SH-SY5Y cells.   
SH-SY5YUntr cells were seeded into a tissue culture plate and lysed 24 hours later. 
Next, expression of TrkA, TrkB and p75NTR were assessed by western blotting. Three 
main bands were detected by the anti-TrkA antibody (Figure 6.2a), the most intense 
of which was ~90 kDa. Human TrkA can be glycosylated at up to 13 sites, which 
greatly increases the molecular weight. Therefore, the diffuse band at ~120 kDa most 
likely corresponds to fully glycosylated TrkA, whilst the 90 kDa band is probably 
unglycosylated TrkA (actual molecular weight of 87.5 kDa). The lower band at 
~80 kDa is most likely one of the additional TrkA isoforms that can be created by 
alternative splicing. Glycosylated bands on a western blot tend to be fuzzy and 
poorly defined because the glycans attached to a protein can vary in length (Gates et 
al., 2004); since the 80 kDa band is quite sharp, the TrkA isoform detected is 
probably unglycosylated.     
Unglycoyslated TrkA is reported to be constitutively active in the absence of ligand 
and also seems unable to bind NGF, presumably because of a failure in trafficking…  
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Figure 6.2 – SH-SY5Y cells expressed TrkA and p75NTR but not TrkB   
A) Western blot image showing detection in an SH-SY5YUntr lysate of three distinct bands 
(80, 90 and 120 kDa) corresponding to different forms of TrkA. B) Western blot image 
showing detection of phosphorylated TrkA (p-TrkA) in cell lysates prepared from clone 1G3 
cells that had been stimulated with NGF for 5 min. This confirmed that the 80 and 120 kDa 
forms of TrkA were NGF-responsive and the 90 kDa form was not. C) Western blot image 
showing detection of p75NTR in an SH-SY5YUntr lysate. Arrows indicate full length, 
glycosylated p75NTR (78 kDa), the C-terminal fragment (24 kDa) and the intracellular domain 
(19 kDa). D) Western blot image showing absence of TrkB staining in an SH-SY5YUntr lysate. 
Mouse forebrain homogenates were used as positive controls for TrkB detection. p75NTR was 
detected by use of 9992 antiserum (see main text for details). The other primary antibodies 
were from Cell Signalling Technology and had the following catalogue numbers: #2505 (A), 
#4169 (B; specific for TrkA phosphorylated at Tyr785) and #4603 (D). 
















…of the receptor to the cell surface (Watson et al., 1999). Given the hypothesis that 
PrPC modulates NGF signalling, it was important to determine which TrkA 
isoforms/glycoforms were responsive to NGF. This was achieved by culturing clone 
1G3 cells in the absence of serum for 3.5 hours to allow TrkA phosphorylation to 
return to baseline prior to stimulating the cells with NGF concentrations of 3-
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100 ng/ml for five minutes. At that point, the cells were lysed and levels of 
phosphorylated TrkA determined by western blotting. Figure 6.2b shows that, 
following NGF stimulation, bands at 80 and 120 kDa were detected at intensities that 
increased as NGF concentration increased. No 90 kDa band was identified, 
seemingly confirming that the unglycosylated TrkA was not phosphorylated in 
response to NGF, at least not by doses up to 100 ng/ml. However, in contrast to the 
findings of Watson et al. (1999), this result also suggested that the unglycosylated 
TrkA was not constitutively active. The most likely candidate for the 80 kDa band is 
the isoform designated TrkA-III (actual molecular weight of 77.1 kDa), which is also 
thought to be constitutively active and unresponsive to NGF (Luberg et al., 2015). 
Figure 6.2b indicates that both of these assumptions are incorrect for this band, at 
least in these cells. Nevertheless, both the 80 and 120 kDa forms of TrkA were 
activated by NGF stimulation and, therefore, were considered relevant for 
understanding how PrPC expression was affecting the cellular response to NGF.  
p75NTR was detected in the SH-SY5YUntr lysate using antiserum (designated 9992) 
originally produced by the research group of Prof. Moses V. Chao at New York 
University and provided as a gift by Dr Andrea Caporali of the University of 
Edinburgh. The antibody binds to the intracellular domain of p75NTR, which enables 
it to detect the full length protein, p75-CTF and p75-ICD, although not the other 
fragments produced by each cleavage event. The protein was named p75NTR because 
it usually migrates to ~75 kDa in SDS-PAGE, mainly due to the presence of glycans 
that increase the molecular weight from the 45.2 kDa predicted by its amino acid 
sequence (Anastasia et al., 2015). Therefore, the band of ~78 kDa in Figure 6.2c was 
thought most likely to correspond to full length p75NTR, although the sharpness of the 
band is unusual for a glycosylated protein. It is possible that the bands at ~24 and 
19 kDa represent detection of p75-CTF and p75-ICD, respectively, because Zampieri 
et al. (2005) identified these p75NTR fragments at identical apparent molecular 
weights in human cell lysates when using the same antibody. The sharp band at 
~47 kDa is probably unglycosylated p75NTR but the identities of the remaining bands 
in Figure 6.2c are unclear. Alternative splicing of p75NTR is thought to produce a 
35.8 kDa isoform, so the bands at ~38 and 65 kDa could be unglycosylated and 
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glycosylated forms of that isoform, respectively. However, the shorter p75NTR 
isoform is reportedly unable to bind neurotrophins (Dechant and Barde, 2002), which 
makes it less relevant when investigating the links between PrPC and NGF signalling.  
The anti-TrkB antibody did not detect any bands in the SH-SY5YUntr cell lysate 
(Figure 6.2d), although TrkB was present in large amounts in the mouse forebrain 
homogenates used as positive controls. TrkB is a similar size to TrkA and is 
glycosylated in a similar manner, so the band at ~110 kDa in the brain homogenates 
is probably the glycosylated form of the canonical isoform, whilst the lower band 
could be one of the numerous splice variants of the receptor. 
6.4.2 Altered expression of TrkA and p75NTR in stably transfected 
clones compared with untransfected SH-SY5Y cells  
The results in the previous section show that the SH-SY5Y cells expressed p75NTR 
and the high affinity NGF receptor TrkA but not the high affinity BDNF (and NT-4) 
receptor TrkB. Therefore, it seemed sensible to focus on the potential links between 
PrPC and NGF signalling rather than any connection to BDNF signalling. Differences 
in the expression levels of TrkA and/or p75NTR between the stably transfected clones 
and SH-SY5YUntr would be expected to alter the cellular response to NGF present in 
the culture medium – this NGF might derive from the FBS used to supplement the 
medium, which is thought to contain small amounts of the neurotrophin (Bonini et 
al., 2013), or from the SH-SY5Y cells themselves, which are purported to synthesise 
and secrete NGF (Tang et al., 2005). As in previous experiments, SH-SY5YUntr and 
clones 2E3 and 1G3 were seeded into tissue culture plates and lysed 24 hours later. 
Expression levels of TrkA and p75NTR in five independently prepared sets of cell 
lysates were assessed by western blotting. Total TrkA levels (80, 90 and 120 kDa 
forms combined) did not vary significantly between SH-SY5YUntr and the stably 
transfected clones (Figure 6.3a & b). However, Figure 6.3c indicates that the 
proportion of TrkA that was in the 120 kDa (glycoyslated) form was increased in 
clone 1G3 compared with SH-SY5YUntr (19.9 vs 5.8 %) and by a lesser amount in 
clone 2E3 (10.5 vs 5.8 %). The difference between the two clones was also… 
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Figure 6.3 – Increased levels of glycosylated TrkA in stably transfected clones 
compared with untransfected SH-SY5Y cells  
A) Representative western blot image showing TrkA immunostaining in SH-SY5Y cell lysates. 
The primary antibody used for TrkA detection was from Cell Signalling Technology (#2505). 
B-D) Bar charts summarising quantification of TrkA immunostaining from five independently 
prepared sets of cell lysates. Charts B shows total TrkA expression (all three bands 
combined), chart C shows the percentage of TrkA that was in the 120 kDa (glycosylated) 
form and chart D shows the percentage of TrkA that was NGF-responsive (80 and 120 kDa 
bands combined). For each membrane, after correction or loading errors, data were 
normalised to the signal from the SH-SY5YUntr lane. The mean normalised expression values 
(or percentages) are displayed in the bar charts (+/- standard error of the mean). Expression 
differences between the clones and SH-SY5YUntr were tested for significance (p < 0.05) using 
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one-sample or unpaired, two-sample t-tests as appropriate. Key: * for p < 0.05; ** for 
p < 0.01.   
 
…statistically significant (unpaired, two-sample t-test: p = 0.033). Since data 
presented in the previous section showed that both the 80 and 120 kDa forms of TrkA 
were phosphorylated following NGF stimulation, the signal intensities of these bands 
were combined to enable calculation of the percentage of TrkA that was 
NGF-responsive. Again, this percentage was significantly increased in stably 
transfected clones 2E3 and 1G3 compared with SH-SY5YUntr (Figure 6.3d). In 
contrast, the level of full length, glycosylated p75NTR (78 kDa) was reduced by 
almost 50 % in clone 1G3 compared with SH-SY5YUntr, although it was unchanged 
in clone 2E3 (Figure 6.4b). Additionally, Figure 6.4c shows that both stably 
transfected clones had reduced levels of the ~24 kDa band thought to correspond to 
p75-CTF. A similar trend was evident for the putative p75-ICD band at ~19 kDa 
(Figure 6.4d) but the reductions were not statistically significant in this case.  
 
It has been proposed that p75NTR molecules can self-assemble into trimeric 
complexes that are less able to mediate downstream signalling than the monomeric 
form (Anastasia et al., 2015). Although the intense bands at the very top of the 
Figure 6.4a western blot (~200 kDa) could represent detection of trimeric p75NTR, the 
blotted samples were prepared under denaturing and reducing conditions that should 
disassemble protein complexes. It is, however, possible that this process may not 
have been completely effective. Alternatively, the putative trimers could have been 
artefactually created when heating the samples prior to loading the SDS-PAGE gels – 
certain membrane proteins are known to be prone to this form of aggregation (Sagne 
et al., 1996). Either way, the quantification of the levels of full length p75NTR shown 
in Figure 6.4b may be incomplete, because it was only based upon the 78 kDa bands. 
However, the ~200 kDa bands were towards the top end of the western blot 
membrane, at a position where the transfer quality was poor and seemingly quite 
variable between lanes. Because of this, I decided that any quantification of the 
~200 kDa bands would not be accurate.   
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Figure 6.4 – Reduced levels of p75NTR C-terminal fragment in stably 
transfected clones compared with untransfected SH-SY5Y cells  
A) Representative western blot image showing p75NTR immunostaining in SH-SY5Y cell 
lysates. Rabbit 9992 anti-serum was used for p75NTR detection (see Appendix I for details). 
B-D) Bar charts summarising quantification of p75NTR immunostaining from five 
independently prepared sets of cell lysates. Charts B, C and D show the data for the 78 kDa 
(full length, glycosylated), 24 kDa (p75-CTF) and 19 kDa (p75-ICD) forms of p75NTR, 
respectively. For each membrane, after correction for loading errors, data were normalised 
to the signal from the SH-SY5YUntr lane. The mean normalised expression values (+/- 
standard error of the mean) are indicated in the bar charts. Expression differences between 
clones and SH-SY5YUntr were tested for significance (p < 0.05) using one-sample t-tests. Key: 
* for p < 0.05; *** for p < 0.001.  
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Figure 6.5 – Altered sortilin expression in stably transfected clones compared 
with untransfected SH-SY5Y cells  
A & B) Representative western blot image and bar chart summarising quantification of 
sortilin immunostaining from four independently prepared sets of SH-SY5Y cell lysates. The 
primary antibody for sortilin detection was from Proteintech (#12369-1-AP). For each 
experiment, after correction for loading errors, data were normalised to the signal from the 
SH-SY5YUntr lane. The mean normalised expression values (+/- standard error of the mean) 
are displayed in the bar charts. Expression differences between clones and SH-SY5YUntr were 
tested for significance (p < 0.05) using one-sample t-tests. Key: ** for p < 0.01.   
Overall, the data presented in this section indicate that PrPC transfection increased 
the amount of NGF-responsive TrkA, specifically by increasing the levels of the 
120 kDa glycoform. Although altered expression of full length p75NTR was only 
found in clone 1G3, levels of p75-CTF did appear to be reduced in both clones tested 
compared with SH-SY5YUntr. Combined, these results suggest that PrPC expression 
might tip the balance in favour of NGF signalling through TrkA rather than p75NTR.   
 
Pro-apoptotic signalling mediated by p75NTR seems to require expression of the 
sortilin receptor (Nykjaer et al., 2004). Therefore, the levels of this receptor were 
also relevant when considering the effect of PrPC expression on the cellular response 
to NGF, especially given a recent report that sortilin interacts with PrPC directly in 
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...analysis of four independently prepared sets of lysates determined that sortilin 
expression was higher in clone 2E3 (+1.92 fold) compared with SH-SY5YUntr 
(Figure 6.5). No significant change was observed in clone 1G3, although the trend 
was in the opposite direction to clone 2E3. The implications of these results are 
unclear, given the lack of consistent change to sortilin expression induced by PrPC 
transfection. Higher sortilin levels in clone 2E3 compared with SH-SY5YUntr might 
suggest a greater tendency towards pro-apoptotic signalling in response to 
neurotrophins (both the “pro” and mature forms) but the increase in NGF-responsive 
TrkA could counteract this.   
6.4.3 Knockdown of PrPC did not reverse the changes to p75NTR 
expression that seemed to have been induced by PrPC 
transfection  
Stably transfected clones 2E3 and 1G3 displayed increased levels of the 120 kDa 
TrkA glycoform and also appeared to express lower levels of p75-CTF compared 
with SH-SY5YUntr. The assumption was that these changes were induced by PrPC 
expression, so, in an attempt to confirm this, I investigated the effects of knocking 
down PrPC expression in the clones. PrPC knockdown was achieved by use of the PrP 
siRNA (designated s72188) that was introduced in section 4.1. To make the 
experiments manageable from a technical point of view, the effects of PrPC 
knockdown on TrkA and p75NTR expression were assessed only in clone 1G3 and 
SH-SY5YUntr cultures. Cells were subjected to one of three treatments: 1) transient 
transfection with 15 nM PrP siRNA; 2) transient transfection with 15 nM of a 
negative control siRNA with “no significant sequence similarity to mouse, rat, or 
human gene sequences” (Thermo Fisher Scientific, [n.d.]-b); or 3) exposure only to 
the carrier medium for the transfection reagent-siRNA complexes. The culture 
medium was refreshed the day after transfection and the cells were subcultured into 
fresh plates two days later to ensure the SH-SY5YUntr and clone 1G3 cultures were at 
similar densities – this was necessary due to the faster proliferation rate of 
SH-SY5YUntr. Lysis was performed the following day i.e. four days post-transfection, 
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which should have allowed sufficient time for any effect of reduced PrPC levels on 
NGF receptor expression to take place. 
 
Prior to carrying out these experiments, I noted that when the effects of PrPC 
knockdown on the proliferation rates of the SH-SY5Y cell lines were assessed (see 
section 5.2) the culture medium contained a small amount (roughly 9 % (v/v)) of 
OptiMEM medium, which is the recommended carrier solution for formation of the 
complexes between the siRNAs and the transfection reagent. The cells were cultured 
in this OptiMEM-containing medium for the duration of those proliferation assays to 
avoid any detachment from the plates that might have occurred during medium 
changes. Although the presence of OptiMEM seemed unimportant at the time, 
OptiMEM contains insulin, in addition to its other components (Thermo Fisher 
Scientific, [n.d.]-a). Given the putative connection between PrPC and NGF signalling 
and the reported involvement of p75NTR in insulin signalling pathways (Passino et al., 
2007; Baeza-Raja et al., 2013), it seemed worth investigating whether the presence or 
absence of OptiMEM had any influence on the effect of PrPC knockdown on 
expression levels of the NGF receptors. Ultimately, including OptiMEM in the 
medium did not alter the results (data not shown) and, because one more 
experimental replicate was performed in OptiMEM-containing medium, the data 
from those experiments are the results presented here.     
 
Western blotting of clone 1G3 lysates confirmed that PrPC expression was greatly 
reduced by the PrP siRNA, whilst the negative control siRNA had no effect 
(Figure 6.6a). Unfortunately, because of the low initial seeding density required for 
efficient transfection, it was difficult to reliably obtain cell lysates at sufficient 
protein concentrations for western blot detection of the 120 kDa TrkA glycoform 
(data not shown). It was, however, possible to analyse the levels of p75NTR 
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Figure 6.6 – PrPC knockdown did not rescue the difference in levels of p75NTR 
C-terminal fragment between clone 1G3 and untransfected SH-SY5Y cells  
A) Representative western blot image showing markedly reduced PrPC immunostaining from 
a clone 1G3 lysate prepared four days after transient transfection with the PrP siRNA 
s72188 compared with lysates prepared from cells either transiently transfected with a 
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negative control siRNA (neg ctrl) or not transfected with any siRNA at all (nor exposed to the 
transfection reagent). PrPC was detected by use of the BC6 anti-PrPC primary antibody 
(McCutcheon et al., 2014). B & C) Representative western blot images showing p75NTR 
immunostaining in the same lysates as in image A as well as in lysates of SH-SY5YUntr cells 
that had undergone the same treatments. The relevant bands are shown with arrows. 9992 
antiserum (see Appendix I for more details) was used for p75NTR detection in the case of 
image B. Image C shows the pattern obtained when using a primary antibody from Millipore 
(#07-046; see explanation in footnote 15). Only p75-CTF (24 kDa) was conclusively detected 
by the commercial antibody. D & E) Bar charts summarising quantification of p75NTR 
immunostaining in SH-SY5YUntr (D) and clone 1G3 (E) lysates obtained from four 
independent experiments. For each experiment, after correction for loading errors, data 
were normalised to the signal from the negative control siRNA-transfected lysate. The mean 
normalised expression values (+/- standard error of the mean) are indicated in the bar 
charts. Expression differences between negative control siRNA- and PrP siRNA-transfected 
cells were tested for significance (p < 0.05; indicated with *) using one-sample t-tests. 
 
…four independent experiments15 are presented in Figure 6.6b-e. Initially, the data 
were normalised to the SH-SY5YUntr “no siRNA” lanes but it was difficult to isolate 
any effects of the PrP siRNA from the assay-to-assay variability in the expression 
levels of p75NTR by SH-SY5YUntr and clone 1G3. Therefore, for each cell type, the 
band intensities for p75NTR and its cleavage fragments in the PrP siRNA-transfected 
lysates were normalised to those from the negative control siRNA-transfected 
lysates. Figure 6.6d shows that transfection of the PrP siRNA did not significantly 
alter the levels in SH-SY5YUntr of the bands thought to correspond to full length 
p75NTR, p75-CTF and p75-ICD, which was as expected due to the lack of detectable 
PrPC expression in those cells normally. For clone 1G3, knockdown of PrPC 
expression slightly but significantly (p = 0.033) reduced the abundance of the 
~78 kDa band thought to be full length p75NTR (Figure 6.6e). This change was 
                                                 
15 The fourth experiment required the use of a commercial p75NTR antibody since no more of the 9992 
p75NTR antiserum was available. Figure 6.6c shows that the commercial antibody only detected 
p75-CTF conclusively. A ~78 kDa band corresponding to full length p75NTR was just about visible but 
not quantifiable, whilst p75-ICD was not detected at all. Therefore, the bar charts in Figure 6.6 
summarise data from only three experiments for full length p75NTR and p75-ICD.   
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opposite to the expected direction given the already lower levels of full length 
p75NTR in clone 1G3 compared with SH-SY5YUntr. However, non-significant trends 
towards increased levels of the ~24 and 19 kDa bands possibly corresponding to the 
p75NTR cleavage fragments were noticeable in the PrP siRNA-transfected clone 1G3 
cells. These effects could be relevant considering that both p75-CTF and p75-ICD 
are thought to be functionally active (Kenchappa et al., 2006; Coulson et al., 2008; 
Matusica et al., 2013; Verbeke et al., 2013). Indeed, one could speculate that four 
days of reduced PrPC expression is insufficient to affect overall levels of p75NTR but 
does increase cleavage rates to bring the levels of p75-CTF and p75-ICD closer to 
those observed in SH-SY5YUntr.  
As described above, knocking down PrPC did not conclusively prove that the 
differential expression of the NGF receptors in the stably transfected clones was the 
result of PrPC expression in the SH-SY5Y cells. However, another obvious question 
to ask was whether the altered expression levels translated into differences in the 
activities of downstream signalling pathways. One way to assess this was to measure 
the levels of activated NGF receptors in the cells. The activation status of p75NTR is 
difficult to determine directly: whilst the receptor can be phosphorylated, this is not 
thought to occur in response to ligand binding. Moreover, phosphorylation of p75NTR 
may only occur when receptor molecules are transported along axons (Butowt and 
von Bartheld, 2009) and, although SH-SY5Y cells do extend neurite-like processes, 
they do not have axons. Since p75-CTF and p75-ICD are biologically active, 
cleavage rates could be considered correlates of receptor activation but, again, the 
cleavage processes do not appear to be induced by neurotrophin binding to p75NTR. 
However, TrkA activation is much easier to assess. In response to NGF stimulation, 
TrkA is phosphorylated at a number of tyrosine residues, which activates the receptor 
and, consequently, initiates downstream signalling.  
I performed western blotting experiments using an antibody specific to the 
phosphorylated form of TrkA (p-TrkA) in order to assess baseline levels of TrkA 
activation in SH-SY5Y cells growing in their standard culture medium. As explained 
previously, the NGF required for receptor activation would either have come from 
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the FBS used to supplement the medium (Bonini et al., 2013) or from its secretion by 
the cells themselves (Tang et al., 2005). Bands at ~120 kDa, perhaps corresponding 
to the 120 kDa TrkA glycoform, were detected by the p-TrkA antibody in 
SH-SY5YUntr lysates but were too faint to quantify accurately (data not shown). 
However, this finding did suggest that NGF-TrkA signalling was occurring at low 
levels in the SH-SY5Y cells. An alternative approach for investigating whether 
baseline p-TrkA levels were higher in clones 2E3 and 1G3 than SH-SY5YUntr was to 
quantify TrkA phosphorylation in response to NGF stimulation. If p-TrkA were more 
abundant in the stably transfected clones following exposure to exogenous NGF then 
p-TrkA levels would also be predicted to be higher when the cells were cultured 
normally in serum-containing medium (which is thought to contain some NGF). 
Unfortunately, there was not enough time to optimise these NGF stimulation assays. 
Therefore, I was unable to confirm that PrPC transfection into SH-SY5Y cells had 
caused increased baseline levels of TrkA activation.  
6.4.4 Neurotrophin receptors expressed at similar levels in wild type 
and PrPC-null mouse forebrains 
The data presented in section 6.4.2 indicate that PrPC transfection altered expression 
of NGF receptors in the SH-SY5Y cells. Because of the availability of homogenised 
forebrain tissues from age- and sex-matched wild type and PrPC-null mice (see 
sections 5.3 and 5.5 for more information), I decided to investigate whether the 
expression changes identified in SH-SY5Y cells were also present in ex vivo tissues. 
In addition to TrkA and p75NTR, TrkB expression was also assessed, because analysis 
of the genes usually coexpressed with PRNP suggested a potential link between PrPC 
and BDNF signalling, as reported in section 6.2. Moreover, mouse forebrain tissues 
had already been shown to express TrkB (Figure 6.2d) unlike the SH-SY5Y cells.  
Figure 6.7a shows that the glycosylated form of TrkA was detected in the forebrain 
homogenates, although at a slightly higher molecular weight (~130 kDa) than in the 
cells, presumably as a result of differential glycosylation. However, western blot…  
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Figure 6.7 – Expression levels of neurotrophin receptors did not vary 
between wild type and PrPC-null mouse forebrains 
See following page for legend… 
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Figure 6.7 – Expression levels of neurotrophin receptors did not vary between 
wild type and PrPC-null mouse forebrains 
A, C & G) Representative Images of western blots of wild type (WT) and PrPC-null mouse 
forebrain homogenates that were probed for TrkA, p75NTR and TrkB, respectively. The 
relevant bands on image C are shown with arrows. Rabbit 9992 anti-serum (see Appendix I 
for more details) was used for p75NTR detection. Anti-TrkA and anti-TrkB primary antibodies 
were from Cell Signalling Technology (#2505 and #4603, respectively). B) Bar chart 
summarising quantification of TrkA immunostaining from 10 tissues of each genotype (5 
male, 5 female). After correction for loading errors, signals on each membrane were 
normalised to a fixed reference sample – a “pool” consisting of equal amounts of all 20 
brain homogenates. D-F) Bar charts summarising quantification of p75NTR immunostaining 
from six tissues of each genotype. After correction for loading errors, the data were 
normalised to the mean signal from the WT tissues. Bar charts D, E and F show the data for 
the 78 kDa (full length, glycosylated), 24 kDa (p75-CTF) and 19 kDa (p75-ICD) bands, 
respectively. For bar chart D, the 78 kDa band in the 5th lane from the right was not 
quantified due to presence of an air bubble. H) Bar chart summarising quantification of TrkB 
immunostaining from six tissues of each genotype (signals from 80 and 120 kDa bands were 
combined). After correction for loading errors, the data were normalised to the mean signal 
from the WT tissues. B, D-F & H) Overall mean normalised expression values for each 
genotype were calculated and these are indicated in the bar charts (+/- standard error of 
the mean). Expression differences between genotypes were tested for significance 
(p < 0.05) using unpaired, two-sample t-tests but no comparisons met the threshold. 
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…analysis of 10 wild type and 10 PrPC-null tissues identified no differences in TrkA 
expression between the genotypes (Figure 6.7b). No other specific bands were 
detected by the anti-TrkA antibody. To save on the time required for these 
experiments, p75NTR expression was initially assessed in just six tissues of each 
genotype and the results showed that levels of the bands thought to correspond to the 
full length receptor and its cleavage fragments did not vary between PrPC-null and 
wild type control tissues (Figure 6.7c-f). Western blots for TrkB showed a single at 
band around 120 kDa and a doublet at 80 kDa (Figure 6.7g) – TrkB can be 
glycosylated much like TrkA, which suggests that the higher band is the glycosylated 
form of the canonical isoform. The 80 kDa TrkB bands are probably the result of 
alternative splicing, since the Uniprot entry (#Q16620) for human TrkB indicates 
that multiple isoforms exist. Figure 6.7h shows quantification of TrkB expression 
based on the combined signal intensities of the 80 and 120 kDa bands, because the 
results were virtually identical when each set of bands were analysed separately (data 
not shown). In a similar manner to TrkA and p75NTR, TrkB levels did not vary 
according to PrPC genotype. 
 
The lack of in vivo confirmation of in vitro results is a common theme in the study of 
PrPC function. For example, in spite of cell culture experiments performed by various 
groups identifying numerous putative roles for PrPC, one proteomic study did not 
identify a single protein that was differentially expressed between wild type and 
PrPC-null mouse brain homogenates (Crecelius et al., 2008). Others have explained 
similar results by suggesting that PrPC regulates processes in a cell type-specific 
manner, leading to an averaging out of these effects over an entire tissue (Mehrabian 
et al., 2014; Mehrabian et al., 2016). Alternatively, the role of PrPC in the immature, 
neuronal precursor-like SH-SY5Y cells (Kovalevich and Langford, 2013) may not be 
the same as its role in the forebrains of aged mice – the tissues used in these analyses 
were from mice culled at around 550 days old. A final potential explanation for the 
lack of differences in neurotrophin receptor expression levels between genotypes is 
that absence of PrPC in the knockout mice could be compensated for by other 
proteins, as has been suggested previously (Shmerling et al., 1998; Hajj et al., 2007).   
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6.5 Investigating the effects of PrPC expression on the 
activities of growth factor signalling pathways   
6.5.1 PrPC transfection into SH-SY5Y cells alters activities of growth 
factor signalling pathways  
As explained in section 6.4.3, I was unable to confirm that the higher levels of 
NGF-responsive TrkA in the stably transfected clones compared with SH-SY5YUntr 
led to equivalent increases in p-TrkA. The levels of activated p75NTR could also not 
be determined directly due to the lack of a well-defined marker for its activation. An 
alternative approach was to assess the activities of signalling pathways downstream 
of the NGF receptors. I decided to focus on the PI3K/Akt and ERK1/2 pathways, 
which play important roles in facilitating the neurotrophic activity of NGF that is 
initiated by binding to TrkA (Huang and Reichardt, 2003). Independent binding of 
NGF to p75NTR can also activate PI3K/Akt signalling (Chen et al., 2009).  
Akt and ERK1/2 are activated by phosphorylation mediated by upstream protein 
kinases. Therefore, levels of phosphorylated Akt (p-Akt) and ERK1/2 (p-ERK1/2) in 
the SH-SY5Y cell lines were assessed by western blotting, making use of an 
antibody that specifically detects Akt phosphorylated at Ser473 and another antibody 
specific for the Thr202 and Tyr204 phosphorylation sites of ERK1 and the Thr185 
and Tyr187 sites of ERK2. Total levels of Akt and ERK1/2 were also quantified 
using antibodies able to pick up all forms of the proteins. As in similar experiments, 
cells were seeded into plates and cultured in their standard, serum-containing 
medium for 24 hours prior to lysis. Western blot analysis of four independently 
prepared sets of cell lysates revealed intense p-Akt and total Akt bands that migrated 
to around the expected molecular weight of 56 kDa (Figure 6.8a & b). Figure 6.8c 
shows that overall Akt expression did not vary significantly between SH-SY5YUntr 
and stably transfected clones 2E3 and 1G3. However, the p-Akt/total Akt ratio was 
significantly reduced by 17 % in clone 2E3 and by 31 % in clone 1G3 compared with 
the control cell line (Figure 6.8d).  
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F) Total ERK1/2 
 
Figure 6.8 – Decreased activation of Akt in clones 2E3 and 1G3 and increased 
activation of ERK1/2 in clone 2E3 compared with untransfected SH-SY5Y cells  
Representative images of western blots of SH-SY5Y cell lysates that were simultaneously 
probed for Akt phosphorylated at Ser473 and total Akt (A & B) or phosphorylated ERK1/2 
(Thr202/Tyr204 for ERK1 and Thr185/Tyr187 for ERK2) and total ERK1/2 (E & F), 
respectively. Primary antibodies were all from Cell Signalling Technology and had the 
following catalogue numbers: #4060 (A), #2920 (B), #4370 (E) and #9107 (F). Also shown 
are bar charts summarising quantification of total Akt (C) and total ERK1/2 (G) 
immunostaining from at least three independently prepared sets of cell lysates as well as 
normalised ratios of phospho-/total Akt (D) and phospho-/total ERK1/2 (H) levels. For 
ERK1/2 blots, signals from ERK1 (42 kDa) and ERK2 (40 kDa) bands were combined. For each 
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membrane, after correction for loading errors, total Akt or total ERK1/2 band signals were 
normalised to the signal from the SH-SY5YUntr lane. Normalised phospho/total ratios were 
calculated by normalising the ratios for each lane to the ratio from the SH-SY5YUntr lane. The 
overall mean normalised expression values/ratios (+/- standard error of the mean) are 
displayed in the bar charts. Expression differences between clones and SH-SY5YUntr were 
tested for significance (p < 0.05) using one-sample t-tests. Key: * for p < 0.05; ** for 
p < 0.01.   
 
The ~42 and 40 kDa bands detected by the ERK1/2 antibodies correspond to ERK1 
and ERK2, respectively (Figure 6.8e & f). For quantification, the signal intensities of 
these bands were combined because ERK1 and 2 are thought to have very similar 
functions and to be regulated similarly, at least in most cell types (Wortzel and Seger, 
2011). Western blot analysis of three independently prepared sets of cell lysates 
showed that total ERK1/2 levels were similar among the cell lines (Figure 6.8g), as 
was the case for Akt. In contrast, the p-ERK1/2/total ERK1/2 ratio was increased in 
clone 2E3 by 147 % compared with SH-SY5YUntr, although no such effect was 
evident in clone 1G3, which displayed similar levels of p-ERK1/2 to the control cell 
line.    
The PI3K/Akt pathway is considered a positive regulator of proliferation. Moreover, 
high levels of p-Akt have been shown to block cell cycle arrest induced by NGF 
stimulation (Bang et al., 2001). Therefore, the reduced Akt signalling activity in the 
stably transfected clones is in agreement with their slower proliferation compared 
with SH-SY5YUntr, as was reported in section 5.2. Akt activation was also greater in 
clone 2E3 than in clone 1G3 (unpaired, two-sample t-test: p = 0.008), which could 
explain the faster proliferation rate of clone 2E3. Intriguingly, these differences 
between the clones are in line with the data for the 120 kDa TrkA glycoform, which 
was more upregulated in clone 1G3 compared with SH-SY5YUntr than it was in clone 
2E3. 
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At first glance, reduced Akt signalling in the stably transfected clones seems strange 
given that NGF, whether signalling through TrkA or p75NTR, is usually considered to 
activate Akt. One conclusion could be that PrPC expression makes SH-SY5Y cells 
less responsive to NGF but, as reported in section 6.1, pathway analysis of the 
proteomic data suggested that NGF signalling pathways were more active in the 
stably transfected clones, not less. However, whilst NGF does cause an initial 
increase in p-Akt, rapid dephosphorylation then seems to occur and Akt activity 
drops back to a much lower, constant level if NGF stimulation is maintained (Bang et 
al., 2001). This situation may have applied to the experiments reported in Figure 6.8, 
given that the cells had been cultured in serum-containing medium for 24 hours prior 
to lysis and, therefore, would have been exposed for that time period to any NGF 
present. Therefore, in this context, lower levels of p-Akt may not necessarily indicate 
that the stably transfected clones were less responsive to NGF.  
ERK1/2 signalling is thought to be the key driver of NGF-mediated neuronal 
differentiation (Klesse et al., 1999). Therefore, the increased ERK1/2 activity in 
clone 2E3 compared with SH-SY5YUntr is in agreement with the proposed increased 
activity of NGF signalling pathways in the PrPC-transfected cells. The counter 
evidence is that the degree of ERK1/2 activation was similar in clone 1G3 and in the 
control cell line, suggesting that the increase in clone 2E3 may not have been caused 
by PrPC expression. Strangely, enhanced ERK1/2 signalling in clone 2E3 compared 
with clone 1G3 would suggest that clone 2E3 had the more neuronal phenotype and 
yet several lines of evidence indicated that this was not the case. Firstly, cell cycle 
arrest is required for complete neuronal differentiation, since neurons are 
post-mitotic, and yet, as eluded to earlier, clone 1G3 proliferated slower than clone 
2E3. Secondly, as reported in section 4.2.2, it was clone 1G3 not 2E3 that displayed 
increased expression of neuroblast differentiation-associated protein AHNAK and 
reduced expression of the immature neuronal marker proliferation cell nuclear 
antigen compared with SH-SY5YUntr. Thirdly, another feature of neuronal 
differentiation is neurite outgrowth and, although Figure 3.9 in section 3.3.3 clearly 
shows that clone 2E3 extended more neuritic processes than clone 1G3, 
SH-SY5YUntr seemed to produce just as many of these processes as clone 2E3 in 
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spite of having much lower p-ERK1/2 levels. The explanation for this confusing 
picture is probably the involvement in neuronal differentiation of other signalling 
pathways not considered in these analyses.  
6.5.2 Knockdown of PrPC did not appear to rescue the alterations to 
growth factor signalling pathways that were induced by PrPC 
transfection  
Whilst the effects of PrPC transfection on ERK1/2 activity were not consistent, the 
reduced levels of p-Akt in stably transfection clones 2E3 and 1G3 in the absence of 
any significant changes to total Akt expression did suggest that PrPC expression may 
have altered the cellular response to specific growth factors. In an attempt to gather 
more evidence for the direct involvement of PrPC in this process, I assessed how 
depleting PrPC expression in the stably transfected clones affected Akt activation. 
The method used was the same as per the experiments to determine whether PrPC 
knockdown rescued the altered p75NTR expression in clone 1G3 – cells were either 
transiently transfected with the PrP siRNA s72188 or the negative control siRNA or 
were exposed only to the carrier medium for the transfection reagent-siRNA 
complexes. Again, the culture medium was refreshed the day after transfection and 
the cells were subcultured into fresh plates two days later to ensure all the cultures 
were at similar densities. Cell lysis was performed on the fourth day post 
transfection. For the experiments to be technically manageable it was only possible 
to include SH-SY5YUntr and clone 1G3 cultures and, due to time limitations, Akt 
activation could only be assessed in two independent experiments, which limits the 
conclusions that can be made from the data.   
Quantitative western blotting indicated that total Akt levels and p-Akt/total Akt ratios 
in SH-SY5YUntr and clone 1G3 cells not transfected with either siRNA were similar 
to the results presented in the previous section (Figure 6.9a-d). The data also 
indicated that transfection with the PrP siRNA did not increase Akt activation in 
clone 1G3; if anything, there was a tendency towards a lower p-Akt/total Akt ratio 
compared with negative control siRNA-transfected clone 1G3 cells (Figure 6.9d).  
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C) Total Akt  D) Phospho/total Akt ratio 
 
 
Figure 6.9 – PrPC knockdown did not appear to rescue the differences in Akt 
activation between clone 1G3 and untransfected SH-SY5Y cells  
Representative images of western blots of SH-SY5Y cell lysates that were simultaneously 
probed for Akt phosphorylated at Ser473 and total Akt (A & B). Lysates had been prepared 4 
days after SH-SY5YUntr and clone 1G3 cells were transiently transfected either with the 
PrP-specific siRNA s72188 or a negative control siRNA. Control lysates were also prepared 
from cells not exposed to the transfection reagent. Primary antibodies were from Cell 
Signalling Technology and had the following catalogue numbers: #4060 (A) and #2920 (B). 
Also shown are bar charts summarising quantification of total Akt (C) immunostaining in 
lysates obtained from two independent experiments as well as normalised ratios of 
phospho-/total Akt (D) levels. For each membrane, after correction for loading errors, total 
Akt band signals were normalised to the signal from SH-SY5YUntr cells not exposed to the 
transfection reagent. Normalised phospho/total ratios were calculated by normalising the 
ratios for each lane to the ratio from the SH-SY5YUntr lane. The overall mean normalised 
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expression values/ratios (+/- standard error of the mean) are displayed in the bar charts. 
Error bars are shown only for the clone 1G3 cultures, because siRNA transfections of 
SH-SY5YUntr were performed only for one of the experimental replicates.    
 
Neither siRNA noticeably affected Akt activation in SH-SY5YUntr cultures nor total 
Akt levels in either cell line. As previously mentioned, the data in Figure 6.9 are only 
suggestive, because just two experimental replicates could be performed. 
Nevertheless, there was little evidence for PrPC knockdown rescuing the altered Akt 
signalling displayed by clone 1G3. This was definitely not due to a lack of activity of 
the PrP siRNA, because PrPC expression had already been shown to be knocked 
down effectively when using this method (Figure 6.6a). One possibility is that 
transient reduction of PrPC expression is not sufficient to reverse the effects of stably 
transfecting SH-SY5Y cells with a protein they do not normally express, at least not 
at detectable levels. Indeed, a previous study found that complete knockout of PrPC 
in an epithelial cell line had rather different effects compared to a transient 
knockdown of expression (Mehrabian et al., 2015). Whatever the reason for the lack 
of effect of PrPC knockdown, what can be said is that, compared with SH-SY5YUntr, 
Akt activation was reduced in the stably transfected clones and differential activation 
of the PI3K-Akt pathway fits reasonably well with the altered expression of the NGF 
receptors TrkA and p75NTR, although the PI3K/Akt pathway can also be modulated 
by growth factors other than NGF.     
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6.6 No evidence for direct interactions between PrPC and 
receptors for nerve growth factor  
The data presented in this chapter so far suggest that transfection of PrPC into 
SH-SY5Y cells increased TrkA glycosylation and reduced p75-CTF levels, which 
may, in turn, have caused reduced activation of the PI3K/Akt pathway. What has yet 
to be addressed is how PrPC could have altered expression of the NGF receptors. An 
indirect effect is plausible; for example, PrPC could have affected the cellular 
response to a growth factor other than NGF, thereby affecting the expression of TrkA 
and p75NTR. However, of the growth factors suggested by IPA as potential upstream 
regulators of the PrPC transfection-induced proteomic changes (see section 6.1), NGF 
was the best candidate because it had a high activation state z-score. A second 
possibility is that PrPC expression slowed down cell cycle progression by some other 
mechanism and, as a consequence, the proportions of the cells in each stage of the 
cell cycle were altered. This might have affected the overall expression levels of the 
NGF receptors in the cultures, since TrkA in preferentially expressed in the M and 
late G1 phases and p75
NTR in the S, G2 and early G1 phases (Urdiales et al., 1998; 
Bono et al., 1999). It was TrkA glycosylation, though, rather than its overall 
expression level that seemed to be altered in the stably transfected clones. TrkA is N-
glycosylated, so a global effect of PrPC expression on protein N-glycosylation could 
have been responsible for the increased levels of the 120 kDa TrkA glycoform. 
However, there was no evidence in the proteomic data obtained from the SH-SY5Y 
cell lines of any altered expression of enzymes involved in the early stages of N-
glycosylation. For example, three subunits of the oligosaccharyltransferase enzyme 
complex that transfers glycan precursors to polypeptide chains being synthesised in 
the ER were identified in the proteomic datasets and were expressed at similar levels 
among the cell lines – the mean fold changes compared with SH-SY5YUntr for these 
subunits were +1.12, +1.15 and +1.03 in clone 2E3 and -1.04, +1.03 and -1.05 in 
clone 1G3. Therefore, it is more likely that the differential glycosylation of TrkA was 
specific to that protein. Unfortunately, exactly what regulates whether a TrkA 
receptor does or does not get glycosylated within the ER seems to be unknown.  
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Activation of certain signalling pathways downstream of p75NTR, such as the nuclear 
factor-kappa B pathway, seems to increase p75NTR expression (Choi and Friedman, 
2009), thereby further enhancing signalling in a positive feedback loop. Therefore, if 
PrPC were interacting with p75NTR directly and consequently altering its affinity for 
NGF and/or TrkA, downstream signalling would be affected and this might lead to a 
change in p75NTR expression. One problem with this idea is that expression of full 
length p75NTR was reduced only in clone 1G3 compared with SH-SY5YUntr, not in 
clone 2E3. p75-CTF levels appeared to be reduced in both clones, which might 
suggest that PrPC inhibits alpha-cleavage of p75NTR but, because of its lower 
expression of the full length receptor, the proportion of p75NTR that was cleaved by 
clone 1G3 may actually have been higher than in SH-SY5YUntr. Nonetheless, it still 
seemed likely that if PrPC were causing the altered expression of the NGF receptors, 
it would be by direct interaction, especially because PrPC, p75NTR and TrkA are all 
found in the same cell membrane microdomains known as lipid rafts (Vey et al., 
1996; Huang et al., 1999). To investigate putative interactions between PrPC and the 
NGF receptors, analyses of the proteins that co-immunoprecipitated with PrPC were 
performed. In the absence of cross-linking, cell lysis prior to co-immunoprecipitation 
(co-IP) has to be performed under non-denaturing conditions to maintain the existing 
protein-protein interactions. However, non-denaturing detergents like Triton X-100 
may insufficiently solubilise proteins residing in lipid rafts. Therefore, a buffer 
containing 1 % (v/v) Triton, 0.25 % (w/v) sodium deoxycholate (SDA) and 1.5 % 
(w/v) N-octyl glucopyranoside was initially used for lysis. SDA effectively 
solubilises membrane proteins (Zhou et al., 2006), although it can also be denaturing, 
which meant the concentration had to be kept low. N-octyl glucopyranoside is also 
known to improve extraction of membrane proteins (Kan et al., 2013) but is not 
thought to disrupt protein-protein interactions. After lysis, the anti-PrPC antibody 
BC6 (McCutcheon et al., 2014) was used for immunoprecipitation of PrPC along 
with any interacting partners. Protein G-conjugated magnetic beads were used to 
extract the antibody-protein complexes and, following washes to remove 
non-specific binders, the remaining proteins were eluted from the beads and analysed 
by western blotting. Because initial experiments showed that a large proportion of 
the PrPC in the original cell lysates was not carried through to the final samples (data 
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Figure 6.10 – Nerve growth factor receptors did not co-immunoprecipitate 
with PrPC 
See following page for legend… 
not shown), SDA was removed from the lysis buffer in case it was disrupting the 
interactions between protein G and the antibody or between the antibody and PrPC. 
Figure 6.10 mainly shows the data from co-IP experiments performed on lysates 
prepared without SDA in the buffer. Loss of PrPC from the final samples was reduced 
by this method – Figure 6.10a demonstrates that PrPC was present at high levels in a 
BC6 co-IP sample prepared from a clone 1G3 lysate, whilst minimal staining was 
observed in the sample prepared using an isotype control antibody (IgG1). The 
~50 kDa bands near the top of Figure 6.10a represent detection of the heavy chains 
of the antibodies used for co-IP by the secondary antibody used for western blotting. 
Figure 6.10b & c indicate that all the TrkA iso/glycoforms and the various forms of 
p75NTR were detectable in the original cell lysates but did not co-immunoprecipitate 
with PrPC – any staining from the BC6 co-IP sample was also present in the isotype 
control co-IP sample. Again, the bands at 25 and 50 kDa in Figure 6.10c are from the 
antibodies used for co-IP (light and heavy chains, respectively).  
Sortilin can interact with p75NTR to modulate NGF signalling (Nykjaer et al., 2004) 
and was recently reported to interact with PrPC (Uchiyama and Sakaguchi, 2016). 
Therefore, whether sortilin co-immunoprecipitated with the PrPC expressed by the… 
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Figure 6.10 – Nerve growth factor receptors did not co-immunoprecipitate with 
PrPC  
A-E) Images of western blots from PrPC co-IP experiments that were probed for PrPC (A), 
TrkA (B), p75NTR (C), annexin A2 (D) or sortilin (E) using the following antibodies: A) BC6 anti-
PrPC (McCutcheon et al., 2014), B) Cell Signalling Technology #2505, C) rabbit 9992 anti-
serum (see Appendix I for details), D) Cell Signalling Technology #8235, and E) Proteintech 
#12369-1AP. The relevant bands are indicated with arrows. In each case, the samples 
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obtained following PrPC immunoprecipitation from cell lysates using the BC6 anti-PrPC 
antibody were analysed alongside samples of the isotype control (IgG1) reaction (antibody 
from Cell Signalling Technology, #5415) and the original cell lysate. Image A shows data from 
clone 1G3 cells, images C and E the data from clone 2E3 cells. B) PrPC was strongly detected 
in the BC6 co-IP reaction and the original lysate, whilst minimal staining was observed in the 
isotype control lane. C-E) Any specific immunostaining was found equally in the BC6 and 
isotype control co-IP reactions. F) Image of a representative silver-stained gel from a PrPC 
co-IP experiment.  
 
…stably transfected SH-SY5Y cells was investigated. Figure 6.10e shows that 
sortilin was easily detectable in the original cell lysate (clone 2E3) but was not 
present in the BC6 co-IP sample. In a further attempt to validate the co-IP assay, a 
western blot of the co-IP samples was probed for annexin A2. This protein is thought 
to be an interacting of partner of PrPC (Morel et al., 2008) and, therefore, would be 
expected to co-immunoprecipitate with PrPC. However, Figure 6.10d indicates that, 
although the BC6 co-IP sample contained a small amount of annexin A2, it was also 
present in the isotype control co-IP sample. The lack of specific detection in the BC6 
co-IP sample of two proteins that reportedly interact with PrPC is strange, since the 
non-specific co-IP of limited amounts of annexin A2 seemingly rules out the 
possibility that the bead washes were so “harsh” that the proteins interacting with 
PrPC were simply washed away. Interestingly, when analysing the co-IP samples on a 
gel and silver staining to detect protein bands (Figure 6.10f), the most intense bands 
corresponded to antibody heavy and light chains, whilst the fainter bands all 
appeared to be non-specific contaminants, since they were present in both BC6 and 
isotype control co-IP samples. This raises the question of whether any proteins were 
co-immunoprecipitated with PrPC in sufficient amounts for western blot detection. 
Because of this, the results of these co-IP experiments are inconclusive: it is still 
plausible that PrPC interacts with a receptor for NGF but the interaction may be too 
weak and/or transient for detection by this method. A future approach might be to use 
a cross-linking reagent to stabilise the interactions between proteins prior to lysis, 
which would be more effective for identifying weaker interactions. Additionally, it 
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would be useful to repeat the co-IP experiments with another PrPC antibody that 
recognises a different epitope of the protein, since it may be that the epitope bound 
by BC6 is obscured by interactions with other proteins, leading to 
immunoprecipitation of only the PrPC molecules not involved in any interactions at 
that time.  
In spite of the lack of data for a direct interaction between PrPC and one or more of 
the receptors for NGF, several lines of evidence reported in this chapter do support 
the idea that PrPC modulates NGF signalling pathways. Such a role for PrPC gives 
rise to a number of predictions for phenotypes one would expect to observe in 
PrPC-null mice. In this vein, Chapter 6 ends by covering preliminary experiments to 
investigate whether PrPC knockout affects the expression of key proteins in certain 
metabolic processes that are known to be regulated by p75NTR.   
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6.7 No evidence for PrPC knockout affecting specific 
metabolic processes in vivo  
If PrPC can modulate NGF signalling then PrPC-null mice would be expected to 
display certain phenotypes consistent with deregulation of NGF signalling. As 
previously described, p75NTR is perhaps the most likely target for modulation by 
PrPC. Among other roles, p75NTR appears to be part of a network of proteins, the 
circadian clock, that work together to regulate circadian rhythms (Baeza-Raja et al., 
2013). Metabolic processes are typically regulated in a circadian manner (Dibner et 
al., 2010), which may explain why knockout of p75NTR in mice results in several 
metabolic defects; for instance, Baeza-Raja et al. (2013) showed that mRNA 
expression levels of solute carrier family 2, facilitated glucose transporter member 4 
(GLUT4) were increased and the levels of phosphoenolpyruvate carboxykinase, 
cytosolic (PCK1) and fatty acid synthase (FASN) decreased in the livers of 
p75NTR-null mice compared with wild type controls. GLUT4 is the main 
insulin-responsive glucose transporter – insulin promotes its translocation from the 
cytoplasm to the cell membrane where its function is to transport glucose into the 
cell (Herman and Kahn, 2006). PCK1 is also involved in glucose homeostasis, since 
it is one of the rate-limiting enzymes in gluconeogenesis (Yoon et al., 2001), the 
process that synthesises glucose from non-carbohydrate substrates. Finally, FASN is 
a multi-enzyme protein that catalyses de novo production of fatty acids from other 
metabolites (Menendez and Lupu, 2007). These molecular changes, and others, result 
in hypersensitivity to insulin and altered glucose metabolism in p75NTR-null mice 
(Baeza-Raja et al., 2012; Baeza-Raja et al., 2013). p75NTR knockout also disrupts the 
ability of the liver to repair itself after injury (Passino et al., 2007). Interestingly, 
Prnp mRNA levels oscillate in a circadian manner in the brain (Cagampang et al., 
1999) and PrPC-null mice display circadian rhythm disruption, including impaired 
melatonin production (Brown et al., 2002), altered sleep structure and altered 
response to sleep deprivation (Tobler et al., 1996; Sanchez-Alavez et al., 2007). 
Moreover, there are indications that PrPC-null mice also have altered responsiveness 
to insulin, though in this case they are hyposensitive, which leads to an impaired 
ability to control blood glucose (Strom et al., 2011; Brito et al., 2013).  
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Given the changes to glucose homeostasis that reportedly arise from both p75NTR and 
PrPC knockout, I decided to perform a simple pilot experiment to determine whether 
similar molecular changes to those observed in p75NTR-null livers were also found in 
the livers of mice lacking PrPC. Firstly, four PrPC-null and four wild type mice were 
culled and their livers removed and snap frozen in liquid nitrogen. These steps were 
performed by Ms. Rebecca Hogan, a senior animal technician within the Roslin 
Institute’s Biological Resource Facility. The liver tissues were from relatively young 
(3-4 months of age), adult mice of the same lines (Manson et al., 1994) as the 
forebrain tissues used in previous experiments (see sections 5.3, 5.5 and 6.4.4). Next, 
the livers were homogenised by following the same method as was used for brain 
homogenisation, and PrPC expression was assessed by western blotting. An earlier 
study found a lack of PrPC expression in healthy liver tissue (Savas et al., 2010), 
although detection at the protein level has been reported in diseased human livers 
(Savas et al., 2010), probably as a result of its upregulation in liver injury-activated 
hepatic stellate cells (Ikeda et al., 1998). My analysis showed that PrPC was, in fact, 
expressed in the wild type livers, albeit in small amounts, and was absent from the 
PrPC-null livers as expected (Figure 6.11a). p75NTR expression was also investigated 
to determine if it varied according to Prnp genotype. Use of the 9992 p75NTR 
antibody produced a noticeably different band pattern to that obtained from the 
forebrain tissues (see Figure 6.7c for image of the blot from the brains). Figure 6.11b 
shows that the most intense band was detected at ~45 kDa, presumably 
corresponding to unglycosylated p75NTR. No clear band for the glycosylated, full 
length protein could be identified at the expected 78 kDa, although the ~19 and 24 
kDa bands thought to correspond to the p75NTR cleavage fragments were detected. In 
any case, Figure 6.11c demonstrates that none of the various forms of p75NTR varied 
in their expression between the livers of PrPC-null and wild type control mice. 
Finally, TrkA expression in the liver tissues was investigated but the receptor was not 
present in sufficient amounts for quantification (data not shown). 
The next step was to investigate the expression of GLUT4, FASN and PCK1, which 
were reportedly differentially expressed at the transcript level in p75NTR-null mice, as 
described previously. I was able to detect all three proteins in the liver tissues, as… 
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Figure 6.11 – p75NTR expression did not vary between wild type and PrPC-null 
mouse livers  
A) Western blot image showing detection of PrPC immunostaining in 4 wild type (WT) but 
not 4 PrPC-null liver homogenates. PrPC was detected by use of the BC6 anti-PrPC primary 
antibody (McCutcheon et al., 2014). B) Image of a western blot of the same homogenates 
that was probed for p75NTR using the 9992 antiserum (see Appendix I for more details). The 
bottom part is the same image but focusing on the approximately 45 kDa bands with the 
brightness setting reduced. C) Bar chart summarising quantification of p75NTR 
immunostaining in image B. Data is shown for the 45 kDa, 24 kDa (p75-CTF) and 19 kDa 
(p75-ICD) bands. After correction for loading errors, the data were normalised to the mean 
signal from the WT homogenates. Overall mean normalised expression values for each 
genotype were calculated and are indicated in the charts (+/- standard error of the mean). 
Expression differences between genotypes were tested for significance (p < 0.05) using 
unpaired, two-sample t-tests but no comparisons met the threshold. 
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demonstrated in Figure 6.12a-c – the relevant bands are shown with arrows. The 
bands at 25 kDa and just over 50 kDa on the GLUT4 blot (Figure 6.12a) are the light 
and heavy chains of antibodies present in the homogenised livers. Since the actual 
molecular weight of GLUT4 is 54.8 kDa it is possible that GLUT4 staining was 
masked by the antibody heavy chain. However, previous studies have shown that the 
apparent molecular weight of GLUT4 on a western blot can be ~45 kDa (Brosius et 
al., 1992; Stuart et al., 2009), so the bands at approximately that molecular weight in 
Figure 6.12a were presumed to be GLUT4 and were quantified. The apparent 
molecular weight of PCK1 on a western blot was predicted to be 63 kDa according to 
the antibody manufacturer. Therefore, the higher of the two bands on Figure 6.12b 
was quantified. The identity of the lower band is unclear, since the Uniprot entry for 
PCK1 (#Q9Z2V4) does not report any other isoforms for the protein. Figure 6.12d 
demonstrates that none of GLUT4, PCK1 and FASN were significantly altered in 
their expression in PrPC-null livers compared with wild type controls. Given the 
putative opposing effects of p75NTR and PrPC knockout on insulin resistance, the 
apparent increase in GLUT4 expression in p75NTR-null mice might suggest a 
decrease in expression in mice lacking PrPC. Although non-significant (unpaired, 
two-sample t-test: p = 0.187), there was a trend towards reduced GLUT4 levels in the 
PrPC-null mice compared with wild type controls (-1.12 fold change). Unfortunately, 
there was not enough time to expand this analysis to encompass more than four 
tissues of each genotype, which might have revealed a significant difference in 
GLUT4 expression.    
Because forebrain homogenates from wild type and PrPC-null mice had already been 
prepared for other experiments reported in this thesis, it seemed worthwhile to also 
assess GLUT4, PCK1 and FASN expression in these tissues, particularly because 10 
tissues of each genotype had been homogenised, providing greater potential 
statistical power than the analyses of the liver tissues. Initially though, expression 
levels of the three target proteins were assessed in six forebrain homogenates (three 
male, three female) of each genotype, again by western blotting. Figure 6.13a shows 
that, for many of the homogenates, the 45 kDa GLUT4 bands were weaker relative…  
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Figure 6.12 – Expression levels of key proteins involved in glucose 
homeostasis and lipogenesis did not vary between wild type and PrPC-null 
mouse livers 
Representative images of western blots of 4 wild type (WT) and 4 PrPC-null mouse liver 
homogenates that were probed for GLUT4 (A), PCK1 (B) or FASN (C). The relevant bands are 
indicated with arrows. Primary antibodies were all from Cell Signalling Technology and had 
the following catalogue numbers: #2213 (A), #12940 (B) and #3180 (C). D) Bar chart 
summarising quantification of GLUT4, PCK1 and FASN immunostaining. For each membrane, 
after correction for loading errors, the data were normalised to the mean signal from the 
WT tissues. Next, the means of the normalised expression values from at least two technical 
replicates were calculated for each tissue. Overall mean normalised expression values for 
each genotype were calculated and are indicated in the bar charts (+/- standard error of the 
mean). Expression differences between genotypes were tested for significance (p < 0.05) 
using unpaired, two-sample t-tests but no comparisons met the threshold. 
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Figure 6.13 – Expression levels of key proteins involved in glucose 
homeostasis and lipogenesis did not vary between wild type and PrPC-null 
mouse forebrains 
Representative images of western blots of 6 wild type (WT) and 6 PrPC-null mouse forebrain 
homogenates that were probed for GLUT4 (A), PCK1 (B) or FASN (C). The relevant bands are 
indicated with arrows. Primary antibodies were all from Cell Signalling Technology and had 
the following catalogue numbers: #2213 (A), #12940 (B) and #3180 (C). D) Bar chart 
summarising quantification of PCK1 and FASN immunostaining. For each membrane, after 
correction for loading errors, the data were normalised to the mean signal from the WT 
tissues. Next, the means of the normalised expression values from two technical replicates 
were calculated for each tissue. Overall mean normalised expression values for each 
genotype were calculated and are indicated in the bar charts (+/- standard error of the 
mean). Expression differences between genotypes were tested for significance (p < 0.05) 
using unpaired, two-sample t-tests but no comparisons met the threshold. 
 




















…to the ~50 kDa antibody heavy chain bands than they were in blots of the liver 
homogenates. The result was that the antibody heavy chain bands interfered with 
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quantification of the 45 kDa bands in some of the lanes, making reliable assessment 
of GLUT4 levels impossible. PCK1 and FASN were easily detectable in the 
forebrain homogenates (Figure 6.13b & c) but, as was the case for the analyses of the 
liver tissues, their expression levels did not vary significantly according to genotype 
(Figure 6.13d), although FASN displayed a trend towards upregulation in the 
PrPC-null tissues (+1.13 fold) that was close to significance (unpaired two-sample 
t-test: p = 0.051). 
In conclusion, no compelling evidence was obtained for PrPC knockout significantly 
affecting expression levels of GLUT4, PCK1 and FASN in either liver or forebrain 
tissues, although GLUT4 levels could not be quantified accurately in mouse 
forebrain. However, levels of Glut4, Pck1 and Fasn transcripts are reportedly subject 
to circadian oscillations and the differential expression of these genes between 
p75NTR-null and wild type control mice fluctuated similarly (Baeza-Raja et al., 2013). 
Analysing the expression of GLUT4, PCK1 and FASN in livers of mice culled at 
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6.8 Discussion 
The previous chapter explored the downstream effects of PrPC transfection into 
SH-SY5Y cells, which included altered expression of proteins involved in 
cytoskeletal organisation and reduced proliferation rates. This chapter has focused on 
a potential upstream mechanism to explain these changes, specifically that PrPC 
modulates NGF signalling. This hypothesis arose from pathway analysis of the 
proteomic changes induced by PrPC transfection, which showed that several targets 
of NGF were differentially expressed in a manner that hinted at altered regulation of 
NGF signalling pathways. Subsequent analysis of the expression levels of NGF 
receptors in the SH-SY5Y cells found that, although overall levels of the high 
affinity receptor TrkA were unaffected by PrPC expression, the amount of TrkA that 
was glycosylated seemed to be increased. This change did not appear to be due to a 
global effect on protein N-glycosylation, although how PrPC expression could 
regulate TrkA glycosylation specifically is not clear. PrPC knockout had no effect on 
TrkA expression in the mouse forebrain but, interestingly, only the glycosylated form 
of the receptor was detected – this finding questions the physiological relevance of 
the results from the SH-SY5Y cells, in which the majority of TrkA was 
unglycosylated. Consequently, it would be useful to investigate whether there are any 
tissues that do express some TrkA in the unglycosylated form.   
Unglycosylated TrkA is unresponsive to NGF, as shown in this thesis and by others 
(Watson et al., 1999), whilst the glycosylated receptor is phosphorylated and, 
therefore, activated by binding of NGF. Consequently, increased expression of 
glycosylated TrkA in the stably transfected clones compared with SH-SY5YUntr 
suggested that p-TrkA levels would be similarly increased in response to any NGF 
present in the culture medium. However, this could not be proved because, whilst 
p-TrkA could just about be detected on a western blot, the bands were too faint for 
accurate quantification. Measuring p-TrkA levels following stimulation with 
exogenous NGF at a range of concentrations would the best way to obtain conclusive 
evidence for increased TrkA activation following PrPC transfection.  
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In addition to the altered TrkA glycosylation, western blotting results suggested that 
p75-CTF, which is produced by alpha-cleavage of the p75NTR receptor, was 
downregulated in the stably transfected clones compared with SH-SY5YUntr. 
p75-CTF can be further processed to produce p75-ICD, which showed similar trends 
towards downregulation in clones 2E3 and 1G3, although these were not significant. 
The lack of statistical significance seemed to be because the levels of p75-ICD varied 
between experimental replicates more than the levels of p75-CTF, possibly because 
of the greater instability of p75-ICD (Zampieri et al., 2005). Whether cleavage of 
p75NTR is required for initiation of downstream signalling is unclear; certainly both 
p75-CTF and p75-ICD are bio-active, although there are conflicting reports of their 
exact functions (Jung et al., 2003; Kenchappa et al., 2006; Coulson et al., 2008; 
Matusica et al., 2013; Verbeke et al., 2013). Interestingly, compared with its 
cleavage fragments, full length p75NTR seemed to be affected quite differently by 
PrPC transfection – it appeared to be downregulated in clone 1G3 compared with 
SH-SY5YUntr but unaffected in clone 2E3. However, this may not be the full story 
because p75NTR receptors can self-assemble into homotrimeric complexes (Anastasia 
et al., 2015) and bands approximately matching the expected molecular weight of 
trimeric p75NTR were detected in western blots of SH-SY5Y cell lysates. Whether 
these bands were physiologically generated trimers, artefacts of the western blot 
process, or not p75NTR at all is unclear. In any case, the bands were detected at the 
very top of the western blot membranes, which meant that the transfer quality was 
too variable for accurate quantification. Nevertheless, the presence of trimeric 
p75NTR in addition to the monomeric form that was quantified could explain why the 
apparent expression trends for full length p75NTR were different from those for the 
cleavage fragments.  
The PI3K/Akt and ERK1/2 pathways are key downstream mediators of the cellular 
response to various growth factors, including NGF. Given that NGF signalling via 
TrkA can modulate both pathways (Huang and Reichardt, 2003) and independent 
signalling through p75NTR can affect the PI3K/Akt pathway (Chen et al., 2009), it 
seemed possible that the altered expression of the NGF receptors in the stably 
transfected clones would translate into differential activation of these downstream 
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pathways. Akt activation was indeed shown to be affected by PrPC transfection but 
ERK1/2 activation was altered only in clone 2E3 compared with SH-SY5YUntr, not in 
clone 1G3. These findings suggest that PrPC modulates the PI3K-Akt pathway in 
SH-SY5Y cells but may not have any direct effect on ERK1/2 signalling. The PI3K-
Akt signalling pathway promotes proliferation, so the reduced Akt activation in the 
stably transfected clones was in agreement with their slower proliferation compared 
with SH-SY5YUntr. Furthermore, since this pathway is considered important for 
neuronal survival (Chang et al., 2003), lower levels of Akt phosphorylation could 
explain the enhanced susceptibility to serum deprivation that resulted from PrPC 
transfection (see section 3.4). This is because when cells are transferred to serum-free 
medium, p-Akt levels would be expected to drop due to the loss of growth factors 
present in the serum. In cells with lower baseline Akt activity it might take less time 
for p-Akt levels to reduce sufficiently for induction of apoptosis, potentially 
explaining why the stably transfected clones were less viable than SH-SY5YUntr after 
the same period of serum deprivation. Furthermore, the p-Akt/total Akt ratio was 
significantly lower in clone 1G3 than in clone 2E3, which is in line with the more 
pronounced sensitivity to serum deprivation of clone 1G3.  
siRNA-mediated knockdown of PrPC in the stably transfected clones was used in an 
attempt to confirm that the changes in expression of the NGF receptors and in the 
activity of the PI3K-Akt signalling pathway were under the control of PrPC. No 
convincing evidence of PrPC knockdown rescuing these phenotypes was obtained, 
although I did not have time to perform sufficient experimental replicates to 
determine conclusively the impacts on Akt activation, whilst some technical issues 
meant that the levels of glycosylated TrkA could not be quantified. It is also possible 
that transiently reducing PrPC levels, albeit by a large amount, was not sufficient to 
reverse the original changes induced by stable transfection of PrPC. This might 
especially be the case if PrPC expression had driven the SH-SY5Y cells towards a 
more neuronal phenotype via increased NGF signalling. Such differentiation 
processes might not be reversible at all, even if PrPC were knocked out completely. 
However, it is notable that, in spite of the lack of impact of PrPC knockdown on Akt 
activation, the slower proliferation of the stably transfected clones was partially 
Chapter 6: Investigating the links between 
PrPC and growth factor signalling  255 
rescued by knocking down PrPC expression. Consequently, reduced activation of the 
Akt signalling pathway may not have been responsible for the slower proliferation of 
the clones. 
One way for PrPC to modulate NGF signalling pathways is by directly interacting 
with one or more of the NGF receptors. This is a credible hypothesis since PrPC, 
p75NTR and TrkA all mainly reside in the lipid raft microdomains of the cell 
membrane (Vey et al., 1996; Huang et al., 1999). However, I found that neither TrkA 
nor p75NTR nor the p75NTR co-receptor sortilin co-immunoprecipitated with the PrPC 
expressed by the stably transfected SH-SY5Y cells. These experiments do not rule 
out such interactions though: further experiments employing cross-linking of proteins 
prior to cell lysis as well as use of additional PrPC antibodies recognising different 
epitopes of the protein would be useful for clarifying the situation. An interaction 
between PrPC and full length p75NTR still seems plausible, especially because 
analysis of the genes with similar expression patterns to PrPC in vivo hinted at 
involvement of PrPC in BDNF signalling and both NGF and BDNF can bind to 
p75NTR. By interacting with p75NTR, PrPC could modulate downstream signalling by 
affecting the affinity of p75NTR for NGF and/or TrkA. This, combined with the 
existence of feedback loops that connect activities of the downstream pathways to 
expression levels of the receptors (Lei and Parada, 2007; Choi and Friedman, 2009), 
could result in altered expression of TrkA and p75NTR, although it would not explain 
why TrkA glycosylation was affected by PrPC transfection.    
Aside from the data obtained from the SH-SY5Y cells, the results of earlier studies in 
vivo also hint at a connection between PrPC and p75NTR signalling. For example, 
p75NTR-null mice displayed alterations to glucose homeostasis and other metabolic 
processes that may stem from the putative role of p75NTR in generating circadian 
rhythms (Baeza-Raja et al., 2012; Baeza-Raja et al., 2013). Similarly, PrPC-null mice 
show signs of impaired blood glucose control (Strom et al., 2011; Brito et al., 2013) 
and have disrupted sleep patterns (Tobler et al., 1996; Sanchez-Alavez et al., 2007), 
which also links PrPC to the regulation of circadian rhythm. An underlying 
mechanism of the changes to glucose homeostasis in p75NTR-null mice is reported to 
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be altered expression in the liver of two key proteins: GLUT4 and PCK1. Therefore, 
the expression levels of these proteins and of FASN, which is involved in lipogenesis 
and was also differentially expressed in p75NTR-null mice, were assessed in PrPC-null 
and wild type livers. PrPC genotype had no significant effects on the levels of these 
proteins in liver or on PCK1 and FASN expression in mouse forebrain – technical 
reasons meant that GLUT4 could not be quantified accurately in the brain tissues. 
However, these were just pilot experiments and, since GLUT4, PCK1 and FASN 
expression levels in the liver vary considerably throughout the day (Baeza-Raja et 
al., 2013), it would be more informative to analyse expression in livers isolated at 
different times of the day/night. Furthermore, the expression changes to these 
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7.1 Conclusions  
7.1.1 Lack of direct stress protection by PrPC  
PrPC has previously been associated with numerous functions, including stress 
protection, neurite outgrowth, circadian rhythm generation and myelin maintenance. 
However, understanding of the basic molecular mechanisms controlled by PrPC is 
still limited. The aim of my project was to investigate these mechanisms to shed light 
on the physiological function of PrPC. I began by stably transfecting the SH-SY5Y 
neuroblastoma cell line with the Prnp CDS and isolating monoclonal, 
PrPC-expressing lines. Initial characterisation work confirmed that the exogenous 
PrPC was correctly targeted to the cell surface and that the four clones used in 
subsequent experiments expressed PrPC at similar levels. Next, the putative role of 
PrPC as a stress-protective protein was assessed by exposing the cells to several 
forms of stress. Two of four stably transfected clones (named 1G3 and 1F3) 
displayed significantly improved survival compared with SH-SY5YUntr in response to 
treatment with three chemical toxins: the oxidative toxin paraquat, the broad-
spectrum protein kinase inhibitor staurosporine and the ER stress-inducer 
tunicamycin. However, the other two clones (2E3 and 1B5) were generally no more 
resistant to these toxins than the control line. The clone-specific nature of the altered 
stress responses meant that further evidence for the involvement of PrPC was 
required. These follow-up experiments showed that transient knockdown of PrPC 
expression did not affect the response to stress, suggesting that the enhanced 
resistance to the toxins that was displayed by clones 1G3 and 1F3 may have been 
independent of PrPC expression. It is possible that a transient reduction in PrPC levels 
was not sufficient to rescue the changes induced by stable transfection but this does 
not explain why the other two clones were no more resistant to the toxins than 
SH-SY5YUntr. Moreover, all four stably transfected clones displayed reduced 
viability in response to serum deprivation compared with SH-SY5YUntr. The 
observation that PrPC transfection reduced the baseline activation state of Akt, a key 
player in the PI3K-Akt signalling pathway that is considered important for neuronal 
survival (Chang et al., 2003), could explain the increased sensitivity to serum 
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withdrawal. This is because in the absence of serum growth factors that stimulate the 
PI3K-Akt pathway, it is conceivable that a lower baseline level of signalling would 
result in the activity of the pathway reducing more quickly to a level that results in 
the induction of apoptosis. Additionally, analysis of proteomic data demonstrated that 
proteins involved in cell death and survival processes were overrepresented among 
the proteins differentially expressed upon PrPC transfection. Furthermore, the 
directionality of these expression changes suggested that the stably transfected clones 
were less viable than SH-SHY5YUntr under standard culture conditions.  
Overall, the data reported in this thesis are not consistent with a role for PrPC in 
stress protection. It is, perhaps, not overly surprising that PrPC expression failed to 
confer robust protection against staurosporine treatment or paraquat-induced 
oxidative stress given the contradictory reports in the literature – whilst many studies 
report that PrPC expression is protective (Brown et al., 2002; Senator et al., 2004; 
Lopes et al., 2005), several others found no evidence of stress protection or even that 
PrPC expression enhances sensitivity to these forms of stress (Paitel et al., 2004; 
Vassallo et al., 2005; Guillot-Sestier et al., 2009; Steinacker et al., 2010). However, 
the observation that PrPC transfection reduces the viability of SH-SY5Y cells in 
response to serum deprivation does contradict the majority of studies that suggest a 
protective role for PrPC (Kuwahara et al., 1999; Bounhar et al., 2001; Kim et al., 
2004; Roucou et al., 2005; Krebs et al., 2007; Wu et al., 2008). The results from 
several of these studies (Kuwahara et al., 1999; Kim et al., 2004; Wu et al., 2008) are 
questionable though due to expression of doppel, another member of the prion 
protein family, by the hippocampal neuronal cell line used in the experiments. 
Publically available transcriptomic data (GeneAtlas U133A dataset (Su et al., 2004) 
accessed through BioGPS (Wu et al., 2016)) indicate that doppel expression is 
normally confined to the testes. Moreover, doppel was not detected in proteomic 
analyses of the SH-SY5Y cells used for the experiments reported in this thesis. 
Therefore, my data support the hypothesis that the stress-protective effect of PrPC 
expression observed in the doppel-expressing hippocampal cell line was a result of 
PrPC interacting with doppel to suppress its reported neurotoxic properties (Moore et 
al., 1999; Sakudo et al., 2005; Qin et al., 2006). This is unlikely to be a 
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physiologically relevant function of PrPC given that PrPC and doppel are not typically 
expressed in the same tissues.  
Proteomic analyses of the SH-SY5Y cells were carried out to identify the pathways 
and processes affected by PrPC transfection and to investigate why the stably 
transfected clones varied in their responses to stress in spite of similar PrPC 
expression levels and localisation patterns. These experiments consisted of separate 
comparisons between SH-SY5YUntr and clone 1G3, a clone that displayed enhanced 
resistance to the three chemical toxins, and between SH-SY5YUntr and clone 2E3, a 
clone that was generally no more resistant than the control line. The proteomic data 
contained some indications that clone 1G3 was more differentiated towards a mature 
neuronal phenotype than clone 2E3 or SH-SY5YUntr; for example, neuroblast 
differentiation-associated protein AHNAK was upregulated by almost three fold in 
clone 1G3 compared with SH-SY5YUntr but essentially unchanged in its expression 
in clone 2E3. However, neuromodulin and neurosecretory protein VGF, which are 
involved in neurite outgrowth processes, were upregulated in both clones compared 
with SH-SY5YUntr. Additionally, almost no neurite-like protrusions could be 
identified in phase contrast images of clone 1G3, whereas these structures were 
abundant in clone 2E3 and SH-SY5YUntr cultures. Given that neurite outgrowth is a 
key feature of neuronal differentiation, these results were not consistent with clone 
1G3 displaying a more mature neuronal phenotype. Therefore, to investigate further 
the differences between the clones in their responses to stress, additional proteomic 
experiments were carried out to identify the proteins differentially expressed 
following staurosporine treatment in SH-SY5YUntr and in clones 2E3 and 1G3. In 
agreement with the cell viability data, pathway analysis of these datasets 
demonstrated that the molecular signatures of cell death were less pronounced in 
clone 1G3 than in either SH-SY5YUntr or clone 2E3 in response to staurosporine 
exposure. Furthermore, the same analysis indicated that activity of the ERK1/2 
signalling pathway, which normally promotes cell survival (Mebratu and Tesfaigzi, 
2009), was reduced in clone 2E3 and SH-SY5YUntr during stress but was possibly 
less affected in clone 1G3. One potential explanation was that the baseline 
expression level of STAT3, a pro-survival transcription factor activated by ERK1/2, 
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seemed to be higher in clone 1G3 compared with clone 2E3 and SH-SY5YUntr. This 
suggested that the pathway may have been more active under normal culture 
conditions in clone 1G3, thereby leading to its increased resistance to the protein 
kinase inhibitor staurosporine. However, western blotting data showed that baseline 
p-ERK1/2/total ERK1/2 ratios were similar in clone 1G3 and SH-SY5YUntr, whilst 
ERK1/2 activation in clone 2E3 was significantly greater than in both clone 1G3 and 
SH-SY5YUntr. Therefore, differential activation of the ERK1/2 signalling pathway 
does not explain the differing stress responses among the clones and no obvious 
alternative explanation could be identified from the proteomic data. 
7.1.2 Downstream processes regulated by PrPC  
The proteomic datasets separately comparing SH-SY5YUntr with clones 2E3 and 1G3 
were combined to select only the proteins differentially expressed in both stably 
transfected clones compared with SH-SY5YUntr – we hypothesised that these changes 
were the most likely to have resulted from PrPC expression. Pathway analysis of 
these data suggested roles for PrPC in cell cycle regulation, cytoskeletal organisation 
and ubiquitination, among other processes. Follow-up studies showed that the stably 
transfected clones proliferated more slowly than SH-SY5YUntr, a phenotype that was 
partially rescued by transient knockdown of PrPC expression. A role for PrPC as a 
negative regulator of proliferation has been observed previously in oligodendrocyte 
precursors, a neuronal cell line, and in cells derived from the intestinal epithelium 
(Kim et al., 2005; Morel et al., 2008; Bribian et al., 2012). In contrast, other studies 
have found that PrPC promotes proliferation of neural precursors and mouse 
neuroblastoma cells (Steele et al., 2006; Llorens et al., 2013; Haigh and Collins, 
2014).   
No effects of PrPC transfection on overall levels of protein ubiquitination were 
identified from western blotting experiments that made use of an antibody able to 
detect monomeric, unconjugated ubiquitin as well as ubiquitinated proteins. 
However, further analysis of the proteomic data showed that two E3 ubiquitin-
protein ligases, SUGT1 and PRPF19, were downregulated in clones 2E3 and 1G3 
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compared with SH-SY5YUntr. The reduced SUGT1 expression may have been a 
consequence of the slower proliferation of the stably transfected clones, since 
SUGT1 is a member of the SCF ubiquitin ligase complex that controls the turnover 
of proteins involved in cell cycle regulation (Kitagawa et al., 1999). PRPF19 has a 
very different role – it ubiquitinates certain splicing factors to modify spliceosome 
function (Chanarat and Strasser, 2013). Other proteins involved in pre-mRNA 
splicing were also expressed at lower levels in the PrPC-transfected cells, which 
could suggest a reduction in overall spliceosome activity. Although the mechanism 
for such an effect is not immediately clear, it is possible that the rate of protein 
synthesis is lower in slower-proliferating cells, which may result in a reduced 
requirement for spliceosome activity.   
Western blotting of cell lysates showed that expression levels of three proteins 
involved in cytoskeletal organisation, seemed to be increased by PrPC transfection – 
compared with SH-SY5YUntr, vimentin, caldesmon and zyxin were significantly 
upregulated in two, three and four stably transfected clones, respectively. Trends 
towards upregulation of vimentin and caldesmon that were close to significance were 
also observed in the remaining clones. The increase in caldesmon expression is 
particularly striking, since this protein is reportedly involved in Schwann cell 
migration during peripheral nerve regeneration (Han et al., 2007) and an adult-onset 
demyelination of the PNS has been observed in several PrPC knockout mouse lines 
(Bremer et al., 2010; Nuvolone et al., 2016). To follow up this observation, 
caldesmon levels were assessed in age- and sex-matched wild type and PrPC-null 
mouse forebrains but no significant difference between the genotypes was observed, 
perhaps because cell type-specific effects of PrPC expression were averaged out over 
the entire tissue. Moreover, since the demyelinating phenotype of the PrPC-null mice 
appears restricted to the PNS (Bremer et al., 2010), assessing caldesmon expression 
in peripheral nerves may be more informative. Such tissues were not immediately 
available however.   
Confocal imaging showed that the actin cytoskeleton of clone 1G3 differed from 
clone 2E3 and SH-SY5YUntr – clone 1G3 cells seemed to contain thick stress fibres, 
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which are associated with reduced cell motility and greater cytoskeletal stability 
(Troller and Larsson, 2006). Increased stability of actin microfilaments disrupts the 
formation, extension and movement of filopodia, which are dynamic protrusions 
from the neurite growth cone that respond to extracellular signals to guide migration 
of developing neurites (O'Connor et al., 1990). This may explain why clone 1G3 
produced fewer neurite-like protrusions than the other cell lines. The RhoA-ROCK 
signalling pathway, which PrPC has previously been reported to modulate, is known 
to promote the formation of stress fibres and inhibit neurite outgrowth (Altun-
Gultekin et al., 1998; Loubet et al., 2012), so this pathway may have been more 
active in clone 1G3. However, this is not a complete explanation, since activated 
RhoA is reported to promote proliferation (Yu and Brown, 2015), whereas clone 1G3 
proliferated slower than SH-SY5YUntr and clone 2E3. Interestingly, neuromodulin, 
annexin A2, neurosecretory protein VGF and zyxin – proteins that positively 
correlate with neurite outgrowth in their expression – were generally more abundant 
in the stably transfected clones than in SH-SY5YUntr. It is unclear why PrPC 
transfection induced proteomic alterations associated with increased neurite 
outgrowth at the same time as causing other molecular changes linked to its 
repression.  
In spite of the tendency towards increased caldesmon expression in the PrPC-
transfected SH-SY5Y cells, differential expression was not observed between 
PrPC-null and wild type forebrains. Similarly, no genotype-dependent alterations in 
the expression levels of annexin A2, neurosecretory protein VGF or zyxin were 
identified in the same tissues. These results are in line with published proteomic 
studies that found no differentially expressed proteins in the brains of PrPC knockout 
mice compared with controls (Crecelius et al., 2008; Mehrabian et al., 2016). 
However, I was able to identify two proteins that were upregulated in the mouse 
forebrain as a result of PrPC knockout; these were connexin-43 and GLUD1. These 
proteins were targeted as a part of an attempt to validate an earlier study performed 
by my research group that identified proteomic and transcriptomic changes in the 
forebrain resulting from PrPC ablation in the mouse. Importantly, these forebrain 
tissues were from the Npu line of PrPC knockout mice, which is free from the issues 
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of mixed genetic background and ectopic doppel expression in the brain that affect 
most of the other knockout lines. Consequently, the differential expression of 
connexin-43 and GLUD1 is highly likely to have been caused by an absence of PrPC 
expression. GLUD1 is involved in the metabolism of glutamate, which is of note 
given that PrPC has been suggested previously to protect neurons from excitotoxic 
cell death caused by hyperactivation of glutamate receptors (Sakurai-Yamashita et 
al., 2005; Frigg et al., 2006; Khosravani et al., 2008). Connexin-43 is part of a 
protein family that forms gap junctions, which provide cytoplasmic connections 
between neighbouring cells and allow regulated intercellular transport of molecules, 
including calcium ions (Evans and Martin, 2002). Gap junctions between neurons, 
known as electrical synapses, enable the synchronised firing of large neuronal 
networks that is characteristic of the immature CNS (Ben-Ari, 2001). The 
upregulation of connexin-43 suggests that PrPC-null mice could have a greater 
density of electrical synapses and, since this form of synapse becomes rarer as the 
CNS develops (Arumugam et al., 2005), it may be that PrPC knockout subtly impairs 
the maturation of the CNS. This could provide an alternative explanation for the 
reported learning and memory deficits of PrPC-null mice (Rial et al., 2009; Schmitz 
et al., 2014). Furthermore, PrPC downregulating connexin-43 expression in the brain 
could be the reason why connexin-43 levels are reportedly increased in mouse 
models of TSEs (Lee et al., 2015), since PrPC levels tend to fall as disease progresses 
(Mays et al., 2014).  
7.1.3 Connections between PrPC and NGF/neurotrophin signalling  
Pathway analysis of the aforementioned proteomic datasets suggested that altered 
activity of NGF signalling pathways could explain some of the proteomic changes 
induced by PrPC transfection into the SH-SY5Y cells. Additionally, analysis of 
publically available microarray data from various tissues and cell types showed that 
targets of BDNF were overrepresented among the genes with similar spatial 
expression patterns to PRNP in both mice and humans. Taken together, these results 
suggested that PrPC might modulate the cellular response to neurotrophins. Since 
SH-SY5Y cells do not express TrkB, the high affinity receptor for BDNF, subsequent 
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experiments focused solely on NGF signalling. Firstly, I examined the expression 
levels of the NGF receptors and found that, although overall TrkA expression was 
unaffected by PrPC transfection, the levels of NGF-responsive TrkA were increased, 
mainly because a greater proportion of TrkA was glycosylated. A further examination 
of the proteomic datasets suggested that any alteration to TrkA glycosylation was 
unlikely to have resulted from a global effect of PrPC expression on N-glycosylation, 
since key components of this pathway did not vary in their expression between the 
stably transfected clones and SH-SY5YUntr. Therefore, TrkA glycosylation may have 
been affected specifically, although no information about the regulation of TrkA 
glycosylation could be identified from the literature. In contrast to the effects on 
TrkA expression, western blotting data suggested that levels of p75-CTF were lower 
in the stably transfected clones compared with SH-SY5YUntr. p75-ICD expression 
seemed to vary similarly, although these changes were not statistically significant. 
Furthermore, it was not possible to determine conclusively the expression levels of 
full length p75NTR by western blotting due to the tendency of the receptor to 
self-assemble into trimers. As a consequence, I cannot be certain whether PrPC 
transfection reduced the rate of p75NTR cleavage or lowered the overall expression 
level of p75NTR. It should also be cautioned that the “messy” nature of the p75NTR 
immunostaining pattern made it difficult to identify the relevant bands with certainty. 
Treatment of cells with compounds that induce p75NTR processing events or use of a 
negative control sample when western blotting would have helped to confirm 
specificity of the antibody.  
The impact on downstream signalling of the differential expression of the NGF 
receptors was assessed by quantifying the activation states of key protein kinases in 
the pathways that mediate NGF-induced neuronal survival and differentiation 
(Huang and Reichardt, 2003). These data demonstrated that p-Akt/total Akt ratios 
were reduced by PrPC transfection, indicating that the PI3K-Akt pathway that 
promotes survival and proliferation was less active. Whilst this finding is consistent 
with the slower proliferation of the stably transfected clones compared with 
SH-SY5YUntr, reduced Akt activity cannot easily be explained by the altered 
expression of the NGF receptors – the PI3K-Akt pathway is reportedly activated by 
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NGF binding to TrkA (Chang et al., 2003; Huang and Reichardt, 2003) and PrPC 
transfection into the SH-SY5Y cells resulted in a greater proportion of TrkA being 
NGF-responsive. Of course it is possible that, in spite of expressing more NGF-
responsive TrkA, NGF-TrkA signalling could have been less active in the stably 
transfected clones than in SH-SY5YUntr.  
A credible hypothesis to explain the putative effect of PrPC expression on NGF 
signalling pathways is that PrPC interacts directly with one of the NGF receptors, 
especially given that PrPC, TrkA and p75NTR all reside mainly in lipid rafts (Vey et 
al., 1996; Huang et al., 1999). Such an interaction might alter the affinity of the 
receptor for NGF or affect how it activates in response to NGF binding, for example. 
Consequently, the effect of PrPC expression on the activities of downstream 
pathways would vary between cell types because of differences in the relative 
expression levels of TrkA, p75NTR and also the p75NTR co-receptor sortilin. This idea 
could explain why PrPC has been associated with such a diverse array of functions 
and also how PrPC expression can have opposing effects on the same process, such as 
proliferation, in different types of cell. In the case of the SH-SY5Y cells used in my 
experiments, a change in NGF signalling caused by PrPC transfection may have 
resulted in altered expression of the NGF receptors via positive or negative feedback 
loops. For example, p75NTR expression is known to be upregulated by nuclear factor-
kappa B signalling, a pathway that is activated through p75NTR itself (Chen et al., 
2009; Choi and Friedman, 2009).  
Preliminary PrPC co-IP experiments performed under non-denaturing conditions did 
not identify any interactions with TrkA or p75NTR or with the cleavage fragments 
p75-CTF or p75-ICD in PrPC-transfected SH-SY5Y cells. Additionally, neither 
sortilin nor annexin A2 co-immunoprecipitated with PrPC in spite of previous 
evidence of interactions between PrPC and these proteins (Morel et al., 2008; 
Uchiyama and Sakaguchi, 2016). However, whilst the use of non-denaturing 
conditions minimises the detection of false positives, weak or transient interactions 
that may still be biologically relevant are unlikely to be detectable; incorporating 
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cross-linking prior to lysis to maintain protein-protein interactions would help to 
identify these less stable interactions.   
One way to investigate the wider impact of the putative link between PrPC and NGF 
signalling is to make use of PrPC-knockout animals, which would be expected to 
display phenotypes consistent with deregulation of NGF signalling and potentially of 
those pathways controlled by other neurotrophins. In this regard, the adult-onset 
demyelination of the PNS in PrPC-null mice is striking (Bremer et al., 2010; 
Nuvolone et al., 2016), given the reported involvement of p75NTR in signalling 
processes mediated by myelin components (Ahmed et al., 2006; Park et al., 2010b; 
Palandri et al., 2015) and the impairment of remyelination after peripheral nerve 
injury that is observed in p75NTR knockout mice (Song et al., 2006). Furthermore, 
p75NTR is proposed to be part of the circadian clock network that generates circadian 
rhythms (Baeza-Raja et al., 2013), and it is conceivable that PrPC has a similar role 
given the report of circadian oscillation of Prnp expression in the brain (Cagampang 
et al., 1999) and the disrupted sleep observed in PrPC-knockout mice (Tobler et al., 
1996; Tobler et al., 1997; Sanchez-Alavez et al., 2007). This sleep disruption 
probably arises from deregulation of melatonin production (Brown et al., 2002) and 
it is interesting to note that my analysis of publically available microarray data from 
human and mouse tissues/cell types showed that components of the melatonin 
signalling pathway were overrepresented among the genes highly coexpressed with 
PRNP. The microarray data also indicate that TrkA gene expression was higher in the 
pineal gland, which produces melatonin, than it was in any other tissues.  
Metabolic processes are regulated in a circadian manner (Dibner et al., 2010), which 
may explain why both p75NTR and PrPC knockout mice display signs of disrupted 
glucose homeostasis (Strom et al., 2011; Baeza-Raja et al., 2012; Brito et al., 2013). 
The molecular changes underlying the altered glucose homeostasis of p75NTR-null 
mice were reported to be differential expression of GLUT1 and PCK1 in the liver 
(Baeza-Raja et al., 2013). Therefore, the expression levels of these proteins and of 
FASN, which is involved in lipogenesis and also displayed altered expression upon 
p75NTR knockout (Baeza-Raja et al., 2013), were assessed in liver and brain tissues 
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from PrPC-null and wild type control mice. No significant effects of PrPC knockout 
on the expression levels of these proteins were identified in these pilot experiments. 
However, it is possible that differential expression would be revealed by analysing 
tissues isolated at different times of the day/night, since GLUT4, PCK1 and FASN 
expression levels oscillate according to circadian rhythms (Baeza-Raja et al., 2013).    
7.1.4 Limitations of the data 
As is the case for any scientific project, there are caveats associated with the results 
obtained from some of the experiments. Several of these limitations have been 
described in the previous sections of this chapter; some additional caveats are 
mentioned here. Firstly, it must be acknowledged that much of the data reported in 
this thesis was obtained from in vitro experiments, which puts the physiological 
relevance of the conclusions up for debate. However, there were several valid 
reasons for adopting such an approach, not least that this project aimed to identify the 
molecular mechanisms underlying PrPC function. Numerous studies have identified 
phenotypes of PrPC-null mice but it is the mechanistic understanding that is lacking, 
and this work is much more practical to carry out in vitro. A second potential 
criticism is that, rather than using a cell line, I could have investigated PrPC function 
using primary neuronal cultures. However, culturing primary neurons is technical 
demanding and there are issues surrounding reproducibility and genetically 
manipulating these cells in culture (Karra and Dahm, 2010). Furthermore, any 
compensatory mechanisms active during the development of PrPC-knockout mice 
might complicate analysis of PrPC function in cells derived from those mice. Indeed, 
examples of mechanisms compensating for a lack of PrPC expression during 
development have been reported previously (Shmerling et al., 1998; Hajj et al., 
2007).  
One potential criticism of the format of the in vitro experiments is that untransfected 
SH-SY5Y cells were not proper controls for the PrPC-independent effects of 
transfection. However, whilst it makes sense to use cells transfected with the empty 
vector to control for presence of the antibiotic resistance gene and other vector 
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components in a transient transfection experiment, when stably transfecting cells 
such an approach does not control for the consequences of the vector integrating into 
the genome, since this will almost certainly occur at different sites for each clone. To 
alleviate this problem, I would have needed to derive and use multiple empty vector-
transfected clones, which would have made the logistics of carrying out experiments 
very difficult. Therefore, on balance, untransfected cells matched to the stably 
transfected clones in terms of weeks in culture were considered acceptable controls. 
Another potential issue with the cell model was that the transgenic PrPC expressed by 
the stably transfected clones was abnormally glycosylated – specifically, the glycans 
on the di-glycosylated form of transgenic PrPC had a greater combined molecular 
weight than the glycans on mouse brain PrPC. However, such alterations to 
glycosylation are reported to occur frequently in cell lines but are thought to have 
few biological consequences (Varki and Lowe, 2009). Additionally, aside from the 
differences in glycan size, the majority of PrPC expressed by the stably transfected 
clones was di-glycosylated as was the case in mouse forebrain. 
The data reported in this thesis do not support a direct role for PrPC in protecting 
cells from stress. Clones 1G3 and 1F3 did display increased viability and cytotoxicity 
in response to three chemical toxins compared with SH-SY5YUntr but the lack of 
effect of PrPC knockdown on this phenotype suggests that it was not a result of PrPC 
expression. However, whilst detailed characterisation of the cells suggested that PrPC 
expression levels and localisation patterns were similar among the clones, a single 
western blot, performed prior to preparing frozen stocks of each clone, showed that 
PrPC expression may have initially been higher in clones 1G3 and 1F3 than in clones 
2E3 and 1B5. Later, PrPC expression may have normalised to a stable level that was 
relatively consistent among the clones. If this were the case then it is conceivable that 
PrPC expression in clones 1G3 and 1F3 may have initially exceeded some kind of 
threshold that resulted in a change to the cells that persisted even after a subsequent 
reduction in PrPC expression. This might especially be the case if PrPC expression 
had driven the SH-SY5Y cells towards a more neuronal phenotype via increased 
NGF signalling. Such a differentiation process might not be reversible even if PrPC 
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expression was subsequently knocked out completely, which could explain the lack 
of effects of siRNA-mediated PrPC knockdown. Nevertheless, aside from that initial 
western blot seemingly showing differences in PrPC expression among the clones, 
there is little evidence to support the above speculation.   
Western blot analyses of the SH-SY5Y cells showed that PrPC transfection perturbed 
the expression of proteins involved in cytoskeletal organisation or neurite outgrowth 
and also affected expression of receptors for NGF. However, these molecular 
changes were not confirmed by experiments comparing PrPC-null and wild type 
mouse forebrain tissues. In some ways, this was not surprising given that, in spite of 
numerous roles for PrPC that have been identified from cell models by various 
groups, two published proteomic studies failed to identify a single differentially 
expressed protein when comparing PrPC-null mouse brain homogenates with wild 
type controls (Crecelius et al., 2008; Mehrabian et al., 2016). One explanation that 
has been put forward is that PrPC regulates processes in a cell type-specific manner, 
leading to an averaging out of these effects over an entire tissue (Mehrabian et al., 
2014; Mehrabian et al., 2016). Additionally, absence of PrPC expression in the 
knockout mice could be compensated for by other proteins, as has been suggested 
previously (Shmerling et al., 1998; Hajj et al., 2007). Finally, and specifically to my 
data, the role of PrPC in the immature, neuronal precursor-like SH-SY5Y cell line 
may not be the same as its role in the forebrain of an aged mice – for reasons 
explained in section 5.5, the tissues used in the experiments reported in this thesis 
were from mice culled at ~550 days of age.  
7.2 Future directions 
7.2.1 Further investigating the molecular details of the putative 
modulation of NGF/neurotrophin signalling by PrPC  
Putting aside concerns over the specificity of the anti-p75NTR antibody, western 
blotting data suggested that levels of p75-CTF were significantly lower in the stably 
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transfected clones than in SH-SY5YUntr. However, expression of the full length 
receptor could not be quantified accurately due to the previously described issue of 
trimer formation. Therefore, it is not clear whether the putative downregulation of 
p75-CTF resulted from a reduced rate of p75NTR alpha-cleavage or from an overall 
reduction in the expression of p75NTR. One way to check would be to analyse the 
subcellular distribution of expression of p75NTR and its cleavage fragments by 
confocal microscopy. If p75NTR cleavage rates were reduced then one might expect 
the staining in the clones to be more confined to the cell membrane than in 
SH-SY5YUntr, because p75-ICD is present in the cytoplasm, whereas p75-CTF and 
the full length receptors are normally associated with the cell membrane (Weskamp 
et al., 2004; Zampieri et al., 2005). On the other hand, if PrPC transfection affects 
overall p75NTR expression levels then the staining pattern should be similar 
irrespective of whether or not the cells express PrPC.  
Interactions between PrPC and TrkA, p75NTR or sortilin were not identified in 
preliminary co-IP experiments. As previously mentioned, one potential follow-up 
experiment would be to use cross-linking prior to cell lysis to enable detection of 
weaker or more transient interactions, should they exist. A second approach would be 
to immunoprecipitate PrPC using an antibody that binds to a different epitope, since 
the epitope recognised by the BC6 antibody used in the experiments reported in this 
thesis could have been obscured by interactions between PrPC and other proteins. 
Such a situation might result in immunoprecipitation of only the PrPC molecules not 
involved in any interactions at that time. The BC6 epitope is reported to be amino 
acids 144-154 in the C-terminal domain of PrPC (McCutcheon et al., 2014), so the 
use of an antibody that binds to the N-terminal domain would be one option. This 
would also enable immunoprecipitation of the N1 fragment that is released from cells 
following alpha-cleavage of PrPC – initial characterisation of the PrPC-transfected 
SH-SY5Y cells confirmed that alpha-cleavage of PrPC did occur and an interaction 
between N1 and one of the NGF receptors is plausible, especially since N1 has been 
specifically implicated in some of the functions ascribed to PrPC (Guillot-Sestier et 
al., 2009; Haigh and Collins, 2014; Haigh et al., 2015b). Finally, if it is the cleavage 
rate of p75NTR that is affected by PrPC transfection then one could investigate 
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whether PrPC interacts with ADAM17, the enzyme reportedly responsible for p75NTR 
alpha-cleavage (Weskamp et al., 2004).  
One way for PrPC to affect signalling pathways downstream of TrkA or p75
NTR 
would be to interact with one of these receptors to modulate their response to NGF 
binding. In addition to assessing these putative interactions by co-IP experiments, 
activation of the receptors and/or downstream protein kinases in response to 
stimulation with exogenous NGF could be investigated. For example, a PrPC 
transfection-dependent alteration in the half-maximal effective concentration of NGF 
for induction of TrkA phosphorylation would indicate that PrPC affects the response 
of TrkA to NGF. 
Instead of interacting with a receptor for NGF, PrPC could modulate NGF signalling 
pathways by upregulating the expression of NGF itself; this could be assessed by 
quantifying the NGF present in conditioned media from transfected and 
untransfected SH-SY5Y cells. Since neuronal cell lines have been shown to 
upregulate PrPC expression upon NGF stimulation (Kuwahara et al., 2000; Zawlik et 
al., 2006), PrPC could have a similar effect on NGF expression via a positive 
feedback loop. However, an interaction between PrPC and another as yet unknown 
protein would be required for PrPC to initiate the downstream signalling pathways 
that would affect NGF gene transcription.  
7.2.2 Further investigation of the consequences in vivo of a role for 
PrPC in modulating NGF/neurotrophin signalling  
NGF signalling is important for the proper development of sensory neurons with cell 
bodies in the dorsal root ganglia (DRGs) (Hefti et al., 2006). PrPC may play a similar 
role, since its expression has been observed in the dorsal and ventral root ganglia of 
the developing spinal cord (Tremblay et al., 2007; Peralta et al., 2012; Ganley et al., 
2015) as well as in sensory and motor axons (Manson et al., 1992) and associated 
Schwann cells (Follet et al., 2002). Furthermore, interactions between PrPC and the 
extracellular matrix protein vitronectin are reported to promote the developmental 
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growth of axons that project from DRGs (Hajj et al., 2007), whilst vitronectin also 
seems to be important for the neurite outgrowth displayed by the neuronal cell line 
PC12 following exposure to NGF (Grabham et al., 1992). PrPC knockout does not 
appear to affect neurite outgrowth from cultured DRG neurons; however, this is 
reportedly because integrins substitute for PrPC in interactions with vitronectin (Hajj 
et al., 2007). This putative compensatory mechanism may not be completely 
effective though, since PrPC knockout has been reported to alter pain sensitivity 
(Meotti et al., 2007; Gadotti and Zamponi, 2011). NGF is a key pain mediator, partly 
because it is required for the development and survival of nociceptive neurons but 
also because it can alter neuronal excitability directly. For example, spinal cord 
NMDARs, which are important for the onward processing of pain signals (Petrenko 
et al., 2003), can be phosphorylated in response to signals from NGF and other 
neurotrophins, potentially affecting NMDAR activity (Di Luca et al., 2001; Slack et 
al., 2004; Salter et al., 2009). Modulation of neurotrophin signalling by PrPC could 
explain why an NMDAR inhibitor rescued an increase in pain sensitivity that 
resulted from PrPC knockout (Gadotti and Zamponi, 2011) and also provides an 
alternative explanation for the finding that PrPC affects NMDAR activity in the brain 
(Khosravani et al., 2008). To investigate this apparent connection in more detail, one 
could analyse whether NMDAR phosphorylation and/or expression in the spinal cord 
is affected by PrPC knockout. Additionally, one might expect disrupted NGF 
signalling to affect the numbers of nociceptive neurons, and sensory neurons in 
general, that develop and survive into adulthood. This could be assessed in PrPC-null 
mice by examining the morphologies of their DRGs and by quantifying the numbers 
of neuronal cell bodies present.       
Several proteins involved in cytoskeletal organisation and/or neurite outgrowth were 
altered in their expression in the stably transfected clones compared with 
SH-SY5YUntr. However, the expression levels of these proteins did not vary 
significantly between PrPC-null and wild type forebrains, possibly because cell type-
specific effects of PrPC were averaged out or “diluted” when analysing homogenates 
of the entire tissue. A more effective approach might be to study different regions of 
the brain separately, especially focusing on areas where NGF signalling is important 
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for neuronal survival, such as the basal forebrain (Sofroniew et al., 2001). 
Alternatively, the effects of PrPC knockout on the expression of proteins involved in 
cytoskeletal organisation might be more noticeable in peripheral nerves due to the 
aforementioned function of NGF in the development of sensory neurons.    
As mentioned previously, a comprehensive analysis of GLUT4, PCK1 and FASN 
expression levels in liver tissues from mice culled at different times of the day/night 
might reveal an effect of PrPC knockout. Additionally, analysing expression at the 
mRNA level could be more effective at detecting differences associated with Prnp 
genotype. Assuming that any effects of PrPC expression on metabolic processes 
derive from a role in generating circadian rhythms, possibly linked to modulation of 
signalling through p75NTR, it would be useful to confirm that PrPC expression is 
subject to circadian oscillation in the suprachiasmatic nucleus at the protein level; as 
far as I am aware, oscillations have only been identified in Prnp mRNA levels 
(Cagampang et al., 1999). Furthermore, since p75NTR knockout reportedly disrupts 
circadian oscillations in the expression of other clock network genes, one could 
investigate whether PrPC knockout has a similar effect. A better understanding of the 
putative role of PrPC in generating circadian rhythms would help to determine 
whether a loss of PrPC function is involved in the pathogenesis of the TSE known as 
fatal familial insomnia, the clinical phase of which is characterised by disruptions to 
sleep-wake patterns (Collins et al., 2001).  
PrPC is highly expressed by mast cells and can be shed from the cell surface in the 
form of the N3 fragment. Shedding seems to occur at a low level constitutively but 
when mast cells are activated by inflammatory stimuli a large amount of N3 can be 
released (Haddon et al., 2009). Strikingly, NGF can activate mast cells and is also 
released from the cells upon their activation (Stempelj and Ferjan, 2005; Cantarella 
et al., 2011), which suggests an autocrine or paracrine positive feedback mechanism, 
potentially involving PrPC, that further increases mast cell activity. Therefore, one 
might expect PrPC knockout to impair mast cell function. Since activated mast cells 
release various inflammatory mediators, including histamine, prostaglandins and 
cytokines (Stempelj and Ferjan, 2005), the production of these compounds by mast 
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cells isolated from PrPC-null and wild type mice could be compared following 
exposure to compounds that induce activation.  
PrPC expression has been detected in human teeth, including within the odontoblasts 
that form and calcify dentin. Furthermore, variations in dentin structure have been 
identified between PrPC-null and wild type mice (Schneider et al., 2007). If PrPC is 
expressed by odontoblasts then it may also be found in osteoblasts, which form bone. 
Intriguingly, targets of a protein called osteonectin were overrepresented among the 
proteins differentially expressed in PrPC-transfected cells compared with 
SH-SY5YUntr. Although multifunctional, a major role of osteonectin is to promote 
bone mineralisation and the production of new osteoblasts (Ribeiro et al., 2014). A 
role for PrPC in bone homeostasis can be explained by an involvement in NGF 
signalling pathways, since p75NTR knockout mice display decreased bone mineral 
content (IMPC, [n.d.]) and pro-NGF reportedly promotes bone regeneration by 
stimulating osteoblast and inhibiting osteoclast differentiation from precursors in 
bone marrow (Mediero et al., 2014). In order to investigate whether PrPC has a 
function in bone, the structure and mineral content of bones from PrPC-null and wild 
type mice could be examined. Additionally, one could investigate whether a lack of 
PrPC expression affects the ability of precursor cells to differentiate into osteoblasts 
or osteoclasts in culture.   
Whilst a complete description of PrPC function is some way off, this thesis 
contributes towards our understanding of the molecular mechanisms regulated by 
PrPC. Firstly, the data presented suggests that PrPC is not involved in stress protection 
directly, which is in contrast to much of the published literature. Secondly, PrPC 
expression inhibits proliferation of the SH-SY5Y cell line and alters the expression 
levels of proteins involved in cytoskeletal organisation and/or neurite outgrowth. 
Thirdly, changes to the expression of receptors for NGF and to the activities of 
downstream growth factor signalling pathways suggested that the phenotypes 
induced by PrPC transfection may have resulted from modulation of NGF signalling 
pathways by PrPC. A role for PrPC in modulating NGF signalling, or neurotrophin 
signalling more generally, has the potential to explain many of the diverse 
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phenotypic observations in PrPC-null mice, could indicate that loss of PrPC function 
is an important part of TSE pathogenesis, and opens up various avenues for future 
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Appendices 






phospho-Akt (Ser473) CST #4060 1:2000 to 1:4000 
Akt (pan) CST #2920 1:2000 to 1:4000 
Annexin A2 CST #8235 1:2000 
ATP synthase subunit alpha, mitochondrial Sigma #SAB4502040 1:1000 
E3 ubiquitin-protein ligase BRE1A CST #11974 1:2000 
Caldesmon CST #12503 1:2000 
Connexin-43 CST #3512 1:1000 to 1:2000 
Eukaryotic translation initiation factor 1 CST #12496 1:2000 
phospho-ERK1/2 (Thr202/Tyr204 for ERK1 and 
Thr185/Tyr187 for ERK2) 
CST #4370 1:2000 to 1:4000 
ERK1/2 CST #9107 1:2000 to 1:4000 
FASN CST #3180 1:1000 
Glutamate dehydrogenase 1, mitochondrial AVIVA #ARP45709 1:1000 to 1:2000 
GLUT4 CST #2213 1:1000 
Microsomal glutathione S-transferase 3 AVIVA #ARP60342 1:2000 
Myotubularin AVIVA #ARP56078 1:2000 
p75NTR N/A16 1:2000 to 1:5000 
p75NTR Millipore #07-046 1:4000 
Pantothenate kinase 2, mitochondrial AVIVA #ARP43984 1:2000 
PCK1 CST #12940 1:2000 
Proliferation cell nuclear antigen CST #13110 1:2000 
Peroxiredoxin-1 AVIVA #ARP48454 1:2000 
Peroxiredoxin-6 AVIVA #ARP48267 1:1000 
Protein kinase C alpha type CST #2056 1:2000 
PrPC N/A17 0.15-0.2 µg/ml 
PrPC Thermo #7500996 1:1000 (IF) 
Neuromodulin CST #5307 1:1000 
Ribonucleoside-diphosphate reductase large 
subunit 
CST #8637 1:2000 





SRSF protein kinase 2 AVIVA #ARP61851 1:2000 
phospho-TrkA (Tyr785) /phospho-TrkB (Tyr816) CST #4168 1:1000 
                                                 
16 This anti-p75NTR antibody (9992 antiserum), originally developed in the lab of Prof. Moses V. Chao 
from New York University, was a gift from Dr Andrea Caporali of the University of Edinburgh.  
17 This anti-PrPC antibody, known as BC6, was developed in house, as described by McCutcheon et al. 
(2014). 






TrkA CST #2505 1:1000 
TrkB CST #4603 1:1000 
Ubiquitin Millipore #MAB1510 1:1600 
Voltage-dependent anion-selective channel 
protein 2 
AVIVA #ARP35124 1:2000 to 1:4000 
Vimentin CST #5741 1:2000 or 1:100 (IF) 
Neurosecretory protein VGF Abcam #ab74140 1:1000 
Zyxin CST #3553 1:2000 
 
Supplementary Table 1 – Primary antibodies used for western blotting and 
immunofluorescence 
Antibodies were used for western blotting except for those marked with (IF); these were 
used for immunofluorescence. Company abbreviations are as follows: AVIVA Systems 
Biology (AVIVA), Cell Signalling Technology (CST), Sigma-Aldrich (Sigma) and Thermo Fisher 
Scientific (Thermo).  
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Supplementary Table 2 – List of proteins differentially expressed in clone 1G3 
compared with untransfected SH-SY5Y cells 
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Supplementary Table 3 – List of proteins differentially expressed in 
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Supplementary Table 4 – List of proteins differentially expressed in clone 2E3 
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Supplementary Table 5 – List of proteins differentially expressed in clone 1G3 
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Supplementary Table 6 – List of genes highly coexpressed with PrPC (mouse 
data) 
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